{"text":"Caspofungin and amphotericin B association has been shown to be synergistic in vitro and effective in murine models .","paragraph":"<h3><u>[Successful treatment of a persistent rhino-cerebral mucormycosis in a pediatric patient with a debut of acute lymphoblastic leukemia].</u></h3>The fungi of the order Mucorales cause mucormycosis, which usually presents as an invasive fungal disease with rapid angioinvasion in immunocompromised patients. Rhinocerebral is the most common presentation. The lipid formulations of <b style='color:Tomato;'><i>amphotericin</i></b> B are used as primary treatment in invasive mucormycosis; the combined use of <b style='color:Tomato;'><i>posaconazole</i></b> could allow a reduction in the dose of <b style='color:Tomato;'><i>amphotericin</i></b> B improving tolerance and adherence to treatment. <b style='color:MediumOrchid;'><i>Caspofungin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>association</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>murine</i></b> <b style='color:DodgerBlue;'><i>models</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We present the case of a preschool patient that during the debut of acute lymphoblastic leukemia developed a rhinocerebral mucormycosis successfully responding to antifungal treatment with the combination of liposomal <b style='color:Tomato;'><i>amphotericin</i></b> and <b style='color:Tomato;'><i>caspofungin</i></b>. ","tokens":[{"text":"Caspofungin","start":0,"end":11,"id":0,"ws":true},{"text":"and","start":12,"end":15,"id":1,"ws":true},{"text":"amphotericin","start":16,"end":28,"id":2,"ws":true},{"text":"B","start":29,"end":30,"id":3,"ws":true},{"text":"association","start":31,"end":42,"id":4,"ws":true},{"text":"has","start":43,"end":46,"id":5,"ws":true},{"text":"been","start":47,"end":51,"id":6,"ws":true},{"text":"shown","start":52,"end":57,"id":7,"ws":true},{"text":"to","start":58,"end":60,"id":8,"ws":true},{"text":"be","start":61,"end":63,"id":9,"ws":true},{"text":"synergistic","start":64,"end":75,"id":10,"ws":true},{"text":"in","start":76,"end":78,"id":11,"ws":true},{"text":"vitro","start":79,"end":84,"id":12,"ws":true},{"text":"and","start":85,"end":88,"id":13,"ws":true},{"text":"effective","start":89,"end":98,"id":14,"ws":true},{"text":"in","start":99,"end":101,"id":15,"ws":true},{"text":"murine","start":102,"end":108,"id":16,"ws":true},{"text":"models","start":109,"end":115,"id":17,"ws":true},{"text":".","start":116,"end":117,"id":18,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":28,"token_start":2,"token_end":2,"label":"DRUG"}],"_input_hash":-445877258,"_task_hash":-714108797,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":16,"end":28,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Canine leishmaniosis is most frequently treated with the drugs meglumine antimoniate , allopurinol , amphotericin B , or a combination of meglumine antimoniate and allopurinol .","paragraph":"<h3><u>Chemotherapy of canine leishmaniosis.</u></h3>Visceral leishmaniosis is a widespread and potentially fatal disease of dogs and humans common in the Mediterranean region, the Middle East, and South America. <b style='color:DodgerBlue;'><i>Canine</i></b> <b style='color:DodgerBlue;'><i>leishmaniosis</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>frequently</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:MediumOrchid;'><i>meglumine</i></b> <b style='color:DodgerBlue;'><i>antimoniate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>allopurinol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>meglumine</i></b> <b style='color:DodgerBlue;'><i>antimoniate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>allopurinol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therapy with the currently used drugs often achieves temporary clinical improvement and changes in immunologic parameters with restoration of the ability to mount parasite-specific cell mediated responses and decrease in anti-leishmanial antibody titers. However, treatment usually does not prevent relapse of disease or eliminate parasite carriage. Due to the current lack of an ultimate and effective therapy for canine leishmaniosis, new drugs, delivery systems and treatment strategies are necessary to achieve a consistent parasitological cure in infected dogs.","tokens":[{"text":"Canine","start":0,"end":6,"id":0,"ws":true},{"text":"leishmaniosis","start":7,"end":20,"id":1,"ws":true},{"text":"is","start":21,"end":23,"id":2,"ws":true},{"text":"most","start":24,"end":28,"id":3,"ws":true},{"text":"frequently","start":29,"end":39,"id":4,"ws":true},{"text":"treated","start":40,"end":47,"id":5,"ws":true},{"text":"with","start":48,"end":52,"id":6,"ws":true},{"text":"the","start":53,"end":56,"id":7,"ws":true},{"text":"drugs","start":57,"end":62,"id":8,"ws":true},{"text":"meglumine","start":63,"end":72,"id":9,"ws":true},{"text":"antimoniate","start":73,"end":84,"id":10,"ws":true},{"text":",","start":85,"end":86,"id":11,"ws":true},{"text":"allopurinol","start":87,"end":98,"id":12,"ws":true},{"text":",","start":99,"end":100,"id":13,"ws":true},{"text":"amphotericin","start":101,"end":113,"id":14,"ws":true},{"text":"B","start":114,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"or","start":118,"end":120,"id":17,"ws":true},{"text":"a","start":121,"end":122,"id":18,"ws":true},{"text":"combination","start":123,"end":134,"id":19,"ws":true},{"text":"of","start":135,"end":137,"id":20,"ws":true},{"text":"meglumine","start":138,"end":147,"id":21,"ws":true},{"text":"antimoniate","start":148,"end":159,"id":22,"ws":true},{"text":"and","start":160,"end":163,"id":23,"ws":true},{"text":"allopurinol","start":164,"end":175,"id":24,"ws":true},{"text":".","start":176,"end":177,"id":25,"ws":false}],"spans":[{"start":63,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},{"start":87,"end":98,"token_start":12,"token_end":12,"label":"DRUG"},{"start":101,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},{"start":138,"end":147,"token_start":21,"token_end":21,"label":"DRUG"},{"start":164,"end":175,"token_start":24,"token_end":24,"label":"DRUG"}],"_input_hash":719757590,"_task_hash":27978270,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":21,"child":24,"head_span":{"start":138,"end":147,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":164,"end":175,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":12,"head_span":{"start":73,"end":84,"token_start":10,"token_end":10,"label":null},"child_span":{"start":87,"end":98,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":12,"child":14,"head_span":{"start":87,"end":98,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":101,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"Haloperidol , carbamazepine and levomepromazine were then discontinued .","paragraph":"<h3><u>Pituitary microadenoma treated with antipsychotic drug aripiprazole.</u></h3>Male patient 24 years old with a pituitary microadenoma and mental and behavioural disorders due to multiple drug use and use of other psychoactive substances (cocaine, cannabis and alcohol) were treated with <b style='color:Tomato;'><i>haloperidol</i></b> (dopamine receptor blocker) 10 mg daily. In the last control, the patient presented mammary hypertrophy; laboratory testing and brain magnetic resonance imaging (MRI) was performed, reporting the presence of a pituitary microadenoma syndrome with hormonal alteration (Prolactin levels 28.4 ng/ml). <b style='color:MediumOrchid;'><i>Haloperidol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carbamazepine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>levomepromazine</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>.</i></b> He was started on <b style='color:Tomato;'><i>aripiprazole</i></b> 15 mg po daily for 4 days; the dosage was then increased to 30 mg po daily, with <b style='color:Tomato;'><i>valproic</i></b> Acid 500 mg po tid. After 3 weeks on <b style='color:Tomato;'><i>aripiprazole</i></b>, the mammary hypertrophy that had increased in the patient had resolved. After 10 weeks follow up of prolactin revealed a normal level, at 4.33 ng/ml. Insomnia, aggressiveness, irritability, visual, tactile and auditory hallucinations remained absent after treatment with <b style='color:Tomato;'><i>aripiprazole</i></b> which is not a first line drug in multiple drug use patient with psychosis. We also consider the correlation of drug use in patient with psychosis, <b style='color:Tomato;'><i>haloperidol</i></b> treatment, pituitary microadenoma syndrome, hyperprolactinemia, and dopamine D2- receptor partial agonist <b style='color:Tomato;'><i>aripiprazole</i></b> treatment. This article also summarizes some relevant patents.","tokens":[{"text":"Haloperidol","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"carbamazepine","start":14,"end":27,"id":2,"ws":true},{"text":"and","start":28,"end":31,"id":3,"ws":true},{"text":"levomepromazine","start":32,"end":47,"id":4,"ws":true},{"text":"were","start":48,"end":52,"id":5,"ws":true},{"text":"then","start":53,"end":57,"id":6,"ws":true},{"text":"discontinued","start":58,"end":70,"id":7,"ws":true},{"text":".","start":71,"end":72,"id":8,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":14,"end":27,"token_start":2,"token_end":2,"label":"DRUG"}],"_input_hash":1246555372,"_task_hash":1684855099,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":14,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Recent clinical work has questioned the safety of a combined therapy of oral quinidine and intravenous verapamil , because some patients were reported to react with severe hypotension probably due to drug interactions with vascular alpha-adrenergic receptors .","paragraph":"<h3><u>Additive competitive interaction of verapamil and quinidine at alpha-adrenergic receptors of isolated cardiac guinea pig myocytes and human platelets.</u></h3> <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>work</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>questioned</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>quinidine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>some</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>react</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>hypotension</i></b> <b style='color:DodgerBlue;'><i>probably</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>alpha-adrenergic</i></b> <b style='color:DodgerBlue;'><i>receptors</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In order to obtain further quantitative information on the underlying mechanism, we used the radioligands (3H)-<b style='color:Tomato;'><i>prazosin</i></b> and (3H)-<b style='color:Tomato;'><i>yohimbine</i></b> to perform binding studies on intact cells, with predominantly alpha-1 (isolated myocytes) or alpha-2 subtypes (human platelets) of adrenergic receptors. Our studies confirm that both <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinidine</i></b> possess a distinct alpha-adrenergic receptor blocking activity and do not discriminate between the alpha-1 and alpha-2 subtype (Ki-values were between 0.24-0.28 mumol/l for alpha-1 receptors and 0.49-0.50 mumol/l for alpha-2 receptors). Their interaction was competitive and in the presence of both drugs inhibition of radioligand binding was additive. The alpha-adrenergic blockade by <b style='color:Tomato;'><i>verapamil</i></b> was stereospecific as D-<b style='color:Tomato;'><i>verapamil</i></b> increased the dissociation constant of the radioligand to a much lesser degree than L-<b style='color:Tomato;'><i>verapamil</i></b> (Ki = 1.67 +/- 0.29 mumol/l for D-<b style='color:Tomato;'><i>verapamil</i></b>). The calcium channel blocker <b style='color:Tomato;'><i>nitrendipine</i></b>, a 1,4-dihydropyridine derivative, did not show any competition up to concentrations of 10 mumol/l. Our results thus give evidence that <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>quinidine</i></b> have already at therapeutic blood levels significant alpha-adrenergic blocking activities which may be of clinical interest. In addition our results show that adult cardiac myocytes are very well suited for pharmacological adrenergic interaction studies.","tokens":[{"text":"Recent","start":0,"end":6,"id":0,"ws":true},{"text":"clinical","start":7,"end":15,"id":1,"ws":true},{"text":"work","start":16,"end":20,"id":2,"ws":true},{"text":"has","start":21,"end":24,"id":3,"ws":true},{"text":"questioned","start":25,"end":35,"id":4,"ws":true},{"text":"the","start":36,"end":39,"id":5,"ws":true},{"text":"safety","start":40,"end":46,"id":6,"ws":true},{"text":"of","start":47,"end":49,"id":7,"ws":true},{"text":"a","start":50,"end":51,"id":8,"ws":true},{"text":"combined","start":52,"end":60,"id":9,"ws":true},{"text":"therapy","start":61,"end":68,"id":10,"ws":true},{"text":"of","start":69,"end":71,"id":11,"ws":true},{"text":"oral","start":72,"end":76,"id":12,"ws":true},{"text":"quinidine","start":77,"end":86,"id":13,"ws":true},{"text":"and","start":87,"end":90,"id":14,"ws":true},{"text":"intravenous","start":91,"end":102,"id":15,"ws":true},{"text":"verapamil","start":103,"end":112,"id":16,"ws":true},{"text":",","start":113,"end":114,"id":17,"ws":true},{"text":"because","start":115,"end":122,"id":18,"ws":true},{"text":"some","start":123,"end":127,"id":19,"ws":true},{"text":"patients","start":128,"end":136,"id":20,"ws":true},{"text":"were","start":137,"end":141,"id":21,"ws":true},{"text":"reported","start":142,"end":150,"id":22,"ws":true},{"text":"to","start":151,"end":153,"id":23,"ws":true},{"text":"react","start":154,"end":159,"id":24,"ws":true},{"text":"with","start":160,"end":164,"id":25,"ws":true},{"text":"severe","start":165,"end":171,"id":26,"ws":true},{"text":"hypotension","start":172,"end":183,"id":27,"ws":true},{"text":"probably","start":184,"end":192,"id":28,"ws":true},{"text":"due","start":193,"end":196,"id":29,"ws":true},{"text":"to","start":197,"end":199,"id":30,"ws":true},{"text":"drug","start":200,"end":204,"id":31,"ws":true},{"text":"interactions","start":205,"end":217,"id":32,"ws":true},{"text":"with","start":218,"end":222,"id":33,"ws":true},{"text":"vascular","start":223,"end":231,"id":34,"ws":true},{"text":"alpha-adrenergic","start":232,"end":248,"id":35,"ws":true},{"text":"receptors","start":249,"end":258,"id":36,"ws":true},{"text":".","start":259,"end":260,"id":37,"ws":false}],"spans":[{"start":77,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":103,"end":112,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":1905844453,"_task_hash":-629758087,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":13,"child":16,"head_span":{"start":77,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":103,"end":112,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10","NEG1T0"],"answer":"accept"}
{"text":"The mean duration of total ( i.v . and oral ) therapy was significantly shorter for the azithromycin group than for the cefuroxime group ( 6.2 days vs 10.1 days ) .","paragraph":"<h3><u>Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study.</u></h3>An international, randomized, open-label, comparative study was undertaken in order to assess the efficacy and safety of <b style='color:Tomato;'><i>azithromycin</i></b> and <b style='color:Tomato;'><i>cefuroxime</i></b>, short sequential vs standard sequential therapy, respectively, in the treatment of patients with community-acquired pneumonia (CAP). 180 adult patients were included in the study. 89 patients received <b style='color:Tomato;'><i>azithromycin</i></b> 500 mg intravenously (i.v.) once daily for 1-4 days followed by <b style='color:Tomato;'><i>azithromycin</i></b> 500 mg orally once daily for 3 days. 91 patients received <b style='color:Tomato;'><i>cefuroxime</i></b> 1.5 g i.v. three times daily for 1-4 days followed by <b style='color:Tomato;'><i>cefuroxime</i></b> axetil 500 mg orally twice daily for 7 days. Clinical efficacy was achieved in 67/82 (81.7%) patients treated with <b style='color:Tomato;'><i>azithromycin</i></b>, and in 73/89 (82.0%) patients treated with <b style='color:Tomato;'><i>cefuroxime</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>duration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>shorter</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>azithromycin</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>cefuroxime</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6.2</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>10.1</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Adverse events were recorded in 38.2% of patients treated with <b style='color:Tomato;'><i>azithromycin</i></b>, and in 29.7% of patients treated with <b style='color:Tomato;'><i>cefuroxime</i></b> (p = 0.20). Shorter sequential i.v.-to-oral <b style='color:Tomato;'><i>azithromycin</i></b> therapy of patients with CAP was as effective as standard sequential i.v.-to-oral <b style='color:Tomato;'><i>cefuroxime</i></b> therapy.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"mean","start":4,"end":8,"id":1,"ws":true},{"text":"duration","start":9,"end":17,"id":2,"ws":true},{"text":"of","start":18,"end":20,"id":3,"ws":true},{"text":"total","start":21,"end":26,"id":4,"ws":true},{"text":"(","start":27,"end":28,"id":5,"ws":true},{"text":"i.v","start":29,"end":32,"id":6,"ws":true},{"text":".","start":33,"end":34,"id":7,"ws":true},{"text":"and","start":35,"end":38,"id":8,"ws":true},{"text":"oral","start":39,"end":43,"id":9,"ws":true},{"text":")","start":44,"end":45,"id":10,"ws":true},{"text":"therapy","start":46,"end":53,"id":11,"ws":true},{"text":"was","start":54,"end":57,"id":12,"ws":true},{"text":"significantly","start":58,"end":71,"id":13,"ws":true},{"text":"shorter","start":72,"end":79,"id":14,"ws":true},{"text":"for","start":80,"end":83,"id":15,"ws":true},{"text":"the","start":84,"end":87,"id":16,"ws":true},{"text":"azithromycin","start":88,"end":100,"id":17,"ws":true},{"text":"group","start":101,"end":106,"id":18,"ws":true},{"text":"than","start":107,"end":111,"id":19,"ws":true},{"text":"for","start":112,"end":115,"id":20,"ws":true},{"text":"the","start":116,"end":119,"id":21,"ws":true},{"text":"cefuroxime","start":120,"end":130,"id":22,"ws":true},{"text":"group","start":131,"end":136,"id":23,"ws":true},{"text":"(","start":137,"end":138,"id":24,"ws":true},{"text":"6.2","start":139,"end":142,"id":25,"ws":true},{"text":"days","start":143,"end":147,"id":26,"ws":true},{"text":"vs","start":148,"end":150,"id":27,"ws":true},{"text":"10.1","start":151,"end":155,"id":28,"ws":true},{"text":"days","start":156,"end":160,"id":29,"ws":true},{"text":")","start":161,"end":162,"id":30,"ws":true},{"text":".","start":163,"end":164,"id":31,"ws":false}],"spans":[{"start":88,"end":100,"token_start":17,"token_end":17,"label":"DRUG"},{"start":120,"end":130,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1826363337,"_task_hash":1699356868,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"To increase the dose-intensity of two drugs in metastatic breast cancer , we tested the feasibility , in phase I studies , of two schedules of epirubicin ( E ) and cyclophosphamide ( C ) - sequential ( E-- > C ) and alternating ( E/C ) - with respect to the standard combination ( EC ) .","paragraph":"<h3><u>The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dose-intensity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>schedules</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>E</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>E--</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>E/C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>respect</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Drugs were given at three planned-dose levels, plus either G-CSF or GM-CSF. Patients with metastatic (30), inoperable stage IIIb (2) or inflammatory (7) breast cancer were treated. The doses of EC, given every 21 days (4 cycles), were 75/1500, 82.5/2250, 90/3000 mg/m2. In the E/C schedule, <b style='color:Tomato;'><i>epirubicin</i></b> was given at cycles 1, 3 and 5, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> at cycles 2, 4 and 6. In the E--> C schedule, three cycles of <b style='color:Tomato;'><i>epirubicin</i></b> then three cycles of <b style='color:Tomato;'><i>cyclophosphamide</i></b> were administered. In both experimental schedules, drugs were given every 14 days for 6 cycles at doses of 100, 110, 120 mg/m2 (E) and 2000, 3000, 4000 mg/m2 (C). The average relative dose-intensity was 1.2-fold and 2-fold greater with E/C and E--> C, respectively, than with EC. The third level dose was feasible with all schedules. Grade 4 leucopenia occurred in 77% of patients. Thrombocytopenia was absent in 6 cases and grade 4 in 12 (30.8%). Eighty-one percent of patients on experimental schedules required red blood cell support versus 44.4% of patients on EC. At the third level, platelet transfusions were more frequent among patients treated with EC (27. 8%). Non-haematological toxicity was mild: about 20% of patients experienced grade 3 vomiting, irrespective of schedule. Only 2 patients had grade 3 mucositis; no patient developed heart failure. Fever (61% of patients) and bone pain (55.5% of patients) were relevant in the GM-CSF treated groups and 12 patients shifted to G-CSF. The overall response rate was 84.6%: 5/39 (12.8%) complete response and 28/39 (71.8%) partial response. At 30/9/98, median survival was 29.5 months, with no difference between patients with metastatic and stage IIIb/inflammatory breast cancer. Median follow-up of surviving patients was 62 months (range 17-83). The 5-year estimated survival was 19% (95% confidence intervals = 7-31%). Rapidly alternating or sequential cycles of <b style='color:Tomato;'><i>epirubicin</i></b> and <b style='color:Tomato;'><i>cyclophosphamide</i></b> with CSF support is a feasible strategy that allows a higher increase of dose-intensity of the single drugs. Hospitalization and anemia were more frequent with the experimental schedules, and thrombocytopenia with the standard schedule. Overall, this intensified therapy was very active.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"increase","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"dose-intensity","start":16,"end":30,"id":3,"ws":true},{"text":"of","start":31,"end":33,"id":4,"ws":true},{"text":"two","start":34,"end":37,"id":5,"ws":true},{"text":"drugs","start":38,"end":43,"id":6,"ws":true},{"text":"in","start":44,"end":46,"id":7,"ws":true},{"text":"metastatic","start":47,"end":57,"id":8,"ws":true},{"text":"breast","start":58,"end":64,"id":9,"ws":true},{"text":"cancer","start":65,"end":71,"id":10,"ws":true},{"text":",","start":72,"end":73,"id":11,"ws":true},{"text":"we","start":74,"end":76,"id":12,"ws":true},{"text":"tested","start":77,"end":83,"id":13,"ws":true},{"text":"the","start":84,"end":87,"id":14,"ws":true},{"text":"feasibility","start":88,"end":99,"id":15,"ws":true},{"text":",","start":100,"end":101,"id":16,"ws":true},{"text":"in","start":102,"end":104,"id":17,"ws":true},{"text":"phase","start":105,"end":110,"id":18,"ws":true},{"text":"I","start":111,"end":112,"id":19,"ws":true},{"text":"studies","start":113,"end":120,"id":20,"ws":true},{"text":",","start":121,"end":122,"id":21,"ws":true},{"text":"of","start":123,"end":125,"id":22,"ws":true},{"text":"two","start":126,"end":129,"id":23,"ws":true},{"text":"schedules","start":130,"end":139,"id":24,"ws":true},{"text":"of","start":140,"end":142,"id":25,"ws":true},{"text":"epirubicin","start":143,"end":153,"id":26,"ws":true},{"text":"(","start":154,"end":155,"id":27,"ws":true},{"text":"E","start":156,"end":157,"id":28,"ws":true},{"text":")","start":158,"end":159,"id":29,"ws":true},{"text":"and","start":160,"end":163,"id":30,"ws":true},{"text":"cyclophosphamide","start":164,"end":180,"id":31,"ws":true},{"text":"(","start":181,"end":182,"id":32,"ws":true},{"text":"C","start":183,"end":184,"id":33,"ws":true},{"text":")","start":185,"end":186,"id":34,"ws":true},{"text":"-","start":187,"end":188,"id":35,"ws":true},{"text":"sequential","start":189,"end":199,"id":36,"ws":true},{"text":"(","start":200,"end":201,"id":37,"ws":true},{"text":"E--","start":202,"end":205,"id":38,"ws":true},{"text":">","start":206,"end":207,"id":39,"ws":true},{"text":"C","start":208,"end":209,"id":40,"ws":true},{"text":")","start":210,"end":211,"id":41,"ws":true},{"text":"and","start":212,"end":215,"id":42,"ws":true},{"text":"alternating","start":216,"end":227,"id":43,"ws":true},{"text":"(","start":228,"end":229,"id":44,"ws":true},{"text":"E/C","start":230,"end":233,"id":45,"ws":true},{"text":")","start":234,"end":235,"id":46,"ws":true},{"text":"-","start":236,"end":237,"id":47,"ws":true},{"text":"with","start":238,"end":242,"id":48,"ws":true},{"text":"respect","start":243,"end":250,"id":49,"ws":true},{"text":"to","start":251,"end":253,"id":50,"ws":true},{"text":"the","start":254,"end":257,"id":51,"ws":true},{"text":"standard","start":258,"end":266,"id":52,"ws":true},{"text":"combination","start":267,"end":278,"id":53,"ws":true},{"text":"(","start":279,"end":280,"id":54,"ws":true},{"text":"EC","start":281,"end":283,"id":55,"ws":true},{"text":")","start":284,"end":285,"id":56,"ws":true},{"text":".","start":286,"end":287,"id":57,"ws":false}],"spans":[{"start":143,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},{"start":164,"end":180,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":-1267531737,"_task_hash":307427410,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":26,"child":31,"head_span":{"start":143,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":164,"end":180,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"On February 3 , 2015 , the FDA granted accelerated approval to palbociclib ( IBRANCE , Pfizer Inc. ) , an inhibitor of cyclin-dependent kinases 4 and 6 ( CDK4 and CDK6 ) , for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive , HER2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease .","paragraph":"<h3><u>FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.</u></h3> <b style='color:DodgerBlue;'><i>On</i></b> <b style='color:DodgerBlue;'><i>February</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2015</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>granted</i></b> <b style='color:DodgerBlue;'><i>accelerated</i></b> <b style='color:DodgerBlue;'><i>approval</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>palbociclib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IBRANCE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Pfizer</i></b> <b style='color:DodgerBlue;'><i>Inc.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cyclin-dependent</i></b> <b style='color:DodgerBlue;'><i>kinases</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CDK4</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>CDK6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>estrogen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>(ER)-positive</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>HER2-negative</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>endocrine-based</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The approval is based on a randomized, multicenter, open-label phase I/II trial (PALOMA-1) in 165 patients randomized to <b style='color:Tomato;'><i>palbociclib</i></b> (125 mg orally daily for 21 consecutive days, followed by 7 days off treatment) plus <b style='color:Tomato;'><i>letrozole</i></b> (2.5 mg orally daily) or <b style='color:Tomato;'><i>letrozole</i></b> alone. The phase II portion of the trial was divided into two cohorts: cohort 1 enrolled 66 biomarker-unselected patients and cohort 2 enrolled 99 biomarker-positive patients. The major efficacy outcome measure was investigator-assessed progression-free survival (PFS). A large magnitude of improvement in PFS was observed in patients receiving <b style='color:Tomato;'><i>palbociclib</i></b> plus <b style='color:Tomato;'><i>letrozole</i></b> compared with patients receiving <b style='color:Tomato;'><i>letrozole</i></b> alone (HR, 0.488; 95% confidence interval, 0.319-0.748). Multiple sensitivity analyses were supportive of clinical benefit. The most common adverse reaction in patients receiving <b style='color:Tomato;'><i>palbociclib</i></b> plus <b style='color:Tomato;'><i>letrozole</i></b> was neutropenia. This article summarizes the FDA thought process and data supporting accelerated approval based on PALOMA-1 that may be contingent upon verification and description of clinical benefit in the ongoing and fully accrued confirmatory trial PALOMA-2.","tokens":[{"text":"On","start":0,"end":2,"id":0,"ws":true},{"text":"February","start":3,"end":11,"id":1,"ws":true},{"text":"3","start":12,"end":13,"id":2,"ws":true},{"text":",","start":14,"end":15,"id":3,"ws":true},{"text":"2015","start":16,"end":20,"id":4,"ws":true},{"text":",","start":21,"end":22,"id":5,"ws":true},{"text":"the","start":23,"end":26,"id":6,"ws":true},{"text":"FDA","start":27,"end":30,"id":7,"ws":true},{"text":"granted","start":31,"end":38,"id":8,"ws":true},{"text":"accelerated","start":39,"end":50,"id":9,"ws":true},{"text":"approval","start":51,"end":59,"id":10,"ws":true},{"text":"to","start":60,"end":62,"id":11,"ws":true},{"text":"palbociclib","start":63,"end":74,"id":12,"ws":true},{"text":"(","start":75,"end":76,"id":13,"ws":true},{"text":"IBRANCE","start":77,"end":84,"id":14,"ws":true},{"text":",","start":85,"end":86,"id":15,"ws":true},{"text":"Pfizer","start":87,"end":93,"id":16,"ws":true},{"text":"Inc.","start":94,"end":98,"id":17,"ws":true},{"text":")","start":99,"end":100,"id":18,"ws":true},{"text":",","start":101,"end":102,"id":19,"ws":true},{"text":"an","start":103,"end":105,"id":20,"ws":true},{"text":"inhibitor","start":106,"end":115,"id":21,"ws":true},{"text":"of","start":116,"end":118,"id":22,"ws":true},{"text":"cyclin-dependent","start":119,"end":135,"id":23,"ws":true},{"text":"kinases","start":136,"end":143,"id":24,"ws":true},{"text":"4","start":144,"end":145,"id":25,"ws":true},{"text":"and","start":146,"end":149,"id":26,"ws":true},{"text":"6","start":150,"end":151,"id":27,"ws":true},{"text":"(","start":152,"end":153,"id":28,"ws":true},{"text":"CDK4","start":154,"end":158,"id":29,"ws":true},{"text":"and","start":159,"end":162,"id":30,"ws":true},{"text":"CDK6","start":163,"end":167,"id":31,"ws":true},{"text":")","start":168,"end":169,"id":32,"ws":true},{"text":",","start":170,"end":171,"id":33,"ws":true},{"text":"for","start":172,"end":175,"id":34,"ws":true},{"text":"use","start":176,"end":179,"id":35,"ws":true},{"text":"in","start":180,"end":182,"id":36,"ws":true},{"text":"combination","start":183,"end":194,"id":37,"ws":true},{"text":"with","start":195,"end":199,"id":38,"ws":true},{"text":"letrozole","start":200,"end":209,"id":39,"ws":true},{"text":"for","start":210,"end":213,"id":40,"ws":true},{"text":"the","start":214,"end":217,"id":41,"ws":true},{"text":"treatment","start":218,"end":227,"id":42,"ws":true},{"text":"of","start":228,"end":230,"id":43,"ws":true},{"text":"postmenopausal","start":231,"end":245,"id":44,"ws":true},{"text":"women","start":246,"end":251,"id":45,"ws":true},{"text":"with","start":252,"end":256,"id":46,"ws":true},{"text":"estrogen","start":257,"end":265,"id":47,"ws":true},{"text":"receptor","start":266,"end":274,"id":48,"ws":true},{"text":"(ER)-positive","start":275,"end":288,"id":49,"ws":true},{"text":",","start":289,"end":290,"id":50,"ws":true},{"text":"HER2-negative","start":291,"end":304,"id":51,"ws":true},{"text":"advanced","start":305,"end":313,"id":52,"ws":true},{"text":"breast","start":314,"end":320,"id":53,"ws":true},{"text":"cancer","start":321,"end":327,"id":54,"ws":true},{"text":"as","start":328,"end":330,"id":55,"ws":true},{"text":"initial","start":331,"end":338,"id":56,"ws":true},{"text":"endocrine-based","start":339,"end":354,"id":57,"ws":true},{"text":"therapy","start":355,"end":362,"id":58,"ws":true},{"text":"for","start":363,"end":366,"id":59,"ws":true},{"text":"their","start":367,"end":372,"id":60,"ws":true},{"text":"metastatic","start":373,"end":383,"id":61,"ws":true},{"text":"disease","start":384,"end":391,"id":62,"ws":true},{"text":".","start":392,"end":393,"id":63,"ws":false}],"spans":[{"start":63,"end":74,"token_start":12,"token_end":12,"label":"DRUG"},{"start":200,"end":209,"token_start":39,"token_end":39,"label":"DRUG"}],"_input_hash":1382533401,"_task_hash":1544046941,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":12,"child":39,"head_span":{"start":63,"end":74,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":200,"end":209,"token_start":39,"token_end":39,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"a combination treatment : estramustine phosphate , cyproterone acetate or estrogens plus bromocriptine .","paragraph":"<h3><u>[Current aspects of hormonal therapy in prostate cancer].</u></h3>The following endocrine treatment modalities have been used in advanced prostatic carcinoma: 1. orchiectomy plus estrogens; 2. primary orchiectomy with delayed estrogen employment; 3. initial estrogen therapy with delayed orchiectomy; 4. initial <b style='color:Tomato;'><i>cyproterone</i></b> acetate or <b style='color:Tomato;'><i>medroxyprogesterone</i></b> acetate; 5. <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>phosphate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyproterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>estrogens</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>bromocriptine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The application of phase-III studies permits the subsequent conclusions: Simultaneous orchiectomy is to no advantage (exception: urinary stasis). <b style='color:Tomato;'><i>cyproterone</i></b> acetate does neither yield better nor worse results regarding survival than estrogen alone, but has fewer side effects. Estrogens and <b style='color:Tomato;'><i>cyproterone</i></b> acetate produce a rise of serum prolactin justifying the use of <b style='color:Tomato;'><i>bromocriptine</i></b> (or lisuride). <b style='color:Tomato;'><i>estramustine</i></b> phosphate should be reserved for relapsing prostatic cancer.","tokens":[{"text":"a","start":0,"end":1,"id":0,"ws":true},{"text":"combination","start":2,"end":13,"id":1,"ws":true},{"text":"treatment","start":14,"end":23,"id":2,"ws":true},{"text":":","start":24,"end":25,"id":3,"ws":true},{"text":"estramustine","start":26,"end":38,"id":4,"ws":true},{"text":"phosphate","start":39,"end":48,"id":5,"ws":true},{"text":",","start":49,"end":50,"id":6,"ws":true},{"text":"cyproterone","start":51,"end":62,"id":7,"ws":true},{"text":"acetate","start":63,"end":70,"id":8,"ws":true},{"text":"or","start":71,"end":73,"id":9,"ws":true},{"text":"estrogens","start":74,"end":83,"id":10,"ws":true},{"text":"plus","start":84,"end":88,"id":11,"ws":true},{"text":"bromocriptine","start":89,"end":102,"id":12,"ws":true},{"text":".","start":103,"end":104,"id":13,"ws":false}],"spans":[{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":51,"end":62,"token_start":7,"token_end":7,"label":"DRUG"},{"start":89,"end":102,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-1997070014,"_task_hash":-992804212,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":4,"child":7,"head_span":{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":51,"end":62,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":12,"head_span":{"start":74,"end":83,"token_start":10,"token_end":10,"label":null},"child_span":{"start":89,"end":102,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS1T0","POS21","POS2T0"],"answer":"accept"}
{"text":"Hormone induced elevations in temperature and possibly other unidentified factors during thyroid crisis may facilitate the triggering of MH following halothane and succinylcholine challenge .","paragraph":"<h3><u>Differential diagnosis of thyroid crisis and malignant hyperthermia in an anesthetized porcine model.</u></h3>The intra-operative differential diagnosis between thyroid crisis and malignant hyperthermia can be difficult. Also stress alone can trigger MH. The purposes of this study were: 1) to investigate the metabolic and hemodynamic differences between thyroid crisis and MH, 2) determine how thyroid crisis affects the development of MH, and 3) determine if the stress of thyroid crisis can trigger MH in susceptible individuals. We studied MH susceptible and normal swine. Two groups of animals (MH susceptible and normal) were induced into thyroid crisis (critical core hyperthermia, sustained tachycardia and increase in oxygen consumption) by pretreatment with intraperitoneal triiodothyronine (T3) followed by large hourly intravenous injections of T3. Two similar groups were given intravenous T3 but no pretreatment. These animals did not develop thyroid crisis and served as controls. Thyroid crisis did not result in metabolic changes or rigidity characteristic of an acute episode of MH. When the animals were subsequently challenged with MH triggering agents (<b style='color:Tomato;'><i>halothane</i></b> plus <b style='color:Tomato;'><i>succinylcholine</i></b>) dramatic manifestations of fulminant MH episodes (acute serious elevation in exhaled carbon dioxide, arterial CO2, rigidity and acidemia) were noted only in the MH susceptible animals. Although thyroid crisis did not trigger MH in the susceptible animals it did decrease the time to trigger MH (14.1 +/- 7.2 minutes versus 47.2 +/- 17.7 minutes, p < 0.01) in susceptible animals. <b style='color:DodgerBlue;'><i>Hormone</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>elevations</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>temperature</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>possibly</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>unidentified</i></b> <b style='color:DodgerBlue;'><i>factors</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>thyroid</i></b> <b style='color:DodgerBlue;'><i>crisis</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>facilitate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>triggering</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>MH</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:MediumOrchid;'><i>halothane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>succinylcholine</i></b> <b style='color:DodgerBlue;'><i>challenge</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Hormone","start":0,"end":7,"id":0,"ws":true},{"text":"induced","start":8,"end":15,"id":1,"ws":true},{"text":"elevations","start":16,"end":26,"id":2,"ws":true},{"text":"in","start":27,"end":29,"id":3,"ws":true},{"text":"temperature","start":30,"end":41,"id":4,"ws":true},{"text":"and","start":42,"end":45,"id":5,"ws":true},{"text":"possibly","start":46,"end":54,"id":6,"ws":true},{"text":"other","start":55,"end":60,"id":7,"ws":true},{"text":"unidentified","start":61,"end":73,"id":8,"ws":true},{"text":"factors","start":74,"end":81,"id":9,"ws":true},{"text":"during","start":82,"end":88,"id":10,"ws":true},{"text":"thyroid","start":89,"end":96,"id":11,"ws":true},{"text":"crisis","start":97,"end":103,"id":12,"ws":true},{"text":"may","start":104,"end":107,"id":13,"ws":true},{"text":"facilitate","start":108,"end":118,"id":14,"ws":true},{"text":"the","start":119,"end":122,"id":15,"ws":true},{"text":"triggering","start":123,"end":133,"id":16,"ws":true},{"text":"of","start":134,"end":136,"id":17,"ws":true},{"text":"MH","start":137,"end":139,"id":18,"ws":true},{"text":"following","start":140,"end":149,"id":19,"ws":true},{"text":"halothane","start":150,"end":159,"id":20,"ws":true},{"text":"and","start":160,"end":163,"id":21,"ws":true},{"text":"succinylcholine","start":164,"end":179,"id":22,"ws":true},{"text":"challenge","start":180,"end":189,"id":23,"ws":true},{"text":".","start":190,"end":191,"id":24,"ws":false}],"spans":[{"start":150,"end":159,"token_start":20,"token_end":20,"label":"DRUG"},{"start":164,"end":179,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":1558725029,"_task_hash":-657697543,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":150,"end":159,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":164,"end":179,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Mitomycin C plus vinblastine is an effective and well-tolerated regimen for anthracycline resistant cancer .","paragraph":"<h3><u>Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: a phase II study.</u></h3>The purpose of this phase II study was to evaluate the clinical efficacy of <b style='color:Tomato;'><i>mitomycin</i></b> C and <b style='color:Tomato;'><i>vinblastine</i></b> in patients with anthracycline-resistant metastatic breast cancer. This single-center, non-randomized trial enrolled 39 patients. Eligible patients must have received at least three chemotherapy regimens with <b style='color:Tomato;'><i>epirubicin</i></b> or CAF and had treatment failure while on chemotherapy or within 6 months of completing therapy. Treatment consisted of <b style='color:Tomato;'><i>mitomycin</i></b> C at a starting dose of 8 mg/m2 on day 1 and <b style='color:Tomato;'><i>vinblastine</i></b> (8 mg/m2, days 1 and 28). The regimen was repeated every 6 weeks with a 20% dose escalation of both drugs after the first cycle in the absence of grade III hematologic or other toxicity. On an intent-to-treat basis, 38 patients were eligible for assessment; 9 (23.7%, 95% confidence interval 1.92-2.45%) achieved a partial response and 13 (34.2%) had stable disease. The median time to disease progression was 6.21+/-4.26 months (range, 1-15; 95% confidence interval, 4.81-7.61), and the median survival was 10.76+/-7.6 (range, 1-29; 95% confidence interval 8.0-13.1%). Responsive patients had a significantly better survival than those with stable and progressive disease. Treatment was well tolerated. Anemia and neutropenia (grade I-III) developed in 28.9% and 26.3% of the patients, respectively. One patient with grade III granulocytopenia developed fever and infection that required hospitalization. Moderate neurotoxicity, myalgia, constipation, diarrhea and alopecia were observed. No toxic death occurred. <b style='color:MediumOrchid;'><i>Mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>well-tolerated</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>anthracycline</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Mitomycin","start":0,"end":9,"id":0,"ws":true},{"text":"C","start":10,"end":11,"id":1,"ws":true},{"text":"plus","start":12,"end":16,"id":2,"ws":true},{"text":"vinblastine","start":17,"end":28,"id":3,"ws":true},{"text":"is","start":29,"end":31,"id":4,"ws":true},{"text":"an","start":32,"end":34,"id":5,"ws":true},{"text":"effective","start":35,"end":44,"id":6,"ws":true},{"text":"and","start":45,"end":48,"id":7,"ws":true},{"text":"well-tolerated","start":49,"end":63,"id":8,"ws":true},{"text":"regimen","start":64,"end":71,"id":9,"ws":true},{"text":"for","start":72,"end":75,"id":10,"ws":true},{"text":"anthracycline","start":76,"end":89,"id":11,"ws":true},{"text":"resistant","start":90,"end":99,"id":12,"ws":true},{"text":"cancer","start":100,"end":106,"id":13,"ws":true},{"text":".","start":107,"end":108,"id":14,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":17,"end":28,"token_start":3,"token_end":3,"label":"DRUG"}],"_input_hash":-1900533088,"_task_hash":-759012975,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":0,"child":3,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":17,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"An angiotensin 2 type 1 receptor blocker , olmesartan , and a calcium channel blocker , azelnidipine , possess not only an antihypertensive effect but also an antioxidative effect and other beneficial effects .","paragraph":"<h3><u>Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.</u></h3> <b style='color:DodgerBlue;'><i>An</i></b> <b style='color:DodgerBlue;'><i>angiotensin</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>type</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>olmesartan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>calcium</i></b> <b style='color:DodgerBlue;'><i>channel</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>azelnidipine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>possess</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>antihypertensive</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>antioxidative</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the present study, we examined the efficacy of <b style='color:Tomato;'><i>olmesartan</i></b> and <b style='color:Tomato;'><i>azelnidipine</i></b> monotherapy (2 mg/kg or 10 mg/kg each) and their combination therapy (1 mg/kg each) on stroke-prone spontaneously hypertensive rats (SHR-SP) in relation to oxidative stress, inflammation, and the neurovascular unit. In comparison with the vehicle group, body weight, regional cerebral blood flow, and motor function were preserved, whereas systolic blood pressure and diastolic blood pressure decreased in the five drug-treatment groups. Spontaneous infarct volume decreased with the low-dose combination of <b style='color:Tomato;'><i>olmesartan</i></b> plus <b style='color:Tomato;'><i>azelnidipine</i></b> and with the high-dose <b style='color:Tomato;'><i>olmesartan</i></b>, with a further decrease in the high-dose <b style='color:Tomato;'><i>azelnidipine</i></b> group. In addition, these drugs dose-dependently reduced oxidative stresses, proinflammatory molecules, and well-preserved components of the neurovascular unit. The low-dose combination of <b style='color:Tomato;'><i>olmesartan</i></b> plus <b style='color:Tomato;'><i>azelnidipine</i></b> showed a better effect than the low-dose <b style='color:Tomato;'><i>olmesartan</i></b> or <b style='color:Tomato;'><i>azelnidipine</i></b> monotherapy. The present study shows that the low-dose combination of <b style='color:Tomato;'><i>olmesartan</i></b> plus <b style='color:Tomato;'><i>azelnidipine</i></b> demonstrates a greater synergistic benefit than monotherapy with a low-dose of <b style='color:Tomato;'><i>olmesartan</i></b> or <b style='color:Tomato;'><i>azelnidipine</i></b> in SHR-SP for preventing spontaneous infarct volume, reducing oxidative stresses and proinflammatory molecules, and imparting neurovascular protection. In addition, a high-dose of <b style='color:Tomato;'><i>olmesartan</i></b> showed a greater benefit without the lowering of blood pressure, probably because of the antioxidative and anti-inflammatory effects. A high dose of <b style='color:Tomato;'><i>azelnidipine</i></b> showed the best benefit, probably because of the two effects mentioned above related to the lowering of blood pressure.","tokens":[{"text":"An","start":0,"end":2,"id":0,"ws":true},{"text":"angiotensin","start":3,"end":14,"id":1,"ws":true},{"text":"2","start":15,"end":16,"id":2,"ws":true},{"text":"type","start":17,"end":21,"id":3,"ws":true},{"text":"1","start":22,"end":23,"id":4,"ws":true},{"text":"receptor","start":24,"end":32,"id":5,"ws":true},{"text":"blocker","start":33,"end":40,"id":6,"ws":true},{"text":",","start":41,"end":42,"id":7,"ws":true},{"text":"olmesartan","start":43,"end":53,"id":8,"ws":true},{"text":",","start":54,"end":55,"id":9,"ws":true},{"text":"and","start":56,"end":59,"id":10,"ws":true},{"text":"a","start":60,"end":61,"id":11,"ws":true},{"text":"calcium","start":62,"end":69,"id":12,"ws":true},{"text":"channel","start":70,"end":77,"id":13,"ws":true},{"text":"blocker","start":78,"end":85,"id":14,"ws":true},{"text":",","start":86,"end":87,"id":15,"ws":true},{"text":"azelnidipine","start":88,"end":100,"id":16,"ws":true},{"text":",","start":101,"end":102,"id":17,"ws":true},{"text":"possess","start":103,"end":110,"id":18,"ws":true},{"text":"not","start":111,"end":114,"id":19,"ws":true},{"text":"only","start":115,"end":119,"id":20,"ws":true},{"text":"an","start":120,"end":122,"id":21,"ws":true},{"text":"antihypertensive","start":123,"end":139,"id":22,"ws":true},{"text":"effect","start":140,"end":146,"id":23,"ws":true},{"text":"but","start":147,"end":150,"id":24,"ws":true},{"text":"also","start":151,"end":155,"id":25,"ws":true},{"text":"an","start":156,"end":158,"id":26,"ws":true},{"text":"antioxidative","start":159,"end":172,"id":27,"ws":true},{"text":"effect","start":173,"end":179,"id":28,"ws":true},{"text":"and","start":180,"end":183,"id":29,"ws":true},{"text":"other","start":184,"end":189,"id":30,"ws":true},{"text":"beneficial","start":190,"end":200,"id":31,"ws":true},{"text":"effects","start":201,"end":208,"id":32,"ws":true},{"text":".","start":209,"end":210,"id":33,"ws":false}],"spans":[{"start":43,"end":53,"token_start":8,"token_end":8,"label":"DRUG"},{"start":88,"end":100,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-1221260802,"_task_hash":1465535390,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":8,"child":16,"head_span":{"start":43,"end":53,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF ( P ) , which included methotrexate , 60 mg/m2 , and 5-fluorouracil , 700 mg/m2 intravenously on the first and eighth days , in addition to cyclophosphamide , 100 mg/m2 , and prednisone , 40 mg/m2 , by mouth daily from the first to the fourteenth day of a 28-day cycle .","paragraph":"<h3><u>Combination chemotherapy for advanced breast cancer: response and effect on survival.</u></h3> <b style='color:DodgerBlue;'><i>Forty</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>previous</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>program</i></b> <b style='color:DodgerBlue;'><i>CMF</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>700</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>eighth</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>mouth</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>fourteenth</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>28-day</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Only 2 of 25 patients responded to hormonal therapy or endocrine ablation. Twenty-seven of the 40 patients (68%) had a complete response (8 patients) or partial response (19 patients). Lung, soft tissue, and nodal metastases were the most responsive sites. The median survival of 18 months for the responding group. The nonresponders had a median survival of 4 months. The toxicity was primarily hematologic and was especially severe in patients with functional liver impairment due to metastatic disease.","tokens":[{"text":"Forty","start":0,"end":5,"id":0,"ws":true},{"text":"patients","start":6,"end":14,"id":1,"ws":true},{"text":"with","start":15,"end":19,"id":2,"ws":true},{"text":"metastatic","start":20,"end":30,"id":3,"ws":true},{"text":"breast","start":31,"end":37,"id":4,"ws":true},{"text":"cancer","start":38,"end":44,"id":5,"ws":true},{"text":"who","start":45,"end":48,"id":6,"ws":true},{"text":"had","start":49,"end":52,"id":7,"ws":true},{"text":"received","start":53,"end":61,"id":8,"ws":true},{"text":"no","start":62,"end":64,"id":9,"ws":true},{"text":"previous","start":65,"end":73,"id":10,"ws":true},{"text":"cytotoxic","start":74,"end":83,"id":11,"ws":true},{"text":"therapy","start":84,"end":91,"id":12,"ws":true},{"text":"were","start":92,"end":96,"id":13,"ws":true},{"text":"treated","start":97,"end":104,"id":14,"ws":true},{"text":"with","start":105,"end":109,"id":15,"ws":true},{"text":"a","start":110,"end":111,"id":16,"ws":true},{"text":"combination","start":112,"end":123,"id":17,"ws":true},{"text":"chemotherapy","start":124,"end":136,"id":18,"ws":true},{"text":"program","start":137,"end":144,"id":19,"ws":true},{"text":"CMF","start":145,"end":148,"id":20,"ws":true},{"text":"(","start":149,"end":150,"id":21,"ws":true},{"text":"P","start":151,"end":152,"id":22,"ws":true},{"text":")","start":153,"end":154,"id":23,"ws":true},{"text":",","start":155,"end":156,"id":24,"ws":true},{"text":"which","start":157,"end":162,"id":25,"ws":true},{"text":"included","start":163,"end":171,"id":26,"ws":true},{"text":"methotrexate","start":172,"end":184,"id":27,"ws":true},{"text":",","start":185,"end":186,"id":28,"ws":true},{"text":"60","start":187,"end":189,"id":29,"ws":true},{"text":"mg/m2","start":190,"end":195,"id":30,"ws":true},{"text":",","start":196,"end":197,"id":31,"ws":true},{"text":"and","start":198,"end":201,"id":32,"ws":true},{"text":"5-fluorouracil","start":202,"end":216,"id":33,"ws":true},{"text":",","start":217,"end":218,"id":34,"ws":true},{"text":"700","start":219,"end":222,"id":35,"ws":true},{"text":"mg/m2","start":223,"end":228,"id":36,"ws":true},{"text":"intravenously","start":229,"end":242,"id":37,"ws":true},{"text":"on","start":243,"end":245,"id":38,"ws":true},{"text":"the","start":246,"end":249,"id":39,"ws":true},{"text":"first","start":250,"end":255,"id":40,"ws":true},{"text":"and","start":256,"end":259,"id":41,"ws":true},{"text":"eighth","start":260,"end":266,"id":42,"ws":true},{"text":"days","start":267,"end":271,"id":43,"ws":true},{"text":",","start":272,"end":273,"id":44,"ws":true},{"text":"in","start":274,"end":276,"id":45,"ws":true},{"text":"addition","start":277,"end":285,"id":46,"ws":true},{"text":"to","start":286,"end":288,"id":47,"ws":true},{"text":"cyclophosphamide","start":289,"end":305,"id":48,"ws":true},{"text":",","start":306,"end":307,"id":49,"ws":true},{"text":"100","start":308,"end":311,"id":50,"ws":true},{"text":"mg/m2","start":312,"end":317,"id":51,"ws":true},{"text":",","start":318,"end":319,"id":52,"ws":true},{"text":"and","start":320,"end":323,"id":53,"ws":true},{"text":"prednisone","start":324,"end":334,"id":54,"ws":true},{"text":",","start":335,"end":336,"id":55,"ws":true},{"text":"40","start":337,"end":339,"id":56,"ws":true},{"text":"mg/m2","start":340,"end":345,"id":57,"ws":true},{"text":",","start":346,"end":347,"id":58,"ws":true},{"text":"by","start":348,"end":350,"id":59,"ws":true},{"text":"mouth","start":351,"end":356,"id":60,"ws":true},{"text":"daily","start":357,"end":362,"id":61,"ws":true},{"text":"from","start":363,"end":367,"id":62,"ws":true},{"text":"the","start":368,"end":371,"id":63,"ws":true},{"text":"first","start":372,"end":377,"id":64,"ws":true},{"text":"to","start":378,"end":380,"id":65,"ws":true},{"text":"the","start":381,"end":384,"id":66,"ws":true},{"text":"fourteenth","start":385,"end":395,"id":67,"ws":true},{"text":"day","start":396,"end":399,"id":68,"ws":true},{"text":"of","start":400,"end":402,"id":69,"ws":true},{"text":"a","start":403,"end":404,"id":70,"ws":true},{"text":"28-day","start":405,"end":411,"id":71,"ws":true},{"text":"cycle","start":412,"end":417,"id":72,"ws":true},{"text":".","start":418,"end":419,"id":73,"ws":false}],"spans":[{"start":172,"end":184,"token_start":27,"token_end":27,"label":"DRUG"},{"start":289,"end":305,"token_start":48,"token_end":48,"label":"DRUG"},{"start":324,"end":334,"token_start":54,"token_end":54,"label":"DRUG"}],"_input_hash":408160112,"_task_hash":-1051001907,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":27,"child":33,"head_span":{"start":172,"end":184,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":202,"end":216,"token_start":33,"token_end":33,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":33,"child":48,"head_span":{"start":202,"end":216,"token_start":33,"token_end":33,"label":null},"child_span":{"start":289,"end":305,"token_start":48,"token_end":48,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":48,"child":54,"head_span":{"start":289,"end":305,"token_start":48,"token_end":48,"label":"DRUG"},"child_span":{"start":324,"end":334,"token_start":54,"token_end":54,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Isoniazid , a first-line antibiotic used for the treatment of tuberculosis , is a prodrug that requires activation by the Mycobacterium tuberculosis enzyme KatG. The KatG(S315 T ) mutation causes isoniazid resistance while the KatG(R463L ) variation is thought to be a polymorphism .","paragraph":"<h3><u>Purification and characterization of Mycobacterium tuberculosis KatG, KatG(S315T), and Mycobacterium bovis KatG(R463L).</u></h3> <b style='color:MediumOrchid;'><i>Isoniazid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>prodrug</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>requires</i></b> <b style='color:DodgerBlue;'><i>activation</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Mycobacterium</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>enzyme</i></b> <b style='color:DodgerBlue;'><i>KatG.</i></b> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>KatG(S315</i></b> <b style='color:DodgerBlue;'><i>T</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>mutation</i></b> <b style='color:DodgerBlue;'><i>causes</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>KatG(R463L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>variation</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>thought</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>polymorphism</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Much of the work to date focused on <b style='color:Tomato;'><i>isoniazid</i></b> activation by KatG has utilized recombinant enzyme overexpressed in Escherichia coli. In this work, native KatG and KatG(S315T) were purified from M. tuberculosis, and KatG(R463L) was purified from Mycobacterium bovis. The native molecular weight, enzymatic activity, optical, resonance Raman, and EPR spectra, K(D) for <b style='color:Tomato;'><i>isoniazid</i></b> binding, and <b style='color:Tomato;'><i>isoniazid</i></b> oxidation rates were measured and compared for each native enzyme. Further, the properties of the native enzymes were compared and contrasted with those reported for recombinant KatG, KatG(S315T), and KatG(R463L) in order to assess the ability of the recombinant enzymes to act as good models for the native enzymes.","tokens":[{"text":"Isoniazid","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"a","start":12,"end":13,"id":2,"ws":true},{"text":"first-line","start":14,"end":24,"id":3,"ws":true},{"text":"antibiotic","start":25,"end":35,"id":4,"ws":true},{"text":"used","start":36,"end":40,"id":5,"ws":true},{"text":"for","start":41,"end":44,"id":6,"ws":true},{"text":"the","start":45,"end":48,"id":7,"ws":true},{"text":"treatment","start":49,"end":58,"id":8,"ws":true},{"text":"of","start":59,"end":61,"id":9,"ws":true},{"text":"tuberculosis","start":62,"end":74,"id":10,"ws":true},{"text":",","start":75,"end":76,"id":11,"ws":true},{"text":"is","start":77,"end":79,"id":12,"ws":true},{"text":"a","start":80,"end":81,"id":13,"ws":true},{"text":"prodrug","start":82,"end":89,"id":14,"ws":true},{"text":"that","start":90,"end":94,"id":15,"ws":true},{"text":"requires","start":95,"end":103,"id":16,"ws":true},{"text":"activation","start":104,"end":114,"id":17,"ws":true},{"text":"by","start":115,"end":117,"id":18,"ws":true},{"text":"the","start":118,"end":121,"id":19,"ws":true},{"text":"Mycobacterium","start":122,"end":135,"id":20,"ws":true},{"text":"tuberculosis","start":136,"end":148,"id":21,"ws":true},{"text":"enzyme","start":149,"end":155,"id":22,"ws":true},{"text":"KatG.","start":156,"end":161,"id":23,"ws":true},{"text":"The","start":162,"end":165,"id":24,"ws":true},{"text":"KatG(S315","start":166,"end":175,"id":25,"ws":true},{"text":"T","start":176,"end":177,"id":26,"ws":true},{"text":")","start":178,"end":179,"id":27,"ws":true},{"text":"mutation","start":180,"end":188,"id":28,"ws":true},{"text":"causes","start":189,"end":195,"id":29,"ws":true},{"text":"isoniazid","start":196,"end":205,"id":30,"ws":true},{"text":"resistance","start":206,"end":216,"id":31,"ws":true},{"text":"while","start":217,"end":222,"id":32,"ws":true},{"text":"the","start":223,"end":226,"id":33,"ws":true},{"text":"KatG(R463L","start":227,"end":237,"id":34,"ws":true},{"text":")","start":238,"end":239,"id":35,"ws":true},{"text":"variation","start":240,"end":249,"id":36,"ws":true},{"text":"is","start":250,"end":252,"id":37,"ws":true},{"text":"thought","start":253,"end":260,"id":38,"ws":true},{"text":"to","start":261,"end":263,"id":39,"ws":true},{"text":"be","start":264,"end":266,"id":40,"ws":true},{"text":"a","start":267,"end":268,"id":41,"ws":true},{"text":"polymorphism","start":269,"end":281,"id":42,"ws":true},{"text":".","start":282,"end":283,"id":43,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":196,"end":205,"token_start":30,"token_end":30,"label":"DRUG"}],"_input_hash":-472800035,"_task_hash":-1072379818,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"At present , it seems to us that progress has not been made since Grignani reported a phase II cohort trial of sorafenib and sorafenib combined with everolimus for advanced osteosarcoma , which , in a sense , have become a milestone as a second-line therapy for osteosarcoma .","paragraph":"<h3><u>Anti-angiogenesis target therapy for advanced osteosarcoma (Review).</u></h3>Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited treatment options. The greatest advancement in treatments occurred in the 1980s when multi-agent chemotherapy, including <b style='color:Tomato;'><i>doxorubicin</i></b>, cisplatin, high-dose <b style='color:Tomato;'><i>methotrexate</i></b>, and, in some regimens, <b style='color:Tomato;'><i>ifosfamide</i></b>, was demonstrated to improve overall survival compared with surgery alone. However, standard chemotherapeutic options have been limited by poor response rates in patients with relapsed or advanced cases. It has been reported that VEGFR expression correlates with the outcome of patients with osteosarcoma and circulating VEGF level has been associated with the development of lung metastasis. <b style='color:DodgerBlue;'><i>At</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>seems</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>us</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>progress</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>made</i></b> <b style='color:DodgerBlue;'><i>since</i></b> <b style='color:DodgerBlue;'><i>Grignani</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>cohort</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sense</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>milestone</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although the recognization of muramyltripepetide phosphatidyl-ethanolamine has made some progress based on its combination with standard chemotherapy, its effect on refractory cases is controversial. Personalized comprehensive molecular profiling of high-risk osteosarcoma up to now has not changed the therapeutic prospect of advanced osteosarcoma significantly. Thus, how far have we moved forward and what therapeutic strategy should we prefer for anti-angiogenesis therapy? This review provides an overview of the most updated anti-angiogenesis therapy in OS and discusses some clinical options in order to maintain or even improve progression-free survival.","tokens":[{"text":"At","start":0,"end":2,"id":0,"ws":true},{"text":"present","start":3,"end":10,"id":1,"ws":true},{"text":",","start":11,"end":12,"id":2,"ws":true},{"text":"it","start":13,"end":15,"id":3,"ws":true},{"text":"seems","start":16,"end":21,"id":4,"ws":true},{"text":"to","start":22,"end":24,"id":5,"ws":true},{"text":"us","start":25,"end":27,"id":6,"ws":true},{"text":"that","start":28,"end":32,"id":7,"ws":true},{"text":"progress","start":33,"end":41,"id":8,"ws":true},{"text":"has","start":42,"end":45,"id":9,"ws":true},{"text":"not","start":46,"end":49,"id":10,"ws":true},{"text":"been","start":50,"end":54,"id":11,"ws":true},{"text":"made","start":55,"end":59,"id":12,"ws":true},{"text":"since","start":60,"end":65,"id":13,"ws":true},{"text":"Grignani","start":66,"end":74,"id":14,"ws":true},{"text":"reported","start":75,"end":83,"id":15,"ws":true},{"text":"a","start":84,"end":85,"id":16,"ws":true},{"text":"phase","start":86,"end":91,"id":17,"ws":true},{"text":"II","start":92,"end":94,"id":18,"ws":true},{"text":"cohort","start":95,"end":101,"id":19,"ws":true},{"text":"trial","start":102,"end":107,"id":20,"ws":true},{"text":"of","start":108,"end":110,"id":21,"ws":true},{"text":"sorafenib","start":111,"end":120,"id":22,"ws":true},{"text":"and","start":121,"end":124,"id":23,"ws":true},{"text":"sorafenib","start":125,"end":134,"id":24,"ws":true},{"text":"combined","start":135,"end":143,"id":25,"ws":true},{"text":"with","start":144,"end":148,"id":26,"ws":true},{"text":"everolimus","start":149,"end":159,"id":27,"ws":true},{"text":"for","start":160,"end":163,"id":28,"ws":true},{"text":"advanced","start":164,"end":172,"id":29,"ws":true},{"text":"osteosarcoma","start":173,"end":185,"id":30,"ws":true},{"text":",","start":186,"end":187,"id":31,"ws":true},{"text":"which","start":188,"end":193,"id":32,"ws":true},{"text":",","start":194,"end":195,"id":33,"ws":true},{"text":"in","start":196,"end":198,"id":34,"ws":true},{"text":"a","start":199,"end":200,"id":35,"ws":true},{"text":"sense","start":201,"end":206,"id":36,"ws":true},{"text":",","start":207,"end":208,"id":37,"ws":true},{"text":"have","start":209,"end":213,"id":38,"ws":true},{"text":"become","start":214,"end":220,"id":39,"ws":true},{"text":"a","start":221,"end":222,"id":40,"ws":true},{"text":"milestone","start":223,"end":232,"id":41,"ws":true},{"text":"as","start":233,"end":235,"id":42,"ws":true},{"text":"a","start":236,"end":237,"id":43,"ws":true},{"text":"second-line","start":238,"end":249,"id":44,"ws":true},{"text":"therapy","start":250,"end":257,"id":45,"ws":true},{"text":"for","start":258,"end":261,"id":46,"ws":true},{"text":"osteosarcoma","start":262,"end":274,"id":47,"ws":true},{"text":".","start":275,"end":276,"id":48,"ws":false}],"spans":[{"start":111,"end":120,"token_start":22,"token_end":22,"label":"DRUG"},{"start":125,"end":134,"token_start":24,"token_end":24,"label":"DRUG"},{"start":149,"end":159,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":820866740,"_task_hash":-1307229766,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":24,"child":27,"head_span":{"start":125,"end":134,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":149,"end":159,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Failure to sedate patients who might be aware of paralysis occurred in three of 25 succinylcholine and eight of 94 pancuronium uses .","paragraph":"<h3><u>Neuromuscular blockade for critical patients in the emergency department.</u></h3>This retrospective study examines the indications and the effects of 119 doses of <b style='color:Tomato;'><i>succinylcholine</i></b> or <b style='color:Tomato;'><i>pancuronium</i></b> given in the emergency department during a 24-month period to patients considered to have immediately life-threatening emergencies. The most common indication for <b style='color:Tomato;'><i>succinylcholine</i></b> was to accomplish tracheal intubation (20 of 25 patients). Indications for <b style='color:Tomato;'><i>pancuronium</i></b> included computerized tomography of the head (60 of 94), control of agitation (40 of 94), facilitation of tracheal intubation (20 of 94), control of ventilation (12 of 94), and control of seizure unresponsive to anticonvulsants (4 of 94). Deterioration following <b style='color:Tomato;'><i>succinylcholine</i></b> occurred in three cases. These included two involving bradycardia and one involving ventricular tachycardia. Major complications following <b style='color:Tomato;'><i>pancuronium</i></b> included four incidences of ventricular arrhythmias. Intubation failure requiring surgical airway occurred in one patient given <b style='color:Tomato;'><i>succinylcholine</i></b>, two patients given <b style='color:Tomato;'><i>pancuronium</i></b>, and one patient who received both <b style='color:Tomato;'><i>succinylcholine</i></b> and <b style='color:Tomato;'><i>pancuronium</i></b>. Inadequate documentation of neurological examination prior to blockade was noted in six of 25 <b style='color:Tomato;'><i>succinylcholine</i></b> and nine of 94 <b style='color:Tomato;'><i>pancuronium</i></b> cases. <b style='color:DodgerBlue;'><i>Failure</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>sedate</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>aware</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>paralysis</i></b> <b style='color:DodgerBlue;'><i>occurred</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:MediumOrchid;'><i>succinylcholine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>eight</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>94</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>uses</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Neuromuscular blocking agents facilitate expeditious management of selected critical patients in the ED. Their prudent use requires anticipation of potential complications, preparation for surgical airway should intubation fail, documentation of physical examination before paralysis, and prior sedation when the patient responds to pain.","tokens":[{"text":"Failure","start":0,"end":7,"id":0,"ws":true},{"text":"to","start":8,"end":10,"id":1,"ws":true},{"text":"sedate","start":11,"end":17,"id":2,"ws":true},{"text":"patients","start":18,"end":26,"id":3,"ws":true},{"text":"who","start":27,"end":30,"id":4,"ws":true},{"text":"might","start":31,"end":36,"id":5,"ws":true},{"text":"be","start":37,"end":39,"id":6,"ws":true},{"text":"aware","start":40,"end":45,"id":7,"ws":true},{"text":"of","start":46,"end":48,"id":8,"ws":true},{"text":"paralysis","start":49,"end":58,"id":9,"ws":true},{"text":"occurred","start":59,"end":67,"id":10,"ws":true},{"text":"in","start":68,"end":70,"id":11,"ws":true},{"text":"three","start":71,"end":76,"id":12,"ws":true},{"text":"of","start":77,"end":79,"id":13,"ws":true},{"text":"25","start":80,"end":82,"id":14,"ws":true},{"text":"succinylcholine","start":83,"end":98,"id":15,"ws":true},{"text":"and","start":99,"end":102,"id":16,"ws":true},{"text":"eight","start":103,"end":108,"id":17,"ws":true},{"text":"of","start":109,"end":111,"id":18,"ws":true},{"text":"94","start":112,"end":114,"id":19,"ws":true},{"text":"pancuronium","start":115,"end":126,"id":20,"ws":true},{"text":"uses","start":127,"end":131,"id":21,"ws":true},{"text":".","start":132,"end":133,"id":22,"ws":false}],"spans":[{"start":83,"end":98,"token_start":15,"token_end":15,"label":"DRUG"},{"start":115,"end":126,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1752136466,"_task_hash":-486162667,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Thirty-one isolates were classified as resistant to amprolium , 23 resistant to monensin , 10 resistant to diclazuril , and 6 resistant to clopidol .","paragraph":"<h3><u>Sensitivity of isolates of Eimeria from turkey flocks to the anticoccidial drugs amprolium, clopidol, diclazuril, and monensin.</u></h3>The sensitivity of field isolates of turkey coccidia from the United States to the anticoccidial drugs <b style='color:Tomato;'><i>amprolium</i></b>, <b style='color:Tomato;'><i>clopidol</i></b>, <b style='color:Tomato;'><i>diclazuril</i></b>, and monensin was investigated. <b style='color:Tomato;'><i>clopidol</i></b> and <b style='color:Tomato;'><i>diclazuril</i></b> were the most effective, followed by monensin and <b style='color:Tomato;'><i>amprolium</i></b>. <b style='color:DodgerBlue;'><i>Thirty-one</i></b> <b style='color:DodgerBlue;'><i>isolates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>classified</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>amprolium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>23</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>monensin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>diclazuril</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>clopidol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Six isolates were partially resistant to monensin, 10 partially resistant to <b style='color:Tomato;'><i>clopidol</i></b>, and 11 partially resistant to <b style='color:Tomato;'><i>diclazuril</i></b>. Four isolates were sensitive to monensin, 12 sensitive to <b style='color:Tomato;'><i>diclazuril</i></b>, and 17 sensitive to <b style='color:Tomato;'><i>clopidol</i></b>.","tokens":[{"text":"Thirty-one","start":0,"end":10,"id":0,"ws":true},{"text":"isolates","start":11,"end":19,"id":1,"ws":true},{"text":"were","start":20,"end":24,"id":2,"ws":true},{"text":"classified","start":25,"end":35,"id":3,"ws":true},{"text":"as","start":36,"end":38,"id":4,"ws":true},{"text":"resistant","start":39,"end":48,"id":5,"ws":true},{"text":"to","start":49,"end":51,"id":6,"ws":true},{"text":"amprolium","start":52,"end":61,"id":7,"ws":true},{"text":",","start":62,"end":63,"id":8,"ws":true},{"text":"23","start":64,"end":66,"id":9,"ws":true},{"text":"resistant","start":67,"end":76,"id":10,"ws":true},{"text":"to","start":77,"end":79,"id":11,"ws":true},{"text":"monensin","start":80,"end":88,"id":12,"ws":true},{"text":",","start":89,"end":90,"id":13,"ws":true},{"text":"10","start":91,"end":93,"id":14,"ws":true},{"text":"resistant","start":94,"end":103,"id":15,"ws":true},{"text":"to","start":104,"end":106,"id":16,"ws":true},{"text":"diclazuril","start":107,"end":117,"id":17,"ws":true},{"text":",","start":118,"end":119,"id":18,"ws":true},{"text":"and","start":120,"end":123,"id":19,"ws":true},{"text":"6","start":124,"end":125,"id":20,"ws":true},{"text":"resistant","start":126,"end":135,"id":21,"ws":true},{"text":"to","start":136,"end":138,"id":22,"ws":true},{"text":"clopidol","start":139,"end":147,"id":23,"ws":true},{"text":".","start":148,"end":149,"id":24,"ws":false}],"spans":[{"start":52,"end":61,"token_start":7,"token_end":7,"label":"DRUG"},{"start":107,"end":117,"token_start":17,"token_end":17,"label":"DRUG"},{"start":139,"end":147,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":-1949620998,"_task_hash":-413112467,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Approval was based on data from the APHINITY trial , which randomized patients to receive pertuzumab or placebo in combination with trastuzumab and chemotherapy .","paragraph":"<h3><u>FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.</u></h3>On December 20, 2017, the FDA granted regular approval to <b style='color:Tomato;'><i>pertuzumab</i></b> in combination with <b style='color:Tomato;'><i>trastuzumab</i></b> and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) at high risk of recurrence. <b style='color:DodgerBlue;'><i>Approval</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>APHINITY</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After 45.4-month median follow-up, the proportion of invasive disease-free survival (IDFS) events in the intent-to-treat population was 7.1% (","tokens":[{"text":"Approval","start":0,"end":8,"id":0,"ws":true},{"text":"was","start":9,"end":12,"id":1,"ws":true},{"text":"based","start":13,"end":18,"id":2,"ws":true},{"text":"on","start":19,"end":21,"id":3,"ws":true},{"text":"data","start":22,"end":26,"id":4,"ws":true},{"text":"from","start":27,"end":31,"id":5,"ws":true},{"text":"the","start":32,"end":35,"id":6,"ws":true},{"text":"APHINITY","start":36,"end":44,"id":7,"ws":true},{"text":"trial","start":45,"end":50,"id":8,"ws":true},{"text":",","start":51,"end":52,"id":9,"ws":true},{"text":"which","start":53,"end":58,"id":10,"ws":true},{"text":"randomized","start":59,"end":69,"id":11,"ws":true},{"text":"patients","start":70,"end":78,"id":12,"ws":true},{"text":"to","start":79,"end":81,"id":13,"ws":true},{"text":"receive","start":82,"end":89,"id":14,"ws":true},{"text":"pertuzumab","start":90,"end":100,"id":15,"ws":true},{"text":"or","start":101,"end":103,"id":16,"ws":true},{"text":"placebo","start":104,"end":111,"id":17,"ws":true},{"text":"in","start":112,"end":114,"id":18,"ws":true},{"text":"combination","start":115,"end":126,"id":19,"ws":true},{"text":"with","start":127,"end":131,"id":20,"ws":true},{"text":"trastuzumab","start":132,"end":143,"id":21,"ws":true},{"text":"and","start":144,"end":147,"id":22,"ws":true},{"text":"chemotherapy","start":148,"end":160,"id":23,"ws":true},{"text":".","start":161,"end":162,"id":24,"ws":false}],"spans":[{"start":90,"end":100,"token_start":15,"token_end":15,"label":"DRUG"},{"start":132,"end":143,"token_start":21,"token_end":21,"label":"DRUG"}],"_input_hash":1409779373,"_task_hash":-1504196250,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Thirteen patients with interstitial cystitis diagnosed by the NIH criteria were treated with intravesical electromotive administration of lidocaine and dexamethasone followed by cystodistention .","paragraph":"<h3><u>Electromotive drug administration and hydrodistention for the treatment of interstitial cystitis.</u></h3> <b style='color:DodgerBlue;'><i>Thirteen</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>interstitial</i></b> <b style='color:DodgerBlue;'><i>cystitis</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIH</i></b> <b style='color:DodgerBlue;'><i>criteria</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intravesical</i></b> <b style='color:DodgerBlue;'><i>electromotive</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>cystodistention</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After a mean follow-up of 10 (range 3-22) months, 8/13 (62%) of the patients reported complete resolution of bladder symptoms lasting an average 4.5 (range 0.75-17) months. Partial or short-term improvement of bladder symptoms was observed in three patients, while two patients reported aggravation of pain for several days after therapy. A significant increase in bladder capacity, to an average 166% of the pretreatment capacity, was observed in all patients. Whenever symptoms recurred after initially effective therapy, retreatments were performed with equal efficacy in 11 patients. This promising new therapeutic approach, performed on an outpatient basis, may become first-line treatment for patients with interstitial cystitis.","tokens":[{"text":"Thirteen","start":0,"end":8,"id":0,"ws":true},{"text":"patients","start":9,"end":17,"id":1,"ws":true},{"text":"with","start":18,"end":22,"id":2,"ws":true},{"text":"interstitial","start":23,"end":35,"id":3,"ws":true},{"text":"cystitis","start":36,"end":44,"id":4,"ws":true},{"text":"diagnosed","start":45,"end":54,"id":5,"ws":true},{"text":"by","start":55,"end":57,"id":6,"ws":true},{"text":"the","start":58,"end":61,"id":7,"ws":true},{"text":"NIH","start":62,"end":65,"id":8,"ws":true},{"text":"criteria","start":66,"end":74,"id":9,"ws":true},{"text":"were","start":75,"end":79,"id":10,"ws":true},{"text":"treated","start":80,"end":87,"id":11,"ws":true},{"text":"with","start":88,"end":92,"id":12,"ws":true},{"text":"intravesical","start":93,"end":105,"id":13,"ws":true},{"text":"electromotive","start":106,"end":119,"id":14,"ws":true},{"text":"administration","start":120,"end":134,"id":15,"ws":true},{"text":"of","start":135,"end":137,"id":16,"ws":true},{"text":"lidocaine","start":138,"end":147,"id":17,"ws":true},{"text":"and","start":148,"end":151,"id":18,"ws":true},{"text":"dexamethasone","start":152,"end":165,"id":19,"ws":true},{"text":"followed","start":166,"end":174,"id":20,"ws":true},{"text":"by","start":175,"end":177,"id":21,"ws":true},{"text":"cystodistention","start":178,"end":193,"id":22,"ws":true},{"text":".","start":194,"end":195,"id":23,"ws":false}],"spans":[{"start":138,"end":147,"token_start":17,"token_end":17,"label":"DRUG"},{"start":152,"end":165,"token_start":19,"token_end":19,"label":"DRUG"}],"_input_hash":-2025170165,"_task_hash":-1109462315,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":138,"end":147,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":152,"end":165,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":22,"head_span":{"start":152,"end":165,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":178,"end":193,"token_start":22,"token_end":22,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Drug therapy included omega-3 fish oil , extended-release niacin , colesevelam hydrochloride , and a fixed combination of 10-mg ezetimibe and 40-mg simvastatin .","paragraph":"<h3><u>Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.</u></h3>Lipoprotein-associated phospholipase A2 (Lp-PLA(2)) mass is a novel inflammatory biomarker. In human blood, Lp-PLA(2) is predominately associated with low-density lipoprotein (LDL). This study examines the ability of lifestyle modification (diet and exercise) and combination lipid therapy to reduce Lp-PLA(2) levels while also determining the relationship between changes in LDL cholesterol and Lp-PLA(2). Thirty dyslipidemic patients who received lifestyle intervention and combination lipid therapy for an average of 6 months were included in these analyses (mean age, 60.9 years); 40% had stable angiographically established coronary artery disease, 40% had the metabolic syndrome, and 70% were men. <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>omega-3</i></b> <b style='color:DodgerBlue;'><i>fish</i></b> <b style='color:DodgerBlue;'><i>oil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>extended-release</i></b> <b style='color:DodgerBlue;'><i>niacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>colesevelam</i></b> <b style='color:DodgerBlue;'><i>hydrochloride</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fixed</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>10-mg</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>40-mg</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The study revealed a 33% reduction in mean Lp-PLA(2) values (baseline 224.9+/-47.5 vs posttreatment 149.5+/-35.5 ng/mL; P<.001). Significant changes in mean LDL cholesterol from baseline (127.9+/-49.3 vs posttreatment 65.2+/-32.1 mg/dL; P<.001) were also observed. However, regression analysis revealed only a weak positive relationship between changes in LDL cholesterol and Lp-PLA(2) mass (R(2)=0.29; P<.01). Thus, Lp-PLA(2) mass is significantly reduced with lifestyle and combination lipid therapy. Changes in Lp-PLA(2) were only partially explained by the changes observed for LDL cholesterol.","tokens":[{"text":"Drug","start":0,"end":4,"id":0,"ws":true},{"text":"therapy","start":5,"end":12,"id":1,"ws":true},{"text":"included","start":13,"end":21,"id":2,"ws":true},{"text":"omega-3","start":22,"end":29,"id":3,"ws":true},{"text":"fish","start":30,"end":34,"id":4,"ws":true},{"text":"oil","start":35,"end":38,"id":5,"ws":true},{"text":",","start":39,"end":40,"id":6,"ws":true},{"text":"extended-release","start":41,"end":57,"id":7,"ws":true},{"text":"niacin","start":58,"end":64,"id":8,"ws":true},{"text":",","start":65,"end":66,"id":9,"ws":true},{"text":"colesevelam","start":67,"end":78,"id":10,"ws":true},{"text":"hydrochloride","start":79,"end":92,"id":11,"ws":true},{"text":",","start":93,"end":94,"id":12,"ws":true},{"text":"and","start":95,"end":98,"id":13,"ws":true},{"text":"a","start":99,"end":100,"id":14,"ws":true},{"text":"fixed","start":101,"end":106,"id":15,"ws":true},{"text":"combination","start":107,"end":118,"id":16,"ws":true},{"text":"of","start":119,"end":121,"id":17,"ws":true},{"text":"10-mg","start":122,"end":127,"id":18,"ws":true},{"text":"ezetimibe","start":128,"end":137,"id":19,"ws":true},{"text":"and","start":138,"end":141,"id":20,"ws":true},{"text":"40-mg","start":142,"end":147,"id":21,"ws":true},{"text":"simvastatin","start":148,"end":159,"id":22,"ws":true},{"text":".","start":160,"end":161,"id":23,"ws":false}],"spans":[{"start":22,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":58,"end":64,"token_start":8,"token_end":8,"label":"DRUG"},{"start":67,"end":92,"token_start":10,"token_end":11,"label":"DRUG"},{"start":128,"end":137,"token_start":19,"token_end":19,"label":"DRUG"},{"start":148,"end":159,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":-1623992510,"_task_hash":2036274618,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":3,"child":8,"head_span":{"start":22,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":58,"end":64,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":22,"head_span":{"start":128,"end":137,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":148,"end":159,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":11,"head_span":{"start":58,"end":64,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":67,"end":92,"token_start":10,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":19,"head_span":{"start":67,"end":92,"token_start":10,"token_end":11,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI ( bolus irinotecan , folinic acid , and fluorouracil followed by 46-hour fluorouracil infusion ) followed by bevacizumab ( 5 mg/kg ) in Cycle 1 .","paragraph":"<h3><u>Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.</u></h3>Previous reports of the influence of UGT1A1 gene polymorphisms on the pharmacokinetics of <b style='color:Tomato;'><i>irinotecan</i></b> metabolism have not assessed Asian patients treated with FOLFIRI plus <b style='color:Tomato;'><i>bevacizumab</i></b> for advanced and recurrent colorectal cancer. <b style='color:DodgerBlue;'><i>Twenty-one</i></b> <b style='color:DodgerBlue;'><i>Japanese</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>FOLFIRI</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>folinic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>46-hour</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Cycle</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In Cycle 2, patients received <b style='color:Tomato;'><i>bevacizumab</i></b> followed by FOLFIRI. The regimen was in 2-week cycles. The area under-the-curves ratio (AUC0-last) (Cycle 2/Cycle 1) was determined from plasma concentrations of <b style='color:Tomato;'><i>irinotecan</i></b> and metabolites (SN-38, SN-38G). Safety, efficacy, and drug-drug interactions were analyzed. Median observation period was 7.8 months; median number of cycles 15. Drug-drug interactions were evaluated in eight patients without <b style='color:Tomato;'><i>irinotecan</i></b> dose reduction. Mean AUC0-last ratios (with/without <b style='color:Tomato;'><i>bevacizumab</i></b>) of <b style='color:Tomato;'><i>irinotecan</i></b>, SN-38, and SN-38G were 0.959, 0.927, and 0.931 respectively. Response rate was 65%; median progression-free survival 16.4 months. Response occurred in four patients with, and nine without, UGT1A1 polymorphism. No significant differences occurred between efficacy, safety, or polymorphism status. This cohort showed no differences in safety or efficacy compared to previous reports. <b style='color:Tomato;'><i>bevacizumab</i></b> did not affect the pharmacokinetics of <b style='color:Tomato;'><i>irinotecan</i></b> and its metabolites, irrespective of UGT1A1 polymorphism status. ","tokens":[{"text":"Twenty-one","start":0,"end":10,"id":0,"ws":true},{"text":"Japanese","start":11,"end":19,"id":1,"ws":true},{"text":"colorectal","start":20,"end":30,"id":2,"ws":true},{"text":"cancer","start":31,"end":37,"id":3,"ws":true},{"text":"patients","start":38,"end":46,"id":4,"ws":true},{"text":"received","start":47,"end":55,"id":5,"ws":true},{"text":"intravenous","start":56,"end":67,"id":6,"ws":true},{"text":"FOLFIRI","start":68,"end":75,"id":7,"ws":true},{"text":"(","start":76,"end":77,"id":8,"ws":true},{"text":"bolus","start":78,"end":83,"id":9,"ws":true},{"text":"irinotecan","start":84,"end":94,"id":10,"ws":true},{"text":",","start":95,"end":96,"id":11,"ws":true},{"text":"folinic","start":97,"end":104,"id":12,"ws":true},{"text":"acid","start":105,"end":109,"id":13,"ws":true},{"text":",","start":110,"end":111,"id":14,"ws":true},{"text":"and","start":112,"end":115,"id":15,"ws":true},{"text":"fluorouracil","start":116,"end":128,"id":16,"ws":true},{"text":"followed","start":129,"end":137,"id":17,"ws":true},{"text":"by","start":138,"end":140,"id":18,"ws":true},{"text":"46-hour","start":141,"end":148,"id":19,"ws":true},{"text":"fluorouracil","start":149,"end":161,"id":20,"ws":true},{"text":"infusion","start":162,"end":170,"id":21,"ws":true},{"text":")","start":171,"end":172,"id":22,"ws":true},{"text":"followed","start":173,"end":181,"id":23,"ws":true},{"text":"by","start":182,"end":184,"id":24,"ws":true},{"text":"bevacizumab","start":185,"end":196,"id":25,"ws":true},{"text":"(","start":197,"end":198,"id":26,"ws":true},{"text":"5","start":199,"end":200,"id":27,"ws":true},{"text":"mg/kg","start":201,"end":206,"id":28,"ws":true},{"text":")","start":207,"end":208,"id":29,"ws":true},{"text":"in","start":209,"end":211,"id":30,"ws":true},{"text":"Cycle","start":212,"end":217,"id":31,"ws":true},{"text":"1","start":218,"end":219,"id":32,"ws":true},{"text":".","start":220,"end":221,"id":33,"ws":false}],"spans":[{"start":84,"end":94,"token_start":10,"token_end":10,"label":"DRUG"},{"start":97,"end":109,"token_start":12,"token_end":13,"label":"DRUG"},{"start":116,"end":128,"token_start":16,"token_end":16,"label":"DRUG"},{"start":149,"end":161,"token_start":20,"token_end":20,"label":"DRUG"},{"start":185,"end":196,"token_start":25,"token_end":25,"label":"DRUG"}],"_input_hash":-593380136,"_task_hash":-1648654394,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":10,"child":13,"head_span":{"start":84,"end":94,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":97,"end":109,"token_start":12,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":16,"head_span":{"start":97,"end":109,"token_start":12,"token_end":13,"label":"DRUG"},"child_span":{"start":116,"end":128,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":16,"child":25,"head_span":{"start":116,"end":128,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":185,"end":196,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":16,"child":20,"head_span":{"start":116,"end":128,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":149,"end":161,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Patients received vinorelbine starting at 20 mg/m(2 ) ( to 25 mg/m(2 ) ) and carboplatin area under the curve ( AUC ) 2.5 in divided-doses , both given on Days 1 and 8 every 21-day cycle for up to 6 cycles or until disease progression .","paragraph":"<h3><u>Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer.</u></h3><b style='color:Tomato;'><i>vinorelbine</i></b> administered in a doublet with cisplatin has become a standard treatment in patients with advanced non-small cell lung cancer (NSCLC). However, <b style='color:Tomato;'><i>carboplatin</i></b> appears to provide comparable efficacy with a better nonhematologic safety profile than cisplatin. Herein we report the results of a phase I/II trial of weekly <b style='color:Tomato;'><i>vinorelbine</i></b> and divided-dose <b style='color:Tomato;'><i>carboplatin</i></b> in patients with stage IIIB/IV NSCLC, Eastern Cooperative Oncology Group performance status < or = 2, and adequate bone marrow. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>starting</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>2.5</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>divided-doses</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>Days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21-day</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Dose-limiting toxicity was defined for Cycles 1 and 2. Tumor response and toxicity were assessed using standard criteria. Twenty-one patients with a mean age of 67 years (range, 43-79) and stage IIIB/IV (8/13) disease were enrolled. All but 1 patient were chemotherapy-nai;ve; the majority (n = 20) had good performance status (< or = 1). Seventy-nine courses (median, 4) were administered. The <b style='color:Tomato;'><i>vinorelbine</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> doublet was well tolerated, with 7 courses interrupted or delayed because of toxicity. Toxicities were generally mild and evenly divided between hematologic (i.e., neutropenia) and nonhematologic (i.e., fatigue). No growth factor support was required for hematologic toxicity. There was only one case of grade 2 alopecia, and no cases of > or = grade 2 neurotoxicity. There were 5 (24%) partial responses, and 9 (43%) patients had stable disease. Weekly <b style='color:Tomato;'><i>vinorelbine</i></b> 25 mg/m(2) and divided-dose <b style='color:Tomato;'><i>carboplatin</i></b> AUC 2.5 is a well tolerated regimen with activity in advanced NSCLC patients. Further evaluation of this regimen in combination with novel targeted biologic therapy is warranted.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"vinorelbine","start":18,"end":29,"id":2,"ws":true},{"text":"starting","start":30,"end":38,"id":3,"ws":true},{"text":"at","start":39,"end":41,"id":4,"ws":true},{"text":"20","start":42,"end":44,"id":5,"ws":true},{"text":"mg/m(2","start":45,"end":51,"id":6,"ws":true},{"text":")","start":52,"end":53,"id":7,"ws":true},{"text":"(","start":54,"end":55,"id":8,"ws":true},{"text":"to","start":56,"end":58,"id":9,"ws":true},{"text":"25","start":59,"end":61,"id":10,"ws":true},{"text":"mg/m(2","start":62,"end":68,"id":11,"ws":true},{"text":")","start":69,"end":70,"id":12,"ws":true},{"text":")","start":71,"end":72,"id":13,"ws":true},{"text":"and","start":73,"end":76,"id":14,"ws":true},{"text":"carboplatin","start":77,"end":88,"id":15,"ws":true},{"text":"area","start":89,"end":93,"id":16,"ws":true},{"text":"under","start":94,"end":99,"id":17,"ws":true},{"text":"the","start":100,"end":103,"id":18,"ws":true},{"text":"curve","start":104,"end":109,"id":19,"ws":true},{"text":"(","start":110,"end":111,"id":20,"ws":true},{"text":"AUC","start":112,"end":115,"id":21,"ws":true},{"text":")","start":116,"end":117,"id":22,"ws":true},{"text":"2.5","start":118,"end":121,"id":23,"ws":true},{"text":"in","start":122,"end":124,"id":24,"ws":true},{"text":"divided-doses","start":125,"end":138,"id":25,"ws":true},{"text":",","start":139,"end":140,"id":26,"ws":true},{"text":"both","start":141,"end":145,"id":27,"ws":true},{"text":"given","start":146,"end":151,"id":28,"ws":true},{"text":"on","start":152,"end":154,"id":29,"ws":true},{"text":"Days","start":155,"end":159,"id":30,"ws":true},{"text":"1","start":160,"end":161,"id":31,"ws":true},{"text":"and","start":162,"end":165,"id":32,"ws":true},{"text":"8","start":166,"end":167,"id":33,"ws":true},{"text":"every","start":168,"end":173,"id":34,"ws":true},{"text":"21-day","start":174,"end":180,"id":35,"ws":true},{"text":"cycle","start":181,"end":186,"id":36,"ws":true},{"text":"for","start":187,"end":190,"id":37,"ws":true},{"text":"up","start":191,"end":193,"id":38,"ws":true},{"text":"to","start":194,"end":196,"id":39,"ws":true},{"text":"6","start":197,"end":198,"id":40,"ws":true},{"text":"cycles","start":199,"end":205,"id":41,"ws":true},{"text":"or","start":206,"end":208,"id":42,"ws":true},{"text":"until","start":209,"end":214,"id":43,"ws":true},{"text":"disease","start":215,"end":222,"id":44,"ws":true},{"text":"progression","start":223,"end":234,"id":45,"ws":true},{"text":".","start":235,"end":236,"id":46,"ws":false}],"spans":[{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},{"start":77,"end":88,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":2145871370,"_task_hash":817815991,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":2,"child":15,"head_span":{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":77,"end":88,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity , in a dose-dependent fashion .","paragraph":"<h3><u>Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer.</u></h3>The effect of topical co-administration of promoter drugs with <b style='color:Tomato;'><i>paclitaxel</i></b> to increase anti-tumor effects of <b style='color:Tomato;'><i>paclitaxel</i></b> was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with <b style='color:Tomato;'><i>paclitaxel</i></b> and a specific promoter drug. Several promoter drugs were evaluated, including: <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>losartan</i></b>, <b style='color:Tomato;'><i>nicotinamide</i></b>, Azone, and oleic acid. <b style='color:MediumOrchid;'><i>Dexamethasone</i></b> <b style='color:DodgerBlue;'><i>exhibited</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>highest</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>anti-tumor</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>dose-dependent</i></b> <b style='color:DodgerBlue;'><i>fashion</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, this effect was accompanied by systemic effects of <b style='color:Tomato;'><i>dexamethasone</i></b>, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.","tokens":[{"text":"Dexamethasone","start":0,"end":13,"id":0,"ws":true},{"text":"exhibited","start":14,"end":23,"id":1,"ws":true},{"text":"the","start":24,"end":27,"id":2,"ws":true},{"text":"highest","start":28,"end":35,"id":3,"ws":true},{"text":"effect","start":36,"end":42,"id":4,"ws":true},{"text":"on","start":43,"end":45,"id":5,"ws":true},{"text":"paclitaxel","start":46,"end":56,"id":6,"ws":true},{"text":"anti-tumor","start":57,"end":67,"id":7,"ws":true},{"text":"activity","start":68,"end":76,"id":8,"ws":true},{"text":",","start":77,"end":78,"id":9,"ws":true},{"text":"in","start":79,"end":81,"id":10,"ws":true},{"text":"a","start":82,"end":83,"id":11,"ws":true},{"text":"dose-dependent","start":84,"end":98,"id":12,"ws":true},{"text":"fashion","start":99,"end":106,"id":13,"ws":true},{"text":".","start":107,"end":108,"id":14,"ws":false}],"spans":[{"start":0,"end":13,"token_start":0,"token_end":0,"label":"DRUG"},{"start":46,"end":56,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-946772428,"_task_hash":-1644731951,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":0,"child":6,"head_span":{"start":0,"end":13,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":46,"end":56,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The first available studies demonstrate the value of these compounds with an improved prognosis of metastatic patients in combination with endocrine therapy ( palbociclib , ribociclib ) or in monotherapy ( abemaciclib ) .","paragraph":"<h3><u>[Cell cycle inhibitors in endocrine receptor positive breast cancer].</u></h3>Dysregulation of cellular cycle is a key component of carcinogenesis and its targeting represents an interesting approach. Recently, the development of selective inhibitors of the cycle targeting the cyclin-dependent kinases (CDK) 4\u00a0and 6\u00a0revived interest in this therapeutic class after the failure of pan-inhibitors. <b style='color:Tomato;'><i>palbociclib</i></b>, <b style='color:Tomato;'><i>ribociclib</i></b>, and <b style='color:Tomato;'><i>abemaciclib</i></b> are the 3\u00a0drugs with the most advanced development. They demonstrated preclinical activity in luminal breast cancer models and are under clinical evaluation. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>available</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>demonstrate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>compounds</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>endocrine</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>palbociclib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ribociclib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>abemaciclib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The results of ongoing studies will clarify the role of these agents in our new strategies and the individualisation of biomarkers will help to define patients who benefit most from this approach.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"first","start":4,"end":9,"id":1,"ws":true},{"text":"available","start":10,"end":19,"id":2,"ws":true},{"text":"studies","start":20,"end":27,"id":3,"ws":true},{"text":"demonstrate","start":28,"end":39,"id":4,"ws":true},{"text":"the","start":40,"end":43,"id":5,"ws":true},{"text":"value","start":44,"end":49,"id":6,"ws":true},{"text":"of","start":50,"end":52,"id":7,"ws":true},{"text":"these","start":53,"end":58,"id":8,"ws":true},{"text":"compounds","start":59,"end":68,"id":9,"ws":true},{"text":"with","start":69,"end":73,"id":10,"ws":true},{"text":"an","start":74,"end":76,"id":11,"ws":true},{"text":"improved","start":77,"end":85,"id":12,"ws":true},{"text":"prognosis","start":86,"end":95,"id":13,"ws":true},{"text":"of","start":96,"end":98,"id":14,"ws":true},{"text":"metastatic","start":99,"end":109,"id":15,"ws":true},{"text":"patients","start":110,"end":118,"id":16,"ws":true},{"text":"in","start":119,"end":121,"id":17,"ws":true},{"text":"combination","start":122,"end":133,"id":18,"ws":true},{"text":"with","start":134,"end":138,"id":19,"ws":true},{"text":"endocrine","start":139,"end":148,"id":20,"ws":true},{"text":"therapy","start":149,"end":156,"id":21,"ws":true},{"text":"(","start":157,"end":158,"id":22,"ws":true},{"text":"palbociclib","start":159,"end":170,"id":23,"ws":true},{"text":",","start":171,"end":172,"id":24,"ws":true},{"text":"ribociclib","start":173,"end":183,"id":25,"ws":true},{"text":")","start":184,"end":185,"id":26,"ws":true},{"text":"or","start":186,"end":188,"id":27,"ws":true},{"text":"in","start":189,"end":191,"id":28,"ws":true},{"text":"monotherapy","start":192,"end":203,"id":29,"ws":true},{"text":"(","start":204,"end":205,"id":30,"ws":true},{"text":"abemaciclib","start":206,"end":217,"id":31,"ws":true},{"text":")","start":218,"end":219,"id":32,"ws":true},{"text":".","start":220,"end":221,"id":33,"ws":false}],"spans":[{"start":159,"end":170,"token_start":23,"token_end":23,"label":"DRUG"},{"start":173,"end":183,"token_start":25,"token_end":25,"label":"DRUG"},{"start":206,"end":217,"token_start":31,"token_end":31,"label":"DRUG"}],"_input_hash":1842650963,"_task_hash":-734384376,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Flunarizine pretreatment abolished the augmented behavioral response to repeated cocaine administration while diltiazem was less effective .","paragraph":"<h3><u>Augmented behavioral response and enhanced synaptosomal calcium transport induced by repeated cocaine administration are decreased by calcium channel blockers.</u></h3>Recent studies suggest that calcium influx via L-type calcium channels is necessary for psychostimulant-induced behavioral sensitization. In addition, chronic amphetamine upregulates subtype Cav1.2-containing L-type calcium channels. In the present studies, we assessed the effect of calcium channel blockers (CCBs) on cocaine-induced behavioral sensitization and determined whether the functional activity of L-type calcium channels is altered after repeated cocaine administration. Rats were administered daily intraperitoneal injections of either <b style='color:Tomato;'><i>flunarizine</i></b> (40 mg/kg), <b style='color:Tomato;'><i>diltiazem</i></b> (40 mg/kg) or cocaine (20 mg/kg) and the combination of the CCBs and cocaine for 30 days. Motor activities were monitored on Day 1, and every 6th day during the 30-day treatment period. Daily cocaine administration produced increased locomotor activity. Maximal augmentation of behavioral response to repeated cocaine administration was observed on Day 18. <b style='color:MediumOrchid;'><i>Flunarizine</i></b> <b style='color:DodgerBlue;'><i>pretreatment</i></b> <b style='color:DodgerBlue;'><i>abolished</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>augmented</i></b> <b style='color:DodgerBlue;'><i>behavioral</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>cocaine</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:MediumOrchid;'><i>diltiazem</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Measurement of tissue monoamine levels on Day 18 revealed cocaine-induced increases in DA and 5-HT in the nucleus accumbens. By contrast to behavioral response, <b style='color:Tomato;'><i>diltiazem</i></b> was more effective in attenuating increases in monoamine levels than <b style='color:Tomato;'><i>flunarizine</i></b>. Cocaine administration for 18 days produced increases in calcium uptake in synaptosomes prepared from the nucleus accumbens and frontal cortex. Increases in calcium uptake were abolished by <b style='color:Tomato;'><i>flunarizine</i></b> and <b style='color:Tomato;'><i>diltiazem</i></b> pretreatment. Taken together, the augmented cocaine-induced behavioral response on Day 18 may be due to increased calcium uptake in the nucleus accumbens leading to increased dopamine (DA) and serotonin (5-HT) release. <b style='color:Tomato;'><i>flunarizine</i></b> and <b style='color:Tomato;'><i>diltiazem</i></b> attenuated the behavioral response by decreasing calcium uptake and decreasing neurochemical release.","tokens":[{"text":"Flunarizine","start":0,"end":11,"id":0,"ws":true},{"text":"pretreatment","start":12,"end":24,"id":1,"ws":true},{"text":"abolished","start":25,"end":34,"id":2,"ws":true},{"text":"the","start":35,"end":38,"id":3,"ws":true},{"text":"augmented","start":39,"end":48,"id":4,"ws":true},{"text":"behavioral","start":49,"end":59,"id":5,"ws":true},{"text":"response","start":60,"end":68,"id":6,"ws":true},{"text":"to","start":69,"end":71,"id":7,"ws":true},{"text":"repeated","start":72,"end":80,"id":8,"ws":true},{"text":"cocaine","start":81,"end":88,"id":9,"ws":true},{"text":"administration","start":89,"end":103,"id":10,"ws":true},{"text":"while","start":104,"end":109,"id":11,"ws":true},{"text":"diltiazem","start":110,"end":119,"id":12,"ws":true},{"text":"was","start":120,"end":123,"id":13,"ws":true},{"text":"less","start":124,"end":128,"id":14,"ws":true},{"text":"effective","start":129,"end":138,"id":15,"ws":true},{"text":".","start":139,"end":140,"id":16,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":110,"end":119,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":-1531444058,"_task_hash":-1924337870,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We therefore explored the in vitro combination of amphotericin B with itraconazole against 14 clinical Aspergillus fumigatus isolates ( 9 itraconazole susceptible and 5 itraconazole resistant ) with a colorimetric broth microdilution checkerboard technique using two drug interaction models able to explore complicated patterns of interactions : the response surface analysis of Bliss independence and the isobolographic analysis of Loewe additivity zero interaction theories .","paragraph":"<h3><u>The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.</u></h3>The interaction between polyenes and azoles is not well understood. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>explored</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>Aspergillus</i></b> <b style='color:DodgerBlue;'><i>fumigatus</i></b> <b style='color:DodgerBlue;'><i>isolates</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>9</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>susceptible</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:MediumOrchid;'><i>itraconazole</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>colorimetric</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>microdilution</i></b> <b style='color:DodgerBlue;'><i>checkerboard</i></b> <b style='color:DodgerBlue;'><i>technique</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>models</i></b> <b style='color:DodgerBlue;'><i>able</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>explore</i></b> <b style='color:DodgerBlue;'><i>complicated</i></b> <b style='color:DodgerBlue;'><i>patterns</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>surface</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Bliss</i></b> <b style='color:DodgerBlue;'><i>independence</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>isobolographic</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Loewe</i></b> <b style='color:DodgerBlue;'><i>additivity</i></b> <b style='color:DodgerBlue;'><i>zero</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>theories</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Synergy was found at combinations with low concentrations of <b style='color:Tomato;'><i>amphotericin</i></b> B (<0.125 mg/L), whereas antagonism was found at combinations with higher concentrations of <b style='color:Tomato;'><i>amphotericin</i></b> B. For <b style='color:Tomato;'><i>itraconazole</i></b>-resistant isolates, synergistic interactions were observed at high concentrations of <b style='color:Tomato;'><i>itraconazole</i></b> (>0.5 mg/L). Synergy was more frequently observed for the <b style='color:Tomato;'><i>itraconazole</i></b>-resistant isolates than for the <b style='color:Tomato;'><i>itraconazole</i></b>-susceptible isolates.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"therefore","start":3,"end":12,"id":1,"ws":true},{"text":"explored","start":13,"end":21,"id":2,"ws":true},{"text":"the","start":22,"end":25,"id":3,"ws":true},{"text":"in","start":26,"end":28,"id":4,"ws":true},{"text":"vitro","start":29,"end":34,"id":5,"ws":true},{"text":"combination","start":35,"end":46,"id":6,"ws":true},{"text":"of","start":47,"end":49,"id":7,"ws":true},{"text":"amphotericin","start":50,"end":62,"id":8,"ws":true},{"text":"B","start":63,"end":64,"id":9,"ws":true},{"text":"with","start":65,"end":69,"id":10,"ws":true},{"text":"itraconazole","start":70,"end":82,"id":11,"ws":true},{"text":"against","start":83,"end":90,"id":12,"ws":true},{"text":"14","start":91,"end":93,"id":13,"ws":true},{"text":"clinical","start":94,"end":102,"id":14,"ws":true},{"text":"Aspergillus","start":103,"end":114,"id":15,"ws":true},{"text":"fumigatus","start":115,"end":124,"id":16,"ws":true},{"text":"isolates","start":125,"end":133,"id":17,"ws":true},{"text":"(","start":134,"end":135,"id":18,"ws":true},{"text":"9","start":136,"end":137,"id":19,"ws":true},{"text":"itraconazole","start":138,"end":150,"id":20,"ws":true},{"text":"susceptible","start":151,"end":162,"id":21,"ws":true},{"text":"and","start":163,"end":166,"id":22,"ws":true},{"text":"5","start":167,"end":168,"id":23,"ws":true},{"text":"itraconazole","start":169,"end":181,"id":24,"ws":true},{"text":"resistant","start":182,"end":191,"id":25,"ws":true},{"text":")","start":192,"end":193,"id":26,"ws":true},{"text":"with","start":194,"end":198,"id":27,"ws":true},{"text":"a","start":199,"end":200,"id":28,"ws":true},{"text":"colorimetric","start":201,"end":213,"id":29,"ws":true},{"text":"broth","start":214,"end":219,"id":30,"ws":true},{"text":"microdilution","start":220,"end":233,"id":31,"ws":true},{"text":"checkerboard","start":234,"end":246,"id":32,"ws":true},{"text":"technique","start":247,"end":256,"id":33,"ws":true},{"text":"using","start":257,"end":262,"id":34,"ws":true},{"text":"two","start":263,"end":266,"id":35,"ws":true},{"text":"drug","start":267,"end":271,"id":36,"ws":true},{"text":"interaction","start":272,"end":283,"id":37,"ws":true},{"text":"models","start":284,"end":290,"id":38,"ws":true},{"text":"able","start":291,"end":295,"id":39,"ws":true},{"text":"to","start":296,"end":298,"id":40,"ws":true},{"text":"explore","start":299,"end":306,"id":41,"ws":true},{"text":"complicated","start":307,"end":318,"id":42,"ws":true},{"text":"patterns","start":319,"end":327,"id":43,"ws":true},{"text":"of","start":328,"end":330,"id":44,"ws":true},{"text":"interactions","start":331,"end":343,"id":45,"ws":true},{"text":":","start":344,"end":345,"id":46,"ws":true},{"text":"the","start":346,"end":349,"id":47,"ws":true},{"text":"response","start":350,"end":358,"id":48,"ws":true},{"text":"surface","start":359,"end":366,"id":49,"ws":true},{"text":"analysis","start":367,"end":375,"id":50,"ws":true},{"text":"of","start":376,"end":378,"id":51,"ws":true},{"text":"Bliss","start":379,"end":384,"id":52,"ws":true},{"text":"independence","start":385,"end":397,"id":53,"ws":true},{"text":"and","start":398,"end":401,"id":54,"ws":true},{"text":"the","start":402,"end":405,"id":55,"ws":true},{"text":"isobolographic","start":406,"end":420,"id":56,"ws":true},{"text":"analysis","start":421,"end":429,"id":57,"ws":true},{"text":"of","start":430,"end":432,"id":58,"ws":true},{"text":"Loewe","start":433,"end":438,"id":59,"ws":true},{"text":"additivity","start":439,"end":449,"id":60,"ws":true},{"text":"zero","start":450,"end":454,"id":61,"ws":true},{"text":"interaction","start":455,"end":466,"id":62,"ws":true},{"text":"theories","start":467,"end":475,"id":63,"ws":true},{"text":".","start":476,"end":477,"id":64,"ws":false}],"spans":[{"start":50,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},{"start":70,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},{"start":138,"end":150,"token_start":20,"token_end":20,"label":"DRUG"},{"start":169,"end":181,"token_start":24,"token_end":24,"label":"DRUG"}],"_input_hash":-126080632,"_task_hash":-122720977,"_session_id":"drug_drug_pilot_split-yosi","_view_id":"blocks","relations":[{"head":8,"child":11,"head_span":{"start":50,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":70,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"This study evaluated the safety and efficacy of inotuzumab ozogamicin ( INO ) , a targeted humanized anti-CD22 antibody conjugated to calicheamicin , plus rituximab ( R-INO ) every 3 weeks , up to six cycles , followed by high dose therapy and autologous stem cell transplant ( HDT-aSCT ) in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) .","paragraph":"<h3><u>A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.</u></h3> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>inotuzumab</i></b> <b style='color:MediumOrchid;'><i>ozogamicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>INO</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>humanized</i></b> <b style='color:DodgerBlue;'><i>anti-CD22</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>conjugated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>calicheamicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>R-INO</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>autologous</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplant</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HDT-aSCT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>diffuse</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>B-cell</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DLBCL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary endpoint was overall response (OR) rate after three cycles of R-INO. Sixty-three patients were enrolled. Common grade 3/4 adverse events during R-INO treatment were thrombocytopenia, lymphopenia and neutropenia. OR rate after three cycles of R-INO was 28.6% (95% confidence interval: 17.9-41.4). Eighteen patients underwent HDT-aSCT; 2-year progression-free survival (PFS) for these patients was 61.1%. Serious infections and hepatic toxicity following aSCT occurred in 33% and 22%, respectively. One- and 2-year PFS rates for all enrolled patients were 28.9% and 25.3%, respectively (median, 3.0 months). R-INO had lower than expected activity as a salvage regimen for transplant eligible patients with DLBCL. ","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"evaluated","start":11,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"safety","start":25,"end":31,"id":4,"ws":true},{"text":"and","start":32,"end":35,"id":5,"ws":true},{"text":"efficacy","start":36,"end":44,"id":6,"ws":true},{"text":"of","start":45,"end":47,"id":7,"ws":true},{"text":"inotuzumab","start":48,"end":58,"id":8,"ws":true},{"text":"ozogamicin","start":59,"end":69,"id":9,"ws":true},{"text":"(","start":70,"end":71,"id":10,"ws":true},{"text":"INO","start":72,"end":75,"id":11,"ws":true},{"text":")","start":76,"end":77,"id":12,"ws":true},{"text":",","start":78,"end":79,"id":13,"ws":true},{"text":"a","start":80,"end":81,"id":14,"ws":true},{"text":"targeted","start":82,"end":90,"id":15,"ws":true},{"text":"humanized","start":91,"end":100,"id":16,"ws":true},{"text":"anti-CD22","start":101,"end":110,"id":17,"ws":true},{"text":"antibody","start":111,"end":119,"id":18,"ws":true},{"text":"conjugated","start":120,"end":130,"id":19,"ws":true},{"text":"to","start":131,"end":133,"id":20,"ws":true},{"text":"calicheamicin","start":134,"end":147,"id":21,"ws":true},{"text":",","start":148,"end":149,"id":22,"ws":true},{"text":"plus","start":150,"end":154,"id":23,"ws":true},{"text":"rituximab","start":155,"end":164,"id":24,"ws":true},{"text":"(","start":165,"end":166,"id":25,"ws":true},{"text":"R-INO","start":167,"end":172,"id":26,"ws":true},{"text":")","start":173,"end":174,"id":27,"ws":true},{"text":"every","start":175,"end":180,"id":28,"ws":true},{"text":"3","start":181,"end":182,"id":29,"ws":true},{"text":"weeks","start":183,"end":188,"id":30,"ws":true},{"text":",","start":189,"end":190,"id":31,"ws":true},{"text":"up","start":191,"end":193,"id":32,"ws":true},{"text":"to","start":194,"end":196,"id":33,"ws":true},{"text":"six","start":197,"end":200,"id":34,"ws":true},{"text":"cycles","start":201,"end":207,"id":35,"ws":true},{"text":",","start":208,"end":209,"id":36,"ws":true},{"text":"followed","start":210,"end":218,"id":37,"ws":true},{"text":"by","start":219,"end":221,"id":38,"ws":true},{"text":"high","start":222,"end":226,"id":39,"ws":true},{"text":"dose","start":227,"end":231,"id":40,"ws":true},{"text":"therapy","start":232,"end":239,"id":41,"ws":true},{"text":"and","start":240,"end":243,"id":42,"ws":true},{"text":"autologous","start":244,"end":254,"id":43,"ws":true},{"text":"stem","start":255,"end":259,"id":44,"ws":true},{"text":"cell","start":260,"end":264,"id":45,"ws":true},{"text":"transplant","start":265,"end":275,"id":46,"ws":true},{"text":"(","start":276,"end":277,"id":47,"ws":true},{"text":"HDT-aSCT","start":278,"end":286,"id":48,"ws":true},{"text":")","start":287,"end":288,"id":49,"ws":true},{"text":"in","start":289,"end":291,"id":50,"ws":true},{"text":"patients","start":292,"end":300,"id":51,"ws":true},{"text":"with","start":301,"end":305,"id":52,"ws":true},{"text":"high-risk","start":306,"end":315,"id":53,"ws":true},{"text":"relapsed/refractory","start":316,"end":335,"id":54,"ws":true},{"text":"diffuse","start":336,"end":343,"id":55,"ws":true},{"text":"large","start":344,"end":349,"id":56,"ws":true},{"text":"B-cell","start":350,"end":356,"id":57,"ws":true},{"text":"lymphoma","start":357,"end":365,"id":58,"ws":true},{"text":"(","start":366,"end":367,"id":59,"ws":true},{"text":"DLBCL","start":368,"end":373,"id":60,"ws":true},{"text":")","start":374,"end":375,"id":61,"ws":true},{"text":".","start":376,"end":377,"id":62,"ws":false}],"spans":[{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},{"start":59,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},{"start":155,"end":164,"token_start":24,"token_end":24,"label":"DRUG"},{"start":278,"end":286,"token_start":48,"token_end":48,"label":"DRUG"}],"_input_hash":801353175,"_task_hash":363166702,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":24,"child":8,"head_span":{"start":155,"end":164,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":48,"child":24,"head_span":{"start":278,"end":286,"token_start":48,"token_end":48,"label":"DRUG"},"child_span":{"start":155,"end":164,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"These are the first 2 reports of successful treatment of this condition by use of a combination of methylprednisolone and mycophenolate mofetil , and , in 1 of the cases , additional medication with intravenous immunoglobulin .","paragraph":"<h3><u>Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.</u></h3><b style='color:Tomato;'><i>ipilimumab</i></b> binds and blocks cytotoxic T-lymphocyte-associated antigen-4, causing enhanced T-cell reaction, antitumor response, and significant improvement of the overall survival of patients with metastatic melanoma. Patients treated with <b style='color:Tomato;'><i>ipilimumab</i></b> can develop immune-related adverse effects, primarily dermatitis, colitis, hepatitis, and hypophysitis. Although, in phase I-III studies, 64.2% of all patients suffered from immune-related adverse effects, ocular adverse effects occurred in 1.3% only. In the cases reported below, 2 patients with metastatic melanoma developed severe ocular myositis after treatment with <b style='color:Tomato;'><i>ipilimumab</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>reports</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>condition</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>additional</i></b> <b style='color:DodgerBlue;'><i>medication</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"are","start":6,"end":9,"id":1,"ws":true},{"text":"the","start":10,"end":13,"id":2,"ws":true},{"text":"first","start":14,"end":19,"id":3,"ws":true},{"text":"2","start":20,"end":21,"id":4,"ws":true},{"text":"reports","start":22,"end":29,"id":5,"ws":true},{"text":"of","start":30,"end":32,"id":6,"ws":true},{"text":"successful","start":33,"end":43,"id":7,"ws":true},{"text":"treatment","start":44,"end":53,"id":8,"ws":true},{"text":"of","start":54,"end":56,"id":9,"ws":true},{"text":"this","start":57,"end":61,"id":10,"ws":true},{"text":"condition","start":62,"end":71,"id":11,"ws":true},{"text":"by","start":72,"end":74,"id":12,"ws":true},{"text":"use","start":75,"end":78,"id":13,"ws":true},{"text":"of","start":79,"end":81,"id":14,"ws":true},{"text":"a","start":82,"end":83,"id":15,"ws":true},{"text":"combination","start":84,"end":95,"id":16,"ws":true},{"text":"of","start":96,"end":98,"id":17,"ws":true},{"text":"methylprednisolone","start":99,"end":117,"id":18,"ws":true},{"text":"and","start":118,"end":121,"id":19,"ws":true},{"text":"mycophenolate","start":122,"end":135,"id":20,"ws":true},{"text":"mofetil","start":136,"end":143,"id":21,"ws":true},{"text":",","start":144,"end":145,"id":22,"ws":true},{"text":"and","start":146,"end":149,"id":23,"ws":true},{"text":",","start":150,"end":151,"id":24,"ws":true},{"text":"in","start":152,"end":154,"id":25,"ws":true},{"text":"1","start":155,"end":156,"id":26,"ws":true},{"text":"of","start":157,"end":159,"id":27,"ws":true},{"text":"the","start":160,"end":163,"id":28,"ws":true},{"text":"cases","start":164,"end":169,"id":29,"ws":true},{"text":",","start":170,"end":171,"id":30,"ws":true},{"text":"additional","start":172,"end":182,"id":31,"ws":true},{"text":"medication","start":183,"end":193,"id":32,"ws":true},{"text":"with","start":194,"end":198,"id":33,"ws":true},{"text":"intravenous","start":199,"end":210,"id":34,"ws":true},{"text":"immunoglobulin","start":211,"end":225,"id":35,"ws":true},{"text":".","start":226,"end":227,"id":36,"ws":false}],"spans":[{"start":99,"end":117,"token_start":18,"token_end":18,"label":"DRUG"},{"start":122,"end":135,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":2082941197,"_task_hash":1452488152,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":18,"child":20,"head_span":{"start":99,"end":117,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":122,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":20,"head_span":{"start":99,"end":117,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":122,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":20,"child":35,"head_span":{"start":122,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":211,"end":225,"token_start":35,"token_end":35,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"The introduction of the selective serotonin reuptake inhibitors , moclobemide and mianserin has been a major advance in the treatment of depression , and is already leading to major shifts in the pattern of antidepressants prescribing .","paragraph":"<h3><u>The management of depression. The place of the new antidepressants. Part 1. General overview.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>introduction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>selective</i></b> <b style='color:DodgerBlue;'><i>serotonin</i></b> <b style='color:DodgerBlue;'><i>reuptake</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>moclobemide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mianserin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>major</i></b> <b style='color:DodgerBlue;'><i>advance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>depression</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>already</i></b> <b style='color:DodgerBlue;'><i>leading</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>major</i></b> <b style='color:DodgerBlue;'><i>shifts</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pattern</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>antidepressants</i></b> <b style='color:DodgerBlue;'><i>prescribing</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These antidepressants are safe, well tolerated and effective, and in conjunction with older agents such as the tricyclics, provide the clinician with a broad range of treatments for this common and disabling disorder. This two-part review will focus on the management of depression in general practice.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"introduction","start":4,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"the","start":20,"end":23,"id":3,"ws":true},{"text":"selective","start":24,"end":33,"id":4,"ws":true},{"text":"serotonin","start":34,"end":43,"id":5,"ws":true},{"text":"reuptake","start":44,"end":52,"id":6,"ws":true},{"text":"inhibitors","start":53,"end":63,"id":7,"ws":true},{"text":",","start":64,"end":65,"id":8,"ws":true},{"text":"moclobemide","start":66,"end":77,"id":9,"ws":true},{"text":"and","start":78,"end":81,"id":10,"ws":true},{"text":"mianserin","start":82,"end":91,"id":11,"ws":true},{"text":"has","start":92,"end":95,"id":12,"ws":true},{"text":"been","start":96,"end":100,"id":13,"ws":true},{"text":"a","start":101,"end":102,"id":14,"ws":true},{"text":"major","start":103,"end":108,"id":15,"ws":true},{"text":"advance","start":109,"end":116,"id":16,"ws":true},{"text":"in","start":117,"end":119,"id":17,"ws":true},{"text":"the","start":120,"end":123,"id":18,"ws":true},{"text":"treatment","start":124,"end":133,"id":19,"ws":true},{"text":"of","start":134,"end":136,"id":20,"ws":true},{"text":"depression","start":137,"end":147,"id":21,"ws":true},{"text":",","start":148,"end":149,"id":22,"ws":true},{"text":"and","start":150,"end":153,"id":23,"ws":true},{"text":"is","start":154,"end":156,"id":24,"ws":true},{"text":"already","start":157,"end":164,"id":25,"ws":true},{"text":"leading","start":165,"end":172,"id":26,"ws":true},{"text":"to","start":173,"end":175,"id":27,"ws":true},{"text":"major","start":176,"end":181,"id":28,"ws":true},{"text":"shifts","start":182,"end":188,"id":29,"ws":true},{"text":"in","start":189,"end":191,"id":30,"ws":true},{"text":"the","start":192,"end":195,"id":31,"ws":true},{"text":"pattern","start":196,"end":203,"id":32,"ws":true},{"text":"of","start":204,"end":206,"id":33,"ws":true},{"text":"antidepressants","start":207,"end":222,"id":34,"ws":true},{"text":"prescribing","start":223,"end":234,"id":35,"ws":true},{"text":".","start":235,"end":236,"id":36,"ws":false}],"spans":[{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},{"start":82,"end":91,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-910831067,"_task_hash":1925078850,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Topotecan , a semisynthetic camptothecin , exerts its cytotoxic effect through inhibition of DNA topoisomerase I. Single-agent topotecan has demonstrated activity against persistent , metastatic and recurrent cancer of the uterine cervix .","paragraph":"<h3><u>Topotecan in the management of cervical cancer.</u></h3> <b style='color:MediumOrchid;'><i>Topotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>semisynthetic</i></b> <b style='color:DodgerBlue;'><i>camptothecin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>exerts</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>through</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>DNA</i></b> <b style='color:DodgerBlue;'><i>topoisomerase</i></b> <b style='color:DodgerBlue;'><i>I.</i></b> <b style='color:DodgerBlue;'><i>Single-agent</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>persistent</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>uterine</i></b> <b style='color:DodgerBlue;'><i>cervix</i></b> <b style='color:DodgerBlue;'><i>.</i></b> When combined with cisplatin in Phase II trials, further improved response rates have been reported. The cisplatin/<b style='color:Tomato;'><i>topotecan</i></b> doublet subsequently proved to be the first regimen in a series of multiple Phase III studies to demonstrate improved disease-free and overall survival in this setting compared with cisplatin alone, thus leading to its third indication by both the US FDA and the European Medicines Agency in 2006. This survival advantage was achieved at the expense of an increase in grade 3-4 hematologic toxicity; however, there was no difference in patient-reported quality of life between the cisplatin/<b style='color:Tomato;'><i>topotecan</i></b> doublet and single-agent cisplatin. This article reviews the pharmacology of <b style='color:Tomato;'><i>topotecan</i></b> and its evolution as an active agent in advanced and metastatic cervical cancer that is not amenable to cure with surgery or radiotherapy.","tokens":[{"text":"Topotecan","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"a","start":12,"end":13,"id":2,"ws":true},{"text":"semisynthetic","start":14,"end":27,"id":3,"ws":true},{"text":"camptothecin","start":28,"end":40,"id":4,"ws":true},{"text":",","start":41,"end":42,"id":5,"ws":true},{"text":"exerts","start":43,"end":49,"id":6,"ws":true},{"text":"its","start":50,"end":53,"id":7,"ws":true},{"text":"cytotoxic","start":54,"end":63,"id":8,"ws":true},{"text":"effect","start":64,"end":70,"id":9,"ws":true},{"text":"through","start":71,"end":78,"id":10,"ws":true},{"text":"inhibition","start":79,"end":89,"id":11,"ws":true},{"text":"of","start":90,"end":92,"id":12,"ws":true},{"text":"DNA","start":93,"end":96,"id":13,"ws":true},{"text":"topoisomerase","start":97,"end":110,"id":14,"ws":true},{"text":"I.","start":111,"end":113,"id":15,"ws":true},{"text":"Single-agent","start":114,"end":126,"id":16,"ws":true},{"text":"topotecan","start":127,"end":136,"id":17,"ws":true},{"text":"has","start":137,"end":140,"id":18,"ws":true},{"text":"demonstrated","start":141,"end":153,"id":19,"ws":true},{"text":"activity","start":154,"end":162,"id":20,"ws":true},{"text":"against","start":163,"end":170,"id":21,"ws":true},{"text":"persistent","start":171,"end":181,"id":22,"ws":true},{"text":",","start":182,"end":183,"id":23,"ws":true},{"text":"metastatic","start":184,"end":194,"id":24,"ws":true},{"text":"and","start":195,"end":198,"id":25,"ws":true},{"text":"recurrent","start":199,"end":208,"id":26,"ws":true},{"text":"cancer","start":209,"end":215,"id":27,"ws":true},{"text":"of","start":216,"end":218,"id":28,"ws":true},{"text":"the","start":219,"end":222,"id":29,"ws":true},{"text":"uterine","start":223,"end":230,"id":30,"ws":true},{"text":"cervix","start":231,"end":237,"id":31,"ws":true},{"text":".","start":238,"end":239,"id":32,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":127,"end":136,"token_start":17,"token_end":17,"label":"DRUG"}],"_input_hash":-1055736483,"_task_hash":1549491903,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Four of these had equivocal plasma levels of both norepinephrine and epinephrine , suggesting that overnight clonidine suppression may be of particular value when tumor secretion is intermittent or low .","paragraph":"<h3><u>Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytoma.</u></h3>In a prospective study designed to differentiate pheochromocytoma from other forms of hypertension, urinary catecholamines were measured after sleep and <b style='color:Tomato;'><i>clonidine</i></b> administration in 12 patients with pheochromocytoma, 19 hypertensive patients in whom pheochromocytoma was suspected but later excluded, and 31 hypertensive patients in whom pheochromocytoma was never suspected. The test correctly identified all 12 patients in whom pheochromocytoma was present. <b style='color:DodgerBlue;'><i>Four</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>equivocal</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>norepinephrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>overnight</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>particular</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>intermittent</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>.</i></b> When pheochromocytoma was not present, urinary nor<b style='color:Tomato;'><i>epinephrine</i></b> and <b style='color:Tomato;'><i>epinephrine</i></b> levels were suppressed below 60 and 20 nmol/mmol creatinine, respectively, after sleep and <b style='color:Tomato;'><i>clonidine</i></b>, the two in combination giving better suppression than sleep alone. Since urinary catecholamines can be determined relatively easily by high-pressure liquid chromatography with electrochemical detection, this test may be more widely applicable than suppression tests based on plasma measurements.","tokens":[{"text":"Four","start":0,"end":4,"id":0,"ws":true},{"text":"of","start":5,"end":7,"id":1,"ws":true},{"text":"these","start":8,"end":13,"id":2,"ws":true},{"text":"had","start":14,"end":17,"id":3,"ws":true},{"text":"equivocal","start":18,"end":27,"id":4,"ws":true},{"text":"plasma","start":28,"end":34,"id":5,"ws":true},{"text":"levels","start":35,"end":41,"id":6,"ws":true},{"text":"of","start":42,"end":44,"id":7,"ws":true},{"text":"both","start":45,"end":49,"id":8,"ws":true},{"text":"norepinephrine","start":50,"end":64,"id":9,"ws":true},{"text":"and","start":65,"end":68,"id":10,"ws":true},{"text":"epinephrine","start":69,"end":80,"id":11,"ws":true},{"text":",","start":81,"end":82,"id":12,"ws":true},{"text":"suggesting","start":83,"end":93,"id":13,"ws":true},{"text":"that","start":94,"end":98,"id":14,"ws":true},{"text":"overnight","start":99,"end":108,"id":15,"ws":true},{"text":"clonidine","start":109,"end":118,"id":16,"ws":true},{"text":"suppression","start":119,"end":130,"id":17,"ws":true},{"text":"may","start":131,"end":134,"id":18,"ws":true},{"text":"be","start":135,"end":137,"id":19,"ws":true},{"text":"of","start":138,"end":140,"id":20,"ws":true},{"text":"particular","start":141,"end":151,"id":21,"ws":true},{"text":"value","start":152,"end":157,"id":22,"ws":true},{"text":"when","start":158,"end":162,"id":23,"ws":true},{"text":"tumor","start":163,"end":168,"id":24,"ws":true},{"text":"secretion","start":169,"end":178,"id":25,"ws":true},{"text":"is","start":179,"end":181,"id":26,"ws":true},{"text":"intermittent","start":182,"end":194,"id":27,"ws":true},{"text":"or","start":195,"end":197,"id":28,"ws":true},{"text":"low","start":198,"end":201,"id":29,"ws":true},{"text":".","start":202,"end":203,"id":30,"ws":false}],"spans":[{"start":69,"end":80,"token_start":11,"token_end":11,"label":"DRUG"},{"start":109,"end":118,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-52607172,"_task_hash":824137051,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In conclusion , concurrent introduction of ATGAM and tacrolimus is a promising therapeutic combination for GVHD refractory to steroids and cyclosporine .","paragraph":"<h3><u>Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis.</u></h3>We report our experience with the combination of anti-thymocyte globulin (ATGAM) and <b style='color:Tomato;'><i>tacrolimus</i></b> in the treatment of 20 patients with steroid refractory and dependent acute graft-versus-host disease (GVHD) transplanted between August 1996 and February 2000. All patients received <b style='color:Tomato;'><i>cyclosporin</i></b>e-based GVHD prophylaxis. Thirteen patients developed a maximum of grade IV, five grade III and two grade II acute GVHD, with 15 patients being refractory to steroids and five dependent on steroids. Patients were treated with ATGAM (15 mg/kg for 5 d) and <b style='color:Tomato;'><i>tacrolimus</i></b> (0.025--0.1 mg/kg/d) in addition to continuation of their high-dose steroids and cessation of their <b style='color:Tomato;'><i>cyclosporin</i></b>e. Within 28 d of treatment, we observed eight complete responses (CR), six partial responses (PR) and six with no response. Overall response (CR + PR) was predicted by GVHD severity. Infectious complications occurred in 80% of patients. The median survival was 86.5 d (range, 21--1081 d) with 35% of patients remaining alive. Survival following combination therapy was significantly more likely in men (P < 0.001), skin-only GVHD (P = 0.027), less severe GVHD (P = 0.048), and in responders to <b style='color:Tomato;'><i>tacrolimus</i></b> and ATGAM (P < 0.001). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>conclusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>concurrent</i></b> <b style='color:DodgerBlue;'><i>introduction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ATGAM</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tacrolimus</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>promising</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>GVHD</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>steroids</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"conclusion","start":3,"end":13,"id":1,"ws":true},{"text":",","start":14,"end":15,"id":2,"ws":true},{"text":"concurrent","start":16,"end":26,"id":3,"ws":true},{"text":"introduction","start":27,"end":39,"id":4,"ws":true},{"text":"of","start":40,"end":42,"id":5,"ws":true},{"text":"ATGAM","start":43,"end":48,"id":6,"ws":true},{"text":"and","start":49,"end":52,"id":7,"ws":true},{"text":"tacrolimus","start":53,"end":63,"id":8,"ws":true},{"text":"is","start":64,"end":66,"id":9,"ws":true},{"text":"a","start":67,"end":68,"id":10,"ws":true},{"text":"promising","start":69,"end":78,"id":11,"ws":true},{"text":"therapeutic","start":79,"end":90,"id":12,"ws":true},{"text":"combination","start":91,"end":102,"id":13,"ws":true},{"text":"for","start":103,"end":106,"id":14,"ws":true},{"text":"GVHD","start":107,"end":111,"id":15,"ws":true},{"text":"refractory","start":112,"end":122,"id":16,"ws":true},{"text":"to","start":123,"end":125,"id":17,"ws":true},{"text":"steroids","start":126,"end":134,"id":18,"ws":true},{"text":"and","start":135,"end":138,"id":19,"ws":true},{"text":"cyclosporine","start":139,"end":151,"id":20,"ws":true},{"text":".","start":152,"end":153,"id":21,"ws":false}],"spans":[{"start":43,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":53,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":126,"end":134,"token_start":18,"token_end":18,"label":"DRUG"},{"start":139,"end":151,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":138213155,"_task_hash":-1185275877,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":43,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":53,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Comparison of geometric least-squares mean PK parameters between arms showed no impact of pertuzumab on the PK of trastuzumab or docetaxel .","paragraph":"<h3><u>Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.</u></h3><b style='color:Tomato;'><i>pertuzumab</i></b> is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody. Combined with <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>pertuzumab</i></b> improved progression-free and overall survival versus <b style='color:Tomato;'><i>trastuzumab</i></b> plus <b style='color:Tomato;'><i>docetaxel</i></b> in the phase III CLEOPATRA trial (NCT00567190) in first-line HER2-positive metastatic breast cancer. Thirty-seven patients participated in a pharmacokinetic (PK)/corrected QT interval substudy of CLEOPATRA, which evaluated potential PK drug-drug interaction (DDI). PK parameters were calculated using noncompartmental methods, and DDI analyses were carried out. In the presence of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, the mean <b style='color:Tomato;'><i>pertuzumab</i></b> Cmin and Cmax in cycle 3 were 63.6 and 183 \u00b5g/ml, respectively. The <b style='color:Tomato;'><i>pertuzumab</i></b> concentrations observed were consistent with simulations from a validated population PK model, indicating that <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> did not alter <b style='color:Tomato;'><i>pertuzumab</i></b> PK. <b style='color:DodgerBlue;'><i>Comparison</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>geometric</i></b> <b style='color:DodgerBlue;'><i>least-squares</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>PK</i></b> <b style='color:DodgerBlue;'><i>parameters</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>arms</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>PK</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In conclusion, no PK DDI was observed when <b style='color:Tomato;'><i>pertuzumab</i></b>, <b style='color:Tomato;'><i>trastuzumab</i></b>, and <b style='color:Tomato;'><i>docetaxel</i></b> were combined for the treatment of HER2-positive metastatic breast cancer. ","tokens":[{"text":"Comparison","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"geometric","start":14,"end":23,"id":2,"ws":true},{"text":"least-squares","start":24,"end":37,"id":3,"ws":true},{"text":"mean","start":38,"end":42,"id":4,"ws":true},{"text":"PK","start":43,"end":45,"id":5,"ws":true},{"text":"parameters","start":46,"end":56,"id":6,"ws":true},{"text":"between","start":57,"end":64,"id":7,"ws":true},{"text":"arms","start":65,"end":69,"id":8,"ws":true},{"text":"showed","start":70,"end":76,"id":9,"ws":true},{"text":"no","start":77,"end":79,"id":10,"ws":true},{"text":"impact","start":80,"end":86,"id":11,"ws":true},{"text":"of","start":87,"end":89,"id":12,"ws":true},{"text":"pertuzumab","start":90,"end":100,"id":13,"ws":true},{"text":"on","start":101,"end":103,"id":14,"ws":true},{"text":"the","start":104,"end":107,"id":15,"ws":true},{"text":"PK","start":108,"end":110,"id":16,"ws":true},{"text":"of","start":111,"end":113,"id":17,"ws":true},{"text":"trastuzumab","start":114,"end":125,"id":18,"ws":true},{"text":"or","start":126,"end":128,"id":19,"ws":true},{"text":"docetaxel","start":129,"end":138,"id":20,"ws":true},{"text":".","start":139,"end":140,"id":21,"ws":false}],"spans":[{"start":90,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},{"start":114,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},{"start":129,"end":138,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1301492706,"_task_hash":-115259479,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":13,"child":18,"head_span":{"start":90,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":114,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":20,"head_span":{"start":90,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":129,"end":138,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["POS11","POS1T0","POS21","POS2T0","COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"This study was designed to test the hypothesis that positively charged dendrimers form a complex with enoxaparin , a low-molecular weight heparin ( LMWH ) , and that the resulting drug-dendrimer complex is effective in preventing deep vein thrombosis after pulmonary administration .","paragraph":"<h3><u>Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin.</u></h3> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>hypothesis</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>positively</i></b> <b style='color:DodgerBlue;'><i>charged</i></b> <b style='color:DodgerBlue;'><i>dendrimers</i></b> <b style='color:DodgerBlue;'><i>form</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>complex</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>enoxaparin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>low-molecular</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:MediumOrchid;'><i>heparin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LMWH</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>resulting</i></b> <b style='color:DodgerBlue;'><i>drug-dendrimer</i></b> <b style='color:DodgerBlue;'><i>complex</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preventing</i></b> <b style='color:DodgerBlue;'><i>deep</i></b> <b style='color:DodgerBlue;'><i>vein</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>pulmonary</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Fourier Transform Infrared (FTIR) spectroscopy and the azure A assay were used to evaluate interactions between dendrimers and <b style='color:Tomato;'><i>enoxaparin</i></b>. The efficacy of polyamidoamine (PAMAM) dendrimers in enhancing pulmonary absorption of <b style='color:Tomato;'><i>enoxaparin</i></b> was studied by administering <b style='color:Tomato;'><i>enoxaparin</i></b>-dendrimer formulations into the lungs of anesthetized rats and monitoring drug absorption by measuring plasma anti-factor Xa activity. The optimized formulations were evaluated for their efficacy in preventing deep vein thrombosis in a rodent model. The safety of the formulations was tested by studying their effects on mucociliary transport rate (MTR) in a frog palate model and by measuring injury markers in rat bronchoalveolar fluid. The FTIR data and azure A assay revealed ionic interactions between the amino groups of cationic dendrimers and the carboxylic and sulfate groups of <b style='color:Tomato;'><i>enoxaparin</i></b>. Positively charged dendrimers increased the relative bioavailability of <b style='color:Tomato;'><i>enoxaparin</i></b> by 40%, while a negatively charged dendrimer had no effect. Formulations containing 1% G2 or 0.5% G3 PAMAM dendrimer plus <b style='color:Tomato;'><i>enoxaparin</i></b> were as efficacious in preventing deep vein thrombosis in a rat model as subcutaneously administered <b style='color:Tomato;'><i>enoxaparin</i></b>. The formulations did not adversely affect the MTR or produce extensive damage to the lungs. Positively charged dendrimers are a suitable carrier for pulmonary delivery of <b style='color:Tomato;'><i>enoxaparin</i></b>. They enhance pulmonary absorption of LMWH probably by reducing negative surface charge density of the drug molecule.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"was","start":11,"end":14,"id":2,"ws":true},{"text":"designed","start":15,"end":23,"id":3,"ws":true},{"text":"to","start":24,"end":26,"id":4,"ws":true},{"text":"test","start":27,"end":31,"id":5,"ws":true},{"text":"the","start":32,"end":35,"id":6,"ws":true},{"text":"hypothesis","start":36,"end":46,"id":7,"ws":true},{"text":"that","start":47,"end":51,"id":8,"ws":true},{"text":"positively","start":52,"end":62,"id":9,"ws":true},{"text":"charged","start":63,"end":70,"id":10,"ws":true},{"text":"dendrimers","start":71,"end":81,"id":11,"ws":true},{"text":"form","start":82,"end":86,"id":12,"ws":true},{"text":"a","start":87,"end":88,"id":13,"ws":true},{"text":"complex","start":89,"end":96,"id":14,"ws":true},{"text":"with","start":97,"end":101,"id":15,"ws":true},{"text":"enoxaparin","start":102,"end":112,"id":16,"ws":true},{"text":",","start":113,"end":114,"id":17,"ws":true},{"text":"a","start":115,"end":116,"id":18,"ws":true},{"text":"low-molecular","start":117,"end":130,"id":19,"ws":true},{"text":"weight","start":131,"end":137,"id":20,"ws":true},{"text":"heparin","start":138,"end":145,"id":21,"ws":true},{"text":"(","start":146,"end":147,"id":22,"ws":true},{"text":"LMWH","start":148,"end":152,"id":23,"ws":true},{"text":")","start":153,"end":154,"id":24,"ws":true},{"text":",","start":155,"end":156,"id":25,"ws":true},{"text":"and","start":157,"end":160,"id":26,"ws":true},{"text":"that","start":161,"end":165,"id":27,"ws":true},{"text":"the","start":166,"end":169,"id":28,"ws":true},{"text":"resulting","start":170,"end":179,"id":29,"ws":true},{"text":"drug-dendrimer","start":180,"end":194,"id":30,"ws":true},{"text":"complex","start":195,"end":202,"id":31,"ws":true},{"text":"is","start":203,"end":205,"id":32,"ws":true},{"text":"effective","start":206,"end":215,"id":33,"ws":true},{"text":"in","start":216,"end":218,"id":34,"ws":true},{"text":"preventing","start":219,"end":229,"id":35,"ws":true},{"text":"deep","start":230,"end":234,"id":36,"ws":true},{"text":"vein","start":235,"end":239,"id":37,"ws":true},{"text":"thrombosis","start":240,"end":250,"id":38,"ws":true},{"text":"after","start":251,"end":256,"id":39,"ws":true},{"text":"pulmonary","start":257,"end":266,"id":40,"ws":true},{"text":"administration","start":267,"end":281,"id":41,"ws":true},{"text":".","start":282,"end":283,"id":42,"ws":false}],"spans":[{"start":102,"end":112,"token_start":16,"token_end":16,"label":"DRUG"},{"start":138,"end":145,"token_start":21,"token_end":21,"label":"DRUG"}],"_input_hash":39743980,"_task_hash":1269543690,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We proved experimentally the use of ECEEM for multiplex determination of kinetic parameters describing weak ( 3 mM > K(d ) > 80 \u03bcM ) and fast ( 0.25 s \u2265 \u03c4 \u2265 0.9 ms ) noncovalent interactions between four small molecule drugs ( ibuprofen , S-flurbiprofen , salicylic acid and phenylbutazone ) and \u03b1- and \u03b2-cyclodextrins .","paragraph":"<h3><u>Revealing equilibrium and rate constants of weak and fast noncovalent interactions.</u></h3>Rate and equilibrium constants of weak noncovalent molecular interactions are extremely difficult to measure. Here, we introduced a homogeneous approach called equilibrium capillary electrophoresis of equilibrium mixtures (ECEEM) to determine k(on), k(off), and K(d) of weak (K(d) > 1 \u03bcM) and fast kinetics (relaxation time, \u03c4 < 0.1 s) in quasi-equilibrium for multiple unlabeled ligands simultaneously in one microreactor. Conceptually, an equilibrium mixture (EM) of a ligand (L), target (T), and a complex (C) is prepared. The mixture is introduced into the beginning of a capillary reactor with aspect ratio >1000 filled with T. Afterward, differential mobility of L, T, and C along the reactor is induced by an electric field. The combination of differential mobility of reactants and their interactions leads to a change of the EM peak shape. This change is a function of rate constants, so the rate and equilibrium constants can be directly determined from the analysis of the EM peak shape (width and symmetry) and propagation pattern along the reactor. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>proved</i></b> <b style='color:DodgerBlue;'><i>experimentally</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ECEEM</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>multiplex</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>kinetic</i></b> <b style='color:DodgerBlue;'><i>parameters</i></b> <b style='color:DodgerBlue;'><i>describing</i></b> <b style='color:DodgerBlue;'><i>weak</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>mM</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>K(d</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>\u03bcM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>fast</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.25</i></b> <b style='color:DodgerBlue;'><i>s</i></b> <b style='color:DodgerBlue;'><i>\u2265</i></b> <b style='color:DodgerBlue;'><i>\u03c4</i></b> <b style='color:DodgerBlue;'><i>\u2265</i></b> <b style='color:DodgerBlue;'><i>0.9</i></b> <b style='color:DodgerBlue;'><i>ms</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>noncovalent</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>molecule</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ibuprofen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>S-flurbiprofen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>salicylic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>phenylbutazone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>\u03b1-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>\u03b2-cyclodextrins</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The affinity of the drugs was significantly higher for \u03b2-cyclodextrin than \u03b1-cyclodextrin and mostly determined by the rate constant of complex formation.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"proved","start":3,"end":9,"id":1,"ws":true},{"text":"experimentally","start":10,"end":24,"id":2,"ws":true},{"text":"the","start":25,"end":28,"id":3,"ws":true},{"text":"use","start":29,"end":32,"id":4,"ws":true},{"text":"of","start":33,"end":35,"id":5,"ws":true},{"text":"ECEEM","start":36,"end":41,"id":6,"ws":true},{"text":"for","start":42,"end":45,"id":7,"ws":true},{"text":"multiplex","start":46,"end":55,"id":8,"ws":true},{"text":"determination","start":56,"end":69,"id":9,"ws":true},{"text":"of","start":70,"end":72,"id":10,"ws":true},{"text":"kinetic","start":73,"end":80,"id":11,"ws":true},{"text":"parameters","start":81,"end":91,"id":12,"ws":true},{"text":"describing","start":92,"end":102,"id":13,"ws":true},{"text":"weak","start":103,"end":107,"id":14,"ws":true},{"text":"(","start":108,"end":109,"id":15,"ws":true},{"text":"3","start":110,"end":111,"id":16,"ws":true},{"text":"mM","start":112,"end":114,"id":17,"ws":true},{"text":">","start":115,"end":116,"id":18,"ws":true},{"text":"K(d","start":117,"end":120,"id":19,"ws":true},{"text":")","start":121,"end":122,"id":20,"ws":true},{"text":">","start":123,"end":124,"id":21,"ws":true},{"text":"80","start":125,"end":127,"id":22,"ws":true},{"text":"\u03bcM","start":128,"end":130,"id":23,"ws":true},{"text":")","start":131,"end":132,"id":24,"ws":true},{"text":"and","start":133,"end":136,"id":25,"ws":true},{"text":"fast","start":137,"end":141,"id":26,"ws":true},{"text":"(","start":142,"end":143,"id":27,"ws":true},{"text":"0.25","start":144,"end":148,"id":28,"ws":true},{"text":"s","start":149,"end":150,"id":29,"ws":true},{"text":"\u2265","start":151,"end":152,"id":30,"ws":true},{"text":"\u03c4","start":153,"end":154,"id":31,"ws":true},{"text":"\u2265","start":155,"end":156,"id":32,"ws":true},{"text":"0.9","start":157,"end":160,"id":33,"ws":true},{"text":"ms","start":161,"end":163,"id":34,"ws":true},{"text":")","start":164,"end":165,"id":35,"ws":true},{"text":"noncovalent","start":166,"end":177,"id":36,"ws":true},{"text":"interactions","start":178,"end":190,"id":37,"ws":true},{"text":"between","start":191,"end":198,"id":38,"ws":true},{"text":"four","start":199,"end":203,"id":39,"ws":true},{"text":"small","start":204,"end":209,"id":40,"ws":true},{"text":"molecule","start":210,"end":218,"id":41,"ws":true},{"text":"drugs","start":219,"end":224,"id":42,"ws":true},{"text":"(","start":225,"end":226,"id":43,"ws":true},{"text":"ibuprofen","start":227,"end":236,"id":44,"ws":true},{"text":",","start":237,"end":238,"id":45,"ws":true},{"text":"S-flurbiprofen","start":239,"end":253,"id":46,"ws":true},{"text":",","start":254,"end":255,"id":47,"ws":true},{"text":"salicylic","start":256,"end":265,"id":48,"ws":true},{"text":"acid","start":266,"end":270,"id":49,"ws":true},{"text":"and","start":271,"end":274,"id":50,"ws":true},{"text":"phenylbutazone","start":275,"end":289,"id":51,"ws":true},{"text":")","start":290,"end":291,"id":52,"ws":true},{"text":"and","start":292,"end":295,"id":53,"ws":true},{"text":"\u03b1-","start":296,"end":298,"id":54,"ws":true},{"text":"and","start":299,"end":302,"id":55,"ws":true},{"text":"\u03b2-cyclodextrins","start":303,"end":318,"id":56,"ws":true},{"text":".","start":319,"end":320,"id":57,"ws":false}],"spans":[{"start":227,"end":236,"token_start":44,"token_end":44,"label":"DRUG"},{"start":239,"end":253,"token_start":46,"token_end":46,"label":"DRUG"},{"start":256,"end":270,"token_start":48,"token_end":49,"label":"DRUG"},{"start":275,"end":289,"token_start":51,"token_end":51,"label":"DRUG"},{"start":303,"end":318,"token_start":56,"token_end":56,"label":"DRUG"}],"_input_hash":-640218169,"_task_hash":-2047052720,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":44,"child":56,"head_span":{"start":227,"end":236,"token_start":44,"token_end":44,"label":"DRUG"},"child_span":{"start":303,"end":318,"token_start":56,"token_end":56,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":46,"child":56,"head_span":{"start":239,"end":253,"token_start":46,"token_end":46,"label":"DRUG"},"child_span":{"start":303,"end":318,"token_start":56,"token_end":56,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":51,"child":56,"head_span":{"start":275,"end":289,"token_start":51,"token_end":51,"label":"DRUG"},"child_span":{"start":303,"end":318,"token_start":56,"token_end":56,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB1T0","COMB2T0","COMB3T0"],"answer":"accept"}
{"text":"We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer , who had a positive second-look laparatomy or recurrent disease .","paragraph":"<h3><u>High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.</u></h3>High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>mobilization</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>32</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>second-look</i></b> <b style='color:DodgerBlue;'><i>laparatomy</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>ifosfamide</i></b> was given at 10 g/m2 by continuous i.v. from days 1 to 3. <b style='color:Tomato;'><i>etoposide</i></b> was given at 150 mg/m2 every 12 h for six doses on days 1-3. <b style='color:Tomato;'><i>filgrastim</i></b> was given at 10 microg/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34+ cell dose (>8 x 106 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) x 106 CD34+ cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose <b style='color:Tomato;'><i>ifosfamide</i></b> plus <b style='color:Tomato;'><i>etoposide</i></b> with <b style='color:Tomato;'><i>filgrastim</i></b> support was well tolerated, lead to successful stem cell harvest and had antitumor activity.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"evaluated","start":3,"end":12,"id":1,"ws":true},{"text":"the","start":13,"end":16,"id":2,"ws":true},{"text":"stem","start":17,"end":21,"id":3,"ws":true},{"text":"cell","start":22,"end":26,"id":4,"ws":true},{"text":"mobilization","start":27,"end":39,"id":5,"ws":true},{"text":"regimen","start":40,"end":47,"id":6,"ws":true},{"text":"of","start":48,"end":50,"id":7,"ws":true},{"text":"high-dose","start":51,"end":60,"id":8,"ws":true},{"text":"ifosfamide","start":61,"end":71,"id":9,"ws":true},{"text":"plus","start":72,"end":76,"id":10,"ws":true},{"text":"etoposide","start":77,"end":86,"id":11,"ws":true},{"text":"in","start":87,"end":89,"id":12,"ws":true},{"text":"32","start":90,"end":92,"id":13,"ws":true},{"text":"patients","start":93,"end":101,"id":14,"ws":true},{"text":"with","start":102,"end":106,"id":15,"ws":true},{"text":"epithelial","start":107,"end":117,"id":16,"ws":true},{"text":"ovarian","start":118,"end":125,"id":17,"ws":true},{"text":"cancer","start":126,"end":132,"id":18,"ws":true},{"text":",","start":133,"end":134,"id":19,"ws":true},{"text":"who","start":135,"end":138,"id":20,"ws":true},{"text":"had","start":139,"end":142,"id":21,"ws":true},{"text":"a","start":143,"end":144,"id":22,"ws":true},{"text":"positive","start":145,"end":153,"id":23,"ws":true},{"text":"second-look","start":154,"end":165,"id":24,"ws":true},{"text":"laparatomy","start":166,"end":176,"id":25,"ws":true},{"text":"or","start":177,"end":179,"id":26,"ws":true},{"text":"recurrent","start":180,"end":189,"id":27,"ws":true},{"text":"disease","start":190,"end":197,"id":28,"ws":true},{"text":".","start":198,"end":199,"id":29,"ws":false}],"spans":[{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":86,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":163224387,"_task_hash":1681992957,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":77,"end":86,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Esomeprazole , a proton-pump inhibitor ( PPI ) , is the S-isomer of omeprazole .","paragraph":"<h3><u>Esomeprazole: a clinical review.</u></h3>The pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, and adverse effects of <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> are reviewed. <b style='color:MediumOrchid;'><i>Esomeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>proton-pump</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PPI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>S-isomer</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> has FDA-approved labeling for use in the treatment of symptomatic gastroesophageal reflux disease (GERD), including healing and maintenance of healing of erosive esophagitis and as part of a triple-drug regimen for Helicobocter pylori infection. <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> is structurally similar to other PPIs but is the first PPI to include only the active isomer, which may lead to improved pharmacokinetic and pharmacodynamic characteristics. <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> maintains intragastric pH at a higher level and above 4 for a longer period than other PPIs. Clinical studies have shown that <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> is at least equivalent in safety and efficacy to other drugs in the class. <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> has demonstrated efficacy in the treatment of erosive esophagitis, the maintenance of healing of erosive esophagitis, and the treatment of signs and symptoms of GERD. Effective dosages are 20 or 40 mg orally every day or as needed. <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> magnesium 40 mg once daily in combination with <b style='color:Tomato;'><i>amoxicillin</i></b> and <b style='color:Tomato;'><i>clarithromycin</i></b> is effective in eradicating H. pylori infection. The potential for interacting with other drugs is limited and is similar to that of <b style='color:Tomato;'><i>omeprazole</i></b>. The most common adverse effects are headache, respiratory infection, and abdominal symptoms. <b style='color:Tomato;'><i>es<b style='color:Tomato;'><i>omeprazole</i></b></i></b> has pharmacokinetic properties that may make it more effective than <b style='color:Tomato;'><i>omeprazole</i></b> in some patients.","tokens":[{"text":"Esomeprazole","start":0,"end":12,"id":0,"ws":true},{"text":",","start":13,"end":14,"id":1,"ws":true},{"text":"a","start":15,"end":16,"id":2,"ws":true},{"text":"proton-pump","start":17,"end":28,"id":3,"ws":true},{"text":"inhibitor","start":29,"end":38,"id":4,"ws":true},{"text":"(","start":39,"end":40,"id":5,"ws":true},{"text":"PPI","start":41,"end":44,"id":6,"ws":true},{"text":")","start":45,"end":46,"id":7,"ws":true},{"text":",","start":47,"end":48,"id":8,"ws":true},{"text":"is","start":49,"end":51,"id":9,"ws":true},{"text":"the","start":52,"end":55,"id":10,"ws":true},{"text":"S-isomer","start":56,"end":64,"id":11,"ws":true},{"text":"of","start":65,"end":67,"id":12,"ws":true},{"text":"omeprazole","start":68,"end":78,"id":13,"ws":true},{"text":".","start":79,"end":80,"id":14,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":68,"end":78,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":-1343783874,"_task_hash":1303695463,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This increase in the number of vasopressin and oxytocin containing neurons in the pig hypothalamus is much later in development than has ever been reported so far .","paragraph":"<h3><u>A vasopressin and oxytocin containing nucleus in the pig hypothalamus that shows neuronal changes during puberty.</u></h3>A <b style='color:Tomato;'><i>vasopressin</i></b> and <b style='color:Tomato;'><i>oxytocin</i></b> containing nucleus is described for the first time in the pig hypothalamus. It is located near the third ventricle, just dorsal to the suprachiasmatic nucleus, and consists of magnocellular neurons, similar to those of the supraoptic nucleus and paraventricular nucleus. Morphometric analysis of neuronal number, size, density, and volume was performed at four different ages: 1 day, 7 weeks, 16 weeks, and 30 weeks postnatally. No sex difference in these parameters was observed. In this period the volume of the nucleus increased gradually from 6.6 x 10(-3) to 54.2 x 10(-3) mm3. One day after birth 1,215 +/- 191 (mean +/- SEM) neurons were present in the <b style='color:Tomato;'><i>vasopressin</i></b> and <b style='color:Tomato;'><i>oxytocin</i></b> containing nucleus, followed by a decrease to 771 +/- 80 neurons at 7 weeks and 697 +/- 116 at 16 weeks. Between 16 and 30 weeks (puberty) there was a dramatic increase in neuron number up to 1,765 +/- 214 neurons. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vasopressin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxytocin</i></b> <b style='color:DodgerBlue;'><i>containing</i></b> <b style='color:DodgerBlue;'><i>neurons</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pig</i></b> <b style='color:DodgerBlue;'><i>hypothalamus</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>much</i></b> <b style='color:DodgerBlue;'><i>later</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>ever</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>so</i></b> <b style='color:DodgerBlue;'><i>far</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"increase","start":5,"end":13,"id":1,"ws":true},{"text":"in","start":14,"end":16,"id":2,"ws":true},{"text":"the","start":17,"end":20,"id":3,"ws":true},{"text":"number","start":21,"end":27,"id":4,"ws":true},{"text":"of","start":28,"end":30,"id":5,"ws":true},{"text":"vasopressin","start":31,"end":42,"id":6,"ws":true},{"text":"and","start":43,"end":46,"id":7,"ws":true},{"text":"oxytocin","start":47,"end":55,"id":8,"ws":true},{"text":"containing","start":56,"end":66,"id":9,"ws":true},{"text":"neurons","start":67,"end":74,"id":10,"ws":true},{"text":"in","start":75,"end":77,"id":11,"ws":true},{"text":"the","start":78,"end":81,"id":12,"ws":true},{"text":"pig","start":82,"end":85,"id":13,"ws":true},{"text":"hypothalamus","start":86,"end":98,"id":14,"ws":true},{"text":"is","start":99,"end":101,"id":15,"ws":true},{"text":"much","start":102,"end":106,"id":16,"ws":true},{"text":"later","start":107,"end":112,"id":17,"ws":true},{"text":"in","start":113,"end":115,"id":18,"ws":true},{"text":"development","start":116,"end":127,"id":19,"ws":true},{"text":"than","start":128,"end":132,"id":20,"ws":true},{"text":"has","start":133,"end":136,"id":21,"ws":true},{"text":"ever","start":137,"end":141,"id":22,"ws":true},{"text":"been","start":142,"end":146,"id":23,"ws":true},{"text":"reported","start":147,"end":155,"id":24,"ws":true},{"text":"so","start":156,"end":158,"id":25,"ws":true},{"text":"far","start":159,"end":162,"id":26,"ws":true},{"text":".","start":163,"end":164,"id":27,"ws":false}],"spans":[{"start":31,"end":42,"token_start":6,"token_end":6,"label":"DRUG"},{"start":47,"end":55,"token_start":8,"token_end":8,"label":"DRUG"}],"_input_hash":-86551177,"_task_hash":29716834,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combinations of alkylating agents and fludarabine or cladribine are also synergistic in producing significantly enhanced activity against refractory lymphoid malignancies , but at the cost of increased haematological toxicity .","paragraph":"<h3><u>Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.</u></h3>This review establishes the pharmacokinetic characteristics of the major nucleoside analogues with cytotoxic activity. <b style='color:Tomato;'><i>cytarabine</i></b>, pentostatin, <b style='color:Tomato;'><i>fludarabine</i></b>, <b style='color:Tomato;'><i>cladribine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> are all prodrugs whose plasma pharmacokinetics do not fully reflect their therapeutic activity; after cellular uptake, these compounds undergo phosphorylation by deoxycytidine kinase before their incorporation into DNA results in cell death. <b style='color:Tomato;'><i>cytarabine</i></b> is principally active in the S phase of the cell cycle and is most toxic to replicating cells, whereas pentostatin, <b style='color:Tomato;'><i>fludarabine</i></b> and <b style='color:Tomato;'><i>cladribine</i></b> are incorporated into DNA during the process in which strand breaks are repaired and are therefore cytotoxic to slowly replicating cells (although the action of pentostatin results from its inhibition of adenosine deaminase). <b style='color:Tomato;'><i>gemcitabine</i></b> is unusual in being highly metabolised in solid tumour cells. The cytotoxic activity of pentostatin, <b style='color:Tomato;'><i>fludarabine</i></b> and <b style='color:Tomato;'><i>cladribine</i></b> against the clonal cells of lymphoproliferative disorders is accompanied by damage to normal lymphoid cells, which results in significant and long-lasting immunosuppression. Useful interactions between nucleoside analogues have been defined. Cells that are primed by exposure to <b style='color:Tomato;'><i>fludarabine</i></b> or <b style='color:Tomato;'><i>cladribine</i></b> exhibit enhanced accumulation of <b style='color:Tomato;'><i>cytarabine</i></b> triphosphate (the cytotoxic nucleotide of <b style='color:Tomato;'><i>cytarabine</i></b>) and an improved therapeutic effect against acute myeloid leukaemia and chronic lymphocytic leukaemia can be achieved by clinical schedules that exploit this effect. <b style='color:DodgerBlue;'><i>Combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>alkylating</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>cladribine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>producing</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>lymphoid</i></b> <b style='color:DodgerBlue;'><i>malignancies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>haematological</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Developments in the clinical administration of <b style='color:Tomato;'><i>gemcitabine</i></b> are concentrating on efforts to extend the duration of exposure to the drug as a means of counteracting its rapid catabolism in the circulation. Future developments with this group of agents will further explore the use of <b style='color:Tomato;'><i>fludarabine</i></b>-based combination therapies to produce a transient period of myelosuppression and immunosuppression that is sufficient to permit the engraftment of allogeneic haemopoietic stem cells and also exploit the immunological benefits of graft-versus-tumour reactions. In addition, the clinical spectrum of activity of <b style='color:Tomato;'><i>gemcitabine</i></b> is also being extended by combining the drug with other active chemotherapeutic agents, such as cisplatin, and by early studies of its role as a radiosensitiser.","tokens":[{"text":"Combinations","start":0,"end":12,"id":0,"ws":true},{"text":"of","start":13,"end":15,"id":1,"ws":true},{"text":"alkylating","start":16,"end":26,"id":2,"ws":true},{"text":"agents","start":27,"end":33,"id":3,"ws":true},{"text":"and","start":34,"end":37,"id":4,"ws":true},{"text":"fludarabine","start":38,"end":49,"id":5,"ws":true},{"text":"or","start":50,"end":52,"id":6,"ws":true},{"text":"cladribine","start":53,"end":63,"id":7,"ws":true},{"text":"are","start":64,"end":67,"id":8,"ws":true},{"text":"also","start":68,"end":72,"id":9,"ws":true},{"text":"synergistic","start":73,"end":84,"id":10,"ws":true},{"text":"in","start":85,"end":87,"id":11,"ws":true},{"text":"producing","start":88,"end":97,"id":12,"ws":true},{"text":"significantly","start":98,"end":111,"id":13,"ws":true},{"text":"enhanced","start":112,"end":120,"id":14,"ws":true},{"text":"activity","start":121,"end":129,"id":15,"ws":true},{"text":"against","start":130,"end":137,"id":16,"ws":true},{"text":"refractory","start":138,"end":148,"id":17,"ws":true},{"text":"lymphoid","start":149,"end":157,"id":18,"ws":true},{"text":"malignancies","start":158,"end":170,"id":19,"ws":true},{"text":",","start":171,"end":172,"id":20,"ws":true},{"text":"but","start":173,"end":176,"id":21,"ws":true},{"text":"at","start":177,"end":179,"id":22,"ws":true},{"text":"the","start":180,"end":183,"id":23,"ws":true},{"text":"cost","start":184,"end":188,"id":24,"ws":true},{"text":"of","start":189,"end":191,"id":25,"ws":true},{"text":"increased","start":192,"end":201,"id":26,"ws":true},{"text":"haematological","start":202,"end":216,"id":27,"ws":true},{"text":"toxicity","start":217,"end":225,"id":28,"ws":true},{"text":".","start":226,"end":227,"id":29,"ws":false}],"spans":[{"start":16,"end":33,"token_start":2,"token_end":3,"label":"DRUG"},{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},{"start":53,"end":63,"token_start":7,"token_end":7,"label":"DRUG"}],"_input_hash":-1611777427,"_task_hash":-1674770064,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":16,"end":33,"token_start":2,"token_end":3,"label":"DRUG"},"child_span":{"start":38,"end":49,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":3,"child":7,"head_span":{"start":16,"end":33,"token_start":2,"token_end":3,"label":"DRUG"},"child_span":{"start":53,"end":63,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"The pharmacodynamic effects of single doses of trazodone ( 100 mg ) , amitriptyline ( 50 mg ) or placebo either alone or with ethanol ( 0.5 ml/kg ) were investigated in 6 healthy volunteers in a double-blind crossover study .","paragraph":"<h3><u>Evaluation of possible interactions between ethanol and trazodone or amitriptyline.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>pharmacodynamic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trazodone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ethanol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>ml/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>crossover</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Plasma concentrations of the drugs and ethanol were also measured. Pharmacodynamic tests were critical flicker fusion frequency threshold (CFF), choice reaction time (CRT), manual dexterity, a digit span test and visual analogue scales. Blood ethanol concentrations were not influenced by the co-administration of either antidepressant. tmax for <b style='color:Tomato;'><i>trazodone</i></b> was prolonged by ethanol but the other pharmacokinetic parameters for <b style='color:Tomato;'><i>trazodone</i></b> and <b style='color:Tomato;'><i>amitriptyline</i></b> were not influenced by ethanol. <b style='color:Tomato;'><i>trazodone</i></b> and <b style='color:Tomato;'><i>amitriptyline</i></b> caused the expected profound depressant effects on CFF, CRT, manual dexterity and on the rating scales for drowsiness, 'clearheadedness', aggression and disinhibition. Ethanol alone impaired manual dexterity, increased drowsiness, reduced 'clearheadedness' and also tended to reduce feelings of aggression. In combination with either <b style='color:Tomato;'><i>trazodone</i></b> or <b style='color:Tomato;'><i>amitriptyline</i></b>, ethanol caused little additional effect except in the case of manual dexterity, which was further impaired. This result may reflect the profound effects of the antidepressants alone and does not suggest that it is safe for patients receiving antidepressant medication to take ethanolic drinks.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"pharmacodynamic","start":4,"end":19,"id":1,"ws":true},{"text":"effects","start":20,"end":27,"id":2,"ws":true},{"text":"of","start":28,"end":30,"id":3,"ws":true},{"text":"single","start":31,"end":37,"id":4,"ws":true},{"text":"doses","start":38,"end":43,"id":5,"ws":true},{"text":"of","start":44,"end":46,"id":6,"ws":true},{"text":"trazodone","start":47,"end":56,"id":7,"ws":true},{"text":"(","start":57,"end":58,"id":8,"ws":true},{"text":"100","start":59,"end":62,"id":9,"ws":true},{"text":"mg","start":63,"end":65,"id":10,"ws":true},{"text":")","start":66,"end":67,"id":11,"ws":true},{"text":",","start":68,"end":69,"id":12,"ws":true},{"text":"amitriptyline","start":70,"end":83,"id":13,"ws":true},{"text":"(","start":84,"end":85,"id":14,"ws":true},{"text":"50","start":86,"end":88,"id":15,"ws":true},{"text":"mg","start":89,"end":91,"id":16,"ws":true},{"text":")","start":92,"end":93,"id":17,"ws":true},{"text":"or","start":94,"end":96,"id":18,"ws":true},{"text":"placebo","start":97,"end":104,"id":19,"ws":true},{"text":"either","start":105,"end":111,"id":20,"ws":true},{"text":"alone","start":112,"end":117,"id":21,"ws":true},{"text":"or","start":118,"end":120,"id":22,"ws":true},{"text":"with","start":121,"end":125,"id":23,"ws":true},{"text":"ethanol","start":126,"end":133,"id":24,"ws":true},{"text":"(","start":134,"end":135,"id":25,"ws":true},{"text":"0.5","start":136,"end":139,"id":26,"ws":true},{"text":"ml/kg","start":140,"end":145,"id":27,"ws":true},{"text":")","start":146,"end":147,"id":28,"ws":true},{"text":"were","start":148,"end":152,"id":29,"ws":true},{"text":"investigated","start":153,"end":165,"id":30,"ws":true},{"text":"in","start":166,"end":168,"id":31,"ws":true},{"text":"6","start":169,"end":170,"id":32,"ws":true},{"text":"healthy","start":171,"end":178,"id":33,"ws":true},{"text":"volunteers","start":179,"end":189,"id":34,"ws":true},{"text":"in","start":190,"end":192,"id":35,"ws":true},{"text":"a","start":193,"end":194,"id":36,"ws":true},{"text":"double-blind","start":195,"end":207,"id":37,"ws":true},{"text":"crossover","start":208,"end":217,"id":38,"ws":true},{"text":"study","start":218,"end":223,"id":39,"ws":true},{"text":".","start":224,"end":225,"id":40,"ws":false}],"spans":[{"start":47,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":70,"end":83,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1802055597,"_task_hash":-1961579312,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":7,"child":24,"head_span":{"start":47,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":126,"end":133,"token_start":24,"token_end":24,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":24,"head_span":{"start":70,"end":83,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":126,"end":133,"token_start":24,"token_end":24,"label":null},"color":"#ffd1b2","label":"COMB2"},{"head":19,"child":24,"head_span":{"start":97,"end":104,"token_start":19,"token_end":19,"label":null},"child_span":{"start":126,"end":133,"token_start":24,"token_end":24,"label":null},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB1T0","COMB2T0","COMB3T0"],"answer":"accept"}
{"text":"A 70-year-old Asian man was diagnosed with PVT two months after initiating 5-fluorouracil/leucovorin , irinotecan , and bevacizumab therapy for rectal cancer with liver metastases .","paragraph":"<h3><u>Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.</u></h3>Portal vein thrombosis (PVT) while using an angiogenesis inhibitor is relatively rare. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>70-year-old</i></b> <b style='color:DodgerBlue;'><i>Asian</i></b> <b style='color:DodgerBlue;'><i>man</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>PVT</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>initiating</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil/leucovorin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>rectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>liver</i></b> <b style='color:DodgerBlue;'><i>metastases</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Because the metastases were small and shrinking, we suspected that the thrombosis might have been caused by <b style='color:Tomato;'><i>bevacizumab</i></b>-containing chemotherapy. We stopped <b style='color:Tomato;'><i>bevacizumab</i></b> and started <b style='color:Tomato;'><i>apixaban</i></b>, a direct oral anticoagulant (DOAC). Eight months later, the complete dissolution of the thrombus and recanalization of the portal vein were attained. Our case suggests that PVT can occur during <b style='color:Tomato;'><i>bevacizumab</i></b>-containing chemotherapy, and DOAC therapy might be beneficial for treating PVT in patients with cancer.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"70-year-old","start":2,"end":13,"id":1,"ws":true},{"text":"Asian","start":14,"end":19,"id":2,"ws":true},{"text":"man","start":20,"end":23,"id":3,"ws":true},{"text":"was","start":24,"end":27,"id":4,"ws":true},{"text":"diagnosed","start":28,"end":37,"id":5,"ws":true},{"text":"with","start":38,"end":42,"id":6,"ws":true},{"text":"PVT","start":43,"end":46,"id":7,"ws":true},{"text":"two","start":47,"end":50,"id":8,"ws":true},{"text":"months","start":51,"end":57,"id":9,"ws":true},{"text":"after","start":58,"end":63,"id":10,"ws":true},{"text":"initiating","start":64,"end":74,"id":11,"ws":true},{"text":"5-fluorouracil/leucovorin","start":75,"end":100,"id":12,"ws":true},{"text":",","start":101,"end":102,"id":13,"ws":true},{"text":"irinotecan","start":103,"end":113,"id":14,"ws":true},{"text":",","start":114,"end":115,"id":15,"ws":true},{"text":"and","start":116,"end":119,"id":16,"ws":true},{"text":"bevacizumab","start":120,"end":131,"id":17,"ws":true},{"text":"therapy","start":132,"end":139,"id":18,"ws":true},{"text":"for","start":140,"end":143,"id":19,"ws":true},{"text":"rectal","start":144,"end":150,"id":20,"ws":true},{"text":"cancer","start":151,"end":157,"id":21,"ws":true},{"text":"with","start":158,"end":162,"id":22,"ws":true},{"text":"liver","start":163,"end":168,"id":23,"ws":true},{"text":"metastases","start":169,"end":179,"id":24,"ws":true},{"text":".","start":180,"end":181,"id":25,"ws":false}],"spans":[{"start":75,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},{"start":103,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},{"start":120,"end":131,"token_start":17,"token_end":17,"label":"DRUG"}],"_input_hash":-1381778451,"_task_hash":1360507323,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":75,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":103,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":14,"child":17,"head_span":{"start":103,"end":113,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":120,"end":131,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"All these isolates were found to survive in presence of heavy metals like cadmium , lead and zinc and were resistant to antibiotics like ampicillin , tetracycline , streptomycin , penicillin and chloramphenicol as indicated by their Minimum Inhibitory Concentrations ( MIC ) .","paragraph":"<h3><u>Identification and Characterization of the microbial communities found in electronic industrial effluent and their potential for bioremediation.</u></h3>Microbial communities are dynamic systems that develop depending on the ecological niche in which they survive. Electronic industry effluent, rich in heavy metals and salts is one such ecosystem where diverse heavy metal resistant microbes exist. Taxonomic identification of this microbial community would be interesting as no information on the microbial diversity from electronic industry effluent is available till date. Our paper attempts to characterize the microbial inhabitants of this niche. Culture dependent microbiological methods were used to establish and identify various microbial species from the effluent. Culture independent methods of identification involving biochemical tests and molecular biology based methods like 16 S- r DNA sequencing and lipid analyses (FAME analysis) were also carried out to confirm the identity of isolated species. Our study, first of its kind revealed the presence of a diverse group of resistant aerobic microbes and disclosed a total of ten bacterial and two fungal isolates. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>isolates</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>survive</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>heavy</i></b> <b style='color:DodgerBlue;'><i>metals</i></b> <b style='color:DodgerBlue;'><i>like</i></b> <b style='color:DodgerBlue;'><i>cadmium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>lead</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>zinc</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>antibiotics</i></b> <b style='color:DodgerBlue;'><i>like</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tetracycline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>chloramphenicol</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>indicated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>Minimum</i></b> <b style='color:DodgerBlue;'><i>Inhibitory</i></b> <b style='color:DodgerBlue;'><i>Concentrations</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MIC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Such resistant isolates harbor possibilities of metal adaptive/selective pathways which render them as economically beneficial bio-sorbent alternatives in bioremediation of heavy metals.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"these","start":4,"end":9,"id":1,"ws":true},{"text":"isolates","start":10,"end":18,"id":2,"ws":true},{"text":"were","start":19,"end":23,"id":3,"ws":true},{"text":"found","start":24,"end":29,"id":4,"ws":true},{"text":"to","start":30,"end":32,"id":5,"ws":true},{"text":"survive","start":33,"end":40,"id":6,"ws":true},{"text":"in","start":41,"end":43,"id":7,"ws":true},{"text":"presence","start":44,"end":52,"id":8,"ws":true},{"text":"of","start":53,"end":55,"id":9,"ws":true},{"text":"heavy","start":56,"end":61,"id":10,"ws":true},{"text":"metals","start":62,"end":68,"id":11,"ws":true},{"text":"like","start":69,"end":73,"id":12,"ws":true},{"text":"cadmium","start":74,"end":81,"id":13,"ws":true},{"text":",","start":82,"end":83,"id":14,"ws":true},{"text":"lead","start":84,"end":88,"id":15,"ws":true},{"text":"and","start":89,"end":92,"id":16,"ws":true},{"text":"zinc","start":93,"end":97,"id":17,"ws":true},{"text":"and","start":98,"end":101,"id":18,"ws":true},{"text":"were","start":102,"end":106,"id":19,"ws":true},{"text":"resistant","start":107,"end":116,"id":20,"ws":true},{"text":"to","start":117,"end":119,"id":21,"ws":true},{"text":"antibiotics","start":120,"end":131,"id":22,"ws":true},{"text":"like","start":132,"end":136,"id":23,"ws":true},{"text":"ampicillin","start":137,"end":147,"id":24,"ws":true},{"text":",","start":148,"end":149,"id":25,"ws":true},{"text":"tetracycline","start":150,"end":162,"id":26,"ws":true},{"text":",","start":163,"end":164,"id":27,"ws":true},{"text":"streptomycin","start":165,"end":177,"id":28,"ws":true},{"text":",","start":178,"end":179,"id":29,"ws":true},{"text":"penicillin","start":180,"end":190,"id":30,"ws":true},{"text":"and","start":191,"end":194,"id":31,"ws":true},{"text":"chloramphenicol","start":195,"end":210,"id":32,"ws":true},{"text":"as","start":211,"end":213,"id":33,"ws":true},{"text":"indicated","start":214,"end":223,"id":34,"ws":true},{"text":"by","start":224,"end":226,"id":35,"ws":true},{"text":"their","start":227,"end":232,"id":36,"ws":true},{"text":"Minimum","start":233,"end":240,"id":37,"ws":true},{"text":"Inhibitory","start":241,"end":251,"id":38,"ws":true},{"text":"Concentrations","start":252,"end":266,"id":39,"ws":true},{"text":"(","start":267,"end":268,"id":40,"ws":true},{"text":"MIC","start":269,"end":272,"id":41,"ws":true},{"text":")","start":273,"end":274,"id":42,"ws":true},{"text":".","start":275,"end":276,"id":43,"ws":false}],"spans":[{"start":137,"end":147,"token_start":24,"token_end":24,"label":"DRUG"},{"start":150,"end":162,"token_start":26,"token_end":26,"label":"DRUG"},{"start":165,"end":177,"token_start":28,"token_end":28,"label":"DRUG"},{"start":195,"end":210,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":337222417,"_task_hash":30708591,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5\u2011Fu synergistically inhibited cell growth , compared with treatment with any of these drugs alone .","paragraph":"<h3><u>Imatinib\u2011induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress.</u></h3><b style='color:Tomato;'><i>imatinib</i></b> is a powerful tyrosine kinase inhibitor that specifically targets BCR\u2011ABL, c\u2011KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of <b style='color:Tomato;'><i>imatinib</i></b> in gastric cancer have not yet been explored. The present study evaluated the in\u00a0vitro effects of <b style='color:Tomato;'><i>imatinib</i></b> on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that <b style='color:Tomato;'><i>imatinib</i></b> induced mitochondria\u2011mediated apoptosis of gastric cancer cells by involving endoplasmic reticulum (ER) stress\u2011associated activation of c\u2011Jun NH2\u2011terminal kinase (JNK). We also found that <b style='color:Tomato;'><i>imatinib</i></b> suppressed cell proliferation in a time\u2011\u00a0and dose\u2011dependent manner. Cell cycle analysis revealed that <b style='color:Tomato;'><i>imatinib</i></b>\u2011treated AGS cells were arrested in the G2/M\u00a0phase of the cell cycle. Moreover, <b style='color:Tomato;'><i>imatinib</i></b>\u2011treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor\u00a0C/EBP homologous protein, an ER stress\u2011associated apoptotic molecule. <b style='color:DodgerBlue;'><i>Results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>assays</i></b> <b style='color:DodgerBlue;'><i>revealed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>5\u2011Fu</i></b> <b style='color:DodgerBlue;'><i>synergistically</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These data indicated that <b style='color:Tomato;'><i>imatinib</i></b> exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress\u2011associated JNK activation. Furthermore, we revealed that <b style='color:Tomato;'><i>imatinib</i></b> induced the apoptosis of gastric cancer cells by inhibiting platelet\u2011derived growth factor receptor signaling. Collectively, our results strongly support the use of <b style='color:Tomato;'><i>imatinib</i></b> in the treatment of treating gastric cancer.","tokens":[{"text":"Results","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"cell","start":11,"end":15,"id":2,"ws":true},{"text":"viability","start":16,"end":25,"id":3,"ws":true},{"text":"assays","start":26,"end":32,"id":4,"ws":true},{"text":"revealed","start":33,"end":41,"id":5,"ws":true},{"text":"that","start":42,"end":46,"id":6,"ws":true},{"text":"treatment","start":47,"end":56,"id":7,"ws":true},{"text":"with","start":57,"end":61,"id":8,"ws":true},{"text":"a","start":62,"end":63,"id":9,"ws":true},{"text":"combination","start":64,"end":75,"id":10,"ws":true},{"text":"of","start":76,"end":78,"id":11,"ws":true},{"text":"imatinib","start":79,"end":87,"id":12,"ws":true},{"text":"and","start":88,"end":91,"id":13,"ws":true},{"text":"chemotherapy","start":92,"end":104,"id":14,"ws":true},{"text":"agents","start":105,"end":111,"id":15,"ws":true},{"text":"irinotecan","start":112,"end":122,"id":16,"ws":true},{"text":"or","start":123,"end":125,"id":17,"ws":true},{"text":"5\u2011Fu","start":126,"end":130,"id":18,"ws":true},{"text":"synergistically","start":131,"end":146,"id":19,"ws":true},{"text":"inhibited","start":147,"end":156,"id":20,"ws":true},{"text":"cell","start":157,"end":161,"id":21,"ws":true},{"text":"growth","start":162,"end":168,"id":22,"ws":true},{"text":",","start":169,"end":170,"id":23,"ws":true},{"text":"compared","start":171,"end":179,"id":24,"ws":true},{"text":"with","start":180,"end":184,"id":25,"ws":true},{"text":"treatment","start":185,"end":194,"id":26,"ws":true},{"text":"with","start":195,"end":199,"id":27,"ws":true},{"text":"any","start":200,"end":203,"id":28,"ws":true},{"text":"of","start":204,"end":206,"id":29,"ws":true},{"text":"these","start":207,"end":212,"id":30,"ws":true},{"text":"drugs","start":213,"end":218,"id":31,"ws":true},{"text":"alone","start":219,"end":224,"id":32,"ws":true},{"text":".","start":225,"end":226,"id":33,"ws":false}],"spans":[{"start":79,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},{"start":112,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-1268574207,"_task_hash":-1619094870,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":12,"child":16,"head_span":{"start":79,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":112,"end":122,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":18,"head_span":{"start":79,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":126,"end":130,"token_start":18,"token_end":18,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0"],"answer":"accept"}
{"text":"We concluded that ifosfamide is an active agent even in patients with tumours resistant to cyclophosphamide .","paragraph":"<h3><u>Ifosfamide in the treatment of high-grade recurrent non-Hodgkin's lymphomas.</u></h3>We report the results of two phase II trials of <b style='color:Tomato;'><i>ifosfamide</i></b> in very high risk patients with either partially responsive or recurrent non-Hodgkin's lymphomas. In the first study, in which patients were extremely heavily pretreated (50 per cent had received a very intensive salvage regimen containing very high dose <b style='color:Tomato;'><i>cyclophosphamide</i></b>), there were two complete responses, two partial responses and one objective (minimal) response among 14 patients treated. Toxicity was acceptable even in this end-stage patient group. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>concluded</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>tumours</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The second trial was a pilot study in 13 patients of a regimen incorporating VP16, <b style='color:Tomato;'><i>ifosfamide</i></b>/<b style='color:Tomato;'><i>mesna</i></b>, and high dose ara-C (VIPA). There were four complete responses, five partial responses and two objective responses. Two patients died in complete remission from toxic complications, while a third, with a stably regressed mediastinal mass died after completion of the protocol. While very toxic, we considered that this regimen was highly effective, and have since incorporated a slightly less intensive combination of the same drugs into the primary therapy of high risk patients. Since the primary toxicity of the VIPA combination was myelosuppression, the use of a modified protocol incorporating colony stimulating factors to ameliorate the side-effects and possibly increase dose rate is worthy of further exploration in patients with recurrent B cell tumours.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"concluded","start":3,"end":12,"id":1,"ws":true},{"text":"that","start":13,"end":17,"id":2,"ws":true},{"text":"ifosfamide","start":18,"end":28,"id":3,"ws":true},{"text":"is","start":29,"end":31,"id":4,"ws":true},{"text":"an","start":32,"end":34,"id":5,"ws":true},{"text":"active","start":35,"end":41,"id":6,"ws":true},{"text":"agent","start":42,"end":47,"id":7,"ws":true},{"text":"even","start":48,"end":52,"id":8,"ws":true},{"text":"in","start":53,"end":55,"id":9,"ws":true},{"text":"patients","start":56,"end":64,"id":10,"ws":true},{"text":"with","start":65,"end":69,"id":11,"ws":true},{"text":"tumours","start":70,"end":77,"id":12,"ws":true},{"text":"resistant","start":78,"end":87,"id":13,"ws":true},{"text":"to","start":88,"end":90,"id":14,"ws":true},{"text":"cyclophosphamide","start":91,"end":107,"id":15,"ws":true},{"text":".","start":108,"end":109,"id":16,"ws":false}],"spans":[{"start":18,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":91,"end":107,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":-375006410,"_task_hash":2089131408,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Reduction of ASS1 expression by siRNA significantly sensitized mesothelioma spheroids to the pro-apoptotic effects of bortezomib and of cisplatin plus pemetrexed .","paragraph":"<h3><u>Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.</u></h3>To investigate the underlying causes of chemoresistance in malignant pleural mesothelioma, we have studied mesothelioma cell lines as 3D spheroids, which acquire increased chemoresistance compared to 2D monolayers. We asked whether the gene expression of 3D spheroids would reveal mechanisms of resistance. To address this, we measured gene expression of three mesothelioma cell lines, M28, REN and VAMT, grown as 2D monolayers and 3D spheroids. A total of 209 genes were differentially expressed in common by the three cell lines in 3D (138 upregulated and 71 downregulated), although a clear resistance pathway was not apparent. We then compared the list of 3D genes with two publicly available datasets of gene expression of 56 pleural mesotheliomas compared to normal tissues. Interestingly, only three genes were increased in both 3D spheroids and human tumors: argininosuccinate synthase 1 (ASS1), annexin A4 (ANXA4) and major vault protein (MVP); of these, ASS1 was the only consistently upregulated of the three genes by qRT-PCR. To measure ASS1 protein expression, we stained 2 sets of tissue microarrays (TMA): one with 88 pleural mesothelioma samples and the other with additional 88 pleural mesotheliomas paired with matched normal tissues. Of the 176 tumors represented on the two TMAs, ASS1 was expressed in 87 (50%; staining greater than 1 up to 3+). For the paired samples, ASS1 expression in mesothelioma was significantly greater than in the normal tissues. <b style='color:DodgerBlue;'><i>Reduction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ASS1</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>siRNA</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>sensitized</i></b> <b style='color:DodgerBlue;'><i>mesothelioma</i></b> <b style='color:DodgerBlue;'><i>spheroids</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pro-apoptotic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although mesothelioma is considered by many to be an ASS1-deficient tumor, our results show that ASS1 is elevated at the mRNA and protein levels in mesothelioma 3D spheroids and in human pleural mesotheliomas. We also have uncovered a survival role for ASS1, which may be amenable to targeting to undermine mesothelioma multicellular resistance. ","tokens":[{"text":"Reduction","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"ASS1","start":13,"end":17,"id":2,"ws":true},{"text":"expression","start":18,"end":28,"id":3,"ws":true},{"text":"by","start":29,"end":31,"id":4,"ws":true},{"text":"siRNA","start":32,"end":37,"id":5,"ws":true},{"text":"significantly","start":38,"end":51,"id":6,"ws":true},{"text":"sensitized","start":52,"end":62,"id":7,"ws":true},{"text":"mesothelioma","start":63,"end":75,"id":8,"ws":true},{"text":"spheroids","start":76,"end":85,"id":9,"ws":true},{"text":"to","start":86,"end":88,"id":10,"ws":true},{"text":"the","start":89,"end":92,"id":11,"ws":true},{"text":"pro-apoptotic","start":93,"end":106,"id":12,"ws":true},{"text":"effects","start":107,"end":114,"id":13,"ws":true},{"text":"of","start":115,"end":117,"id":14,"ws":true},{"text":"bortezomib","start":118,"end":128,"id":15,"ws":true},{"text":"and","start":129,"end":132,"id":16,"ws":true},{"text":"of","start":133,"end":135,"id":17,"ws":true},{"text":"cisplatin","start":136,"end":145,"id":18,"ws":true},{"text":"plus","start":146,"end":150,"id":19,"ws":true},{"text":"pemetrexed","start":151,"end":161,"id":20,"ws":true},{"text":".","start":162,"end":163,"id":21,"ws":false}],"spans":[{"start":118,"end":128,"token_start":15,"token_end":15,"label":"DRUG"},{"start":151,"end":161,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1445510775,"_task_hash":1860769775,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":18,"child":20,"head_span":{"start":136,"end":145,"token_start":18,"token_end":18,"label":null},"child_span":{"start":151,"end":161,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The combination of a fluoropyrimidine ( 5-fluorouracil or capecitabine ) with either oxaliplatin or irinotecan has been widely accepted as standard cytotoxic chemotherapy for either the first- or second-line treatment of mCRC .","paragraph":"<h3><u>Options for Second-Line Treatment in Metastatic Colorectal Cancer.</u></h3>Colorectal cancer (CRC) remains a major public health problem in the United States and worldwide. The majority of patients who have CRC eventually present with metastatic disease. The overall therapeutic goals for most patients with metastatic CRC (mCRC) are to control the disease, prolong life span, and maximize quality of life. Therefore, the ratio of efficacy to toxicity is one of the most important factors in choosing among treatment options and sequencing regimens. In addition, the choice of first-line systemic therapy will affect the options for second-line treatment. Several newer cytotoxic agents for the treatment of mCRC have been approved during the past 2 decades by the US Food and Drug Administration (FDA), including <b style='color:Tomato;'><i>irinotecan</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b>, and <b style='color:Tomato;'><i>capecitabine</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fluoropyrimidine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>accepted</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The FDA has approved several pathway-targeting agents for the treatment of mCRC; these include agents that target the vascular endothelial growth factor receptor pathway (<b style='color:Tomato;'><i>bevacizumab</i></b>, ziv-<b style='color:Tomato;'><i>aflibercept</i></b>, and <b style='color:Tomato;'><i>ramucirumab</i></b>) and those that target the epidermal growth factor receptor pathway (<b style='color:Tomato;'><i>cetuximab</i></b> and <b style='color:Tomato;'><i>panitumumab</i></b>). Here, we review the current clinical options for the second-line treatment of mCRC and the rationales for their use. ","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"a","start":19,"end":20,"id":3,"ws":true},{"text":"fluoropyrimidine","start":21,"end":37,"id":4,"ws":true},{"text":"(","start":38,"end":39,"id":5,"ws":true},{"text":"5-fluorouracil","start":40,"end":54,"id":6,"ws":true},{"text":"or","start":55,"end":57,"id":7,"ws":true},{"text":"capecitabine","start":58,"end":70,"id":8,"ws":true},{"text":")","start":71,"end":72,"id":9,"ws":true},{"text":"with","start":73,"end":77,"id":10,"ws":true},{"text":"either","start":78,"end":84,"id":11,"ws":true},{"text":"oxaliplatin","start":85,"end":96,"id":12,"ws":true},{"text":"or","start":97,"end":99,"id":13,"ws":true},{"text":"irinotecan","start":100,"end":110,"id":14,"ws":true},{"text":"has","start":111,"end":114,"id":15,"ws":true},{"text":"been","start":115,"end":119,"id":16,"ws":true},{"text":"widely","start":120,"end":126,"id":17,"ws":true},{"text":"accepted","start":127,"end":135,"id":18,"ws":true},{"text":"as","start":136,"end":138,"id":19,"ws":true},{"text":"standard","start":139,"end":147,"id":20,"ws":true},{"text":"cytotoxic","start":148,"end":157,"id":21,"ws":true},{"text":"chemotherapy","start":158,"end":170,"id":22,"ws":true},{"text":"for","start":171,"end":174,"id":23,"ws":true},{"text":"either","start":175,"end":181,"id":24,"ws":true},{"text":"the","start":182,"end":185,"id":25,"ws":true},{"text":"first-","start":186,"end":192,"id":26,"ws":true},{"text":"or","start":193,"end":195,"id":27,"ws":true},{"text":"second-line","start":196,"end":207,"id":28,"ws":true},{"text":"treatment","start":208,"end":217,"id":29,"ws":true},{"text":"of","start":218,"end":220,"id":30,"ws":true},{"text":"mCRC","start":221,"end":225,"id":31,"ws":true},{"text":".","start":226,"end":227,"id":32,"ws":false}],"spans":[{"start":21,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},{"start":40,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},{"start":58,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},{"start":85,"end":96,"token_start":12,"token_end":12,"label":"DRUG"},{"start":100,"end":110,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":2025826457,"_task_hash":681576688,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":8,"child":12,"head_span":{"start":58,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":85,"end":96,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":4,"child":14,"head_span":{"start":21,"end":37,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":100,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":8,"child":14,"head_span":{"start":58,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":100,"end":110,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":["POS10","POS1T0","POS20","POS2T0","POS30","POS3T0","COMB1T0","COMB2T0","COMB3T0"],"answer":"accept"}
{"text":"In 1517 poor prognosis patients , 21 regimens were used , the commonest being CAV , EV ( etoposide , vincristine ) , CbE , CAV alternating with PE , and oral etoposide .","paragraph":"<h3><u>A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom.</u></h3>Many chemotherapy regimens are used for treating SCLC in the United Kingdom, but it is not known, in any detail, which regimens are used, by which specialists, for which types of patient. We conducted a survey among all medical and clinical oncologists, respiratory physicians and general physicians with respiratory interest in the United Kingdom to find out. The questionnaire asked for the number of SCLC patients treated annually; how many were given chemotherapy; the drugs, doses and schedules chosen according to prognostic group (as defined by the clinician); and the reasons for choice of regimen. 1214 questionnaires were sent out, and responses were received from 1070 (88%) clinicians; 266 (25%) of these treated SCLC with chemotherapy. Of 4674 patients given chemotherapy annually, 36% were given it by clinical oncologists, 30% by medical oncologists, 27% by respiratory physicians, and 7% by general physicians. In all, 34 regimens were reported with 151 different combinations of dose and schedule. In 2311 good prognosis patients, 23 regimens were used, the commonest being ACE (<b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>etoposide</i></b>), ICbE (<b style='color:Tomato;'><i>ifosfamide</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>etoposide</i></b>), CAV (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>), CbE (<b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>etoposide</i></b>), and PE (cisplatin, <b style='color:Tomato;'><i>etoposide</i></b>). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>1517</i></b> <b style='color:DodgerBlue;'><i>poor</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>commonest</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>CAV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>EV</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CbE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CAV</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>PE</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 452 patients were treated regardless of prognosis and for 219 no prognostic criteria were specified. The remaining 175 were given second-line chemotherapy or were given regimens chosen to avoid toxicity or because of intercurrent disease or other reasons. The main reasons affecting choice of regimen were routine local practice, patients' convenience, quality of life considerations, trial results and cost. The results show wide variation in routine practice and will be useful in reporting and planning clinical trials and in deciding on local treatment policies.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"1517","start":3,"end":7,"id":1,"ws":true},{"text":"poor","start":8,"end":12,"id":2,"ws":true},{"text":"prognosis","start":13,"end":22,"id":3,"ws":true},{"text":"patients","start":23,"end":31,"id":4,"ws":true},{"text":",","start":32,"end":33,"id":5,"ws":true},{"text":"21","start":34,"end":36,"id":6,"ws":true},{"text":"regimens","start":37,"end":45,"id":7,"ws":true},{"text":"were","start":46,"end":50,"id":8,"ws":true},{"text":"used","start":51,"end":55,"id":9,"ws":true},{"text":",","start":56,"end":57,"id":10,"ws":true},{"text":"the","start":58,"end":61,"id":11,"ws":true},{"text":"commonest","start":62,"end":71,"id":12,"ws":true},{"text":"being","start":72,"end":77,"id":13,"ws":true},{"text":"CAV","start":78,"end":81,"id":14,"ws":true},{"text":",","start":82,"end":83,"id":15,"ws":true},{"text":"EV","start":84,"end":86,"id":16,"ws":true},{"text":"(","start":87,"end":88,"id":17,"ws":true},{"text":"etoposide","start":89,"end":98,"id":18,"ws":true},{"text":",","start":99,"end":100,"id":19,"ws":true},{"text":"vincristine","start":101,"end":112,"id":20,"ws":true},{"text":")","start":113,"end":114,"id":21,"ws":true},{"text":",","start":115,"end":116,"id":22,"ws":true},{"text":"CbE","start":117,"end":120,"id":23,"ws":true},{"text":",","start":121,"end":122,"id":24,"ws":true},{"text":"CAV","start":123,"end":126,"id":25,"ws":true},{"text":"alternating","start":127,"end":138,"id":26,"ws":true},{"text":"with","start":139,"end":143,"id":27,"ws":true},{"text":"PE","start":144,"end":146,"id":28,"ws":true},{"text":",","start":147,"end":148,"id":29,"ws":true},{"text":"and","start":149,"end":152,"id":30,"ws":true},{"text":"oral","start":153,"end":157,"id":31,"ws":true},{"text":"etoposide","start":158,"end":167,"id":32,"ws":true},{"text":".","start":168,"end":169,"id":33,"ws":false}],"spans":[{"start":89,"end":98,"token_start":18,"token_end":18,"label":"DRUG"},{"start":101,"end":112,"token_start":20,"token_end":20,"label":"DRUG"},{"start":158,"end":167,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":-2092705091,"_task_hash":-1691342253,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Utilizing this data , we suggest that nivolumab plus ipilimumab and cabozantinib may be favored for first-line treatment of specific populations of older patients .","paragraph":"<h3><u>Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.</u></h3>Given the underrepresentation of older patients in registration trials for metastatic renal cell carcinoma (mRCC), data to support the use of any particular systemic therapy over others, based on age, is limited. This is further complicated by clinical trials not commonly reporting adverse events by age. Thus, recommendations on treatment of older patients with mRCC are generally extrapolated from data on younger patients enrolled in these trials, which may not be ideal as many older patients are frail, have age-related organ dysfunction, or have multiple medical co-morbidities. In the last decade, the treatment landscape for mRCC has drastically changed with the approval of more than ten targeted therapies, as well as immune checkpoint inhibitors. Thus, treatment selection and sequencing of treatments can be especially challenging for clinicians. We begin this review by analyzing the available efficacy and toxicity data of these treatments in younger and older patients. We also discuss a network meta-analysis that compares the efficacy of these agents in older patients with mRCC. <b style='color:DodgerBlue;'><i>Utilizing</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cabozantinib</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>favored</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>specific</i></b> <b style='color:DodgerBlue;'><i>populations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>older</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For salvage treatment, we suggest that <b style='color:Tomato;'><i>cabozantinib</i></b> may be the preferred agent for older patients.","tokens":[{"text":"Utilizing","start":0,"end":9,"id":0,"ws":true},{"text":"this","start":10,"end":14,"id":1,"ws":true},{"text":"data","start":15,"end":19,"id":2,"ws":true},{"text":",","start":20,"end":21,"id":3,"ws":true},{"text":"we","start":22,"end":24,"id":4,"ws":true},{"text":"suggest","start":25,"end":32,"id":5,"ws":true},{"text":"that","start":33,"end":37,"id":6,"ws":true},{"text":"nivolumab","start":38,"end":47,"id":7,"ws":true},{"text":"plus","start":48,"end":52,"id":8,"ws":true},{"text":"ipilimumab","start":53,"end":63,"id":9,"ws":true},{"text":"and","start":64,"end":67,"id":10,"ws":true},{"text":"cabozantinib","start":68,"end":80,"id":11,"ws":true},{"text":"may","start":81,"end":84,"id":12,"ws":true},{"text":"be","start":85,"end":87,"id":13,"ws":true},{"text":"favored","start":88,"end":95,"id":14,"ws":true},{"text":"for","start":96,"end":99,"id":15,"ws":true},{"text":"first-line","start":100,"end":110,"id":16,"ws":true},{"text":"treatment","start":111,"end":120,"id":17,"ws":true},{"text":"of","start":121,"end":123,"id":18,"ws":true},{"text":"specific","start":124,"end":132,"id":19,"ws":true},{"text":"populations","start":133,"end":144,"id":20,"ws":true},{"text":"of","start":145,"end":147,"id":21,"ws":true},{"text":"older","start":148,"end":153,"id":22,"ws":true},{"text":"patients","start":154,"end":162,"id":23,"ws":true},{"text":".","start":163,"end":164,"id":24,"ws":false}],"spans":[{"start":38,"end":47,"token_start":7,"token_end":7,"label":"DRUG"},{"start":53,"end":63,"token_start":9,"token_end":9,"label":"DRUG"},{"start":68,"end":80,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":1070053474,"_task_hash":896096080,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":38,"end":47,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":53,"end":63,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":53,"end":63,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":68,"end":80,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"In conclusion , the combination of thalidomide and cyclosporine in subtherapeutic doses may be useful for the treatment of skin allografts .","paragraph":"<h3><u>Effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in rabbits.</u></h3>The present study evaluated the effects of <b style='color:Tomato;'><i>thalidomide</i></b>, <b style='color:Tomato;'><i>cyclosporin</i></b>e, and <b style='color:Tomato;'><i>diclofenac</i></b> on skin allograft survival in 42 rabbits divided into the following groups (n = 6): group 1, autograft control; group 2, allograft control; group 3, allografts under <b style='color:Tomato;'><i>thalidomide</i></b> (100 mg/kg/d); group 4, allografts under sodium <b style='color:Tomato;'><i>diclofenac</i></b> (2 mg/kg/d); group 5, allografts under <b style='color:Tomato;'><i>cyclosporin</i></b>e (10 mg/kg/d); group 6, allografts under <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg/d); group 7, allografts under <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg/d) plus <b style='color:Tomato;'><i>thalidomide</i></b> (100 mg/kg/d). The drugs were given via the orogastric tube the day before transplantation and daily during the postoperative period. Total circular skin grafts from the ear were exchanged between California and White New Zealand rabbits. <b style='color:Tomato;'><i>cyclosporin</i></b>e (10 mg/kg/d) increased allograft survival, an effect that was comparable to <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg/d) plus <b style='color:Tomato;'><i>thalidomide</i></b> (100 mg/kg/d). <b style='color:Tomato;'><i>thalidomide</i></b> and <b style='color:Tomato;'><i>diclofenac</i></b> given alone had minimally significant effects on the mean survival of skin allografts. The number of eosinophils around the necrotic skin was higher in the <b style='color:Tomato;'><i>diclofenac</i></b> group. The group receiving <b style='color:Tomato;'><i>cyclosporin</i></b>e combined with <b style='color:Tomato;'><i>thalidomide</i></b> displayed the lowest number of eosinophils surrounding the allograft. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>conclusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>subtherapeutic</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>useful</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>skin</i></b> <b style='color:DodgerBlue;'><i>allografts</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"conclusion","start":3,"end":13,"id":1,"ws":true},{"text":",","start":14,"end":15,"id":2,"ws":true},{"text":"the","start":16,"end":19,"id":3,"ws":true},{"text":"combination","start":20,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"thalidomide","start":35,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"cyclosporine","start":51,"end":63,"id":8,"ws":true},{"text":"in","start":64,"end":66,"id":9,"ws":true},{"text":"subtherapeutic","start":67,"end":81,"id":10,"ws":true},{"text":"doses","start":82,"end":87,"id":11,"ws":true},{"text":"may","start":88,"end":91,"id":12,"ws":true},{"text":"be","start":92,"end":94,"id":13,"ws":true},{"text":"useful","start":95,"end":101,"id":14,"ws":true},{"text":"for","start":102,"end":105,"id":15,"ws":true},{"text":"the","start":106,"end":109,"id":16,"ws":true},{"text":"treatment","start":110,"end":119,"id":17,"ws":true},{"text":"of","start":120,"end":122,"id":18,"ws":true},{"text":"skin","start":123,"end":127,"id":19,"ws":true},{"text":"allografts","start":128,"end":138,"id":20,"ws":true},{"text":".","start":139,"end":140,"id":21,"ws":false}],"spans":[{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"}],"_input_hash":1913800972,"_task_hash":2090767235,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"We now wish to report that , under these conditions , the pss-8 mutant is hypersensitive to certain antibiotics , especially to streptomycin , kanamycin , and gentamicin , although also to ampicillin and novobiocin .","paragraph":"<h3><u>Envelope composition and antibiotic hypersensitivity of Escherichia coli mutants defective in phosphatidylserine synthetase.</u></h3>Mutants of Escherichia coli K12, defective in phosphatidylserine synthetase (pss), can be isolated as temperature-sensitive, conditional lethals. When cultivated at intermediate temperatures (30 degrees), such mutants contain approximately 3 times more phosphatidylglycerol plus cardiolipin (and less phosphatidylethanolamine) than normal. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>wish</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>conditions</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pss-8</i></b> <b style='color:DodgerBlue;'><i>mutant</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>hypersensitive</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>certain</i></b> <b style='color:DodgerBlue;'><i>antibiotics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>kanamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>novobiocin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> At 30 degrees, the membrane protein and fatty acid composition of pss-8 is nearly normal, i.e. identical with an isogenic pss+ organism. Radiochemical labeling and bacteriophage growth studies show that lipopolysaccharide is also unaltered. Therefore, the antibiotic hypersensitivity of pss-8 differs from previously reported hypersensitivities, associated with lipopolysaccharide defects. These results suggest that the polar phospholipid headgroups may play an important role in maintaining the barrier function of the outer gramnegative membrane and that putative inhibitors of the phosphatidylserine synthetase might potentiate the action of numerous antibiotics currently in clinical use.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"now","start":3,"end":6,"id":1,"ws":true},{"text":"wish","start":7,"end":11,"id":2,"ws":true},{"text":"to","start":12,"end":14,"id":3,"ws":true},{"text":"report","start":15,"end":21,"id":4,"ws":true},{"text":"that","start":22,"end":26,"id":5,"ws":true},{"text":",","start":27,"end":28,"id":6,"ws":true},{"text":"under","start":29,"end":34,"id":7,"ws":true},{"text":"these","start":35,"end":40,"id":8,"ws":true},{"text":"conditions","start":41,"end":51,"id":9,"ws":true},{"text":",","start":52,"end":53,"id":10,"ws":true},{"text":"the","start":54,"end":57,"id":11,"ws":true},{"text":"pss-8","start":58,"end":63,"id":12,"ws":true},{"text":"mutant","start":64,"end":70,"id":13,"ws":true},{"text":"is","start":71,"end":73,"id":14,"ws":true},{"text":"hypersensitive","start":74,"end":88,"id":15,"ws":true},{"text":"to","start":89,"end":91,"id":16,"ws":true},{"text":"certain","start":92,"end":99,"id":17,"ws":true},{"text":"antibiotics","start":100,"end":111,"id":18,"ws":true},{"text":",","start":112,"end":113,"id":19,"ws":true},{"text":"especially","start":114,"end":124,"id":20,"ws":true},{"text":"to","start":125,"end":127,"id":21,"ws":true},{"text":"streptomycin","start":128,"end":140,"id":22,"ws":true},{"text":",","start":141,"end":142,"id":23,"ws":true},{"text":"kanamycin","start":143,"end":152,"id":24,"ws":true},{"text":",","start":153,"end":154,"id":25,"ws":true},{"text":"and","start":155,"end":158,"id":26,"ws":true},{"text":"gentamicin","start":159,"end":169,"id":27,"ws":true},{"text":",","start":170,"end":171,"id":28,"ws":true},{"text":"although","start":172,"end":180,"id":29,"ws":true},{"text":"also","start":181,"end":185,"id":30,"ws":true},{"text":"to","start":186,"end":188,"id":31,"ws":true},{"text":"ampicillin","start":189,"end":199,"id":32,"ws":true},{"text":"and","start":200,"end":203,"id":33,"ws":true},{"text":"novobiocin","start":204,"end":214,"id":34,"ws":true},{"text":".","start":215,"end":216,"id":35,"ws":false}],"spans":[{"start":128,"end":140,"token_start":22,"token_end":22,"label":"DRUG"},{"start":143,"end":152,"token_start":24,"token_end":24,"label":"DRUG"},{"start":159,"end":169,"token_start":27,"token_end":27,"label":"DRUG"},{"start":189,"end":199,"token_start":32,"token_end":32,"label":"DRUG"},{"start":204,"end":214,"token_start":34,"token_end":34,"label":"DRUG"}],"_input_hash":358410443,"_task_hash":1886440743,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"During the first 5 min of cooling , CVC decreased at control sites ( lactated Ringer solution ) to -45 + /- 6 % ( P < 0.001 ) , increased at adrenoceptor-antagonized sites ( yohimbine + propranolol ) to 15 + /- 14 % ( P = 0.002 ) , and remained unchanged at both Rho kinase-inhibited ( fasudil ) and adrenoceptor-antagonized + Rho kinase-inhibited sites ( yohimbine + propranolol + fasudil ) ( -9 + /- 1 % , P = 0.4 and -6 + /- 2 % , P = 0.4 , respectively ) .","paragraph":"<h3><u>Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin.</u></h3>Cutaneous vasoconstriction (VC) is the initial thermoregulatory response to cold exposure and can be elicited through either whole body or localized skin cooling. However, the mechanisms governing local cold-induced VC are not well understood. We tested the hypothesis that Rho kinase participates in local cold-induced cutaneous VC. In seven men and women (20-27 yr of age), up to four ventral forearm skin sites were instrumented with intradermal microdialysis fibers for localized drug delivery during cooling. Skin blood flow was monitored at each site with laser-Doppler flowmetry while local skin temperature was decreased and maintained at 24 degrees C for 40 min. Cutaneous vascular conductance (CVC; laser-Doppler flowmetry/mean arterial pressure) was expressed as percent change from 34 degrees C baseline. <b style='color:DodgerBlue;'><i>During</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cooling</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CVC</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>sites</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>lactated</i></b> <b style='color:DodgerBlue;'><i>Ringer</i></b> <b style='color:DodgerBlue;'><i>solution</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>-45</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>/-</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>adrenoceptor-antagonized</i></b> <b style='color:DodgerBlue;'><i>sites</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>yohimbine</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>/-</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.002</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>remained</i></b> <b style='color:DodgerBlue;'><i>unchanged</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>Rho</i></b> <b style='color:DodgerBlue;'><i>kinase-inhibited</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fasudil</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adrenoceptor-antagonized</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>Rho</i></b> <b style='color:DodgerBlue;'><i>kinase-inhibited</i></b> <b style='color:DodgerBlue;'><i>sites</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>yohimbine</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>fasudil</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>-9</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>/-</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.4</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>-6</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>/-</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.4</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> During the last 5 min of cooling, CVC further decreased at all sites when compared with baseline values (control, -77 +/- 4%, P < 0.001; adrenoceptor antagonized, -61 +/- 3%, P < 0.001; Rho kinase inhibited, -34 +/- 7%, P < 0.001; and adrenoceptor antagonized + Rho kinase inhibited sites, -35 +/- 3%, P < 0.001). Rho kinase-inhibited and combined treatment sites were significantly attenuated when compared with both adrenoceptor-antagonized (P < 0.01) and control sites (P < 0.0001). Rho kinase mediates both early- and late-phase cold-induced VC, supporting in vitro findings and providing a putative mechanism through which both adrenergic and nonadrenergic cold-induced VC occurs in an in vivo human thermoregulatory model.","tokens":[{"text":"During","start":0,"end":6,"id":0,"ws":true},{"text":"the","start":7,"end":10,"id":1,"ws":true},{"text":"first","start":11,"end":16,"id":2,"ws":true},{"text":"5","start":17,"end":18,"id":3,"ws":true},{"text":"min","start":19,"end":22,"id":4,"ws":true},{"text":"of","start":23,"end":25,"id":5,"ws":true},{"text":"cooling","start":26,"end":33,"id":6,"ws":true},{"text":",","start":34,"end":35,"id":7,"ws":true},{"text":"CVC","start":36,"end":39,"id":8,"ws":true},{"text":"decreased","start":40,"end":49,"id":9,"ws":true},{"text":"at","start":50,"end":52,"id":10,"ws":true},{"text":"control","start":53,"end":60,"id":11,"ws":true},{"text":"sites","start":61,"end":66,"id":12,"ws":true},{"text":"(","start":67,"end":68,"id":13,"ws":true},{"text":"lactated","start":69,"end":77,"id":14,"ws":true},{"text":"Ringer","start":78,"end":84,"id":15,"ws":true},{"text":"solution","start":85,"end":93,"id":16,"ws":true},{"text":")","start":94,"end":95,"id":17,"ws":true},{"text":"to","start":96,"end":98,"id":18,"ws":true},{"text":"-45","start":99,"end":102,"id":19,"ws":true},{"text":"+","start":103,"end":104,"id":20,"ws":true},{"text":"/-","start":105,"end":107,"id":21,"ws":true},{"text":"6","start":108,"end":109,"id":22,"ws":true},{"text":"%","start":110,"end":111,"id":23,"ws":true},{"text":"(","start":112,"end":113,"id":24,"ws":true},{"text":"P","start":114,"end":115,"id":25,"ws":true},{"text":"<","start":116,"end":117,"id":26,"ws":true},{"text":"0.001","start":118,"end":123,"id":27,"ws":true},{"text":")","start":124,"end":125,"id":28,"ws":true},{"text":",","start":126,"end":127,"id":29,"ws":true},{"text":"increased","start":128,"end":137,"id":30,"ws":true},{"text":"at","start":138,"end":140,"id":31,"ws":true},{"text":"adrenoceptor-antagonized","start":141,"end":165,"id":32,"ws":true},{"text":"sites","start":166,"end":171,"id":33,"ws":true},{"text":"(","start":172,"end":173,"id":34,"ws":true},{"text":"yohimbine","start":174,"end":183,"id":35,"ws":true},{"text":"+","start":184,"end":185,"id":36,"ws":true},{"text":"propranolol","start":186,"end":197,"id":37,"ws":true},{"text":")","start":198,"end":199,"id":38,"ws":true},{"text":"to","start":200,"end":202,"id":39,"ws":true},{"text":"15","start":203,"end":205,"id":40,"ws":true},{"text":"+","start":206,"end":207,"id":41,"ws":true},{"text":"/-","start":208,"end":210,"id":42,"ws":true},{"text":"14","start":211,"end":213,"id":43,"ws":true},{"text":"%","start":214,"end":215,"id":44,"ws":true},{"text":"(","start":216,"end":217,"id":45,"ws":true},{"text":"P","start":218,"end":219,"id":46,"ws":true},{"text":"=","start":220,"end":221,"id":47,"ws":true},{"text":"0.002","start":222,"end":227,"id":48,"ws":true},{"text":")","start":228,"end":229,"id":49,"ws":true},{"text":",","start":230,"end":231,"id":50,"ws":true},{"text":"and","start":232,"end":235,"id":51,"ws":true},{"text":"remained","start":236,"end":244,"id":52,"ws":true},{"text":"unchanged","start":245,"end":254,"id":53,"ws":true},{"text":"at","start":255,"end":257,"id":54,"ws":true},{"text":"both","start":258,"end":262,"id":55,"ws":true},{"text":"Rho","start":263,"end":266,"id":56,"ws":true},{"text":"kinase-inhibited","start":267,"end":283,"id":57,"ws":true},{"text":"(","start":284,"end":285,"id":58,"ws":true},{"text":"fasudil","start":286,"end":293,"id":59,"ws":true},{"text":")","start":294,"end":295,"id":60,"ws":true},{"text":"and","start":296,"end":299,"id":61,"ws":true},{"text":"adrenoceptor-antagonized","start":300,"end":324,"id":62,"ws":true},{"text":"+","start":325,"end":326,"id":63,"ws":true},{"text":"Rho","start":327,"end":330,"id":64,"ws":true},{"text":"kinase-inhibited","start":331,"end":347,"id":65,"ws":true},{"text":"sites","start":348,"end":353,"id":66,"ws":true},{"text":"(","start":354,"end":355,"id":67,"ws":true},{"text":"yohimbine","start":356,"end":365,"id":68,"ws":true},{"text":"+","start":366,"end":367,"id":69,"ws":true},{"text":"propranolol","start":368,"end":379,"id":70,"ws":true},{"text":"+","start":380,"end":381,"id":71,"ws":true},{"text":"fasudil","start":382,"end":389,"id":72,"ws":true},{"text":")","start":390,"end":391,"id":73,"ws":true},{"text":"(","start":392,"end":393,"id":74,"ws":true},{"text":"-9","start":394,"end":396,"id":75,"ws":true},{"text":"+","start":397,"end":398,"id":76,"ws":true},{"text":"/-","start":399,"end":401,"id":77,"ws":true},{"text":"1","start":402,"end":403,"id":78,"ws":true},{"text":"%","start":404,"end":405,"id":79,"ws":true},{"text":",","start":406,"end":407,"id":80,"ws":true},{"text":"P","start":408,"end":409,"id":81,"ws":true},{"text":"=","start":410,"end":411,"id":82,"ws":true},{"text":"0.4","start":412,"end":415,"id":83,"ws":true},{"text":"and","start":416,"end":419,"id":84,"ws":true},{"text":"-6","start":420,"end":422,"id":85,"ws":true},{"text":"+","start":423,"end":424,"id":86,"ws":true},{"text":"/-","start":425,"end":427,"id":87,"ws":true},{"text":"2","start":428,"end":429,"id":88,"ws":true},{"text":"%","start":430,"end":431,"id":89,"ws":true},{"text":",","start":432,"end":433,"id":90,"ws":true},{"text":"P","start":434,"end":435,"id":91,"ws":true},{"text":"=","start":436,"end":437,"id":92,"ws":true},{"text":"0.4","start":438,"end":441,"id":93,"ws":true},{"text":",","start":442,"end":443,"id":94,"ws":true},{"text":"respectively","start":444,"end":456,"id":95,"ws":true},{"text":")","start":457,"end":458,"id":96,"ws":true},{"text":".","start":459,"end":460,"id":97,"ws":false}],"spans":[{"start":174,"end":183,"token_start":35,"token_end":35,"label":"DRUG"},{"start":186,"end":197,"token_start":37,"token_end":37,"label":"DRUG"},{"start":286,"end":293,"token_start":59,"token_end":59,"label":"DRUG"},{"start":356,"end":365,"token_start":68,"token_end":68,"label":"DRUG"},{"start":368,"end":379,"token_start":70,"token_end":70,"label":"DRUG"},{"start":382,"end":389,"token_start":72,"token_end":72,"label":"DRUG"}],"_input_hash":226764499,"_task_hash":-543352266,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The aim of this study was to evaluate all E. coli positive blood cultures collected during a 4-y period in a haematological department using piperacillin plus netilmicin for empiric treatment of febrile episodes .","paragraph":"<h3><u>Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome.</u></h3>Escherichia coli is a leading cause of bacteraemia. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>E.</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>cultures</i></b> <b style='color:DodgerBlue;'><i>collected</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>4-y</i></b> <b style='color:DodgerBlue;'><i>period</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>haematological</i></b> <b style='color:DodgerBlue;'><i>department</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>piperacillin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>netilmicin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>empiric</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>febrile</i></b> <b style='color:DodgerBlue;'><i>episodes</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We measured the incidence of <b style='color:Tomato;'><i>piperacillin</i></b>-resistant E. coli bacteraemia among haematological and non-haematological patients, described the importance of previous antibiotic treatment for resistance development in E. coli and evaluated the impact of <b style='color:Tomato;'><i>piperacillin</i></b> resistance on the clinical outcome of E. coli bacteraemia. 114 episodes of E. coli bacteraemia in 104 patients were recorded and 98 episodes in 88 patients (42 males and 46 females) with a median age of 64 y (range 19-85 y) were evaluated. In 81.6% of the episodes the patients had a haematological disorder, dominated by acute leukaemia (41.3%), chronic leukaemia (16.3%) and lymphoma (10%). The proportion of <b style='color:Tomato;'><i>piperacillin</i></b>-resistant E. coli was higher among haematological patients than non-haematological patients (25% vs 0%, p=0.02) and resistance was associated with <b style='color:Tomato;'><i>piperacillin</i></b> therapy during the previous month (p=0.05). No difference in clinical outcome was found between haematological patients infected with <b style='color:Tomato;'><i>piperacillin</i></b>-susceptible or -resistant E. coli (intensive care 12% vs 15%; mortality 22% vs 25%).","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"study","start":16,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"to","start":26,"end":28,"id":6,"ws":true},{"text":"evaluate","start":29,"end":37,"id":7,"ws":true},{"text":"all","start":38,"end":41,"id":8,"ws":true},{"text":"E.","start":42,"end":44,"id":9,"ws":true},{"text":"coli","start":45,"end":49,"id":10,"ws":true},{"text":"positive","start":50,"end":58,"id":11,"ws":true},{"text":"blood","start":59,"end":64,"id":12,"ws":true},{"text":"cultures","start":65,"end":73,"id":13,"ws":true},{"text":"collected","start":74,"end":83,"id":14,"ws":true},{"text":"during","start":84,"end":90,"id":15,"ws":true},{"text":"a","start":91,"end":92,"id":16,"ws":true},{"text":"4-y","start":93,"end":96,"id":17,"ws":true},{"text":"period","start":97,"end":103,"id":18,"ws":true},{"text":"in","start":104,"end":106,"id":19,"ws":true},{"text":"a","start":107,"end":108,"id":20,"ws":true},{"text":"haematological","start":109,"end":123,"id":21,"ws":true},{"text":"department","start":124,"end":134,"id":22,"ws":true},{"text":"using","start":135,"end":140,"id":23,"ws":true},{"text":"piperacillin","start":141,"end":153,"id":24,"ws":true},{"text":"plus","start":154,"end":158,"id":25,"ws":true},{"text":"netilmicin","start":159,"end":169,"id":26,"ws":true},{"text":"for","start":170,"end":173,"id":27,"ws":true},{"text":"empiric","start":174,"end":181,"id":28,"ws":true},{"text":"treatment","start":182,"end":191,"id":29,"ws":true},{"text":"of","start":192,"end":194,"id":30,"ws":true},{"text":"febrile","start":195,"end":202,"id":31,"ws":true},{"text":"episodes","start":203,"end":211,"id":32,"ws":true},{"text":".","start":212,"end":213,"id":33,"ws":false}],"spans":[{"start":141,"end":153,"token_start":24,"token_end":24,"label":"DRUG"},{"start":159,"end":169,"token_start":26,"token_end":26,"label":"DRUG"}],"_input_hash":160927525,"_task_hash":2101039612,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":24,"child":26,"head_span":{"start":141,"end":153,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":159,"end":169,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Thirty-five percent ( 6 of 17 ) of the patients receiving docetaxel alone and 53 % ( 19 of 36 ) of those receiving docetaxel and thalidomide have had a PSA decrease of at least 50 % .","paragraph":"<h3><u>A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.</u></h3>New therapeutic alternatives are needed to improve outcomes in patients with androgen-independent prostate cancer (AIPC). For several years, researchers at the National Cancer Institute have been interested in elucidating the importance of angiogenesis in the pathogenesis of prostate cancer and in identifying inhibitors of this process. <b style='color:Tomato;'><i>thalidomide</i></b> has been shown to inhibit the ability of tumors to recruit new blood vessels. In a recent phase II trial of <b style='color:Tomato;'><i>thalidomide</i></b> in AIPC, 28% of patients achieved a prostate-specific antigen (PSA) decrease of >40%. The taxane <b style='color:Tomato;'><i>docetaxel</i></b> also produces PSA and measurable disease responses when used as monotherapy or as a component of combination chemotherapy for AIPC. Thus, based on the single-agent activity of <b style='color:Tomato;'><i>thalidomide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, we initiated a randomized phase II study of weekly <b style='color:Tomato;'><i>docetaxel</i></b> with or without <b style='color:Tomato;'><i>thalidomide</i></b>, 200 mg at bedtime, in patients with chemotherapy-naive metastatic AIPC. <b style='color:Tomato;'><i>docetaxel</i></b>, 30 mg/m(2) intravenously, was administered every 7 days for 3 weeks, followed by a 1-week rest period. Both regimens have been well tolerated among the first 59 treated patients, with a near absence of grade (3/4) myelosuppression. Fatigue, hyperglycemia, and pulmonary toxicity were seen in both groups. Thrombotic events have been seen in the combination arm. <b style='color:DodgerBlue;'><i>Thirty-five</i></b> <b style='color:DodgerBlue;'><i>percent</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>17</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>53</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>36</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>PSA</i></b> <b style='color:DodgerBlue;'><i>decrease</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combining a cytotoxic agent with an angiogenesis inhibitor is a promising area of investigation for prostate cancer management.","tokens":[{"text":"Thirty-five","start":0,"end":11,"id":0,"ws":true},{"text":"percent","start":12,"end":19,"id":1,"ws":true},{"text":"(","start":20,"end":21,"id":2,"ws":true},{"text":"6","start":22,"end":23,"id":3,"ws":true},{"text":"of","start":24,"end":26,"id":4,"ws":true},{"text":"17","start":27,"end":29,"id":5,"ws":true},{"text":")","start":30,"end":31,"id":6,"ws":true},{"text":"of","start":32,"end":34,"id":7,"ws":true},{"text":"the","start":35,"end":38,"id":8,"ws":true},{"text":"patients","start":39,"end":47,"id":9,"ws":true},{"text":"receiving","start":48,"end":57,"id":10,"ws":true},{"text":"docetaxel","start":58,"end":67,"id":11,"ws":true},{"text":"alone","start":68,"end":73,"id":12,"ws":true},{"text":"and","start":74,"end":77,"id":13,"ws":true},{"text":"53","start":78,"end":80,"id":14,"ws":true},{"text":"%","start":81,"end":82,"id":15,"ws":true},{"text":"(","start":83,"end":84,"id":16,"ws":true},{"text":"19","start":85,"end":87,"id":17,"ws":true},{"text":"of","start":88,"end":90,"id":18,"ws":true},{"text":"36","start":91,"end":93,"id":19,"ws":true},{"text":")","start":94,"end":95,"id":20,"ws":true},{"text":"of","start":96,"end":98,"id":21,"ws":true},{"text":"those","start":99,"end":104,"id":22,"ws":true},{"text":"receiving","start":105,"end":114,"id":23,"ws":true},{"text":"docetaxel","start":115,"end":124,"id":24,"ws":true},{"text":"and","start":125,"end":128,"id":25,"ws":true},{"text":"thalidomide","start":129,"end":140,"id":26,"ws":true},{"text":"have","start":141,"end":145,"id":27,"ws":true},{"text":"had","start":146,"end":149,"id":28,"ws":true},{"text":"a","start":150,"end":151,"id":29,"ws":true},{"text":"PSA","start":152,"end":155,"id":30,"ws":true},{"text":"decrease","start":156,"end":164,"id":31,"ws":true},{"text":"of","start":165,"end":167,"id":32,"ws":true},{"text":"at","start":168,"end":170,"id":33,"ws":true},{"text":"least","start":171,"end":176,"id":34,"ws":true},{"text":"50","start":177,"end":179,"id":35,"ws":true},{"text":"%","start":180,"end":181,"id":36,"ws":true},{"text":".","start":182,"end":183,"id":37,"ws":false}],"spans":[{"start":58,"end":67,"token_start":11,"token_end":11,"label":"DRUG"},{"start":115,"end":124,"token_start":24,"token_end":24,"label":"DRUG"},{"start":129,"end":140,"token_start":26,"token_end":26,"label":"DRUG"}],"_input_hash":801043040,"_task_hash":1936773673,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[{"head":24,"child":26,"head_span":{"start":115,"end":124,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":129,"end":140,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Evidence-based guidelines recommend nicotine replacement therapy , bupropion SR , and varenicline as effective alternatives for smoking cessation therapy , especially when combined with behavioral interventions .","paragraph":"<h3><u>Smoking cessation intervention: an evidence-based approach.</u></h3>Cigarette smoking represents the most important source of preventable morbidity and premature mortality worldwide. Approximately 100 million deaths were caused by tobacco use in the 20th century. There are >1 billion smokers worldwide, and globally the use of tobacco products is increasing, with the epidemic shifting to the developing world. Tobacco dependence is a chronic condition that often requires repeated intervention for success. Just informing a patient about health risks, although necessary, is usually not sufficient for a decision to change. Smokers should be provided with counseling when attempting to quit. Pharmacologic smoking cessation aids are recommended for all smokers who are trying to quit, unless contraindicated. <b style='color:DodgerBlue;'><i>Evidence-based</i></b> <b style='color:DodgerBlue;'><i>guidelines</i></b> <b style='color:DodgerBlue;'><i>recommend</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>replacement</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bupropion</i></b> <b style='color:DodgerBlue;'><i>SR</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>varenicline</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>alternatives</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>smoking</i></b> <b style='color:DodgerBlue;'><i>cessation</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>behavioral</i></b> <b style='color:DodgerBlue;'><i>interventions</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combination pharmacotherapy is indicated for highly <b style='color:Tomato;'><i>nicotine</i></b>-dependent smokers, patients who have failed with monotherapy, and patients with breakthrough cravings. An additional form of <b style='color:Tomato;'><i>nicotine</i></b> replacement therapy or an addition of a non-<b style='color:Tomato;'><i>nicotine</i></b> replacement therapy oral medication (<b style='color:Tomato;'><i>bupropion</i></b> or <b style='color:Tomato;'><i>varenicline</i></b>) may be helpful. The rate of successful smoking cessation at 1 year is 3% to 5% when the patient simply tries to stop, 7% to 16% if the smoker undergoes behavioral intervention, and up to 24% when receiving pharmacological treatment and behavioral support.","tokens":[{"text":"Evidence-based","start":0,"end":14,"id":0,"ws":true},{"text":"guidelines","start":15,"end":25,"id":1,"ws":true},{"text":"recommend","start":26,"end":35,"id":2,"ws":true},{"text":"nicotine","start":36,"end":44,"id":3,"ws":true},{"text":"replacement","start":45,"end":56,"id":4,"ws":true},{"text":"therapy","start":57,"end":64,"id":5,"ws":true},{"text":",","start":65,"end":66,"id":6,"ws":true},{"text":"bupropion","start":67,"end":76,"id":7,"ws":true},{"text":"SR","start":77,"end":79,"id":8,"ws":true},{"text":",","start":80,"end":81,"id":9,"ws":true},{"text":"and","start":82,"end":85,"id":10,"ws":true},{"text":"varenicline","start":86,"end":97,"id":11,"ws":true},{"text":"as","start":98,"end":100,"id":12,"ws":true},{"text":"effective","start":101,"end":110,"id":13,"ws":true},{"text":"alternatives","start":111,"end":123,"id":14,"ws":true},{"text":"for","start":124,"end":127,"id":15,"ws":true},{"text":"smoking","start":128,"end":135,"id":16,"ws":true},{"text":"cessation","start":136,"end":145,"id":17,"ws":true},{"text":"therapy","start":146,"end":153,"id":18,"ws":true},{"text":",","start":154,"end":155,"id":19,"ws":true},{"text":"especially","start":156,"end":166,"id":20,"ws":true},{"text":"when","start":167,"end":171,"id":21,"ws":true},{"text":"combined","start":172,"end":180,"id":22,"ws":true},{"text":"with","start":181,"end":185,"id":23,"ws":true},{"text":"behavioral","start":186,"end":196,"id":24,"ws":true},{"text":"interventions","start":197,"end":210,"id":25,"ws":true},{"text":".","start":211,"end":212,"id":26,"ws":false}],"spans":[{"start":36,"end":44,"token_start":3,"token_end":3,"label":"DRUG"},{"start":67,"end":76,"token_start":7,"token_end":7,"label":"DRUG"},{"start":86,"end":97,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-1962524766,"_task_hash":1315423348,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The efficacy of methotrexate ( MTX ) as a single graft-versus-host disease ( GVHD ) prophylaxis agent was compared to that of cyclosporin A ( CSA ) in 62 pediatric patients ( median age : 8 years ) with hematological malignancies who had undergone bone marrow transplantation ( BMT ) from HLA-identical sibling donors at National Kyushu Cancer Center since 1977 .","paragraph":"<h3><u>Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>graft-versus-host</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GVHD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclosporin</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CSA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>62</i></b> <b style='color:DodgerBlue;'><i>pediatric</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hematological</i></b> <b style='color:DodgerBlue;'><i>malignancies</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>undergone</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>transplantation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>BMT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>HLA-identical</i></b> <b style='color:DodgerBlue;'><i>sibling</i></b> <b style='color:DodgerBlue;'><i>donors</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>National</i></b> <b style='color:DodgerBlue;'><i>Kyushu</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Center</i></b> <b style='color:DodgerBlue;'><i>since</i></b> <b style='color:DodgerBlue;'><i>1977</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In all, 30 patients received MTX by intravenous bolus injection, with a dose of 15 mg/m(2) on day +1, followed by 10 mg/m(2) on days +3, +6, and +11, and then once a week until day +100. A total of 32 patients were treated with CSA, which was given intravenously in the early stages and orally thereafter until day +100, and then gradually tapered and stopped 6 months after BMT. There were no differences between the groups in terms of rates of hematopoietic recovery after BMT. The probabilities of acute GVHD (grades II-IV) and chronic GVHD were 29.6 vs 40.6% (P=0.294) and 19 vs 20% (MTX vs CSA), respectively. Relapse rates and event-free survival were identical. These results suggest that MTX and CSA were equally effective when given after BMT in Japanese pediatric patients with hematological malignancies. Since MTX was given over a shorter time than CSA, it might be more practical in the management of such patients.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"efficacy","start":4,"end":12,"id":1,"ws":true},{"text":"of","start":13,"end":15,"id":2,"ws":true},{"text":"methotrexate","start":16,"end":28,"id":3,"ws":true},{"text":"(","start":29,"end":30,"id":4,"ws":true},{"text":"MTX","start":31,"end":34,"id":5,"ws":true},{"text":")","start":35,"end":36,"id":6,"ws":true},{"text":"as","start":37,"end":39,"id":7,"ws":true},{"text":"a","start":40,"end":41,"id":8,"ws":true},{"text":"single","start":42,"end":48,"id":9,"ws":true},{"text":"graft-versus-host","start":49,"end":66,"id":10,"ws":true},{"text":"disease","start":67,"end":74,"id":11,"ws":true},{"text":"(","start":75,"end":76,"id":12,"ws":true},{"text":"GVHD","start":77,"end":81,"id":13,"ws":true},{"text":")","start":82,"end":83,"id":14,"ws":true},{"text":"prophylaxis","start":84,"end":95,"id":15,"ws":true},{"text":"agent","start":96,"end":101,"id":16,"ws":true},{"text":"was","start":102,"end":105,"id":17,"ws":true},{"text":"compared","start":106,"end":114,"id":18,"ws":true},{"text":"to","start":115,"end":117,"id":19,"ws":true},{"text":"that","start":118,"end":122,"id":20,"ws":true},{"text":"of","start":123,"end":125,"id":21,"ws":true},{"text":"cyclosporin","start":126,"end":137,"id":22,"ws":true},{"text":"A","start":138,"end":139,"id":23,"ws":true},{"text":"(","start":140,"end":141,"id":24,"ws":true},{"text":"CSA","start":142,"end":145,"id":25,"ws":true},{"text":")","start":146,"end":147,"id":26,"ws":true},{"text":"in","start":148,"end":150,"id":27,"ws":true},{"text":"62","start":151,"end":153,"id":28,"ws":true},{"text":"pediatric","start":154,"end":163,"id":29,"ws":true},{"text":"patients","start":164,"end":172,"id":30,"ws":true},{"text":"(","start":173,"end":174,"id":31,"ws":true},{"text":"median","start":175,"end":181,"id":32,"ws":true},{"text":"age","start":182,"end":185,"id":33,"ws":true},{"text":":","start":186,"end":187,"id":34,"ws":true},{"text":"8","start":188,"end":189,"id":35,"ws":true},{"text":"years","start":190,"end":195,"id":36,"ws":true},{"text":")","start":196,"end":197,"id":37,"ws":true},{"text":"with","start":198,"end":202,"id":38,"ws":true},{"text":"hematological","start":203,"end":216,"id":39,"ws":true},{"text":"malignancies","start":217,"end":229,"id":40,"ws":true},{"text":"who","start":230,"end":233,"id":41,"ws":true},{"text":"had","start":234,"end":237,"id":42,"ws":true},{"text":"undergone","start":238,"end":247,"id":43,"ws":true},{"text":"bone","start":248,"end":252,"id":44,"ws":true},{"text":"marrow","start":253,"end":259,"id":45,"ws":true},{"text":"transplantation","start":260,"end":275,"id":46,"ws":true},{"text":"(","start":276,"end":277,"id":47,"ws":true},{"text":"BMT","start":278,"end":281,"id":48,"ws":true},{"text":")","start":282,"end":283,"id":49,"ws":true},{"text":"from","start":284,"end":288,"id":50,"ws":true},{"text":"HLA-identical","start":289,"end":302,"id":51,"ws":true},{"text":"sibling","start":303,"end":310,"id":52,"ws":true},{"text":"donors","start":311,"end":317,"id":53,"ws":true},{"text":"at","start":318,"end":320,"id":54,"ws":true},{"text":"National","start":321,"end":329,"id":55,"ws":true},{"text":"Kyushu","start":330,"end":336,"id":56,"ws":true},{"text":"Cancer","start":337,"end":343,"id":57,"ws":true},{"text":"Center","start":344,"end":350,"id":58,"ws":true},{"text":"since","start":351,"end":356,"id":59,"ws":true},{"text":"1977","start":357,"end":361,"id":60,"ws":true},{"text":".","start":362,"end":363,"id":61,"ws":false}],"spans":[{"start":16,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":126,"end":137,"token_start":22,"token_end":22,"label":"DRUG"}],"_input_hash":1972953011,"_task_hash":549801056,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Owing to the wide spread activation of this pathway in numerous neoplasms , trametinib and cobimetinib are being studied in combination with other targeted and cytotoxic drugs in a variety of clinical situations .","paragraph":"<h3><u>Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.</u></h3>The Ras-Raf-MEK-ERK (Map kinase) cellular pathway is a highly conserved eukaryotic signaling module that transduces extracellular signals from growth factors and cytokines into intracellular regulatory events that are involved in cell growth and proliferation or the contrary pathway of cell differentiation. Dysregulation of this pathway occurs in more than one-third of all malignancies, a process that has fostered the development of targeted Map kinase pathway inhibitors. Cutaneous melanomas, which arise from skin melanocytes, are the most aggressive form of skin cancer. Mutations that activate the Map kinase pathway occur in more than 90% of these melanomas. This has led to the development of the combination of <b style='color:Tomato;'><i>dabrafenib</i></b> and <b style='color:Tomato;'><i>trametinib</i></b> or <b style='color:Tomato;'><i>vemurafenib</i></b> and cobimetanib for the treatment of BRAF V600E mutant melanomas. <b style='color:Tomato;'><i>dabrafenib</i></b> and <b style='color:Tomato;'><i>vemurafenib</i></b> target V600E/K BRAF mutants while <b style='color:Tomato;'><i>trametinib</i></b> and cobimetanib target MEK1/2. The latter two agents bind to MEK1/2 at a site that is adjacent to, but separate from, the ATP-binding site and are therefore classified as type III allosteric protein kinase inhibitors. These agents form a hydrogen bond with a conserved \u03b23-lysine and they make numerous hydrophobic contacts with residues within the \u03b1C-helix, the \u03b25 strand, and within the activation segment, regions of the protein kinase domain that exhibit greater diversity than those found within the ATP-binding site. One advantage of such allosteric inhibitors is that they do not have to compete with millimolar concentrations of cellular ATP, which most FDA-approved small molecule competitive inhibitors such as <b style='color:Tomato;'><i>imatinib</i></b> must do. <b style='color:DodgerBlue;'><i>Owing</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>wide</i></b> <b style='color:DodgerBlue;'><i>spread</i></b> <b style='color:DodgerBlue;'><i>activation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>pathway</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>numerous</i></b> <b style='color:DodgerBlue;'><i>neoplasms</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trametinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cobimetinib</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>variety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>situations</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Except for BRAF and NRAS mutations, there are no other biomarkers correlated with treatment responses following MEK1/2 inhibition and the discovery of such biomarkers would represent an important therapeutic breakthrough.","tokens":[{"text":"Owing","start":0,"end":5,"id":0,"ws":true},{"text":"to","start":6,"end":8,"id":1,"ws":true},{"text":"the","start":9,"end":12,"id":2,"ws":true},{"text":"wide","start":13,"end":17,"id":3,"ws":true},{"text":"spread","start":18,"end":24,"id":4,"ws":true},{"text":"activation","start":25,"end":35,"id":5,"ws":true},{"text":"of","start":36,"end":38,"id":6,"ws":true},{"text":"this","start":39,"end":43,"id":7,"ws":true},{"text":"pathway","start":44,"end":51,"id":8,"ws":true},{"text":"in","start":52,"end":54,"id":9,"ws":true},{"text":"numerous","start":55,"end":63,"id":10,"ws":true},{"text":"neoplasms","start":64,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"trametinib","start":76,"end":86,"id":13,"ws":true},{"text":"and","start":87,"end":90,"id":14,"ws":true},{"text":"cobimetinib","start":91,"end":102,"id":15,"ws":true},{"text":"are","start":103,"end":106,"id":16,"ws":true},{"text":"being","start":107,"end":112,"id":17,"ws":true},{"text":"studied","start":113,"end":120,"id":18,"ws":true},{"text":"in","start":121,"end":123,"id":19,"ws":true},{"text":"combination","start":124,"end":135,"id":20,"ws":true},{"text":"with","start":136,"end":140,"id":21,"ws":true},{"text":"other","start":141,"end":146,"id":22,"ws":true},{"text":"targeted","start":147,"end":155,"id":23,"ws":true},{"text":"and","start":156,"end":159,"id":24,"ws":true},{"text":"cytotoxic","start":160,"end":169,"id":25,"ws":true},{"text":"drugs","start":170,"end":175,"id":26,"ws":true},{"text":"in","start":176,"end":178,"id":27,"ws":true},{"text":"a","start":179,"end":180,"id":28,"ws":true},{"text":"variety","start":181,"end":188,"id":29,"ws":true},{"text":"of","start":189,"end":191,"id":30,"ws":true},{"text":"clinical","start":192,"end":200,"id":31,"ws":true},{"text":"situations","start":201,"end":211,"id":32,"ws":true},{"text":".","start":212,"end":213,"id":33,"ws":false}],"spans":[{"start":76,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":91,"end":102,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":-767749915,"_task_hash":-949601388,"_session_id":"drug_drug_pilot_split-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Rats were subchronically primed with nicotine , clozapine or saline .","paragraph":"<h3><u>Nicotine and clozapine cross-prime the locus coeruleus noradrenergic system to induce long-lasting potentiation in the rat hippocampus.</u></h3>A priming-challenge schedule of <b style='color:Tomato;'><i>nicotine</i></b> treatment causes long-lasting potentiation (LLP), a form of synaptic plasticity closely associated with the nor<b style='color:Tomato;'><i>epinephrine</i></b> (NE) neurotransmitter system, at the medial perforant path (MPP)-dentate gyrus (DG) synapse in the rat hippocampus. Previous reports revealed that <b style='color:Tomato;'><i>nicotine</i></b> activates the locus coeruleus (LC) noradrenergic (NAergic) system and this mechanism may underlie its beta-adrenoceptor sensitive LLP effects. <b style='color:Tomato;'><i>clozapine</i></b>, an atypical antipsychotic, is also known to activate the LC. Interactions between <b style='color:Tomato;'><i>nicotine</i></b> and <b style='color:Tomato;'><i>clozapine</i></b> are of interest because of the prevalence of smoking in patients with schizophrenia and increasing interest in the use of nicotinic receptor ligands as cognitive enhancers. <b style='color:DodgerBlue;'><i>Rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>subchronically</i></b> <b style='color:DodgerBlue;'><i>primed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clozapine</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>saline</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-one to twenty-eight days later, the effects of the <b style='color:Tomato;'><i>nicotine</i></b>, <b style='color:Tomato;'><i>clozapine</i></b> or saline challenge on the evoked field excitatory postsynaptic potentials (fEPSP) at the MPP-DG monosynaptic pathway were recorded as a measure of LLP. We confirmed the hypothesis that a challenge dose of either <b style='color:Tomato;'><i>nicotine</i></b> or <b style='color:Tomato;'><i>clozapine</i></b> induces LLP exclusively in <b style='color:Tomato;'><i>nicotine</i></b>- and <b style='color:Tomato;'><i>clozapine</i></b>-primed rats, and not in saline-primed rats, thus indicating a cross-priming effect. Moreover, unilateral suppression of LC using <b style='color:Tomato;'><i>lidocaine</i></b> abolished the LLP induced by <b style='color:Tomato;'><i>nicotine</i></b> in <b style='color:Tomato;'><i>clozapine</i></b>-primed rats. Furthermore, systemic treatment with <b style='color:Tomato;'><i>clonidine</i></b> (an \u03b12 adrenoceptor agonist that reduces NAergic activity via autoreceptors) prior to the challenge doses blocked the <b style='color:Tomato;'><i>nicotine</i></b>/<b style='color:Tomato;'><i>clozapine</i></b>-induced LLP in <b style='color:Tomato;'><i>nicotine</i></b>- and <b style='color:Tomato;'><i>clozapine</i></b>-primed rats. These findings may add to understanding of the cognitive enhancing effects of <b style='color:Tomato;'><i>nicotine</i></b>.","tokens":[{"text":"Rats","start":0,"end":4,"id":0,"ws":true},{"text":"were","start":5,"end":9,"id":1,"ws":true},{"text":"subchronically","start":10,"end":24,"id":2,"ws":true},{"text":"primed","start":25,"end":31,"id":3,"ws":true},{"text":"with","start":32,"end":36,"id":4,"ws":true},{"text":"nicotine","start":37,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"clozapine","start":48,"end":57,"id":7,"ws":true},{"text":"or","start":58,"end":60,"id":8,"ws":true},{"text":"saline","start":61,"end":67,"id":9,"ws":true},{"text":".","start":68,"end":69,"id":10,"ws":false}],"spans":[{"start":37,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":57,"token_start":7,"token_end":7,"label":"DRUG"}],"_input_hash":1677352852,"_task_hash":1282065066,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":37,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":48,"end":57,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":7,"head_span":{"start":61,"end":67,"token_start":9,"token_end":9,"label":null},"child_span":{"start":48,"end":57,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"The chimeric anti- EGFR monoclonal antibody cetuximab has been approved for EGFR-expressing colorectal tumors in patients who progress after irinotecan-based chemotherapy in combination with irinotecan and in squamous cell head and neck carcinomas for patients with locally advanced disease in combination with radiation therapy or after failure of platinum-based chemotherapy in recurrent or metastatic disease ( FDA ) .","paragraph":"<h3><u>The future of anti-EGFR therapy.</u></h3>We report here on the state of our knowledge of the target--namely, the epidermal growth factor (EGF) and its receptor--and the challenges related to the methods of determination of the epidermal growth factor receptor (EGFR) and associated molecular pathways. A critical review of the anti-EGFR therapeutic strategies is also outlined. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>chimeric</i></b> <b style='color:DodgerBlue;'><i>anti-</i></b> <b style='color:DodgerBlue;'><i>EGFR</i></b> <b style='color:DodgerBlue;'><i>monoclonal</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>approved</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>EGFR-expressing</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>progress</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>irinotecan-based</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>carcinomas</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>radiation</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>platinum-based</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>cetuximab</i></b> has the potential to provide an improvement of clinical outcome also in other indications and tumor types, particularly when used as first-line therapy combined with standard chemotherapy for metastatic disease or in the adjuvant setting. Possible strategies to improve the effectiveness of anti-EGFR agents are suggested and include (i) the use of predictive tools capable of making a more rational selection of patients; (ii) the development of standardized predictive biomarkers as surrogates for early monitoring of drug efficacy; and (iii) adequate study design, statistical analysis and proper end points of efficacy to be applied in future prospective trials.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"chimeric","start":4,"end":12,"id":1,"ws":true},{"text":"anti-","start":13,"end":18,"id":2,"ws":true},{"text":"EGFR","start":19,"end":23,"id":3,"ws":true},{"text":"monoclonal","start":24,"end":34,"id":4,"ws":true},{"text":"antibody","start":35,"end":43,"id":5,"ws":true},{"text":"cetuximab","start":44,"end":53,"id":6,"ws":true},{"text":"has","start":54,"end":57,"id":7,"ws":true},{"text":"been","start":58,"end":62,"id":8,"ws":true},{"text":"approved","start":63,"end":71,"id":9,"ws":true},{"text":"for","start":72,"end":75,"id":10,"ws":true},{"text":"EGFR-expressing","start":76,"end":91,"id":11,"ws":true},{"text":"colorectal","start":92,"end":102,"id":12,"ws":true},{"text":"tumors","start":103,"end":109,"id":13,"ws":true},{"text":"in","start":110,"end":112,"id":14,"ws":true},{"text":"patients","start":113,"end":121,"id":15,"ws":true},{"text":"who","start":122,"end":125,"id":16,"ws":true},{"text":"progress","start":126,"end":134,"id":17,"ws":true},{"text":"after","start":135,"end":140,"id":18,"ws":true},{"text":"irinotecan-based","start":141,"end":157,"id":19,"ws":true},{"text":"chemotherapy","start":158,"end":170,"id":20,"ws":true},{"text":"in","start":171,"end":173,"id":21,"ws":true},{"text":"combination","start":174,"end":185,"id":22,"ws":true},{"text":"with","start":186,"end":190,"id":23,"ws":true},{"text":"irinotecan","start":191,"end":201,"id":24,"ws":true},{"text":"and","start":202,"end":205,"id":25,"ws":true},{"text":"in","start":206,"end":208,"id":26,"ws":true},{"text":"squamous","start":209,"end":217,"id":27,"ws":true},{"text":"cell","start":218,"end":222,"id":28,"ws":true},{"text":"head","start":223,"end":227,"id":29,"ws":true},{"text":"and","start":228,"end":231,"id":30,"ws":true},{"text":"neck","start":232,"end":236,"id":31,"ws":true},{"text":"carcinomas","start":237,"end":247,"id":32,"ws":true},{"text":"for","start":248,"end":251,"id":33,"ws":true},{"text":"patients","start":252,"end":260,"id":34,"ws":true},{"text":"with","start":261,"end":265,"id":35,"ws":true},{"text":"locally","start":266,"end":273,"id":36,"ws":true},{"text":"advanced","start":274,"end":282,"id":37,"ws":true},{"text":"disease","start":283,"end":290,"id":38,"ws":true},{"text":"in","start":291,"end":293,"id":39,"ws":true},{"text":"combination","start":294,"end":305,"id":40,"ws":true},{"text":"with","start":306,"end":310,"id":41,"ws":true},{"text":"radiation","start":311,"end":320,"id":42,"ws":true},{"text":"therapy","start":321,"end":328,"id":43,"ws":true},{"text":"or","start":329,"end":331,"id":44,"ws":true},{"text":"after","start":332,"end":337,"id":45,"ws":true},{"text":"failure","start":338,"end":345,"id":46,"ws":true},{"text":"of","start":346,"end":348,"id":47,"ws":true},{"text":"platinum-based","start":349,"end":363,"id":48,"ws":true},{"text":"chemotherapy","start":364,"end":376,"id":49,"ws":true},{"text":"in","start":377,"end":379,"id":50,"ws":true},{"text":"recurrent","start":380,"end":389,"id":51,"ws":true},{"text":"or","start":390,"end":392,"id":52,"ws":true},{"text":"metastatic","start":393,"end":403,"id":53,"ws":true},{"text":"disease","start":404,"end":411,"id":54,"ws":true},{"text":"(","start":412,"end":413,"id":55,"ws":true},{"text":"FDA","start":414,"end":417,"id":56,"ws":true},{"text":")","start":418,"end":419,"id":57,"ws":true},{"text":".","start":420,"end":421,"id":58,"ws":false}],"spans":[{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},{"start":191,"end":201,"token_start":24,"token_end":24,"label":"DRUG"}],"_input_hash":1306406393,"_task_hash":-819434940,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"New agents , such as taxane , irinotecan and oxaliplatin , combined with old agents , such as cisplatin and 5-FU , are currently under evaluation to further improve treatment outcomes .","paragraph":"<h3><u>Chemotherapy for advanced gastric cancer: slow but further progress.</u></h3>Gastric cancer remains a significant problem in terms of global health, and is the most common cancer in Korea. Surgery is the only potentially curative treatment for localized gastric cancer, but most cases present at an advanced stage. Randomized trials have demonstrated that chemotherapy for advanced gastric cancer improves the quality of life and extends survival, by 4 approximately 6 months, compared with best supportive care alone. Single agents with a proven activity in a first-line setting include 5-<b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU), <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>mitomycin</i></b> C, cisplatin, taxanes (<b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b>) and oral fluoropyrimidines (<b style='color:Tomato;'><i>capecitabine</i></b> and TS-1). Based on the results from several large scale randomized trials, FP (5-FU/cisplatin) and ECF (<b style='color:Tomato;'><i>epirubicin</i></b>/cisplatin/5-FU) combinations are the most widely used regimen against advanced gastric cancer. Phase II studies of the FP and ECF combination reported a 40~51% response rate in previously untreated patients, and this regimen also produced a significantly higher response rate than the FAM (5-FU/<b style='color:Tomato;'><i>doxorubicin</i></b>/<b style='color:Tomato;'><i>mitomycin</i></b>) and FAMTX (5-FU/<b style='color:Tomato;'><i>doxorubicin</i></b>/<b style='color:Tomato;'><i>methotrexate</i></b>) regimens, respectively. However, significant treatment related-toxicities and discomfort were reported from ECF, which prevents this combination from becoming the standard treatment regimen. While no one combination chemotherapy regimen is accepted as the standard for advanced gastric cancer, FP is currently considered a suitable reference regimen worldwide. <b style='color:DodgerBlue;'><i>New</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>taxane</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>evaluation</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Also, oral 5-FU prodrugs are replacing the cumbersome 5-FU long-term infusion due to its convenience and superior toxicity profile. However, the low complete response rate and short response duration are still the main obstacles in the chemotherapy for gastric cancer. Only large scale comparative clinical trials will give clues to improve the results of gastric cancer treatments.","tokens":[{"text":"New","start":0,"end":3,"id":0,"ws":true},{"text":"agents","start":4,"end":10,"id":1,"ws":true},{"text":",","start":11,"end":12,"id":2,"ws":true},{"text":"such","start":13,"end":17,"id":3,"ws":true},{"text":"as","start":18,"end":20,"id":4,"ws":true},{"text":"taxane","start":21,"end":27,"id":5,"ws":true},{"text":",","start":28,"end":29,"id":6,"ws":true},{"text":"irinotecan","start":30,"end":40,"id":7,"ws":true},{"text":"and","start":41,"end":44,"id":8,"ws":true},{"text":"oxaliplatin","start":45,"end":56,"id":9,"ws":true},{"text":",","start":57,"end":58,"id":10,"ws":true},{"text":"combined","start":59,"end":67,"id":11,"ws":true},{"text":"with","start":68,"end":72,"id":12,"ws":true},{"text":"old","start":73,"end":76,"id":13,"ws":true},{"text":"agents","start":77,"end":83,"id":14,"ws":true},{"text":",","start":84,"end":85,"id":15,"ws":true},{"text":"such","start":86,"end":90,"id":16,"ws":true},{"text":"as","start":91,"end":93,"id":17,"ws":true},{"text":"cisplatin","start":94,"end":103,"id":18,"ws":true},{"text":"and","start":104,"end":107,"id":19,"ws":true},{"text":"5-FU","start":108,"end":112,"id":20,"ws":true},{"text":",","start":113,"end":114,"id":21,"ws":true},{"text":"are","start":115,"end":118,"id":22,"ws":true},{"text":"currently","start":119,"end":128,"id":23,"ws":true},{"text":"under","start":129,"end":134,"id":24,"ws":true},{"text":"evaluation","start":135,"end":145,"id":25,"ws":true},{"text":"to","start":146,"end":148,"id":26,"ws":true},{"text":"further","start":149,"end":156,"id":27,"ws":true},{"text":"improve","start":157,"end":164,"id":28,"ws":true},{"text":"treatment","start":165,"end":174,"id":29,"ws":true},{"text":"outcomes","start":175,"end":183,"id":30,"ws":true},{"text":".","start":184,"end":185,"id":31,"ws":false}],"spans":[{"start":30,"end":40,"token_start":7,"token_end":7,"label":"DRUG"},{"start":45,"end":56,"token_start":9,"token_end":9,"label":"DRUG"}],"_input_hash":-2139231366,"_task_hash":-1052135070,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":5,"child":18,"head_span":{"start":21,"end":27,"token_start":5,"token_end":5,"label":null},"child_span":{"start":94,"end":103,"token_start":18,"token_end":18,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":7,"child":18,"head_span":{"start":30,"end":40,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":94,"end":103,"token_start":18,"token_end":18,"label":null},"color":"#ffd1b2","label":"COMB2"},{"head":9,"child":18,"head_span":{"start":45,"end":56,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":94,"end":103,"token_start":18,"token_end":18,"label":null},"color":"#c5bdf4","label":"COMB3"},{"head":5,"child":20,"head_span":{"start":21,"end":27,"token_start":5,"token_end":5,"label":null},"child_span":{"start":108,"end":112,"token_start":20,"token_end":20,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":7,"child":20,"head_span":{"start":30,"end":40,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":108,"end":112,"token_start":20,"token_end":20,"label":null},"color":"#ffd1b2","label":"COMB2"},{"head":9,"child":20,"head_span":{"start":45,"end":56,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":108,"end":112,"token_start":20,"token_end":20,"label":null},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB1T0","COMB2T0","COMB3T0"],"answer":"accept"}
{"text":"Taxinol , Gemcitabine ( GEM ) , Navelbine ( NVB ) , Edatrexate ( ETX ) , CPT-11 and high dose Epirubicin ( EPI HD ) are recommended as new effective drugs .","paragraph":"<h3><u>Non-surgical therapy for patients with advanced non-small cell lung cancer.</u></h3>Advanced non-small cell lung cancer (NSCLC) denotes those of TNM stage III and IV. NSCLC has its specific characteristics in respect of oncological behaviour, molecular biology, sensitivity to chemotherapy (CT) and radiotherapy (RT), and requires different therapeutic strategies in comparison with small cell lung cancer. The therapies include: (1) surgery in combination with new effective drugs is resulted in improved RR from 15% a decade ago to 40-60% today. Cisplatin (C-DDP) is the most attractive drug in the treatment of NSCLC, in lengthening the life-span of Stage IV NSCLC patients and as an indispensable sensitizer in RT. <b style='color:DodgerBlue;'><i>Taxinol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GEM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Navelbine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NVB</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Edatrexate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ETX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CPT-11</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:MediumOrchid;'><i>Epirubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EPI</i></b> <b style='color:DodgerBlue;'><i>HD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Response rates recently reported for the combination CT with the drugs mentioned above for NSCLC are from 30-65%, and with 8-42 weeks of MST. Induction or neoadjuvant therapies for advanced NSCLC, with 40-69% of RR, 25-29% of complete resection rate, 8-34% of CR and 17-45% of one year SR are reviewed. Eight random studies comparing MST between CT with C-DDP and best supportive care for NSCLC are statistically significant. (2) RT for Stage III NSCLC with 2 year and 5 year survivals of 20 and 5% respectively. Although such outcome is hardly acceptable, RT sensitizer, modified RT techniques and chemoradiotherapy (CRT) are imperative to improve the effect of RT in advanced NSCLC. Clinical literature suggest that CRT is better than RT, though without marked difference. Further studies and sufficient follow-up are necessary to judge the efficacy in terms of long-term survival and toxic reaction. (3) Biological therapy: gene therapy of NSCLC is still in the experimental and developmental stage. Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported. Instillation of BRM such as IL-2 or alpha-IFN into the pleura after drainage of cancerous effusion has been reported as the most effective for those whose RR is of 80-90% and the clinical response time is fairly long. Hematological cytokine as a protective adjuvant therapy against CT/RT toxicity makes high dose of CT possible and raises the response and patient tolerance. In multimodality therapy, it plays an important role to reduce post CT infection and septicemia.","tokens":[{"text":"Taxinol","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"Gemcitabine","start":10,"end":21,"id":2,"ws":true},{"text":"(","start":22,"end":23,"id":3,"ws":true},{"text":"GEM","start":24,"end":27,"id":4,"ws":true},{"text":")","start":28,"end":29,"id":5,"ws":true},{"text":",","start":30,"end":31,"id":6,"ws":true},{"text":"Navelbine","start":32,"end":41,"id":7,"ws":true},{"text":"(","start":42,"end":43,"id":8,"ws":true},{"text":"NVB","start":44,"end":47,"id":9,"ws":true},{"text":")","start":48,"end":49,"id":10,"ws":true},{"text":",","start":50,"end":51,"id":11,"ws":true},{"text":"Edatrexate","start":52,"end":62,"id":12,"ws":true},{"text":"(","start":63,"end":64,"id":13,"ws":true},{"text":"ETX","start":65,"end":68,"id":14,"ws":true},{"text":")","start":69,"end":70,"id":15,"ws":true},{"text":",","start":71,"end":72,"id":16,"ws":true},{"text":"CPT-11","start":73,"end":79,"id":17,"ws":true},{"text":"and","start":80,"end":83,"id":18,"ws":true},{"text":"high","start":84,"end":88,"id":19,"ws":true},{"text":"dose","start":89,"end":93,"id":20,"ws":true},{"text":"Epirubicin","start":94,"end":104,"id":21,"ws":true},{"text":"(","start":105,"end":106,"id":22,"ws":true},{"text":"EPI","start":107,"end":110,"id":23,"ws":true},{"text":"HD","start":111,"end":113,"id":24,"ws":true},{"text":")","start":114,"end":115,"id":25,"ws":true},{"text":"are","start":116,"end":119,"id":26,"ws":true},{"text":"recommended","start":120,"end":131,"id":27,"ws":true},{"text":"as","start":132,"end":134,"id":28,"ws":true},{"text":"new","start":135,"end":138,"id":29,"ws":true},{"text":"effective","start":139,"end":148,"id":30,"ws":true},{"text":"drugs","start":149,"end":154,"id":31,"ws":true},{"text":".","start":155,"end":156,"id":32,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":94,"end":104,"token_start":21,"token_end":21,"label":"DRUG"}],"_input_hash":372154893,"_task_hash":-1307413930,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"One group was given enalapril ( EN ) 50 mg/l dissolved in the drinking water ; the second received lovastatin ( L ) 15 mg/kg given daily by gavage ; the third received both agents ; the fourth was left untreated , and the final group received no puromycin and served as the control group .","paragraph":"<h3><u>The combination of lovastatin and enalapril in a model of progressive renal disease.</u></h3><b style='color:Tomato;'><i>puromycin</i></b>-induced nephrotic syndrome is an animal model of progressive renal disease. Both angiotensin converting enzyme inhibitors and lipid-lowering agents have been used to preserve renal structure and function in this model, although neither completely prevents progression. We tested the hypothesis that the combination of the two agents would be more protective than either alone. Rats were divided into five groups; all were uninephrectomized. Four groups were given <b style='color:Tomato;'><i>puromycin</i></b> at a dose of 10 mg/100 g body weight (BW) with additional doses of 4 mg/100 g BW given intraperitoneally at 4, 5, and 6 weeks thereafter. <b style='color:DodgerBlue;'><i>One</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:MediumOrchid;'><i>enalapril</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EN</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg/l</i></b> <b style='color:DodgerBlue;'><i>dissolved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drinking</i></b> <b style='color:DodgerBlue;'><i>water</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>lovastatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>gavage</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>third</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>fourth</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>left</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>final</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:MediumOrchid;'><i>puromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>served</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eight weeks after the initial dose of <b style='color:Tomato;'><i>puromycin</i></b>, glomerular filtration rate (GFR), as inulin clearance, and protein excretion were determined and blood was collected for cholesterol and triglycerides. Blood pressure was not different between any of the groups. At the end of the study period, serum cholesterol [mean +/- SD, 252 +/- 185 mg/dl (L), 135 +/- 101 mg/dl (L + EN)] and triglycerides (239 +/- 200, 148 +/- 158 mg/dl) were significantly lower (P < 0.001) in the <b style='color:Tomato;'><i>lovastatin</i></b>-treated groups than in the untreated <b style='color:Tomato;'><i>puromycin</i></b> group (535 +/- 255 mg/dl and 579 +/- 561 mg/dl, cholesterol and triglyceride, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"One","start":0,"end":3,"id":0,"ws":true},{"text":"group","start":4,"end":9,"id":1,"ws":true},{"text":"was","start":10,"end":13,"id":2,"ws":true},{"text":"given","start":14,"end":19,"id":3,"ws":true},{"text":"enalapril","start":20,"end":29,"id":4,"ws":true},{"text":"(","start":30,"end":31,"id":5,"ws":true},{"text":"EN","start":32,"end":34,"id":6,"ws":true},{"text":")","start":35,"end":36,"id":7,"ws":true},{"text":"50","start":37,"end":39,"id":8,"ws":true},{"text":"mg/l","start":40,"end":44,"id":9,"ws":true},{"text":"dissolved","start":45,"end":54,"id":10,"ws":true},{"text":"in","start":55,"end":57,"id":11,"ws":true},{"text":"the","start":58,"end":61,"id":12,"ws":true},{"text":"drinking","start":62,"end":70,"id":13,"ws":true},{"text":"water","start":71,"end":76,"id":14,"ws":true},{"text":";","start":77,"end":78,"id":15,"ws":true},{"text":"the","start":79,"end":82,"id":16,"ws":true},{"text":"second","start":83,"end":89,"id":17,"ws":true},{"text":"received","start":90,"end":98,"id":18,"ws":true},{"text":"lovastatin","start":99,"end":109,"id":19,"ws":true},{"text":"(","start":110,"end":111,"id":20,"ws":true},{"text":"L","start":112,"end":113,"id":21,"ws":true},{"text":")","start":114,"end":115,"id":22,"ws":true},{"text":"15","start":116,"end":118,"id":23,"ws":true},{"text":"mg/kg","start":119,"end":124,"id":24,"ws":true},{"text":"given","start":125,"end":130,"id":25,"ws":true},{"text":"daily","start":131,"end":136,"id":26,"ws":true},{"text":"by","start":137,"end":139,"id":27,"ws":true},{"text":"gavage","start":140,"end":146,"id":28,"ws":true},{"text":";","start":147,"end":148,"id":29,"ws":true},{"text":"the","start":149,"end":152,"id":30,"ws":true},{"text":"third","start":153,"end":158,"id":31,"ws":true},{"text":"received","start":159,"end":167,"id":32,"ws":true},{"text":"both","start":168,"end":172,"id":33,"ws":true},{"text":"agents","start":173,"end":179,"id":34,"ws":true},{"text":";","start":180,"end":181,"id":35,"ws":true},{"text":"the","start":182,"end":185,"id":36,"ws":true},{"text":"fourth","start":186,"end":192,"id":37,"ws":true},{"text":"was","start":193,"end":196,"id":38,"ws":true},{"text":"left","start":197,"end":201,"id":39,"ws":true},{"text":"untreated","start":202,"end":211,"id":40,"ws":true},{"text":",","start":212,"end":213,"id":41,"ws":true},{"text":"and","start":214,"end":217,"id":42,"ws":true},{"text":"the","start":218,"end":221,"id":43,"ws":true},{"text":"final","start":222,"end":227,"id":44,"ws":true},{"text":"group","start":228,"end":233,"id":45,"ws":true},{"text":"received","start":234,"end":242,"id":46,"ws":true},{"text":"no","start":243,"end":245,"id":47,"ws":true},{"text":"puromycin","start":246,"end":255,"id":48,"ws":true},{"text":"and","start":256,"end":259,"id":49,"ws":true},{"text":"served","start":260,"end":266,"id":50,"ws":true},{"text":"as","start":267,"end":269,"id":51,"ws":true},{"text":"the","start":270,"end":273,"id":52,"ws":true},{"text":"control","start":274,"end":281,"id":53,"ws":true},{"text":"group","start":282,"end":287,"id":54,"ws":true},{"text":".","start":288,"end":289,"id":55,"ws":false}],"spans":[{"start":20,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},{"start":99,"end":109,"token_start":19,"token_end":19,"label":"DRUG"},{"start":246,"end":255,"token_start":48,"token_end":48,"label":"DRUG"}],"_input_hash":-495488448,"_task_hash":1982953344,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":19,"child":4,"head_span":{"start":99,"end":109,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":20,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB1T0","COMB3T0"],"answer":"accept"}
{"text":"Using the Killing-curve method , we tested the in vitro bactericidal activity of fosfomycin alone or in combination with vancomycin or teicoplanin at a concentration of 8 microg/mL , that is easily achievable in serum at standard dosing regimens , against seven methicillin-resistant Staphylococcus aureus strains , isolated from patients with well documented device-associated infections unresponsive to or relapsing after glycopeptide therapy .","paragraph":"<h3><u>In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.</u></h3><b style='color:Tomato;'><i>fosfomycin</i></b> is a molecule that inhibits the early stage of peptidoglycan synthesis and shows a broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. <b style='color:DodgerBlue;'><i>Using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Killing-curve</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>bactericidal</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>fosfomycin</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vancomycin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>teicoplanin</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>microg/mL</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>easily</i></b> <b style='color:DodgerBlue;'><i>achievable</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>dosing</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>methicillin-resistant</i></b> <b style='color:DodgerBlue;'><i>Staphylococcus</i></b> <b style='color:DodgerBlue;'><i>aureus</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>isolated</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>documented</i></b> <b style='color:DodgerBlue;'><i>device-associated</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>unresponsive</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>relapsing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>glycopeptide</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> MICs of <b style='color:Tomato;'><i>vancomycin</i></b> ranged from 1 to 4 microg/mL, MICs of <b style='color:Tomato;'><i>teicoplanin</i></b> from 2 to 8 microg/mL; MICs of <b style='color:Tomato;'><i>fosfomycin</i></b> were 8 microg/mL for two strains and >128 microg/mL for the remaining strains. The seven strains proved tolerant when tested for <b style='color:Tomato;'><i>vancomycin</i></b> and <b style='color:Tomato;'><i>teicoplanin</i></b> used alone at 2x MIC concentration. <b style='color:Tomato;'><i>fosfomycin</i></b> was bactericidal (reduction of 2 log of the inoculum) only against the two susceptible strains. In all cases both <b style='color:Tomato;'><i>vancomycin</i></b> and <b style='color:Tomato;'><i>teicoplanin</i></b> in combination with <b style='color:Tomato;'><i>fosfomycin</i></b> developed bactericidal synergism already at a concentration of 1x MIC. If these results are confirmed by in vivo experiments, the combination of <b style='color:Tomato;'><i>fosfomycin</i></b> with glycopeptides might be useful for treating device-associated infections, and in preventing the phenomenon of increasing MICs for glycopeptides.","tokens":[{"text":"Using","start":0,"end":5,"id":0,"ws":true},{"text":"the","start":6,"end":9,"id":1,"ws":true},{"text":"Killing-curve","start":10,"end":23,"id":2,"ws":true},{"text":"method","start":24,"end":30,"id":3,"ws":true},{"text":",","start":31,"end":32,"id":4,"ws":true},{"text":"we","start":33,"end":35,"id":5,"ws":true},{"text":"tested","start":36,"end":42,"id":6,"ws":true},{"text":"the","start":43,"end":46,"id":7,"ws":true},{"text":"in","start":47,"end":49,"id":8,"ws":true},{"text":"vitro","start":50,"end":55,"id":9,"ws":true},{"text":"bactericidal","start":56,"end":68,"id":10,"ws":true},{"text":"activity","start":69,"end":77,"id":11,"ws":true},{"text":"of","start":78,"end":80,"id":12,"ws":true},{"text":"fosfomycin","start":81,"end":91,"id":13,"ws":true},{"text":"alone","start":92,"end":97,"id":14,"ws":true},{"text":"or","start":98,"end":100,"id":15,"ws":true},{"text":"in","start":101,"end":103,"id":16,"ws":true},{"text":"combination","start":104,"end":115,"id":17,"ws":true},{"text":"with","start":116,"end":120,"id":18,"ws":true},{"text":"vancomycin","start":121,"end":131,"id":19,"ws":true},{"text":"or","start":132,"end":134,"id":20,"ws":true},{"text":"teicoplanin","start":135,"end":146,"id":21,"ws":true},{"text":"at","start":147,"end":149,"id":22,"ws":true},{"text":"a","start":150,"end":151,"id":23,"ws":true},{"text":"concentration","start":152,"end":165,"id":24,"ws":true},{"text":"of","start":166,"end":168,"id":25,"ws":true},{"text":"8","start":169,"end":170,"id":26,"ws":true},{"text":"microg/mL","start":171,"end":180,"id":27,"ws":true},{"text":",","start":181,"end":182,"id":28,"ws":true},{"text":"that","start":183,"end":187,"id":29,"ws":true},{"text":"is","start":188,"end":190,"id":30,"ws":true},{"text":"easily","start":191,"end":197,"id":31,"ws":true},{"text":"achievable","start":198,"end":208,"id":32,"ws":true},{"text":"in","start":209,"end":211,"id":33,"ws":true},{"text":"serum","start":212,"end":217,"id":34,"ws":true},{"text":"at","start":218,"end":220,"id":35,"ws":true},{"text":"standard","start":221,"end":229,"id":36,"ws":true},{"text":"dosing","start":230,"end":236,"id":37,"ws":true},{"text":"regimens","start":237,"end":245,"id":38,"ws":true},{"text":",","start":246,"end":247,"id":39,"ws":true},{"text":"against","start":248,"end":255,"id":40,"ws":true},{"text":"seven","start":256,"end":261,"id":41,"ws":true},{"text":"methicillin-resistant","start":262,"end":283,"id":42,"ws":true},{"text":"Staphylococcus","start":284,"end":298,"id":43,"ws":true},{"text":"aureus","start":299,"end":305,"id":44,"ws":true},{"text":"strains","start":306,"end":313,"id":45,"ws":true},{"text":",","start":314,"end":315,"id":46,"ws":true},{"text":"isolated","start":316,"end":324,"id":47,"ws":true},{"text":"from","start":325,"end":329,"id":48,"ws":true},{"text":"patients","start":330,"end":338,"id":49,"ws":true},{"text":"with","start":339,"end":343,"id":50,"ws":true},{"text":"well","start":344,"end":348,"id":51,"ws":true},{"text":"documented","start":349,"end":359,"id":52,"ws":true},{"text":"device-associated","start":360,"end":377,"id":53,"ws":true},{"text":"infections","start":378,"end":388,"id":54,"ws":true},{"text":"unresponsive","start":389,"end":401,"id":55,"ws":true},{"text":"to","start":402,"end":404,"id":56,"ws":true},{"text":"or","start":405,"end":407,"id":57,"ws":true},{"text":"relapsing","start":408,"end":417,"id":58,"ws":true},{"text":"after","start":418,"end":423,"id":59,"ws":true},{"text":"glycopeptide","start":424,"end":436,"id":60,"ws":true},{"text":"therapy","start":437,"end":444,"id":61,"ws":true},{"text":".","start":445,"end":446,"id":62,"ws":false}],"spans":[{"start":81,"end":91,"token_start":13,"token_end":13,"label":"DRUG"},{"start":121,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},{"start":135,"end":146,"token_start":21,"token_end":21,"label":"DRUG"}],"_input_hash":1658655969,"_task_hash":-12278375,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":13,"child":19,"head_span":{"start":81,"end":91,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":121,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":13,"child":21,"head_span":{"start":81,"end":91,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":135,"end":146,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"Combination therapy with mitomycin , tamoxifen , and UFT proved to be an effective postoperative chemoendocrine therapy for stage II , ER-positive breast cancer .","paragraph":"<h3><u>UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.</u></h3>A trial was designed to examine the combination of UFT and <b style='color:Tomato;'><i>mitomycin</i></b> (Mutamycin) plus <b style='color:Tomato;'><i>tamoxifen</i></b> (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer. <b style='color:Tomato;'><i>mitomycin</i></b> was administered intravenously at 13 mg/m2 on the day of surgery. Patients judged to be ER-positive were randomly allocated to either group A, which received oral <b style='color:Tomato;'><i>tamoxifen</i></b> 20 mg/day 14 days after surgery for 2 years, or group B, receiving oral UFT 400 mg/day plus <b style='color:Tomato;'><i>tamoxifen</i></b> 20 mg/day. A total of 219 patients were enrolled in group A, of which 213 (97.3%) were determined to be eligible; 225 patients enrolled in group B and 223 (99.1%) were eligible. The 5-year survival rates were 93.0% for group A and 95.4% for group B, with no significant difference between groups. The 5-year relapse-free survival rates were 83.1% for group A and 90.7% for group B, a significant advantage (P = .020) for the UFT plus <b style='color:Tomato;'><i>tamoxifen</i></b> group. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>UFT</i></b> <b style='color:DodgerBlue;'><i>proved</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>chemoendocrine</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ER-positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"therapy","start":12,"end":19,"id":1,"ws":true},{"text":"with","start":20,"end":24,"id":2,"ws":true},{"text":"mitomycin","start":25,"end":34,"id":3,"ws":true},{"text":",","start":35,"end":36,"id":4,"ws":true},{"text":"tamoxifen","start":37,"end":46,"id":5,"ws":true},{"text":",","start":47,"end":48,"id":6,"ws":true},{"text":"and","start":49,"end":52,"id":7,"ws":true},{"text":"UFT","start":53,"end":56,"id":8,"ws":true},{"text":"proved","start":57,"end":63,"id":9,"ws":true},{"text":"to","start":64,"end":66,"id":10,"ws":true},{"text":"be","start":67,"end":69,"id":11,"ws":true},{"text":"an","start":70,"end":72,"id":12,"ws":true},{"text":"effective","start":73,"end":82,"id":13,"ws":true},{"text":"postoperative","start":83,"end":96,"id":14,"ws":true},{"text":"chemoendocrine","start":97,"end":111,"id":15,"ws":true},{"text":"therapy","start":112,"end":119,"id":16,"ws":true},{"text":"for","start":120,"end":123,"id":17,"ws":true},{"text":"stage","start":124,"end":129,"id":18,"ws":true},{"text":"II","start":130,"end":132,"id":19,"ws":true},{"text":",","start":133,"end":134,"id":20,"ws":true},{"text":"ER-positive","start":135,"end":146,"id":21,"ws":true},{"text":"breast","start":147,"end":153,"id":22,"ws":true},{"text":"cancer","start":154,"end":160,"id":23,"ws":true},{"text":".","start":161,"end":162,"id":24,"ws":false}],"spans":[{"start":25,"end":34,"token_start":3,"token_end":3,"label":"DRUG"},{"start":37,"end":46,"token_start":5,"token_end":5,"label":"DRUG"}],"_input_hash":-2137971462,"_task_hash":-391542132,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":25,"end":34,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":37,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":8,"head_span":{"start":37,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":53,"end":56,"token_start":8,"token_end":8,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"The remaining 76 patients did not receive anti-thymocyte globulin but were given cyclosporine A and methotrexate or mycophenolate mofetil ( group 3 ) .","paragraph":"<h3><u>The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.</u></h3>The impact of the intensity of graft-versus-host-disease immunoprophylaxis on transplantation outcomes in patients undergoing transplantation following reduced-intensity conditioning is unclear. This study addresses this issue in 228 adult patients above 50 years of age with acute myeloid leukemia in first complete remission given peripheral blood stem cells from HLA-identical siblings after <b style='color:Tomato;'><i>fludarabine</i></b> and 2 days of intravenous <b style='color:Tomato;'><i>busulfan</i></b> reduced-intensity conditioning. A total of 152 patients received anti-thymocyte globulin, either in combination with <b style='color:Tomato;'><i>cyclosporin</i></b>e A in 86 patients (group 1), or with <b style='color:Tomato;'><i>cyclosporin</i></b>e A and <b style='color:Tomato;'><i>mycophenolate</i></b> mofetil or short course <b style='color:Tomato;'><i>methotrexate</i></b> in 66 patients (group 2). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>remaining</i></b> <b style='color:DodgerBlue;'><i>76</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>anti-thymocyte</i></b> <b style='color:DodgerBlue;'><i>globulin</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Incidences of grade II-IV acute graft-versus-host-disease were comparable in the three groups (16.5%, 29.5% and 19.5% in groups 1, 2 and 3, respectively, P=0.15). In multivariate analysis, the absence of anti-thymocyte globulin was the only factor associated with a higher risk of chronic graft-versus-host-disease (P=0.005), while the use of triple immunosuppression (group 3) was associated with an increased risk of relapse (P=0.003). In comparison to anti-thymocyte globulin and <b style='color:Tomato;'><i>cyclosporin</i></b>e A alone, the other two strategies of graft-versus-host-disease prophylaxis were associated with reduced leukemia-free survival and overall survival (P=0.001 for each parameter), independently of the dose of anti-thymocyte globulin. These data suggest that fine tuning of the intensity of this prophylaxis can affect the outcome of transplantation and that anti-thymocyte globulin and <b style='color:Tomato;'><i>cyclosporin</i></b>e A alone should be the preferred combination with the <b style='color:Tomato;'><i>fludarabine</i></b>-<b style='color:Tomato;'><i>busulfan</i></b> reduced-intensity conditioning regimen and sibling donors. ","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"remaining","start":4,"end":13,"id":1,"ws":true},{"text":"76","start":14,"end":16,"id":2,"ws":true},{"text":"patients","start":17,"end":25,"id":3,"ws":true},{"text":"did","start":26,"end":29,"id":4,"ws":true},{"text":"not","start":30,"end":33,"id":5,"ws":true},{"text":"receive","start":34,"end":41,"id":6,"ws":true},{"text":"anti-thymocyte","start":42,"end":56,"id":7,"ws":true},{"text":"globulin","start":57,"end":65,"id":8,"ws":true},{"text":"but","start":66,"end":69,"id":9,"ws":true},{"text":"were","start":70,"end":74,"id":10,"ws":true},{"text":"given","start":75,"end":80,"id":11,"ws":true},{"text":"cyclosporine","start":81,"end":93,"id":12,"ws":true},{"text":"A","start":94,"end":95,"id":13,"ws":true},{"text":"and","start":96,"end":99,"id":14,"ws":true},{"text":"methotrexate","start":100,"end":112,"id":15,"ws":true},{"text":"or","start":113,"end":115,"id":16,"ws":true},{"text":"mycophenolate","start":116,"end":129,"id":17,"ws":true},{"text":"mofetil","start":130,"end":137,"id":18,"ws":true},{"text":"(","start":138,"end":139,"id":19,"ws":true},{"text":"group","start":140,"end":145,"id":20,"ws":true},{"text":"3","start":146,"end":147,"id":21,"ws":true},{"text":")","start":148,"end":149,"id":22,"ws":true},{"text":".","start":150,"end":151,"id":23,"ws":false}],"spans":[{"start":81,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":100,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},{"start":116,"end":129,"token_start":17,"token_end":17,"label":"DRUG"}],"_input_hash":1340374175,"_task_hash":-1745092634,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":12,"child":15,"head_span":{"start":81,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":100,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":12,"child":17,"head_span":{"start":81,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":116,"end":129,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"Propranolol significantly decreased the maximum plasma concentration ( Cmax ) and area under the plasma concentration-time curve ( AUC ) of lacidipine ( by 38 % and 42 % , respectively ) whereas lacidipine significantly increased the Cmax and AUC of propranolol ( by 35 % and 26 % , respectively ) ; neither the time to maximum plasma concentration ( tmax ) nor the terminal half-life ( t 1/2 ) were affected .","paragraph":"<h3><u>The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers.</u></h3>The pharmacokinetic and pharmacodynamic profiles of lacidipine, a 1,4-dihydropyridine calcium antagonist, and the beta-adrenoceptor blocker <b style='color:Tomato;'><i>propranolol</i></b> were determined alone and in combination in 24 healthy male volunteers. One group (I) of 12 subjects received a single oral dose of 4 mg lacidipine on two separate occasions, which was taken together with a single oral dose of either 160 mg <b style='color:Tomato;'><i>propranolol</i></b> or placebo; a second group (II) of 12 subjects received <b style='color:Tomato;'><i>propranolol</i></b> on two occasions, taken with either lacidipine or placebo. <b style='color:MediumOrchid;'><i>Propranolol</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Cmax</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>lacidipine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>38</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>42</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>lacidipine</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Cmax</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>26</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>neither</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>tmax</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>nor</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>terminal</i></b> <b style='color:DodgerBlue;'><i>half-life</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>t</i></b> <b style='color:DodgerBlue;'><i>1/2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>affected</i></b> <b style='color:DodgerBlue;'><i>.</i></b> With regard to the pharmacodynamics, in Group I, there was a greater reduction in supine systolic blood pressure (6 mm Hg) and diastolic blood pressure (4 mm Hg) compared to the reduction produced by lacidipine alone, and pulse rate was approximately 5 beats/min less. In Group II, a significantly greater reduction (6 mm Hg) in supine systolic blood pressure compared to the reduction produced by <b style='color:Tomato;'><i>propranolol</i></b> alone occurred, but there was no marked difference in supine diastolic blood pressure and pulse rate. In conclusion, a modest pharmacokinetic and pharmacodynamic interaction is evident and should be evaluated further in patients with hypertension.","tokens":[{"text":"Propranolol","start":0,"end":11,"id":0,"ws":true},{"text":"significantly","start":12,"end":25,"id":1,"ws":true},{"text":"decreased","start":26,"end":35,"id":2,"ws":true},{"text":"the","start":36,"end":39,"id":3,"ws":true},{"text":"maximum","start":40,"end":47,"id":4,"ws":true},{"text":"plasma","start":48,"end":54,"id":5,"ws":true},{"text":"concentration","start":55,"end":68,"id":6,"ws":true},{"text":"(","start":69,"end":70,"id":7,"ws":true},{"text":"Cmax","start":71,"end":75,"id":8,"ws":true},{"text":")","start":76,"end":77,"id":9,"ws":true},{"text":"and","start":78,"end":81,"id":10,"ws":true},{"text":"area","start":82,"end":86,"id":11,"ws":true},{"text":"under","start":87,"end":92,"id":12,"ws":true},{"text":"the","start":93,"end":96,"id":13,"ws":true},{"text":"plasma","start":97,"end":103,"id":14,"ws":true},{"text":"concentration-time","start":104,"end":122,"id":15,"ws":true},{"text":"curve","start":123,"end":128,"id":16,"ws":true},{"text":"(","start":129,"end":130,"id":17,"ws":true},{"text":"AUC","start":131,"end":134,"id":18,"ws":true},{"text":")","start":135,"end":136,"id":19,"ws":true},{"text":"of","start":137,"end":139,"id":20,"ws":true},{"text":"lacidipine","start":140,"end":150,"id":21,"ws":true},{"text":"(","start":151,"end":152,"id":22,"ws":true},{"text":"by","start":153,"end":155,"id":23,"ws":true},{"text":"38","start":156,"end":158,"id":24,"ws":true},{"text":"%","start":159,"end":160,"id":25,"ws":true},{"text":"and","start":161,"end":164,"id":26,"ws":true},{"text":"42","start":165,"end":167,"id":27,"ws":true},{"text":"%","start":168,"end":169,"id":28,"ws":true},{"text":",","start":170,"end":171,"id":29,"ws":true},{"text":"respectively","start":172,"end":184,"id":30,"ws":true},{"text":")","start":185,"end":186,"id":31,"ws":true},{"text":"whereas","start":187,"end":194,"id":32,"ws":true},{"text":"lacidipine","start":195,"end":205,"id":33,"ws":true},{"text":"significantly","start":206,"end":219,"id":34,"ws":true},{"text":"increased","start":220,"end":229,"id":35,"ws":true},{"text":"the","start":230,"end":233,"id":36,"ws":true},{"text":"Cmax","start":234,"end":238,"id":37,"ws":true},{"text":"and","start":239,"end":242,"id":38,"ws":true},{"text":"AUC","start":243,"end":246,"id":39,"ws":true},{"text":"of","start":247,"end":249,"id":40,"ws":true},{"text":"propranolol","start":250,"end":261,"id":41,"ws":true},{"text":"(","start":262,"end":263,"id":42,"ws":true},{"text":"by","start":264,"end":266,"id":43,"ws":true},{"text":"35","start":267,"end":269,"id":44,"ws":true},{"text":"%","start":270,"end":271,"id":45,"ws":true},{"text":"and","start":272,"end":275,"id":46,"ws":true},{"text":"26","start":276,"end":278,"id":47,"ws":true},{"text":"%","start":279,"end":280,"id":48,"ws":true},{"text":",","start":281,"end":282,"id":49,"ws":true},{"text":"respectively","start":283,"end":295,"id":50,"ws":true},{"text":")","start":296,"end":297,"id":51,"ws":true},{"text":";","start":298,"end":299,"id":52,"ws":true},{"text":"neither","start":300,"end":307,"id":53,"ws":true},{"text":"the","start":308,"end":311,"id":54,"ws":true},{"text":"time","start":312,"end":316,"id":55,"ws":true},{"text":"to","start":317,"end":319,"id":56,"ws":true},{"text":"maximum","start":320,"end":327,"id":57,"ws":true},{"text":"plasma","start":328,"end":334,"id":58,"ws":true},{"text":"concentration","start":335,"end":348,"id":59,"ws":true},{"text":"(","start":349,"end":350,"id":60,"ws":true},{"text":"tmax","start":351,"end":355,"id":61,"ws":true},{"text":")","start":356,"end":357,"id":62,"ws":true},{"text":"nor","start":358,"end":361,"id":63,"ws":true},{"text":"the","start":362,"end":365,"id":64,"ws":true},{"text":"terminal","start":366,"end":374,"id":65,"ws":true},{"text":"half-life","start":375,"end":384,"id":66,"ws":true},{"text":"(","start":385,"end":386,"id":67,"ws":true},{"text":"t","start":387,"end":388,"id":68,"ws":true},{"text":"1/2","start":389,"end":392,"id":69,"ws":true},{"text":")","start":393,"end":394,"id":70,"ws":true},{"text":"were","start":395,"end":399,"id":71,"ws":true},{"text":"affected","start":400,"end":408,"id":72,"ws":true},{"text":".","start":409,"end":410,"id":73,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":250,"end":261,"token_start":41,"token_end":41,"label":"DRUG"}],"_input_hash":-1343390564,"_task_hash":511483589,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":0,"child":21,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":140,"end":150,"token_start":21,"token_end":21,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"For antibiotic treatment , mice were administered a mixture of ciprofloxacin and metronidazole or vancomycin .","paragraph":"<h3><u>Dietary soyasaponin attenuates 2,4-dinitrofluorobenzene-induced contact hypersensitivity via gut microbiota in mice.</u></h3>Soyasaponins (SSs) are abundant in soybeans and display inhibitory activity against contact hypersensitivity (CHS), which is often used as a mouse model for allergic contact dermatitis (ACD); however, their therapeutic mechanisms remain unknown. Here, we attempted to clarify the role of gut microbiota in the inhibition of CHS by dietary soyasaponins. <b style='color:DodgerBlue;'><i>For</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>vancomycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These antibiotics and SSs were given to mice via drinking water 3-weeks prior to CHS induction with 2,4-dinitrofluorobenzene, and the mice were analysed for ear swelling, tissue oedema, infiltration of Gr-1-positive immune cells, the composition of faecal microbiota and regulatory T (T","tokens":[{"text":"For","start":0,"end":3,"id":0,"ws":true},{"text":"antibiotic","start":4,"end":14,"id":1,"ws":true},{"text":"treatment","start":15,"end":24,"id":2,"ws":true},{"text":",","start":25,"end":26,"id":3,"ws":true},{"text":"mice","start":27,"end":31,"id":4,"ws":true},{"text":"were","start":32,"end":36,"id":5,"ws":true},{"text":"administered","start":37,"end":49,"id":6,"ws":true},{"text":"a","start":50,"end":51,"id":7,"ws":true},{"text":"mixture","start":52,"end":59,"id":8,"ws":true},{"text":"of","start":60,"end":62,"id":9,"ws":true},{"text":"ciprofloxacin","start":63,"end":76,"id":10,"ws":true},{"text":"and","start":77,"end":80,"id":11,"ws":true},{"text":"metronidazole","start":81,"end":94,"id":12,"ws":true},{"text":"or","start":95,"end":97,"id":13,"ws":true},{"text":"vancomycin","start":98,"end":108,"id":14,"ws":true},{"text":".","start":109,"end":110,"id":15,"ws":false}],"spans":[{"start":63,"end":76,"token_start":10,"token_end":10,"label":"DRUG"},{"start":81,"end":94,"token_start":12,"token_end":12,"label":"DRUG"},{"start":98,"end":108,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":253932596,"_task_hash":-996811303,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":63,"end":76,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":81,"end":94,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":14,"head_span":{"start":63,"end":76,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":98,"end":108,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"The patient received chemotherapy comprising vincristine , actinomycin D , doxorubicin , cisplatin , and cyclophosphamide .","paragraph":"<h3><u>Autologous peripheral blood stem cell transplantation in a patient with relapsed pleuropulmonary blastoma.</u></h3>Pleuropulmonary blastoma (PPB) is a rare and aggressive primary intrathoracic neoplasma of children. The prognosis is extremely poor with frequent metastasis to the brain and bone. We present a 4-year-old girl with a tumor mass in the right hemithorax initially diagnosed as pneumoniae. Tumor resection was performed and the histologic report indicated the diagnosis of PPB. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>comprising</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Irradiation was performed with total 45 Gy at the right lower pulmonary lobe. She relapsed 29 months later at the pleura between the right middle and lower pulmonary lobe. Tumor resection and total 45 Gy of irradiation were performed again. High-dose chemotherapy comprising cisplatin, adriamycin, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> was performed followed by autologous peripheral blood stem cell transplantation (PBSCT). The patient achieved complete hematologic recovery. Thirty-one months after PBSCT, no signs of relapse have been observed. Although it might be that the patient could have been cured with second surgery alone or by the surgery and subsequent chemotherapy, high-dose chemotherapy and PBSCT should be considered for the treatment of relapsed PPB.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"patient","start":4,"end":11,"id":1,"ws":true},{"text":"received","start":12,"end":20,"id":2,"ws":true},{"text":"chemotherapy","start":21,"end":33,"id":3,"ws":true},{"text":"comprising","start":34,"end":44,"id":4,"ws":true},{"text":"vincristine","start":45,"end":56,"id":5,"ws":true},{"text":",","start":57,"end":58,"id":6,"ws":true},{"text":"actinomycin","start":59,"end":70,"id":7,"ws":true},{"text":"D","start":71,"end":72,"id":8,"ws":true},{"text":",","start":73,"end":74,"id":9,"ws":true},{"text":"doxorubicin","start":75,"end":86,"id":10,"ws":true},{"text":",","start":87,"end":88,"id":11,"ws":true},{"text":"cisplatin","start":89,"end":98,"id":12,"ws":true},{"text":",","start":99,"end":100,"id":13,"ws":true},{"text":"and","start":101,"end":104,"id":14,"ws":true},{"text":"cyclophosphamide","start":105,"end":121,"id":15,"ws":true},{"text":".","start":122,"end":123,"id":16,"ws":false}],"spans":[{"start":45,"end":56,"token_start":5,"token_end":5,"label":"DRUG"},{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":105,"end":121,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":1110465951,"_task_hash":1936435502,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":45,"end":56,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":59,"end":70,"token_start":7,"token_end":7,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":7,"child":10,"head_span":{"start":59,"end":70,"token_start":7,"token_end":7,"label":null},"child_span":{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":10,"child":12,"head_span":{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":89,"end":98,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":12,"child":15,"head_span":{"start":89,"end":98,"token_start":12,"token_end":12,"label":null},"child_span":{"start":105,"end":121,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"It was found that the increase in acoustic startle responses observed with ethanol or nicotine was attenuated by haloperidol .","paragraph":"<h3><u>Nicotine and ethanol enhancements of acoustic startle reflex are mediated in part by dopamine in C57BL/6J mice.</u></h3><b style='color:Tomato;'><i>nicotine</i></b> has been shown to have additive as well as antagonistic effects on behavior stimulated by ethanol. Here, we examine the effects of <b style='color:Tomato;'><i>nicotine</i></b>, ethanol, and the coadministration of each drug on acoustic startle responding in C57BL/6J mice. Mice were tested at a range of decibel levels (80-115 dB, 5 dB increments), with administration of 0.031, 0.062, 0.125, and 0.25 mg/kg <b style='color:Tomato;'><i>nicotine</i></b> or 0.5, 1.0, 1.5, and 2.0 g/kg ethanol. <b style='color:Tomato;'><i>nicotine</i></b> and ethanol each caused an increase in the acoustic startle response at the highest and lowest doses tested, respectively. <b style='color:Tomato;'><i>mecamylamine</i></b>, a nicotinic receptor antagonist, administered in combination with <b style='color:Tomato;'><i>nicotine</i></b> or ethanol attenuated these increases in acoustic startle responding. <b style='color:Tomato;'><i>nicotine</i></b> and ethanol, administered together, did not produce greater enhancement of startle than when administered alone. <b style='color:Tomato;'><i>haloperidol</i></b> (1 mg/kg) was administered in combination with <b style='color:Tomato;'><i>nicotine</i></b> or ethanol to investigate if dopamine modulated <b style='color:Tomato;'><i>nicotine</i></b> or ethanol enhancement of acoustic startle. <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acoustic</i></b> <b style='color:DodgerBlue;'><i>startle</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ethanol</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>attenuated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Thus, ethanol or <b style='color:Tomato;'><i>nicotine</i></b> may enhance the acoustic startle reflex through a common dopaminergic mechanism.","tokens":[{"text":"It","start":0,"end":2,"id":0,"ws":true},{"text":"was","start":3,"end":6,"id":1,"ws":true},{"text":"found","start":7,"end":12,"id":2,"ws":true},{"text":"that","start":13,"end":17,"id":3,"ws":true},{"text":"the","start":18,"end":21,"id":4,"ws":true},{"text":"increase","start":22,"end":30,"id":5,"ws":true},{"text":"in","start":31,"end":33,"id":6,"ws":true},{"text":"acoustic","start":34,"end":42,"id":7,"ws":true},{"text":"startle","start":43,"end":50,"id":8,"ws":true},{"text":"responses","start":51,"end":60,"id":9,"ws":true},{"text":"observed","start":61,"end":69,"id":10,"ws":true},{"text":"with","start":70,"end":74,"id":11,"ws":true},{"text":"ethanol","start":75,"end":82,"id":12,"ws":true},{"text":"or","start":83,"end":85,"id":13,"ws":true},{"text":"nicotine","start":86,"end":94,"id":14,"ws":true},{"text":"was","start":95,"end":98,"id":15,"ws":true},{"text":"attenuated","start":99,"end":109,"id":16,"ws":true},{"text":"by","start":110,"end":112,"id":17,"ws":true},{"text":"haloperidol","start":113,"end":124,"id":18,"ws":true},{"text":".","start":125,"end":126,"id":19,"ws":false}],"spans":[{"start":86,"end":94,"token_start":14,"token_end":14,"label":"DRUG"},{"start":113,"end":124,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":-719966272,"_task_hash":1591726855,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The use of tacrolimus ( 88 % vs 77 % , P=.02 ) and cytolytic therapy ( 81 % vs 46 % , P < .0001 ) was likewise greater among patients who received ganciclovir prophylaxis .","paragraph":"<h3><u>Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.</u></h3>Cytomegalovirus (CMV) infection is associated with reduced graft and patient survival among renal transplant recipients. The purpose of this study was to examine the effect of routine prophylaxis with 12 weeks of oral <b style='color:Tomato;'><i>ganciclovir</i></b> on the incidence of CMV infection in a center that predominantly uses antibody induction together with <b style='color:Tomato;'><i>tacrolimus</i></b>/<b style='color:Tomato;'><i>mycophenolate</i></b> mofetil-based maintenance immunosuppressive therapy. The control group consisted of a historical patient cohort transplanted immediately prior to the use of oral <b style='color:Tomato;'><i>ganciclovir</i></b> prophylaxis. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tacrolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>88</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>77</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>P=.02</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cytolytic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>81</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>vs</i></b> <b style='color:DodgerBlue;'><i>46</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>.0001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>likewise</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ganciclovir</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> CMV infection occurred in 20 (9%) patients in the <b style='color:Tomato;'><i>ganciclovir</i></b> era and 4 (3%) patients in the pre<b style='color:Tomato;'><i>ganciclovir</i></b> era (P=.003). The mean time to CMV infection was longer in patients who received <b style='color:Tomato;'><i>ganciclovir</i></b> prophylaxis than in patients in the pre<b style='color:Tomato;'><i>ganciclovir</i></b> era (23.4 +/- 10.9 weeks vs 9.8 +/- 5.6 weeks, P=.03). We conclude that 12 weeks of <b style='color:Tomato;'><i>ganciclovir</i></b> prophylaxis delays but does not prevent CMV infection from occurring in renal transplant recipients. These results suggest that with the use of 12 weeks of <b style='color:Tomato;'><i>ganciclovir</i></b> prophylaxis, vigilance for CMV infection is needed well beyond 24 weeks posttransplant.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"use","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"tacrolimus","start":11,"end":21,"id":3,"ws":true},{"text":"(","start":22,"end":23,"id":4,"ws":true},{"text":"88","start":24,"end":26,"id":5,"ws":true},{"text":"%","start":27,"end":28,"id":6,"ws":true},{"text":"vs","start":29,"end":31,"id":7,"ws":true},{"text":"77","start":32,"end":34,"id":8,"ws":true},{"text":"%","start":35,"end":36,"id":9,"ws":true},{"text":",","start":37,"end":38,"id":10,"ws":true},{"text":"P=.02","start":39,"end":44,"id":11,"ws":true},{"text":")","start":45,"end":46,"id":12,"ws":true},{"text":"and","start":47,"end":50,"id":13,"ws":true},{"text":"cytolytic","start":51,"end":60,"id":14,"ws":true},{"text":"therapy","start":61,"end":68,"id":15,"ws":true},{"text":"(","start":69,"end":70,"id":16,"ws":true},{"text":"81","start":71,"end":73,"id":17,"ws":true},{"text":"%","start":74,"end":75,"id":18,"ws":true},{"text":"vs","start":76,"end":78,"id":19,"ws":true},{"text":"46","start":79,"end":81,"id":20,"ws":true},{"text":"%","start":82,"end":83,"id":21,"ws":true},{"text":",","start":84,"end":85,"id":22,"ws":true},{"text":"P","start":86,"end":87,"id":23,"ws":true},{"text":"<","start":88,"end":89,"id":24,"ws":true},{"text":".0001","start":90,"end":95,"id":25,"ws":true},{"text":")","start":96,"end":97,"id":26,"ws":true},{"text":"was","start":98,"end":101,"id":27,"ws":true},{"text":"likewise","start":102,"end":110,"id":28,"ws":true},{"text":"greater","start":111,"end":118,"id":29,"ws":true},{"text":"among","start":119,"end":124,"id":30,"ws":true},{"text":"patients","start":125,"end":133,"id":31,"ws":true},{"text":"who","start":134,"end":137,"id":32,"ws":true},{"text":"received","start":138,"end":146,"id":33,"ws":true},{"text":"ganciclovir","start":147,"end":158,"id":34,"ws":true},{"text":"prophylaxis","start":159,"end":170,"id":35,"ws":true},{"text":".","start":171,"end":172,"id":36,"ws":false}],"spans":[{"start":11,"end":21,"token_start":3,"token_end":3,"label":"DRUG"},{"start":147,"end":158,"token_start":34,"token_end":34,"label":"DRUG"}],"_input_hash":-547855769,"_task_hash":1825037205,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Because gemcitabine has been considered a standard treatment for advanced pancreatic cancer for the past decade , several randomized trials have tested the combination of gemcitabine plus a second agent , including platinum based agents , topoisomerase inhibitors , taxanes , bevacizumab and cetuximab , as biologically \" targeted \" agents .","paragraph":"<h3><u>First-line treatment for advanced pancreatic cancer. Highlights from the \"2011 ASCO Gastrointestinal Cancers Symposium\". San Francisco, CA, USA. January 20-22, 2011.</u></h3>Pancreatic adenocarcinoma remains a treatment-refractory cancer. Although pancreatic adenocarcinoma is only the 10th most common cause of new cancer in the United States, it is the fourth most common cause of cancer-related death. Most cases are not suitable for resection and a majority is metastatic at presentation. <b style='color:Tomato;'><i>gemcitabine</i></b>, with or without <b style='color:Tomato;'><i>erlotinib</i></b>, has been the standard chemotherapy in this setting but the benefit is only modest. <b style='color:DodgerBlue;'><i>Because</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>past</i></b> <b style='color:DodgerBlue;'><i>decade</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>several</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>topoisomerase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>taxanes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>biologically</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> At large this approach has not been successful and novel strategies are clearly needed. In this article, the authors summarizes the data from the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including: Abstract #175 (review of survival data in a large cohort); Abstract #286 (rapid change in prescriber patterns after the suggestion of benefit of a new regimen, FOLFIRINOX); Abstracts #238, #277, #304, and #315 (phase II trials looking at combinations that utilized EGFR blockade); Abstracts #221, #266, and #284 (phase I/II trials including VEGF blockade, anticoagulation, and traditional Chinese medicines).","tokens":[{"text":"Because","start":0,"end":7,"id":0,"ws":true},{"text":"gemcitabine","start":8,"end":19,"id":1,"ws":true},{"text":"has","start":20,"end":23,"id":2,"ws":true},{"text":"been","start":24,"end":28,"id":3,"ws":true},{"text":"considered","start":29,"end":39,"id":4,"ws":true},{"text":"a","start":40,"end":41,"id":5,"ws":true},{"text":"standard","start":42,"end":50,"id":6,"ws":true},{"text":"treatment","start":51,"end":60,"id":7,"ws":true},{"text":"for","start":61,"end":64,"id":8,"ws":true},{"text":"advanced","start":65,"end":73,"id":9,"ws":true},{"text":"pancreatic","start":74,"end":84,"id":10,"ws":true},{"text":"cancer","start":85,"end":91,"id":11,"ws":true},{"text":"for","start":92,"end":95,"id":12,"ws":true},{"text":"the","start":96,"end":99,"id":13,"ws":true},{"text":"past","start":100,"end":104,"id":14,"ws":true},{"text":"decade","start":105,"end":111,"id":15,"ws":true},{"text":",","start":112,"end":113,"id":16,"ws":true},{"text":"several","start":114,"end":121,"id":17,"ws":true},{"text":"randomized","start":122,"end":132,"id":18,"ws":true},{"text":"trials","start":133,"end":139,"id":19,"ws":true},{"text":"have","start":140,"end":144,"id":20,"ws":true},{"text":"tested","start":145,"end":151,"id":21,"ws":true},{"text":"the","start":152,"end":155,"id":22,"ws":true},{"text":"combination","start":156,"end":167,"id":23,"ws":true},{"text":"of","start":168,"end":170,"id":24,"ws":true},{"text":"gemcitabine","start":171,"end":182,"id":25,"ws":true},{"text":"plus","start":183,"end":187,"id":26,"ws":true},{"text":"a","start":188,"end":189,"id":27,"ws":true},{"text":"second","start":190,"end":196,"id":28,"ws":true},{"text":"agent","start":197,"end":202,"id":29,"ws":true},{"text":",","start":203,"end":204,"id":30,"ws":true},{"text":"including","start":205,"end":214,"id":31,"ws":true},{"text":"platinum","start":215,"end":223,"id":32,"ws":true},{"text":"based","start":224,"end":229,"id":33,"ws":true},{"text":"agents","start":230,"end":236,"id":34,"ws":true},{"text":",","start":237,"end":238,"id":35,"ws":true},{"text":"topoisomerase","start":239,"end":252,"id":36,"ws":true},{"text":"inhibitors","start":253,"end":263,"id":37,"ws":true},{"text":",","start":264,"end":265,"id":38,"ws":true},{"text":"taxanes","start":266,"end":273,"id":39,"ws":true},{"text":",","start":274,"end":275,"id":40,"ws":true},{"text":"bevacizumab","start":276,"end":287,"id":41,"ws":true},{"text":"and","start":288,"end":291,"id":42,"ws":true},{"text":"cetuximab","start":292,"end":301,"id":43,"ws":true},{"text":",","start":302,"end":303,"id":44,"ws":true},{"text":"as","start":304,"end":306,"id":45,"ws":true},{"text":"biologically","start":307,"end":319,"id":46,"ws":true},{"text":"\"","start":320,"end":321,"id":47,"ws":true},{"text":"targeted","start":322,"end":330,"id":48,"ws":true},{"text":"\"","start":331,"end":332,"id":49,"ws":true},{"text":"agents","start":333,"end":339,"id":50,"ws":true},{"text":".","start":340,"end":341,"id":51,"ws":false}],"spans":[{"start":8,"end":19,"token_start":1,"token_end":1,"label":"DRUG"},{"start":171,"end":182,"token_start":25,"token_end":25,"label":"DRUG"},{"start":276,"end":287,"token_start":41,"token_end":41,"label":"DRUG"},{"start":292,"end":301,"token_start":43,"token_end":43,"label":"DRUG"}],"_input_hash":1637740532,"_task_hash":-715175769,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":25,"child":41,"head_span":{"start":171,"end":182,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":276,"end":287,"token_start":41,"token_end":41,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":25,"child":43,"head_span":{"start":171,"end":182,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":292,"end":301,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"Melatonin , an indoleamine hormone secreted by the pineal gland , plays pleiotropic roles in the cardiovascular system ; however , the effect of melatonin on vulnerable plaque rupture and its underlying mechanisms remains unknown .","paragraph":"<h3><u>Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor ROR\u03b1-dependent manner.</u></h3>Rupture of vulnerable plaques is the main trigger of acute cardio-cerebral vascular events, but mechanisms responsible for transforming a stable atherosclerotic into a vulnerable plaque remain largely unknown. <b style='color:MediumOrchid;'><i>Melatonin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>indoleamine</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>secreted</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pineal</i></b> <b style='color:DodgerBlue;'><i>gland</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>plays</i></b> <b style='color:DodgerBlue;'><i>pleiotropic</i></b> <b style='color:DodgerBlue;'><i>roles</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>system</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>however</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>melatonin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>vulnerable</i></b> <b style='color:DodgerBlue;'><i>plaque</i></b> <b style='color:DodgerBlue;'><i>rupture</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>underlying</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>remains</i></b> <b style='color:DodgerBlue;'><i>unknown</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we generated a rupture-prone vulnerable carotid plaque model induced by endogenous renovascular hypertension combined with low shear stress in hypercholesterolemic ApoE","tokens":[{"text":"Melatonin","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"an","start":12,"end":14,"id":2,"ws":true},{"text":"indoleamine","start":15,"end":26,"id":3,"ws":true},{"text":"hormone","start":27,"end":34,"id":4,"ws":true},{"text":"secreted","start":35,"end":43,"id":5,"ws":true},{"text":"by","start":44,"end":46,"id":6,"ws":true},{"text":"the","start":47,"end":50,"id":7,"ws":true},{"text":"pineal","start":51,"end":57,"id":8,"ws":true},{"text":"gland","start":58,"end":63,"id":9,"ws":true},{"text":",","start":64,"end":65,"id":10,"ws":true},{"text":"plays","start":66,"end":71,"id":11,"ws":true},{"text":"pleiotropic","start":72,"end":83,"id":12,"ws":true},{"text":"roles","start":84,"end":89,"id":13,"ws":true},{"text":"in","start":90,"end":92,"id":14,"ws":true},{"text":"the","start":93,"end":96,"id":15,"ws":true},{"text":"cardiovascular","start":97,"end":111,"id":16,"ws":true},{"text":"system","start":112,"end":118,"id":17,"ws":true},{"text":";","start":119,"end":120,"id":18,"ws":true},{"text":"however","start":121,"end":128,"id":19,"ws":true},{"text":",","start":129,"end":130,"id":20,"ws":true},{"text":"the","start":131,"end":134,"id":21,"ws":true},{"text":"effect","start":135,"end":141,"id":22,"ws":true},{"text":"of","start":142,"end":144,"id":23,"ws":true},{"text":"melatonin","start":145,"end":154,"id":24,"ws":true},{"text":"on","start":155,"end":157,"id":25,"ws":true},{"text":"vulnerable","start":158,"end":168,"id":26,"ws":true},{"text":"plaque","start":169,"end":175,"id":27,"ws":true},{"text":"rupture","start":176,"end":183,"id":28,"ws":true},{"text":"and","start":184,"end":187,"id":29,"ws":true},{"text":"its","start":188,"end":191,"id":30,"ws":true},{"text":"underlying","start":192,"end":202,"id":31,"ws":true},{"text":"mechanisms","start":203,"end":213,"id":32,"ws":true},{"text":"remains","start":214,"end":221,"id":33,"ws":true},{"text":"unknown","start":222,"end":229,"id":34,"ws":true},{"text":".","start":230,"end":231,"id":35,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":145,"end":154,"token_start":24,"token_end":24,"label":"DRUG"}],"_input_hash":-910390700,"_task_hash":1817876690,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Gemcitabine and recently FOLFIRINOX ( 5-flourouracil , leucovorin , oxaliplatin and irinotecan ) have provided some limited survival advantage in advanced pancreatic cancer .","paragraph":"<h3><u>Immunotherapy updates in pancreatic cancer: are we there yet?</u></h3>Pancreatic cancer is a lethal disease and remains one of the most resistant cancers to traditional therapies. Historically, chemotherapy or radiotherapy did not provide meaningful survival benefit in advanced pancreatic cancer. <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>FOLFIRINOX</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-flourouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>some</i></b> <b style='color:DodgerBlue;'><i>limited</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Targeted agents in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> had not shown significant improvement in the survival. Current therapies for pancreatic cancer have their limitations; thus, we are in dire need of newer treatment options. Immunotherapy in pancreatic cancer works by recruiting and activating T cells that recognize tumor-specific antigens which is a different mechanism compared with chemotherapy and radiotherapy. Preclinical models have shown that immunotherapy and targeted therapies like vascular endothelial growth factor and epidermal growth factor inhibitors work synergistically. Hence, new immunotherapy and targeted therapies represent a viable option for pancreatic cancer. In this article, we review the vaccine therapy for pancreatic cancer.","tokens":[{"text":"Gemcitabine","start":0,"end":11,"id":0,"ws":true},{"text":"and","start":12,"end":15,"id":1,"ws":true},{"text":"recently","start":16,"end":24,"id":2,"ws":true},{"text":"FOLFIRINOX","start":25,"end":35,"id":3,"ws":true},{"text":"(","start":36,"end":37,"id":4,"ws":true},{"text":"5-flourouracil","start":38,"end":52,"id":5,"ws":true},{"text":",","start":53,"end":54,"id":6,"ws":true},{"text":"leucovorin","start":55,"end":65,"id":7,"ws":true},{"text":",","start":66,"end":67,"id":8,"ws":true},{"text":"oxaliplatin","start":68,"end":79,"id":9,"ws":true},{"text":"and","start":80,"end":83,"id":10,"ws":true},{"text":"irinotecan","start":84,"end":94,"id":11,"ws":true},{"text":")","start":95,"end":96,"id":12,"ws":true},{"text":"have","start":97,"end":101,"id":13,"ws":true},{"text":"provided","start":102,"end":110,"id":14,"ws":true},{"text":"some","start":111,"end":115,"id":15,"ws":true},{"text":"limited","start":116,"end":123,"id":16,"ws":true},{"text":"survival","start":124,"end":132,"id":17,"ws":true},{"text":"advantage","start":133,"end":142,"id":18,"ws":true},{"text":"in","start":143,"end":145,"id":19,"ws":true},{"text":"advanced","start":146,"end":154,"id":20,"ws":true},{"text":"pancreatic","start":155,"end":165,"id":21,"ws":true},{"text":"cancer","start":166,"end":172,"id":22,"ws":true},{"text":".","start":173,"end":174,"id":23,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":55,"end":65,"token_start":7,"token_end":7,"label":"DRUG"},{"start":68,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":94,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-451421104,"_task_hash":-607729914,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"No synergism was found against Pneumococci and Meningococci but also no antagonism of the lower MIC and MBC values seen with ampicillin and penicillin G. The combination of chloramphenicol with either penicillin or ampicillin constitutes a clinically successful therapeutic regimen which is now also proven by in vitro investigations .","paragraph":"<h3><u>[Bactericidal action of chloramphenicol and synergism with beta-lactam antibiotics].</u></h3>Excellent clinical results were observed with the combination therapy of <b style='color:Tomato;'><i>chloramphenicol</i></b> with beta-lactam-antibiotics in the treatment of purulent meningitis. This came as a surprise as bacteriostatic antibiotics like <b style='color:Tomato;'><i>chloramphenicol</i></b> are commonly thought to antagonize the bactericidal action of penicillin or <b style='color:Tomato;'><i>ampicillin</i></b>. We reevaluated the mode of action of <b style='color:Tomato;'><i>chloramphenicol</i></b> against the three most common meningeal pathogens after the newborn period. <b style='color:Tomato;'><i>chloramphenicol</i></b> was found to be bactericidal against H. influenzae, Streptococcus pneumoniae and Neisseria meningitidis at clinically achievable levels in the CSF. In addition <b style='color:Tomato;'><i>chloramphenicol</i></b> showed synergistic action with <b style='color:Tomato;'><i>ampicillin</i></b> against H. influenzae which can possess clinical relevance particularly with the high inoculum of 10(7) organisms/ml which is frequently seen in bacterial meningitis. <b style='color:DodgerBlue;'><i>No</i></b> <b style='color:DodgerBlue;'><i>synergism</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Pneumococci</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Meningococci</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>antagonism</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>MIC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MBC</i></b> <b style='color:DodgerBlue;'><i>values</i></b> <b style='color:DodgerBlue;'><i>seen</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>G.</i></b> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>chloramphenicol</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>constitutes</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>clinically</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>investigations</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"No","start":0,"end":2,"id":0,"ws":true},{"text":"synergism","start":3,"end":12,"id":1,"ws":true},{"text":"was","start":13,"end":16,"id":2,"ws":true},{"text":"found","start":17,"end":22,"id":3,"ws":true},{"text":"against","start":23,"end":30,"id":4,"ws":true},{"text":"Pneumococci","start":31,"end":42,"id":5,"ws":true},{"text":"and","start":43,"end":46,"id":6,"ws":true},{"text":"Meningococci","start":47,"end":59,"id":7,"ws":true},{"text":"but","start":60,"end":63,"id":8,"ws":true},{"text":"also","start":64,"end":68,"id":9,"ws":true},{"text":"no","start":69,"end":71,"id":10,"ws":true},{"text":"antagonism","start":72,"end":82,"id":11,"ws":true},{"text":"of","start":83,"end":85,"id":12,"ws":true},{"text":"the","start":86,"end":89,"id":13,"ws":true},{"text":"lower","start":90,"end":95,"id":14,"ws":true},{"text":"MIC","start":96,"end":99,"id":15,"ws":true},{"text":"and","start":100,"end":103,"id":16,"ws":true},{"text":"MBC","start":104,"end":107,"id":17,"ws":true},{"text":"values","start":108,"end":114,"id":18,"ws":true},{"text":"seen","start":115,"end":119,"id":19,"ws":true},{"text":"with","start":120,"end":124,"id":20,"ws":true},{"text":"ampicillin","start":125,"end":135,"id":21,"ws":true},{"text":"and","start":136,"end":139,"id":22,"ws":true},{"text":"penicillin","start":140,"end":150,"id":23,"ws":true},{"text":"G.","start":151,"end":153,"id":24,"ws":true},{"text":"The","start":154,"end":157,"id":25,"ws":true},{"text":"combination","start":158,"end":169,"id":26,"ws":true},{"text":"of","start":170,"end":172,"id":27,"ws":true},{"text":"chloramphenicol","start":173,"end":188,"id":28,"ws":true},{"text":"with","start":189,"end":193,"id":29,"ws":true},{"text":"either","start":194,"end":200,"id":30,"ws":true},{"text":"penicillin","start":201,"end":211,"id":31,"ws":true},{"text":"or","start":212,"end":214,"id":32,"ws":true},{"text":"ampicillin","start":215,"end":225,"id":33,"ws":true},{"text":"constitutes","start":226,"end":237,"id":34,"ws":true},{"text":"a","start":238,"end":239,"id":35,"ws":true},{"text":"clinically","start":240,"end":250,"id":36,"ws":true},{"text":"successful","start":251,"end":261,"id":37,"ws":true},{"text":"therapeutic","start":262,"end":273,"id":38,"ws":true},{"text":"regimen","start":274,"end":281,"id":39,"ws":true},{"text":"which","start":282,"end":287,"id":40,"ws":true},{"text":"is","start":288,"end":290,"id":41,"ws":true},{"text":"now","start":291,"end":294,"id":42,"ws":true},{"text":"also","start":295,"end":299,"id":43,"ws":true},{"text":"proven","start":300,"end":306,"id":44,"ws":true},{"text":"by","start":307,"end":309,"id":45,"ws":true},{"text":"in","start":310,"end":312,"id":46,"ws":true},{"text":"vitro","start":313,"end":318,"id":47,"ws":true},{"text":"investigations","start":319,"end":333,"id":48,"ws":true},{"text":".","start":334,"end":335,"id":49,"ws":false}],"spans":[{"start":125,"end":135,"token_start":21,"token_end":21,"label":"DRUG"},{"start":173,"end":188,"token_start":28,"token_end":28,"label":"DRUG"},{"start":215,"end":225,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":-853181729,"_task_hash":-20851030,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":125,"end":135,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":140,"end":150,"token_start":23,"token_end":23,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":28,"child":31,"head_span":{"start":173,"end":188,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":201,"end":211,"token_start":31,"token_end":31,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":28,"child":33,"head_span":{"start":173,"end":188,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":215,"end":225,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS1T0","POS20","POS2T0","COMB1T0"],"answer":"accept"}
{"text":"Similarly , nifedipine , nitroglycerin and hydralazine should not to be considered first-line therapies in the management of hypertensive crises because these agents are associated with significant toxicities and/or adverse effects .","paragraph":"<h3><u>Treatment of acute severe hypertension: current and newer agents.</u></h3>Approximately 72 million people in the US experience hypertension. Worldwide, hypertension may affect as many as 1 billion people and be responsible for approximately 7.1 million deaths per year. It is estimated that approximately 1% of patients with hypertension will, at some point, develop a hypertensive crisis. Hypertensive crises are further defined as either hypertensive emergencies or urgencies, depending on the degree of blood pressure elevation and presence of end-organ damage. Immediate reduction in blood pressure is required only in patients with acute end-organ damage (i.e. hypertensive emergency) and requires treatment with a titratable, short-acting, intravenous antihypertensive agent, while severe hypertension without acute end-organ damage (i.e. hypertensive urgency) is usually treated with oral antihypertensive agents. The primary goal of intervention in a hypertensive crisis is to safely reduce blood pressure. The appropriate therapeutic approach of each patient will depend on their clinical presentation. Patients with hypertensive emergencies are best treated in an intensive care unit with titratable, intravenous, hypotensive agents. Rapid-acting intravenous antihypertensive agents are available, including <b style='color:Tomato;'><i>labetalol</i></b>, <b style='color:Tomato;'><i>esmolol</i></b>, <b style='color:Tomato;'><i>fenoldopam</i></b>, <b style='color:Tomato;'><i>nicardipine</i></b> and sodium nitroprusside. Newer agents, such as <b style='color:Tomato;'><i>clevidipine</i></b> and <b style='color:Tomato;'><i>fenoldopam</i></b>, may hold considerable advantages to other available agents in the management of hypertensive crises. Sodium nitroprusside is an extremely toxic drug and its use in the treatment of hypertensive emergencies should be avoided. <b style='color:DodgerBlue;'><i>Similarly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nifedipine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nitroglycerin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>hydralazine</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>management</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hypertensive</i></b> <b style='color:DodgerBlue;'><i>crises</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>toxicities</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Similarly","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"nifedipine","start":12,"end":22,"id":2,"ws":true},{"text":",","start":23,"end":24,"id":3,"ws":true},{"text":"nitroglycerin","start":25,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"hydralazine","start":43,"end":54,"id":6,"ws":true},{"text":"should","start":55,"end":61,"id":7,"ws":true},{"text":"not","start":62,"end":65,"id":8,"ws":true},{"text":"to","start":66,"end":68,"id":9,"ws":true},{"text":"be","start":69,"end":71,"id":10,"ws":true},{"text":"considered","start":72,"end":82,"id":11,"ws":true},{"text":"first-line","start":83,"end":93,"id":12,"ws":true},{"text":"therapies","start":94,"end":103,"id":13,"ws":true},{"text":"in","start":104,"end":106,"id":14,"ws":true},{"text":"the","start":107,"end":110,"id":15,"ws":true},{"text":"management","start":111,"end":121,"id":16,"ws":true},{"text":"of","start":122,"end":124,"id":17,"ws":true},{"text":"hypertensive","start":125,"end":137,"id":18,"ws":true},{"text":"crises","start":138,"end":144,"id":19,"ws":true},{"text":"because","start":145,"end":152,"id":20,"ws":true},{"text":"these","start":153,"end":158,"id":21,"ws":true},{"text":"agents","start":159,"end":165,"id":22,"ws":true},{"text":"are","start":166,"end":169,"id":23,"ws":true},{"text":"associated","start":170,"end":180,"id":24,"ws":true},{"text":"with","start":181,"end":185,"id":25,"ws":true},{"text":"significant","start":186,"end":197,"id":26,"ws":true},{"text":"toxicities","start":198,"end":208,"id":27,"ws":true},{"text":"and/or","start":209,"end":215,"id":28,"ws":true},{"text":"adverse","start":216,"end":223,"id":29,"ws":true},{"text":"effects","start":224,"end":231,"id":30,"ws":true},{"text":".","start":232,"end":233,"id":31,"ws":false}],"spans":[{"start":12,"end":22,"token_start":2,"token_end":2,"label":"DRUG"},{"start":43,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":760872894,"_task_hash":2117133383,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Bendamustine is effective both with rituximab and as a monotherapy in rituximab-refractory patients .","paragraph":"<h3><u>Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.</u></h3><b style='color:Tomato;'><i>bendamustine</i></b> is a water-soluble, bifunctional chemotherapeutic agent with characteristics of both an alkylator and a purine analog. <b style='color:Tomato;'><i>bendamustine</i></b> combined with <b style='color:Tomato;'><i>rituximab</i></b> in vitro shows synergistic effects against various leukemia and lymphoma cell lines. Clinical trials supporting these results show that <b style='color:Tomato;'><i>bendamustine</i></b> plus <b style='color:Tomato;'><i>rituximab</i></b> is highly effective in relapsed and refractory patients with indolent lymphoma. The results have been found in <b style='color:Tomato;'><i>rituximab</i></b>-naive, <b style='color:Tomato;'><i>rituximab</i></b>-pretreated, and <b style='color:Tomato;'><i>rituximab</i></b>-refractory patients with excellent response rates and toxicity profiles. <b style='color:MediumOrchid;'><i>Bendamustine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>rituximab-refractory</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Interim results from a phase III, randomized trial comparing <b style='color:Tomato;'><i>bendamustine</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> to a standard CHOP (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, and <b style='color:Tomato;'><i>prednisone</i></b>) and <b style='color:Tomato;'><i>rituximab</i></b> regimen suggest that combination <b style='color:Tomato;'><i>bendamustine</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> may provide a viable alternative for treatment of many indolent lymphomas.","tokens":[{"text":"Bendamustine","start":0,"end":12,"id":0,"ws":true},{"text":"is","start":13,"end":15,"id":1,"ws":true},{"text":"effective","start":16,"end":25,"id":2,"ws":true},{"text":"both","start":26,"end":30,"id":3,"ws":true},{"text":"with","start":31,"end":35,"id":4,"ws":true},{"text":"rituximab","start":36,"end":45,"id":5,"ws":true},{"text":"and","start":46,"end":49,"id":6,"ws":true},{"text":"as","start":50,"end":52,"id":7,"ws":true},{"text":"a","start":53,"end":54,"id":8,"ws":true},{"text":"monotherapy","start":55,"end":66,"id":9,"ws":true},{"text":"in","start":67,"end":69,"id":10,"ws":true},{"text":"rituximab-refractory","start":70,"end":90,"id":11,"ws":true},{"text":"patients","start":91,"end":99,"id":12,"ws":true},{"text":".","start":100,"end":101,"id":13,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"}],"_input_hash":-784969323,"_task_hash":1064931495,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[{"head":0,"child":5,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":36,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"In this work , the combination of membrane bioreactor ( MBR ) and electro-oxidation ( EO ) process was studied for the treatment of a synthetic hospital wastewater fortified with four pharmaceutical pollutants namely carbamazepine ( CBZ ) , ibuprofen ( IBU ) , estradiol ( E-E ) at a concentration of 10 \u03bcg L","paragraph":"<h3><u>Synthetic hospital wastewater treatment by coupling submerged membrane bioreactor and electrochemical advanced oxidation process: Kinetic study and toxicity assessment.</u></h3>In this work, the combination of membrane bioreactor (MBR) and electro-oxidation (EO) process was studied for the treatment of a synthetic hospital wastewater fortified with four pharmaceutical pollutants namely <b style='color:Tomato;'><i>carbamazepine</i></b> (CBZ), <b style='color:Tomato;'><i>ibuprofen</i></b> (IBU), estradiol (E-E) at a concentration of 10\u00a0\u03bcg\u00a0 <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>work</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>membrane</i></b> <b style='color:DodgerBlue;'><i>bioreactor</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MBR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>electro-oxidation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EO</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>process</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>synthetic</i></b> <b style='color:DodgerBlue;'><i>hospital</i></b> <b style='color:DodgerBlue;'><i>wastewater</i></b> <b style='color:DodgerBlue;'><i>fortified</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>pharmaceutical</i></b> <b style='color:DodgerBlue;'><i>pollutants</i></b> <b style='color:DodgerBlue;'><i>namely</i></b> <b style='color:MediumOrchid;'><i>carbamazepine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CBZ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ibuprofen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IBU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>estradiol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>E-E</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>concentration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>\u03bcg</i></b> <b style='color:DodgerBlue;'><i>L</i></b>g\u00a0L","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"work","start":8,"end":12,"id":2,"ws":true},{"text":",","start":13,"end":14,"id":3,"ws":true},{"text":"the","start":15,"end":18,"id":4,"ws":true},{"text":"combination","start":19,"end":30,"id":5,"ws":true},{"text":"of","start":31,"end":33,"id":6,"ws":true},{"text":"membrane","start":34,"end":42,"id":7,"ws":true},{"text":"bioreactor","start":43,"end":53,"id":8,"ws":true},{"text":"(","start":54,"end":55,"id":9,"ws":true},{"text":"MBR","start":56,"end":59,"id":10,"ws":true},{"text":")","start":60,"end":61,"id":11,"ws":true},{"text":"and","start":62,"end":65,"id":12,"ws":true},{"text":"electro-oxidation","start":66,"end":83,"id":13,"ws":true},{"text":"(","start":84,"end":85,"id":14,"ws":true},{"text":"EO","start":86,"end":88,"id":15,"ws":true},{"text":")","start":89,"end":90,"id":16,"ws":true},{"text":"process","start":91,"end":98,"id":17,"ws":true},{"text":"was","start":99,"end":102,"id":18,"ws":true},{"text":"studied","start":103,"end":110,"id":19,"ws":true},{"text":"for","start":111,"end":114,"id":20,"ws":true},{"text":"the","start":115,"end":118,"id":21,"ws":true},{"text":"treatment","start":119,"end":128,"id":22,"ws":true},{"text":"of","start":129,"end":131,"id":23,"ws":true},{"text":"a","start":132,"end":133,"id":24,"ws":true},{"text":"synthetic","start":134,"end":143,"id":25,"ws":true},{"text":"hospital","start":144,"end":152,"id":26,"ws":true},{"text":"wastewater","start":153,"end":163,"id":27,"ws":true},{"text":"fortified","start":164,"end":173,"id":28,"ws":true},{"text":"with","start":174,"end":178,"id":29,"ws":true},{"text":"four","start":179,"end":183,"id":30,"ws":true},{"text":"pharmaceutical","start":184,"end":198,"id":31,"ws":true},{"text":"pollutants","start":199,"end":209,"id":32,"ws":true},{"text":"namely","start":210,"end":216,"id":33,"ws":true},{"text":"carbamazepine","start":217,"end":230,"id":34,"ws":true},{"text":"(","start":231,"end":232,"id":35,"ws":true},{"text":"CBZ","start":233,"end":236,"id":36,"ws":true},{"text":")","start":237,"end":238,"id":37,"ws":true},{"text":",","start":239,"end":240,"id":38,"ws":true},{"text":"ibuprofen","start":241,"end":250,"id":39,"ws":true},{"text":"(","start":251,"end":252,"id":40,"ws":true},{"text":"IBU","start":253,"end":256,"id":41,"ws":true},{"text":")","start":257,"end":258,"id":42,"ws":true},{"text":",","start":259,"end":260,"id":43,"ws":true},{"text":"estradiol","start":261,"end":270,"id":44,"ws":true},{"text":"(","start":271,"end":272,"id":45,"ws":true},{"text":"E-E","start":273,"end":276,"id":46,"ws":true},{"text":")","start":277,"end":278,"id":47,"ws":true},{"text":"at","start":279,"end":281,"id":48,"ws":true},{"text":"a","start":282,"end":283,"id":49,"ws":true},{"text":"concentration","start":284,"end":297,"id":50,"ws":true},{"text":"of","start":298,"end":300,"id":51,"ws":true},{"text":"10","start":301,"end":303,"id":52,"ws":true},{"text":"\u03bcg","start":304,"end":306,"id":53,"ws":true},{"text":"L","start":307,"end":308,"id":54,"ws":false}],"spans":[{"start":217,"end":230,"token_start":34,"token_end":34,"label":"DRUG"},{"start":241,"end":250,"token_start":39,"token_end":39,"label":"DRUG"}],"_input_hash":540280106,"_task_hash":163178283,"_session_id":"drug_drug_pilot_split-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Despite preclinical evidence indicating that menadione pretreatment enhances the cytotoxicity of mitomycin C , our study documents the resistance of advanced gastrointestinal cancers , particularly colorectal cancer , to mitomycin C modulated by menadione .","paragraph":"<h3><u>Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial.</u></h3>A phase II trial of <b style='color:Tomato;'><i>menadione</i></b> (2.5 g/m2 as a continuous intravenous infusion over 48 h) followed by <b style='color:Tomato;'><i>mitomycin</i></b> C (10-20 mg/m2 i.v. bolus) administered every 4-6 weeks was performed in 43 patients with advanced gastrointestinal cancer. <b style='color:Tomato;'><i>menadione</i></b>, a vitamin K analog that lowers intracellular pools of reduced glutathione, was combined with <b style='color:Tomato;'><i>mitomycin</i></b> C in an attempt to overcome thiol-mediated resistance to alkylating-agent chemotherapy. The median age of patients entered on this trial was 58 years; performance status ranged from 60%-100%. None of the 43 evaluable patients obtained an objective response to this combination regimen. Median survival was 6.6 months. Treatment with <b style='color:Tomato;'><i>menadione</i></b> and <b style='color:Tomato;'><i>mitomycin</i></b> C was reasonably well tolerated except for hematological toxicity. A total of 27% of treatment courses were complicated by grade 3 or 4 hematological toxicity including one episode of hemolytic anemia and one episode of hemolytic uremic syndrome. One patient developed irreversible interstitial pneumonitis, and 1 patient had an asymptomatic decrease in the left-ventricular ejection fraction. <b style='color:DodgerBlue;'><i>Despite</i></b> <b style='color:DodgerBlue;'><i>preclinical</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>indicating</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>menadione</i></b> <b style='color:DodgerBlue;'><i>pretreatment</i></b> <b style='color:DodgerBlue;'><i>enhances</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cytotoxicity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>documents</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>particularly</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>modulated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>menadione</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Despite","start":0,"end":7,"id":0,"ws":true},{"text":"preclinical","start":8,"end":19,"id":1,"ws":true},{"text":"evidence","start":20,"end":28,"id":2,"ws":true},{"text":"indicating","start":29,"end":39,"id":3,"ws":true},{"text":"that","start":40,"end":44,"id":4,"ws":true},{"text":"menadione","start":45,"end":54,"id":5,"ws":true},{"text":"pretreatment","start":55,"end":67,"id":6,"ws":true},{"text":"enhances","start":68,"end":76,"id":7,"ws":true},{"text":"the","start":77,"end":80,"id":8,"ws":true},{"text":"cytotoxicity","start":81,"end":93,"id":9,"ws":true},{"text":"of","start":94,"end":96,"id":10,"ws":true},{"text":"mitomycin","start":97,"end":106,"id":11,"ws":true},{"text":"C","start":107,"end":108,"id":12,"ws":true},{"text":",","start":109,"end":110,"id":13,"ws":true},{"text":"our","start":111,"end":114,"id":14,"ws":true},{"text":"study","start":115,"end":120,"id":15,"ws":true},{"text":"documents","start":121,"end":130,"id":16,"ws":true},{"text":"the","start":131,"end":134,"id":17,"ws":true},{"text":"resistance","start":135,"end":145,"id":18,"ws":true},{"text":"of","start":146,"end":148,"id":19,"ws":true},{"text":"advanced","start":149,"end":157,"id":20,"ws":true},{"text":"gastrointestinal","start":158,"end":174,"id":21,"ws":true},{"text":"cancers","start":175,"end":182,"id":22,"ws":true},{"text":",","start":183,"end":184,"id":23,"ws":true},{"text":"particularly","start":185,"end":197,"id":24,"ws":true},{"text":"colorectal","start":198,"end":208,"id":25,"ws":true},{"text":"cancer","start":209,"end":215,"id":26,"ws":true},{"text":",","start":216,"end":217,"id":27,"ws":true},{"text":"to","start":218,"end":220,"id":28,"ws":true},{"text":"mitomycin","start":221,"end":230,"id":29,"ws":true},{"text":"C","start":231,"end":232,"id":30,"ws":true},{"text":"modulated","start":233,"end":242,"id":31,"ws":true},{"text":"by","start":243,"end":245,"id":32,"ws":true},{"text":"menadione","start":246,"end":255,"id":33,"ws":true},{"text":".","start":256,"end":257,"id":34,"ws":false}],"spans":[{"start":45,"end":54,"token_start":5,"token_end":5,"label":"DRUG"},{"start":97,"end":106,"token_start":11,"token_end":11,"label":"DRUG"},{"start":221,"end":230,"token_start":29,"token_end":29,"label":"DRUG"},{"start":246,"end":255,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":1855890059,"_task_hash":-1185593158,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":5,"child":11,"head_span":{"start":45,"end":54,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":97,"end":106,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10","NEG1T0"],"answer":"accept"}
{"text":"Objective response rates of approximately 50 % have been observed in the Phase III studies of the BRAF inhibitors vemurafenib and dabrafenib .","paragraph":"<h3><u>Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?</u></h3>The clinical development of selective BRAF inhibitors for metastatic BRAF V600 mutant melanoma patients has been a major breakthrough in targeted therapeutics. <b style='color:DodgerBlue;'><i>Objective</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>approximately</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>BRAF</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:MediumOrchid;'><i>vemurafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dabrafenib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The side effects can be relatively common, including proliferative skin toxicities. The latter range from hyperkeratosis and keratoacanthomas (KAs) to squamous cell carcinomas (SCCs) and new primary melanomas. In addition, case reports on the emergence of gastric/colonic polyps and RAS mutant malignancies have been described during BRAF inhibitor therapy. These events have been attributed to paradoxical activation of the MAPK pathway in BRAF wild-type cells exposed to selective BRAF inhibitors in addition to increased RAS activity. Combined BRAF and MEK inhibition appears to improve clinical outcomes and reduce cutaneous proliferation events as fewer KAs and SCCs have been observed with combination therapy. Next-generation pan-RAF inhibitors ('paradox breakers') and ERK inhibitors may further enhance clinical activity in metastatic BRAF-mutant melanoma patients and mitigate this paradoxical oncogenesis. Further investigation into the potential long-term effects of selective BRAF inhibitors is warranted as expanded use of these agents is expected in patients with BRAF-mutant melanoma and other malignancies. ","tokens":[{"text":"Objective","start":0,"end":9,"id":0,"ws":true},{"text":"response","start":10,"end":18,"id":1,"ws":true},{"text":"rates","start":19,"end":24,"id":2,"ws":true},{"text":"of","start":25,"end":27,"id":3,"ws":true},{"text":"approximately","start":28,"end":41,"id":4,"ws":true},{"text":"50","start":42,"end":44,"id":5,"ws":true},{"text":"%","start":45,"end":46,"id":6,"ws":true},{"text":"have","start":47,"end":51,"id":7,"ws":true},{"text":"been","start":52,"end":56,"id":8,"ws":true},{"text":"observed","start":57,"end":65,"id":9,"ws":true},{"text":"in","start":66,"end":68,"id":10,"ws":true},{"text":"the","start":69,"end":72,"id":11,"ws":true},{"text":"Phase","start":73,"end":78,"id":12,"ws":true},{"text":"III","start":79,"end":82,"id":13,"ws":true},{"text":"studies","start":83,"end":90,"id":14,"ws":true},{"text":"of","start":91,"end":93,"id":15,"ws":true},{"text":"the","start":94,"end":97,"id":16,"ws":true},{"text":"BRAF","start":98,"end":102,"id":17,"ws":true},{"text":"inhibitors","start":103,"end":113,"id":18,"ws":true},{"text":"vemurafenib","start":114,"end":125,"id":19,"ws":true},{"text":"and","start":126,"end":129,"id":20,"ws":true},{"text":"dabrafenib","start":130,"end":140,"id":21,"ws":true},{"text":".","start":141,"end":142,"id":22,"ws":false}],"spans":[{"start":114,"end":125,"token_start":19,"token_end":19,"label":"DRUG"},{"start":130,"end":140,"token_start":21,"token_end":21,"label":"DRUG"}],"_input_hash":-1021037207,"_task_hash":-1164044534,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In our study , the antibiotic resistance rates of 195 P.aeruginosa strains were found as follows : ceftazidime 100 % , tazobactam/piperacillin 90.8 % , aztreonam 60.5 % , cefepime 50.2 % , imipenem 48.2 % , meropenem 47.2 % , ofloxacin 47.2 % , piperacillin 44.1 % , levofloxacin 31.3 % , ciprofloxacin 26.2 % , gentamicin 11.8 % , amikacin 8.7 % and tobramycin 6.2 % .","paragraph":"<h3><u>[Molecular epidemiology of beta-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates].</u></h3>Pseudomonas aeruginosa is an important opportunistic pathogen that cause mainly nosocomial infections especially in the immunocompromised patients, the elderly and patients with severe burns. The bacterial feature of developing high degree of resistance against several antibiotics leads to increased morbidity and mortality of P.aeruginosa infections. The aims of this study were to investigate the antibiotic susceptibilities of P.aeruginosa strains isolated from hospitalized patients and to determine the presence of resistance enzymes namely PER, GES, KPC, VIM, IMP and OXA. A total of 195 P.aeruginosa strains isolated from different clinical samples (29 sputum, 67 wound, 53 tracheal aspirate, 23 blood, 18 urine, 3 cerebrospinal fluid, 2 pleural fluid) of inpatients (134 male, 61 female) in Afyon Kocatepe University School of Medicine Hospital between 2010-2012, were included in the study. The isolates were identified by conventional methods and automated systems (VITEK 2, BioMerieux, France), and their antibiotic susceptibilities were detected by disk diffusion and E-test methods. Inducible beta-lactamase (IBL), extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) productions of the isolates were phenotypically investigated by double disk induction, double disk synergy and E-test methods, respectively. The presence of resistance genes encoding PER, GES, KPC, VIM, IMP and OXA enzymes were determined by real-time polymerase chain reaction, and sequence analysis was applied to positive samples. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>195</i></b> <b style='color:DodgerBlue;'><i>P.aeruginosa</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>follows</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>ceftazidime</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tazobactam/piperacillin</i></b> <b style='color:DodgerBlue;'><i>90.8</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aztreonam</i></b> <b style='color:DodgerBlue;'><i>60.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cefepime</i></b> <b style='color:DodgerBlue;'><i>50.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>48.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>meropenem</i></b> <b style='color:DodgerBlue;'><i>47.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ofloxacin</i></b> <b style='color:DodgerBlue;'><i>47.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>piperacillin</i></b> <b style='color:DodgerBlue;'><i>44.1</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>31.3</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>26.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>11.8</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amikacin</i></b> <b style='color:DodgerBlue;'><i>8.7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tobramycin</i></b> <b style='color:DodgerBlue;'><i>6.2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>.</i></b> With the use of phenotypical methods, IBL, ESBL and MBL production rates in the isolates were detected as 89.2% (174/195), 30.7% (60/195) and 26.7% (52/195), respectively. Molecular studies showed that, five strains harboured OXA-10, four OXA-14, four VIM-2, two IMP-1, 26 GES-1 and 87 ABC transporter permease genes, while PER and KPC genes were not detected in any of the isolates. In conclusion, it was considered that the detection of beta-lactamase genes in bacteria and the identification of beta-lactamase types may provide facilities in selection of antibiotics, monitorization of therapy, prevention of resistance development of infection control programs. ","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"our","start":3,"end":6,"id":1,"ws":true},{"text":"study","start":7,"end":12,"id":2,"ws":true},{"text":",","start":13,"end":14,"id":3,"ws":true},{"text":"the","start":15,"end":18,"id":4,"ws":true},{"text":"antibiotic","start":19,"end":29,"id":5,"ws":true},{"text":"resistance","start":30,"end":40,"id":6,"ws":true},{"text":"rates","start":41,"end":46,"id":7,"ws":true},{"text":"of","start":47,"end":49,"id":8,"ws":true},{"text":"195","start":50,"end":53,"id":9,"ws":true},{"text":"P.aeruginosa","start":54,"end":66,"id":10,"ws":true},{"text":"strains","start":67,"end":74,"id":11,"ws":true},{"text":"were","start":75,"end":79,"id":12,"ws":true},{"text":"found","start":80,"end":85,"id":13,"ws":true},{"text":"as","start":86,"end":88,"id":14,"ws":true},{"text":"follows","start":89,"end":96,"id":15,"ws":true},{"text":":","start":97,"end":98,"id":16,"ws":true},{"text":"ceftazidime","start":99,"end":110,"id":17,"ws":true},{"text":"100","start":111,"end":114,"id":18,"ws":true},{"text":"%","start":115,"end":116,"id":19,"ws":true},{"text":",","start":117,"end":118,"id":20,"ws":true},{"text":"tazobactam/piperacillin","start":119,"end":142,"id":21,"ws":true},{"text":"90.8","start":143,"end":147,"id":22,"ws":true},{"text":"%","start":148,"end":149,"id":23,"ws":true},{"text":",","start":150,"end":151,"id":24,"ws":true},{"text":"aztreonam","start":152,"end":161,"id":25,"ws":true},{"text":"60.5","start":162,"end":166,"id":26,"ws":true},{"text":"%","start":167,"end":168,"id":27,"ws":true},{"text":",","start":169,"end":170,"id":28,"ws":true},{"text":"cefepime","start":171,"end":179,"id":29,"ws":true},{"text":"50.2","start":180,"end":184,"id":30,"ws":true},{"text":"%","start":185,"end":186,"id":31,"ws":true},{"text":",","start":187,"end":188,"id":32,"ws":true},{"text":"imipenem","start":189,"end":197,"id":33,"ws":true},{"text":"48.2","start":198,"end":202,"id":34,"ws":true},{"text":"%","start":203,"end":204,"id":35,"ws":true},{"text":",","start":205,"end":206,"id":36,"ws":true},{"text":"meropenem","start":207,"end":216,"id":37,"ws":true},{"text":"47.2","start":217,"end":221,"id":38,"ws":true},{"text":"%","start":222,"end":223,"id":39,"ws":true},{"text":",","start":224,"end":225,"id":40,"ws":true},{"text":"ofloxacin","start":226,"end":235,"id":41,"ws":true},{"text":"47.2","start":236,"end":240,"id":42,"ws":true},{"text":"%","start":241,"end":242,"id":43,"ws":true},{"text":",","start":243,"end":244,"id":44,"ws":true},{"text":"piperacillin","start":245,"end":257,"id":45,"ws":true},{"text":"44.1","start":258,"end":262,"id":46,"ws":true},{"text":"%","start":263,"end":264,"id":47,"ws":true},{"text":",","start":265,"end":266,"id":48,"ws":true},{"text":"levofloxacin","start":267,"end":279,"id":49,"ws":true},{"text":"31.3","start":280,"end":284,"id":50,"ws":true},{"text":"%","start":285,"end":286,"id":51,"ws":true},{"text":",","start":287,"end":288,"id":52,"ws":true},{"text":"ciprofloxacin","start":289,"end":302,"id":53,"ws":true},{"text":"26.2","start":303,"end":307,"id":54,"ws":true},{"text":"%","start":308,"end":309,"id":55,"ws":true},{"text":",","start":310,"end":311,"id":56,"ws":true},{"text":"gentamicin","start":312,"end":322,"id":57,"ws":true},{"text":"11.8","start":323,"end":327,"id":58,"ws":true},{"text":"%","start":328,"end":329,"id":59,"ws":true},{"text":",","start":330,"end":331,"id":60,"ws":true},{"text":"amikacin","start":332,"end":340,"id":61,"ws":true},{"text":"8.7","start":341,"end":344,"id":62,"ws":true},{"text":"%","start":345,"end":346,"id":63,"ws":true},{"text":"and","start":347,"end":350,"id":64,"ws":true},{"text":"tobramycin","start":351,"end":361,"id":65,"ws":true},{"text":"6.2","start":362,"end":365,"id":66,"ws":true},{"text":"%","start":366,"end":367,"id":67,"ws":true},{"text":".","start":368,"end":369,"id":68,"ws":false}],"spans":[{"start":99,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},{"start":152,"end":161,"token_start":25,"token_end":25,"label":"DRUG"},{"start":171,"end":179,"token_start":29,"token_end":29,"label":"DRUG"},{"start":189,"end":197,"token_start":33,"token_end":33,"label":"DRUG"},{"start":207,"end":216,"token_start":37,"token_end":37,"label":"DRUG"},{"start":245,"end":257,"token_start":45,"token_end":45,"label":"DRUG"},{"start":267,"end":279,"token_start":49,"token_end":49,"label":"DRUG"},{"start":289,"end":302,"token_start":53,"token_end":53,"label":"DRUG"},{"start":312,"end":322,"token_start":57,"token_end":57,"label":"DRUG"},{"start":332,"end":340,"token_start":61,"token_end":61,"label":"DRUG"},{"start":351,"end":361,"token_start":65,"token_end":65,"label":"DRUG"}],"_input_hash":2118350653,"_task_hash":726576004,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"When aspirin is administered to Apc(Min/+ ) mice only postweaning , but not before , it is inefficacious , while curcumin given postweaning is active .","paragraph":"<h3><u>Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin.</u></h3>The nonsteroidal anti-inflammatory drug <b style='color:Tomato;'><i>aspirin</i></b> and the spice <b style='color:Tomato;'><i>curcumin</i></b> retard adenoma formation when administered long-term to Apc(Min/+) mice, a model of human familial adenomatous polyposis coli. Both agents interfere with cyclooxygenase activity. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>Apc(Min/+</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>postweaning</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>before</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>inefficacious</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>postweaning</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here the hypothesis was tested that dietary <b style='color:Tomato;'><i>aspirin</i></b> (0.05%) or <b style='color:Tomato;'><i>curcumin</i></b> (0.2%) prevent or delay adenoma formation in offsprings when administered to Apc(Min/+) mothers and up to the end of weaning, but not afterwards. Whereas <b style='color:Tomato;'><i>curcumin</i></b> was without effect when administered in this way, <b style='color:Tomato;'><i>aspirin</i></b> reduced numbers of intestinal adenomas by 21%. When <b style='color:Tomato;'><i>aspirin</i></b> given up to the end of weaning was combined with <b style='color:Tomato;'><i>curcumin</i></b> administered from the end of weaning for the rest of the animals' lifetime, intestinal adenoma numbers were reduced by 38%. The combination was not superior to intervention postweaning with <b style='color:Tomato;'><i>curcumin</i></b> alone. These results show that <b style='color:Tomato;'><i>aspirin</i></b> exerts chemopreventive activity in the Apc(Min/+) mouse during tumour initiation/early promotion, while <b style='color:Tomato;'><i>curcumin</i></b> is efficacious when given at a later stage of carcinogenic progression. Thus, the results suggest that in this mouse model <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> act during different 'windows' of neoplastic development.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"aspirin","start":5,"end":12,"id":1,"ws":true},{"text":"is","start":13,"end":15,"id":2,"ws":true},{"text":"administered","start":16,"end":28,"id":3,"ws":true},{"text":"to","start":29,"end":31,"id":4,"ws":true},{"text":"Apc(Min/+","start":32,"end":41,"id":5,"ws":true},{"text":")","start":42,"end":43,"id":6,"ws":true},{"text":"mice","start":44,"end":48,"id":7,"ws":true},{"text":"only","start":49,"end":53,"id":8,"ws":true},{"text":"postweaning","start":54,"end":65,"id":9,"ws":true},{"text":",","start":66,"end":67,"id":10,"ws":true},{"text":"but","start":68,"end":71,"id":11,"ws":true},{"text":"not","start":72,"end":75,"id":12,"ws":true},{"text":"before","start":76,"end":82,"id":13,"ws":true},{"text":",","start":83,"end":84,"id":14,"ws":true},{"text":"it","start":85,"end":87,"id":15,"ws":true},{"text":"is","start":88,"end":90,"id":16,"ws":true},{"text":"inefficacious","start":91,"end":104,"id":17,"ws":true},{"text":",","start":105,"end":106,"id":18,"ws":true},{"text":"while","start":107,"end":112,"id":19,"ws":true},{"text":"curcumin","start":113,"end":121,"id":20,"ws":true},{"text":"given","start":122,"end":127,"id":21,"ws":true},{"text":"postweaning","start":128,"end":139,"id":22,"ws":true},{"text":"is","start":140,"end":142,"id":23,"ws":true},{"text":"active","start":143,"end":149,"id":24,"ws":true},{"text":".","start":150,"end":151,"id":25,"ws":false}],"spans":[{"start":5,"end":12,"token_start":1,"token_end":1,"label":"DRUG"},{"start":113,"end":121,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":586478287,"_task_hash":949529154,"_session_id":"drug_drug_pilot_split-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Neither the alpha blocker , phentolamine ( 10(-5 ) M ) , nor the beta blocker , propranolol ( 3 X 10(-5 ) M ) , affected lipolysis or cyclic AMP ; when these agents were incubated in combination with epinephrine , changes occurred indicative of the presence of both alpha and beta adrenergic receptor sites .","paragraph":"<h3><u>In-vitro observations on isolated adipose tissue cells from hyperobese subjects.</u></h3>Isolated adipose tissue cells were prepared from subcutaneous samples obtained from nine morbidly obese subjects weighing from 187 to 306% of ideal body weight. The responsiveness of these adipocytes to a number of test substances was determined by measuring cellular cyclic AMP concentration at one-half hour and glycerol release at four hours. <b style='color:Tomato;'><i>theophylline</i></b> (10(-3) M) and <b style='color:Tomato;'><i>epinephrine</i></b> (10(-5) M) stimulated lipolysis; <b style='color:Tomato;'><i>theophylline</i></b> stimulated an increase in cyclic AMP, while <b style='color:Tomato;'><i>epinephrine</i></b> failed to prompt a significant change in the nucleotide. <b style='color:DodgerBlue;'><i>Neither</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>alpha</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>phentolamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10(-5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>M</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nor</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>blocker</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>X</i></b> <b style='color:DodgerBlue;'><i>10(-5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>M</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>affected</i></b> <b style='color:DodgerBlue;'><i>lipolysis</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>cyclic</i></b> <b style='color:DodgerBlue;'><i>AMP</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>incubated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>changes</i></b> <b style='color:DodgerBlue;'><i>occurred</i></b> <b style='color:DodgerBlue;'><i>indicative</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>alpha</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>adrenergic</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>sites</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Insulin significantly reduced both basal and stimulated lipolysis but failed to affect cyclic AMP. With minor exceptions, adipocytes from hyperobese subjects behaved similarly to cells from unselected donors; at the concentration used, there was no evidence of resistance to insulin.","tokens":[{"text":"Neither","start":0,"end":7,"id":0,"ws":true},{"text":"the","start":8,"end":11,"id":1,"ws":true},{"text":"alpha","start":12,"end":17,"id":2,"ws":true},{"text":"blocker","start":18,"end":25,"id":3,"ws":true},{"text":",","start":26,"end":27,"id":4,"ws":true},{"text":"phentolamine","start":28,"end":40,"id":5,"ws":true},{"text":"(","start":41,"end":42,"id":6,"ws":true},{"text":"10(-5","start":43,"end":48,"id":7,"ws":true},{"text":")","start":49,"end":50,"id":8,"ws":true},{"text":"M","start":51,"end":52,"id":9,"ws":true},{"text":")","start":53,"end":54,"id":10,"ws":true},{"text":",","start":55,"end":56,"id":11,"ws":true},{"text":"nor","start":57,"end":60,"id":12,"ws":true},{"text":"the","start":61,"end":64,"id":13,"ws":true},{"text":"beta","start":65,"end":69,"id":14,"ws":true},{"text":"blocker","start":70,"end":77,"id":15,"ws":true},{"text":",","start":78,"end":79,"id":16,"ws":true},{"text":"propranolol","start":80,"end":91,"id":17,"ws":true},{"text":"(","start":92,"end":93,"id":18,"ws":true},{"text":"3","start":94,"end":95,"id":19,"ws":true},{"text":"X","start":96,"end":97,"id":20,"ws":true},{"text":"10(-5","start":98,"end":103,"id":21,"ws":true},{"text":")","start":104,"end":105,"id":22,"ws":true},{"text":"M","start":106,"end":107,"id":23,"ws":true},{"text":")","start":108,"end":109,"id":24,"ws":true},{"text":",","start":110,"end":111,"id":25,"ws":true},{"text":"affected","start":112,"end":120,"id":26,"ws":true},{"text":"lipolysis","start":121,"end":130,"id":27,"ws":true},{"text":"or","start":131,"end":133,"id":28,"ws":true},{"text":"cyclic","start":134,"end":140,"id":29,"ws":true},{"text":"AMP","start":141,"end":144,"id":30,"ws":true},{"text":";","start":145,"end":146,"id":31,"ws":true},{"text":"when","start":147,"end":151,"id":32,"ws":true},{"text":"these","start":152,"end":157,"id":33,"ws":true},{"text":"agents","start":158,"end":164,"id":34,"ws":true},{"text":"were","start":165,"end":169,"id":35,"ws":true},{"text":"incubated","start":170,"end":179,"id":36,"ws":true},{"text":"in","start":180,"end":182,"id":37,"ws":true},{"text":"combination","start":183,"end":194,"id":38,"ws":true},{"text":"with","start":195,"end":199,"id":39,"ws":true},{"text":"epinephrine","start":200,"end":211,"id":40,"ws":true},{"text":",","start":212,"end":213,"id":41,"ws":true},{"text":"changes","start":214,"end":221,"id":42,"ws":true},{"text":"occurred","start":222,"end":230,"id":43,"ws":true},{"text":"indicative","start":231,"end":241,"id":44,"ws":true},{"text":"of","start":242,"end":244,"id":45,"ws":true},{"text":"the","start":245,"end":248,"id":46,"ws":true},{"text":"presence","start":249,"end":257,"id":47,"ws":true},{"text":"of","start":258,"end":260,"id":48,"ws":true},{"text":"both","start":261,"end":265,"id":49,"ws":true},{"text":"alpha","start":266,"end":271,"id":50,"ws":true},{"text":"and","start":272,"end":275,"id":51,"ws":true},{"text":"beta","start":276,"end":280,"id":52,"ws":true},{"text":"adrenergic","start":281,"end":291,"id":53,"ws":true},{"text":"receptor","start":292,"end":300,"id":54,"ws":true},{"text":"sites","start":301,"end":306,"id":55,"ws":true},{"text":".","start":307,"end":308,"id":56,"ws":false}],"spans":[{"start":28,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},{"start":80,"end":91,"token_start":17,"token_end":17,"label":"DRUG"},{"start":200,"end":211,"token_start":40,"token_end":40,"label":"DRUG"}],"_input_hash":1051574739,"_task_hash":-1196821675,"_session_id":"drug_drug_pilot_split-yakir","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Two of the dogs with complete response also were treated with methotrexate and carmustine .","paragraph":"<h3><u>Intralesional implant for treatment of primary oral malignant melanoma in dogs.</u></h3>The feasibility, safety, and efficacy of a new method of local, sustained-release chemotherapy by use of intralesional cisplatin implants were evaluated in the treatment of oral malignant melanoma. The implant is an injectable viscous gel composed of a protein carrier matrix, a vasoactive modifier, and a chemotherapeutic drug. Twenty dogs with biopsy-proven melanomas were treated at 1- to 2-week intervals by injection with cisplatin implant. Tumors were treated until they resolved or were judged to be unresponsive. In 3 dogs with tumors unresponsive to cisplatin implants, <b style='color:Tomato;'><i>methotrexate</i></b> implants were used, and in 2 of these dogs, <b style='color:Tomato;'><i>carmustine</i></b> implants followed the <b style='color:Tomato;'><i>methotrexate</i></b>. Tumor responses were evaluated by sequential measurements. Melanomas in 14 (70%) of 20 dogs had a > 50% decrease in volume, and in 11 (55%) of these dogs, had a complete response. Tumors with complete responses received a mean cisplatin dose of 11.7 +/- 1.8 mg, delivered in a mean of 2.6 treatments. <b style='color:DodgerBlue;'><i>Two</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dogs</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carmustine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Implants were well tolerated. Local necrosis, limited to the treatment site, developed in most tumors (17/20) and was associated with tumor response. Systemic toxicosis was minimal; renal insufficiency after cisplatin implants was not evident. Median survival times of dogs with complete tumor response (51 weeks) was substantially greater than that of dogs without local tumor control (10.5 weeks). Recursive partitioning analysis of variables indicated that mandibular tumors of short duration were associated with a positive outcome.(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"Two","start":0,"end":3,"id":0,"ws":true},{"text":"of","start":4,"end":6,"id":1,"ws":true},{"text":"the","start":7,"end":10,"id":2,"ws":true},{"text":"dogs","start":11,"end":15,"id":3,"ws":true},{"text":"with","start":16,"end":20,"id":4,"ws":true},{"text":"complete","start":21,"end":29,"id":5,"ws":true},{"text":"response","start":30,"end":38,"id":6,"ws":true},{"text":"also","start":39,"end":43,"id":7,"ws":true},{"text":"were","start":44,"end":48,"id":8,"ws":true},{"text":"treated","start":49,"end":56,"id":9,"ws":true},{"text":"with","start":57,"end":61,"id":10,"ws":true},{"text":"methotrexate","start":62,"end":74,"id":11,"ws":true},{"text":"and","start":75,"end":78,"id":12,"ws":true},{"text":"carmustine","start":79,"end":89,"id":13,"ws":true},{"text":".","start":90,"end":91,"id":14,"ws":false}],"spans":[{"start":62,"end":74,"token_start":11,"token_end":11,"label":"DRUG"},{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":771944534,"_task_hash":-58747065,"_session_id":"drug_drug_pilot_split-yakir","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":62,"end":74,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":79,"end":89,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Preclinical data evaluating the combination of gemcitabine and irinotecan suggest dose-dependent synergistic interactions in SCOG small-cell lung cancer and MCF-7 breast cancer cell lines .","paragraph":"<h3><u>Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.</u></h3><b style='color:Tomato;'><i>gemcitabine</i></b> (Gemzar) and <b style='color:Tomato;'><i>irinotecan</i></b> (CPT-11, Camptosar) are active cytotoxic drugs against pancreatic cancer. <b style='color:DodgerBlue;'><i>Preclinical</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>evaluating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>dose-dependent</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>SCOG</i></b> <b style='color:DodgerBlue;'><i>small-cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Two phase I trials of this combination have been reported to date: the day 1 and 8 every-3-week schedule (IrinoGem trial), and the day 1, 8, and 15 every-4-week schedule (MSKCC trial). Both trials aimed to determine the maximum tolerated dose of <b style='color:Tomato;'><i>irinotecan</i></b> when administered as a 90-minute i.v. infusion either immediately after (IrinoGem) or before or immediately after (MSKCC) <b style='color:Tomato;'><i>gemcitabine</i></b> at 1,000 mg/m2 by 30-minute i.v. infusion in patients with solid tumors. The achieved maximum tolerated dose of IrinoGem has a higher dose intensity of <b style='color:Tomato;'><i>irinotecan</i></b> (100 mg/m2 on days 1 and 8, every-3-week cycle) compared with the MSKCC schedule (60 mg/m2 on days 1, 8, and 15, every-4-week trial). In IrinoGem, two of three previously untreated metastatic pancreas cancer patients had durable radiologic partial responses. The third had stable disease with clinical benefit for eight cycles. In addition, a patient with metastatic adenocarcinoma of unknown primary--potentially pancreatic--has had a durable response and is alive more than 30 months after the diagnosis. Preliminary results of a 45-patient multicenter phase II trial with IrinoGem in advanced and metastatic pancreas cancer were recently reported. Toxicity was modest, with no toxic deaths or neutropenic fever. Radiologic response rate was 20% of patients (9 out of 45), and a CA 19-9 decrease of more than 50% from baseline values occurred in 32.5% of patients (13 out of 40). Median survival was 6 months (range: 0.9 to 12.2+ months) and median time to treatment failure was 2.9 months (range: 0.1 to 11.3+ months). A pivotal international multicenter phase III trial comparing IrinoGem to single-agent <b style='color:Tomato;'><i>gemcitabine</i></b> in advanced and metastatic pancreas cancer is ongoing.","tokens":[{"text":"Preclinical","start":0,"end":11,"id":0,"ws":true},{"text":"data","start":12,"end":16,"id":1,"ws":true},{"text":"evaluating","start":17,"end":27,"id":2,"ws":true},{"text":"the","start":28,"end":31,"id":3,"ws":true},{"text":"combination","start":32,"end":43,"id":4,"ws":true},{"text":"of","start":44,"end":46,"id":5,"ws":true},{"text":"gemcitabine","start":47,"end":58,"id":6,"ws":true},{"text":"and","start":59,"end":62,"id":7,"ws":true},{"text":"irinotecan","start":63,"end":73,"id":8,"ws":true},{"text":"suggest","start":74,"end":81,"id":9,"ws":true},{"text":"dose-dependent","start":82,"end":96,"id":10,"ws":true},{"text":"synergistic","start":97,"end":108,"id":11,"ws":true},{"text":"interactions","start":109,"end":121,"id":12,"ws":true},{"text":"in","start":122,"end":124,"id":13,"ws":true},{"text":"SCOG","start":125,"end":129,"id":14,"ws":true},{"text":"small-cell","start":130,"end":140,"id":15,"ws":true},{"text":"lung","start":141,"end":145,"id":16,"ws":true},{"text":"cancer","start":146,"end":152,"id":17,"ws":true},{"text":"and","start":153,"end":156,"id":18,"ws":true},{"text":"MCF-7","start":157,"end":162,"id":19,"ws":true},{"text":"breast","start":163,"end":169,"id":20,"ws":true},{"text":"cancer","start":170,"end":176,"id":21,"ws":true},{"text":"cell","start":177,"end":181,"id":22,"ws":true},{"text":"lines","start":182,"end":187,"id":23,"ws":true},{"text":".","start":188,"end":189,"id":24,"ws":false}],"spans":[{"start":47,"end":58,"token_start":6,"token_end":6,"label":"DRUG"},{"start":63,"end":73,"token_start":8,"token_end":8,"label":"DRUG"}],"_input_hash":556366485,"_task_hash":1905982835,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":47,"end":58,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":63,"end":73,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Neoadjuvant chemotherapy protocol consisted of methotrexate , vinblastine , doxorubicin , and cisplatin ( MVAC ) or cisplatin , methotrexate , and cisplatin ( CMV ) .","paragraph":"<h3><u>The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.</u></h3>Radical cystectomy is the gold standard in the treatment of invasive bladder cancer. However, five-year disease-free survival is low most probably due to micrometastatic disease at the time of surgery. The neoadjuvant chemotherapy may be performed as the first line management for invasive bladder tumors in order to treat micrometastases found at the diagnosis and improve resectability of larger neoplasms. A total of 43 patients diagnosed with invasive bladder tumors and 11 patients received neoadjuvant chemotherapy. The mean age of patients was 64 (43-74) years, and mean follow-up period was 52 months (12-114). <b style='color:DodgerBlue;'><i>Neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MVAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CMV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients in neoadjuvant chemotherapy group underwent radical cystectomy. There was no significant difference between the groups with respect to disease-free survival time and overall survival time. In patients who received neoadjuvant chemotherapy, the respective disease-free and overall survival times were 31 months and 36 months versus 30 months and 35 months in patients who were treated with surgery only (p > 0.05). Five-year survival rates were 36% and 31% in the chemotherapy and no-chemotherapy groups, respectively. In the present study, 5-year survival rate was not affected by neoadjuvant chemotherapy in invasive bladder tumor. Complete pathological remission (stage p0) was found in 28% and pathological downstaging (stage < T2) was seen in 9% of patients in the neoadjuvant chemotherapy group. Five-year survival rates were 75% and 14.2% in patients who responded to chemotherapy, and in patients with no response, respectively (p < 0.05). The most favorable prognostic factor in this study was the response to neoadjuvant chemotherapy revealed as complete remission or pathological downstaging. The most important issue remains the prediction of patients who would respond and benefit from neoadjuvant chemotherapy.","tokens":[{"text":"Neoadjuvant","start":0,"end":11,"id":0,"ws":true},{"text":"chemotherapy","start":12,"end":24,"id":1,"ws":true},{"text":"protocol","start":25,"end":33,"id":2,"ws":true},{"text":"consisted","start":34,"end":43,"id":3,"ws":true},{"text":"of","start":44,"end":46,"id":4,"ws":true},{"text":"methotrexate","start":47,"end":59,"id":5,"ws":true},{"text":",","start":60,"end":61,"id":6,"ws":true},{"text":"vinblastine","start":62,"end":73,"id":7,"ws":true},{"text":",","start":74,"end":75,"id":8,"ws":true},{"text":"doxorubicin","start":76,"end":87,"id":9,"ws":true},{"text":",","start":88,"end":89,"id":10,"ws":true},{"text":"and","start":90,"end":93,"id":11,"ws":true},{"text":"cisplatin","start":94,"end":103,"id":12,"ws":true},{"text":"(","start":104,"end":105,"id":13,"ws":true},{"text":"MVAC","start":106,"end":110,"id":14,"ws":true},{"text":")","start":111,"end":112,"id":15,"ws":true},{"text":"or","start":113,"end":115,"id":16,"ws":true},{"text":"cisplatin","start":116,"end":125,"id":17,"ws":true},{"text":",","start":126,"end":127,"id":18,"ws":true},{"text":"methotrexate","start":128,"end":140,"id":19,"ws":true},{"text":",","start":141,"end":142,"id":20,"ws":true},{"text":"and","start":143,"end":146,"id":21,"ws":true},{"text":"cisplatin","start":147,"end":156,"id":22,"ws":true},{"text":"(","start":157,"end":158,"id":23,"ws":true},{"text":"CMV","start":159,"end":162,"id":24,"ws":true},{"text":")","start":163,"end":164,"id":25,"ws":true},{"text":".","start":165,"end":166,"id":26,"ws":false}],"spans":[{"start":47,"end":59,"token_start":5,"token_end":5,"label":"DRUG"},{"start":62,"end":73,"token_start":7,"token_end":7,"label":"DRUG"},{"start":76,"end":87,"token_start":9,"token_end":9,"label":"DRUG"},{"start":128,"end":140,"token_start":19,"token_end":19,"label":"DRUG"}],"_input_hash":-1282781617,"_task_hash":-444966106,"_session_id":"drug_drug_pilot_split-yakir","_view_id":"blocks","relations":[{"head":19,"child":22,"head_span":{"start":128,"end":140,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":147,"end":156,"token_start":22,"token_end":22,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":22,"child":7,"head_span":{"start":147,"end":156,"token_start":22,"token_end":22,"label":null},"child_span":{"start":62,"end":73,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":7,"head_span":{"start":47,"end":59,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":62,"end":73,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":7,"child":9,"head_span":{"start":62,"end":73,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":76,"end":87,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":9,"child":12,"head_span":{"start":76,"end":87,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":94,"end":103,"token_start":12,"token_end":12,"label":null},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS1T0","POS21","POS2T0"],"answer":"accept"}
{"text":"Therefore , we investigated the single agents and combination efficacy of HDACs inhibitor Vorinostat , CDK4/6 dual-inhibitor Palbociclib on MCL cell growth/survival and underlying molecular mechanism(s ) using MCL cell lines including therapy-resistant MCL cell lines .","paragraph":"<h3><u>A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.</u></h3>Mantle cell lymphoma (MCL) represents an aggressive B-cell lymphoma with frequent relapse and poor survival. Recently, dysregulated histone-deacetylases (HDACs) and cell cycle CDK-Rb pathway have been shown to be commonly associated with MCL pathogenesis, and are considered promising targets for relapsed-lymphoma therapy. <b style='color:DodgerBlue;'><i>Therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HDACs</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>Vorinostat</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CDK4/6</i></b> <b style='color:DodgerBlue;'><i>dual-inhibitor</i></b> <b style='color:MediumOrchid;'><i>Palbociclib</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>MCL</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>growth/survival</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>underlying</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>mechanism(s</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>MCL</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lines</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>therapy-resistant</i></b> <b style='color:DodgerBlue;'><i>MCL</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lines</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Our results showed that both inhibitors as single agents or combined, significantly suppressed the cell growth and induced apoptosis in therapy-resistant and parental MCL lines. In addition, the combination of <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>palbociclib</i></b> significantly inhibited the activation of the key molecules of the CDK4/6-Rb pathway and HDAC activity and subsequently decreased the expression of Cyclin-D1 and Bcl-2. These studies demonstrated the potential for combining these two inhibitors as a novel therapeutic approach in refractory MCL therapy.","tokens":[{"text":"Therefore","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"we","start":12,"end":14,"id":2,"ws":true},{"text":"investigated","start":15,"end":27,"id":3,"ws":true},{"text":"the","start":28,"end":31,"id":4,"ws":true},{"text":"single","start":32,"end":38,"id":5,"ws":true},{"text":"agents","start":39,"end":45,"id":6,"ws":true},{"text":"and","start":46,"end":49,"id":7,"ws":true},{"text":"combination","start":50,"end":61,"id":8,"ws":true},{"text":"efficacy","start":62,"end":70,"id":9,"ws":true},{"text":"of","start":71,"end":73,"id":10,"ws":true},{"text":"HDACs","start":74,"end":79,"id":11,"ws":true},{"text":"inhibitor","start":80,"end":89,"id":12,"ws":true},{"text":"Vorinostat","start":90,"end":100,"id":13,"ws":true},{"text":",","start":101,"end":102,"id":14,"ws":true},{"text":"CDK4/6","start":103,"end":109,"id":15,"ws":true},{"text":"dual-inhibitor","start":110,"end":124,"id":16,"ws":true},{"text":"Palbociclib","start":125,"end":136,"id":17,"ws":true},{"text":"on","start":137,"end":139,"id":18,"ws":true},{"text":"MCL","start":140,"end":143,"id":19,"ws":true},{"text":"cell","start":144,"end":148,"id":20,"ws":true},{"text":"growth/survival","start":149,"end":164,"id":21,"ws":true},{"text":"and","start":165,"end":168,"id":22,"ws":true},{"text":"underlying","start":169,"end":179,"id":23,"ws":true},{"text":"molecular","start":180,"end":189,"id":24,"ws":true},{"text":"mechanism(s","start":190,"end":201,"id":25,"ws":true},{"text":")","start":202,"end":203,"id":26,"ws":true},{"text":"using","start":204,"end":209,"id":27,"ws":true},{"text":"MCL","start":210,"end":213,"id":28,"ws":true},{"text":"cell","start":214,"end":218,"id":29,"ws":true},{"text":"lines","start":219,"end":224,"id":30,"ws":true},{"text":"including","start":225,"end":234,"id":31,"ws":true},{"text":"therapy-resistant","start":235,"end":252,"id":32,"ws":true},{"text":"MCL","start":253,"end":256,"id":33,"ws":true},{"text":"cell","start":257,"end":261,"id":34,"ws":true},{"text":"lines","start":262,"end":267,"id":35,"ws":true},{"text":".","start":268,"end":269,"id":36,"ws":false}],"spans":[{"start":90,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},{"start":125,"end":136,"token_start":17,"token_end":17,"label":"DRUG"}],"_input_hash":-593950880,"_task_hash":1840957951,"_session_id":"drug_drug_pilot_split-yakir","_view_id":"blocks","relations":[{"head":17,"child":13,"head_span":{"start":125,"end":136,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":90,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS21","POS2T0"],"answer":"accept"}
{"text":"In our wide experience of treating advanced breast carcinoma with chemotherapy , the combination of doxorubicin ( DOX ) , vincristine ( VCR ) , cyclophosphamide ( CPM ) and fluorouracil ( FU ) gave a complete plus partial response rate of over 60 % , with 100 % alopecia and frequent cardiac toxicity depending on total dose .","paragraph":"<h3><u>Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>wide</i></b> <b style='color:DodgerBlue;'><i>experience</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DOX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VCR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CPM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>gave</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>alopecia</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>frequent</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After the EORTC Clinical Screening Group phase II trial we have conducted an \"expected difference method\" comparative phase II trial using the combination DOX, VCR, CPM, FU and the combination of MTX (10mg/m2), VCR, CPM and FU on a population of 50 breast carcinoma patients similar to those taking part in the first study. The reasons for similarity of action will be presented and discussed.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"our","start":3,"end":6,"id":1,"ws":true},{"text":"wide","start":7,"end":11,"id":2,"ws":true},{"text":"experience","start":12,"end":22,"id":3,"ws":true},{"text":"of","start":23,"end":25,"id":4,"ws":true},{"text":"treating","start":26,"end":34,"id":5,"ws":true},{"text":"advanced","start":35,"end":43,"id":6,"ws":true},{"text":"breast","start":44,"end":50,"id":7,"ws":true},{"text":"carcinoma","start":51,"end":60,"id":8,"ws":true},{"text":"with","start":61,"end":65,"id":9,"ws":true},{"text":"chemotherapy","start":66,"end":78,"id":10,"ws":true},{"text":",","start":79,"end":80,"id":11,"ws":true},{"text":"the","start":81,"end":84,"id":12,"ws":true},{"text":"combination","start":85,"end":96,"id":13,"ws":true},{"text":"of","start":97,"end":99,"id":14,"ws":true},{"text":"doxorubicin","start":100,"end":111,"id":15,"ws":true},{"text":"(","start":112,"end":113,"id":16,"ws":true},{"text":"DOX","start":114,"end":117,"id":17,"ws":true},{"text":")","start":118,"end":119,"id":18,"ws":true},{"text":",","start":120,"end":121,"id":19,"ws":true},{"text":"vincristine","start":122,"end":133,"id":20,"ws":true},{"text":"(","start":134,"end":135,"id":21,"ws":true},{"text":"VCR","start":136,"end":139,"id":22,"ws":true},{"text":")","start":140,"end":141,"id":23,"ws":true},{"text":",","start":142,"end":143,"id":24,"ws":true},{"text":"cyclophosphamide","start":144,"end":160,"id":25,"ws":true},{"text":"(","start":161,"end":162,"id":26,"ws":true},{"text":"CPM","start":163,"end":166,"id":27,"ws":true},{"text":")","start":167,"end":168,"id":28,"ws":true},{"text":"and","start":169,"end":172,"id":29,"ws":true},{"text":"fluorouracil","start":173,"end":185,"id":30,"ws":true},{"text":"(","start":186,"end":187,"id":31,"ws":true},{"text":"FU","start":188,"end":190,"id":32,"ws":true},{"text":")","start":191,"end":192,"id":33,"ws":true},{"text":"gave","start":193,"end":197,"id":34,"ws":true},{"text":"a","start":198,"end":199,"id":35,"ws":true},{"text":"complete","start":200,"end":208,"id":36,"ws":true},{"text":"plus","start":209,"end":213,"id":37,"ws":true},{"text":"partial","start":214,"end":221,"id":38,"ws":true},{"text":"response","start":222,"end":230,"id":39,"ws":true},{"text":"rate","start":231,"end":235,"id":40,"ws":true},{"text":"of","start":236,"end":238,"id":41,"ws":true},{"text":"over","start":239,"end":243,"id":42,"ws":true},{"text":"60","start":244,"end":246,"id":43,"ws":true},{"text":"%","start":247,"end":248,"id":44,"ws":true},{"text":",","start":249,"end":250,"id":45,"ws":true},{"text":"with","start":251,"end":255,"id":46,"ws":true},{"text":"100","start":256,"end":259,"id":47,"ws":true},{"text":"%","start":260,"end":261,"id":48,"ws":true},{"text":"alopecia","start":262,"end":270,"id":49,"ws":true},{"text":"and","start":271,"end":274,"id":50,"ws":true},{"text":"frequent","start":275,"end":283,"id":51,"ws":true},{"text":"cardiac","start":284,"end":291,"id":52,"ws":true},{"text":"toxicity","start":292,"end":300,"id":53,"ws":true},{"text":"depending","start":301,"end":310,"id":54,"ws":true},{"text":"on","start":311,"end":313,"id":55,"ws":true},{"text":"total","start":314,"end":319,"id":56,"ws":true},{"text":"dose","start":320,"end":324,"id":57,"ws":true},{"text":".","start":325,"end":326,"id":58,"ws":false}],"spans":[{"start":100,"end":111,"token_start":15,"token_end":15,"label":"DRUG"},{"start":122,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":144,"end":160,"token_start":25,"token_end":25,"label":"DRUG"},{"start":173,"end":185,"token_start":30,"token_end":30,"label":"DRUG"}],"_input_hash":1759297864,"_task_hash":1455966173,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":15,"child":20,"head_span":{"start":100,"end":111,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":122,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":20,"child":25,"head_span":{"start":122,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":144,"end":160,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":25,"child":30,"head_span":{"start":144,"end":160,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":173,"end":185,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10","NEG1T0"],"answer":"accept"}
{"text":"Treatment of invasive Candida krusei infections can be difficult due to its intrinsic fluconazole resistance and its reduced susceptibility to amphotericin B and flucytosine .","paragraph":"<h3><u>Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.</u></h3> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>invasive</i></b> <b style='color:DodgerBlue;'><i>Candida</i></b> <b style='color:DodgerBlue;'><i>krusei</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>difficult</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>intrinsic</i></b> <b style='color:MediumOrchid;'><i>fluconazole</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>flucytosine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>caspofungin</i></b> (CAS) acts on a different cellular target, and its combination with <b style='color:Tomato;'><i>voriconazole</i></b> (VOR) or <b style='color:Tomato;'><i>amphotericin</i></b> B (AmB) appears promising. We evaluated the activity of CAS, VOR and AmB alone and in combination at 1/4, 1, 4xMIC concentrations by time-kill method against 30 C. krusei isolates. All isolates were susceptible to CAS and VOR; AmB MICs were 2 \u03bcg/ml for 50% of isolates by broth microdilution. CAS showed a fast killing activity at all concentrations; it was fungistatic at 1/4xMICs and fungicidal at 1-4xMICs in general. VOR displayed a concentration-independent fungistatic activity against all isolates. AmB exhibited a concentration-dependent activity; it was fungistatic at 1/4-1xMIC and fungicidal at 4xMIC. The most common interaction was indifference for both combinations. Frequency of synergic interaction for the VOR + CAS combination was 66.7% at 1/4xMIC after 48 h. The best results for CAS + AmB combination were obtained at 4xMIC in the first 4-8 h; synergic interaction was detected for 20 isolates (66.7%) at 4xMIC after 4 h. Consequently, VOR and CAS alone have been found effective, and high AmB MICs are remarkable against clinical C. krusei isolates in vitro. The combinations of CAS with VOR or AmB have exhibited promising results.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"invasive","start":13,"end":21,"id":2,"ws":true},{"text":"Candida","start":22,"end":29,"id":3,"ws":true},{"text":"krusei","start":30,"end":36,"id":4,"ws":true},{"text":"infections","start":37,"end":47,"id":5,"ws":true},{"text":"can","start":48,"end":51,"id":6,"ws":true},{"text":"be","start":52,"end":54,"id":7,"ws":true},{"text":"difficult","start":55,"end":64,"id":8,"ws":true},{"text":"due","start":65,"end":68,"id":9,"ws":true},{"text":"to","start":69,"end":71,"id":10,"ws":true},{"text":"its","start":72,"end":75,"id":11,"ws":true},{"text":"intrinsic","start":76,"end":85,"id":12,"ws":true},{"text":"fluconazole","start":86,"end":97,"id":13,"ws":true},{"text":"resistance","start":98,"end":108,"id":14,"ws":true},{"text":"and","start":109,"end":112,"id":15,"ws":true},{"text":"its","start":113,"end":116,"id":16,"ws":true},{"text":"reduced","start":117,"end":124,"id":17,"ws":true},{"text":"susceptibility","start":125,"end":139,"id":18,"ws":true},{"text":"to","start":140,"end":142,"id":19,"ws":true},{"text":"amphotericin","start":143,"end":155,"id":20,"ws":true},{"text":"B","start":156,"end":157,"id":21,"ws":true},{"text":"and","start":158,"end":161,"id":22,"ws":true},{"text":"flucytosine","start":162,"end":173,"id":23,"ws":true},{"text":".","start":174,"end":175,"id":24,"ws":false}],"spans":[{"start":86,"end":97,"token_start":13,"token_end":13,"label":"DRUG"},{"start":143,"end":155,"token_start":20,"token_end":20,"label":"DRUG"},{"start":162,"end":173,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":1858032541,"_task_hash":-1241997051,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Rucaparib and irinotecan was further subjected to detailed examination to determine combination index ( CI ) and underlying mechanism of action .","paragraph":"<h3><u>Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.</u></h3>Intended to explore synthetic lethality and develop better combinatorial regimens, we screened colorectal cancer (CRC) cells using poly ADP-ribose (PAR) polymerase (PARP) inhibitors and cytotoxic agents. We studied four PARP inhibitors and three DNA-damaging agents, and their combinations using sulforhodamine B assay. <b style='color:Tomato;'><i>rucaparib</i></b> demonstrated the greatest synergy with <b style='color:Tomato;'><i>irinotecan</i></b>, followed by <b style='color:Tomato;'><i>olaparib</i></b> and PJ34. <b style='color:MediumOrchid;'><i>Rucaparib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>subjected</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>detailed</i></b> <b style='color:DodgerBlue;'><i>examination</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>index</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>underlying</i></b> <b style='color:DodgerBlue;'><i>mechanism</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Effectiveness and sequence dependence of this combination were assessed in microsatellite stable (MSS) and unstable (MSI) CRC and HCT116 isogenic cell lines. The degree of cell cycle arrest and apoptosis was determined by FACS. In vivo studies were performed to confirm efficacy of this combination. PAR levels in MSI and PARP expression in MSI and MSS cell lines were diminished upon combinatorial treatment. HCT116 isogenic cells revealed the importance of p21, p53 and PTEN in exerting synergy. In MSI cells, administration of <b style='color:Tomato;'><i>rucaparib</i></b> prior to <b style='color:Tomato;'><i>irinotecan</i></b> enhanced cytotoxicity compared to other strategies explored. FACS revealed S-phase arrest and increased late-stage apoptosis in MSS, and G2-M arrest and total and early-stage apoptosis in MSI cells. In in vivo murine xenograft models, a significant reduction in tumor volume and expression of Ki67, pancytokeratin and RPS6KB1, and increase in expression of caspase 3 were observed with the combination. In conclusion, among the various combinations studied, <b style='color:Tomato;'><i>rucaparib</i></b> plus <b style='color:Tomato;'><i>irinotecan</i></b> was the most synergistic one. Alterations in cell cycle arrest and apoptosis were dependent on MSI status in CRC cells.","tokens":[{"text":"Rucaparib","start":0,"end":9,"id":0,"ws":true},{"text":"and","start":10,"end":13,"id":1,"ws":true},{"text":"irinotecan","start":14,"end":24,"id":2,"ws":true},{"text":"was","start":25,"end":28,"id":3,"ws":true},{"text":"further","start":29,"end":36,"id":4,"ws":true},{"text":"subjected","start":37,"end":46,"id":5,"ws":true},{"text":"to","start":47,"end":49,"id":6,"ws":true},{"text":"detailed","start":50,"end":58,"id":7,"ws":true},{"text":"examination","start":59,"end":70,"id":8,"ws":true},{"text":"to","start":71,"end":73,"id":9,"ws":true},{"text":"determine","start":74,"end":83,"id":10,"ws":true},{"text":"combination","start":84,"end":95,"id":11,"ws":true},{"text":"index","start":96,"end":101,"id":12,"ws":true},{"text":"(","start":102,"end":103,"id":13,"ws":true},{"text":"CI","start":104,"end":106,"id":14,"ws":true},{"text":")","start":107,"end":108,"id":15,"ws":true},{"text":"and","start":109,"end":112,"id":16,"ws":true},{"text":"underlying","start":113,"end":123,"id":17,"ws":true},{"text":"mechanism","start":124,"end":133,"id":18,"ws":true},{"text":"of","start":134,"end":136,"id":19,"ws":true},{"text":"action","start":137,"end":143,"id":20,"ws":true},{"text":".","start":144,"end":145,"id":21,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":14,"end":24,"token_start":2,"token_end":2,"label":"DRUG"}],"_input_hash":451391944,"_task_hash":-625694981,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":14,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Cohorts of three to seven patients received vinorelbine at doses ranging from 20 to 25 mg/m(2 ) , and gemcitabine at doses ranging from 600 to 1000 mg/m(2 ) , on days 1 and 8 every 3 weeks .","paragraph":"<h3><u>Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer.</u></h3>For non-small cell lung cancer (NSCLC), which is refractory for both platinum-based chemotherapy and <b style='color:Tomato;'><i>docetaxel</i></b>, no standard regimen has yet been established. We conducted a phase I study of a combination of <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> as third-line chemotherapy for refractory NSCLC to determine both the maximum tolerated dose (MTD) and the recommended dose (RD). Twenty patients with NSCLC refractory for both platinum and <b style='color:Tomato;'><i>docetaxel</i></b> were enrolled, and all patients were eligible for this phase I study. <b style='color:DodgerBlue;'><i>Cohorts</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>seven</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>ranging</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>ranging</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>600</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The dose-limiting toxicities were treatment delay, serum gammaGTP elevation, diarrhea and cerebral infarction, which were resolved without serious sequela, and there was no treatment-related death. The MTD was <b style='color:Tomato;'><i>vinorelbine</i></b> at 25 mg/m(2) and <b style='color:Tomato;'><i>gemcitabine</i></b> at 1000 mg/m(2) and the RD was <b style='color:Tomato;'><i>vinorelbine</i></b> at 25 mg/m(2) and <b style='color:Tomato;'><i>gemcitabine</i></b> at 800 mg/m(2). The median overall survival time was 6.8 months for all 20 patients eligible. As third-line chemotherapy, the combination of <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> was feasible and promising for NSCLC which is refractory for both platinum and <b style='color:Tomato;'><i>docetaxel</i></b>.","tokens":[{"text":"Cohorts","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"three","start":11,"end":16,"id":2,"ws":true},{"text":"to","start":17,"end":19,"id":3,"ws":true},{"text":"seven","start":20,"end":25,"id":4,"ws":true},{"text":"patients","start":26,"end":34,"id":5,"ws":true},{"text":"received","start":35,"end":43,"id":6,"ws":true},{"text":"vinorelbine","start":44,"end":55,"id":7,"ws":true},{"text":"at","start":56,"end":58,"id":8,"ws":true},{"text":"doses","start":59,"end":64,"id":9,"ws":true},{"text":"ranging","start":65,"end":72,"id":10,"ws":true},{"text":"from","start":73,"end":77,"id":11,"ws":true},{"text":"20","start":78,"end":80,"id":12,"ws":true},{"text":"to","start":81,"end":83,"id":13,"ws":true},{"text":"25","start":84,"end":86,"id":14,"ws":true},{"text":"mg/m(2","start":87,"end":93,"id":15,"ws":true},{"text":")","start":94,"end":95,"id":16,"ws":true},{"text":",","start":96,"end":97,"id":17,"ws":true},{"text":"and","start":98,"end":101,"id":18,"ws":true},{"text":"gemcitabine","start":102,"end":113,"id":19,"ws":true},{"text":"at","start":114,"end":116,"id":20,"ws":true},{"text":"doses","start":117,"end":122,"id":21,"ws":true},{"text":"ranging","start":123,"end":130,"id":22,"ws":true},{"text":"from","start":131,"end":135,"id":23,"ws":true},{"text":"600","start":136,"end":139,"id":24,"ws":true},{"text":"to","start":140,"end":142,"id":25,"ws":true},{"text":"1000","start":143,"end":147,"id":26,"ws":true},{"text":"mg/m(2","start":148,"end":154,"id":27,"ws":true},{"text":")","start":155,"end":156,"id":28,"ws":true},{"text":",","start":157,"end":158,"id":29,"ws":true},{"text":"on","start":159,"end":161,"id":30,"ws":true},{"text":"days","start":162,"end":166,"id":31,"ws":true},{"text":"1","start":167,"end":168,"id":32,"ws":true},{"text":"and","start":169,"end":172,"id":33,"ws":true},{"text":"8","start":173,"end":174,"id":34,"ws":true},{"text":"every","start":175,"end":180,"id":35,"ws":true},{"text":"3","start":181,"end":182,"id":36,"ws":true},{"text":"weeks","start":183,"end":188,"id":37,"ws":true},{"text":".","start":189,"end":190,"id":38,"ws":false}],"spans":[{"start":44,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},{"start":102,"end":113,"token_start":19,"token_end":19,"label":"DRUG"}],"_input_hash":37944647,"_task_hash":775913750,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":7,"child":19,"head_span":{"start":44,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":102,"end":113,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"In the S0313 trial , we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy plus involved field radiotherapy ( IFRT ) in patients with limited-stage aggressive B-cell non-Hodgkin lymphoma ( LD-NHL ) .","paragraph":"<h3><u>Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>S0313</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adding</i></b> <b style='color:DodgerBlue;'><i>ibritumomab</i></b> <b style='color:DodgerBlue;'><i>tiuxetan</i></b> <b style='color:DodgerBlue;'><i>consolidation</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CHOP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>involved</i></b> <b style='color:DodgerBlue;'><i>field</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IFRT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>limited-stage</i></b> <b style='color:DodgerBlue;'><i>aggressive</i></b> <b style='color:DodgerBlue;'><i>B-cell</i></b> <b style='color:DodgerBlue;'><i>non-Hodgkin</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LD-NHL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patients with at least 1 stage-modified adverse risk factor (nonbulky stage II, age >60 years, elevated lactate dehydrogenase, or World Health Organization performance status of 2) were treated with CHOP on days 1, 22, and 43, followed 3 weeks later by 40 to 50 Gy of IFRT. An <b style='color:Tomato;'><i>ibritumomab tiuxetan</i></b> regimen was initiated 3 to 6 weeks following IFRT. Forty-six patients were registered and eligible, with median follow-up of 7.3 years. The progression-free survival estimate is 89% at 2 years, 82% at 5 years, and 75% at 7 years. The overall survival estimate is 91% at 2 years, 87% at 5 years, and 82% at 7 years. Grade 4 adverse events occurring more than once included neutropenia (8), leukopenia (5), and lymphopenia (2). Febrile neutropenia was observed in 4 patients. No cases of treatment-related myeloid neoplasms were noted. In conclusion, patients with high-risk LD-NHL treated with 3 cycles of CHOP plus IFRT followed by <b style='color:Tomato;'><i>ibritumomab tiuxetan</i></b> consolidation had outcomes that compare favorably to our historical experience. The clinical trial was registered at www.clinicaltrials.gov as #NCT00070018. ","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"S0313","start":7,"end":12,"id":2,"ws":true},{"text":"trial","start":13,"end":18,"id":3,"ws":true},{"text":",","start":19,"end":20,"id":4,"ws":true},{"text":"we","start":21,"end":23,"id":5,"ws":true},{"text":"evaluated","start":24,"end":33,"id":6,"ws":true},{"text":"the","start":34,"end":37,"id":7,"ws":true},{"text":"impact","start":38,"end":44,"id":8,"ws":true},{"text":"of","start":45,"end":47,"id":9,"ws":true},{"text":"adding","start":48,"end":54,"id":10,"ws":true},{"text":"ibritumomab","start":55,"end":66,"id":11,"ws":true},{"text":"tiuxetan","start":67,"end":75,"id":12,"ws":true},{"text":"consolidation","start":76,"end":89,"id":13,"ws":true},{"text":"to","start":90,"end":92,"id":14,"ws":true},{"text":"3","start":93,"end":94,"id":15,"ws":true},{"text":"cycles","start":95,"end":101,"id":16,"ws":true},{"text":"of","start":102,"end":104,"id":17,"ws":true},{"text":"standard","start":105,"end":113,"id":18,"ws":true},{"text":"cyclophosphamide","start":114,"end":130,"id":19,"ws":true},{"text":",","start":131,"end":132,"id":20,"ws":true},{"text":"doxorubicin","start":133,"end":144,"id":21,"ws":true},{"text":",","start":145,"end":146,"id":22,"ws":true},{"text":"vincristine","start":147,"end":158,"id":23,"ws":true},{"text":",","start":159,"end":160,"id":24,"ws":true},{"text":"and","start":161,"end":164,"id":25,"ws":true},{"text":"prednisone","start":165,"end":175,"id":26,"ws":true},{"text":"(","start":176,"end":177,"id":27,"ws":true},{"text":"CHOP","start":178,"end":182,"id":28,"ws":true},{"text":")","start":183,"end":184,"id":29,"ws":true},{"text":"chemotherapy","start":185,"end":197,"id":30,"ws":true},{"text":"plus","start":198,"end":202,"id":31,"ws":true},{"text":"involved","start":203,"end":211,"id":32,"ws":true},{"text":"field","start":212,"end":217,"id":33,"ws":true},{"text":"radiotherapy","start":218,"end":230,"id":34,"ws":true},{"text":"(","start":231,"end":232,"id":35,"ws":true},{"text":"IFRT","start":233,"end":237,"id":36,"ws":true},{"text":")","start":238,"end":239,"id":37,"ws":true},{"text":"in","start":240,"end":242,"id":38,"ws":true},{"text":"patients","start":243,"end":251,"id":39,"ws":true},{"text":"with","start":252,"end":256,"id":40,"ws":true},{"text":"limited-stage","start":257,"end":270,"id":41,"ws":true},{"text":"aggressive","start":271,"end":281,"id":42,"ws":true},{"text":"B-cell","start":282,"end":288,"id":43,"ws":true},{"text":"non-Hodgkin","start":289,"end":300,"id":44,"ws":true},{"text":"lymphoma","start":301,"end":309,"id":45,"ws":true},{"text":"(","start":310,"end":311,"id":46,"ws":true},{"text":"LD-NHL","start":312,"end":318,"id":47,"ws":true},{"text":")","start":319,"end":320,"id":48,"ws":true},{"text":".","start":321,"end":322,"id":49,"ws":false}],"spans":[{"start":55,"end":75,"token_start":11,"token_end":12,"label":"DRUG"},{"start":114,"end":130,"token_start":19,"token_end":19,"label":"DRUG"},{"start":133,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},{"start":147,"end":158,"token_start":23,"token_end":23,"label":"DRUG"},{"start":165,"end":175,"token_start":26,"token_end":26,"label":"DRUG"},{"start":203,"end":230,"token_start":32,"token_end":34,"label":"DRUG"}],"_input_hash":1515659184,"_task_hash":1662490560,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":12,"child":19,"head_span":{"start":55,"end":75,"token_start":11,"token_end":12,"label":"DRUG"},"child_span":{"start":114,"end":130,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":19,"head_span":{"start":133,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":114,"end":130,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":23,"child":21,"head_span":{"start":147,"end":158,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":133,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":23,"head_span":{"start":165,"end":175,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":147,"end":158,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":34,"child":26,"head_span":{"start":203,"end":230,"token_start":32,"token_end":34,"label":"DRUG"},"child_span":{"start":165,"end":175,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"In this trial , paclitaxel and doxorubicin combination was demonstrated to be a favorable and active regimen in the first-line treatment of metastatic breast cancer .","paragraph":"<h3><u>Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer.</u></h3>Anthracyclines and taxanes are currently the most effective drugs in the treatment of metastatic breast carcinoma. The aim of this study was to determine the efficacy and toxicity of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> combination in the first-line treatment of metastatic breast cancer. Forty-five women with metastatic breast cancer were recruited in the study. Median age was 49 years (range, 33-70). Treatment protocol: <b style='color:Tomato;'><i>doxorubicin</i></b> (50 mg/m2/day, 30-min infusion) followed by <b style='color:Tomato;'><i>paclitaxel</i></b> (200 mg/m2/day, 3-hr infusion) every 3 weeks. Response rates included complete response in 13 (28.9%) patients and partial response in 19 (42.2%) patients, with an overall response rate of 71%. Five (11%) patients had stable disease and 8 (18%) patients had progressive disease. At a median follow-up of 19.7 months, median time to progression for all patients was 19.9 months (95% confidence interval, 12.8 to 27 months). Median overall survival time was 28.4 months. Grade 3-4 nausea/vomiting and hematological toxicities were observed in 12 (26%) and 6 (13.3%) patients, respectively. Cardiac toxicity was observed in 2 (4.4%) patients. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>favorable</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"trial","start":8,"end":13,"id":2,"ws":true},{"text":",","start":14,"end":15,"id":3,"ws":true},{"text":"paclitaxel","start":16,"end":26,"id":4,"ws":true},{"text":"and","start":27,"end":30,"id":5,"ws":true},{"text":"doxorubicin","start":31,"end":42,"id":6,"ws":true},{"text":"combination","start":43,"end":54,"id":7,"ws":true},{"text":"was","start":55,"end":58,"id":8,"ws":true},{"text":"demonstrated","start":59,"end":71,"id":9,"ws":true},{"text":"to","start":72,"end":74,"id":10,"ws":true},{"text":"be","start":75,"end":77,"id":11,"ws":true},{"text":"a","start":78,"end":79,"id":12,"ws":true},{"text":"favorable","start":80,"end":89,"id":13,"ws":true},{"text":"and","start":90,"end":93,"id":14,"ws":true},{"text":"active","start":94,"end":100,"id":15,"ws":true},{"text":"regimen","start":101,"end":108,"id":16,"ws":true},{"text":"in","start":109,"end":111,"id":17,"ws":true},{"text":"the","start":112,"end":115,"id":18,"ws":true},{"text":"first-line","start":116,"end":126,"id":19,"ws":true},{"text":"treatment","start":127,"end":136,"id":20,"ws":true},{"text":"of","start":137,"end":139,"id":21,"ws":true},{"text":"metastatic","start":140,"end":150,"id":22,"ws":true},{"text":"breast","start":151,"end":157,"id":23,"ws":true},{"text":"cancer","start":158,"end":164,"id":24,"ws":true},{"text":".","start":165,"end":166,"id":25,"ws":false}],"spans":[{"start":16,"end":26,"token_start":4,"token_end":4,"label":"DRUG"},{"start":31,"end":42,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":-1691394760,"_task_hash":715555928,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":16,"end":26,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":31,"end":42,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"In contrast administration of mecamylamine ( 50 microM ) close to the locus coeruleus abolished the increase in noradrenaline levels in the ipsilateral hippocampus following a systemic administration of nicotine ( 0.4 mg/kg , s.c . ) , while trimethaphan ( 50 microM ) , a nicotine receptor antagonist , significantly reduced the response .","paragraph":"<h3><u>Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine.</u></h3>Experiments were conducted using in vivo microdialysis to ascertain the role of nicotinic receptors in the terminal, or the cell body area, in the hippocampal noradrenaline response provoked by a systemic administration of <b style='color:Tomato;'><i>nicotine</i></b>. These experiments combined systemic administration of <b style='color:Tomato;'><i>nicotine</i></b> with local administration of antagonists into the hippocampus via the microdialysis probe, or close to the LC via a cannula, while continuously monitoring extracellular levels of NA in the hippocampus. Systemic administration of <b style='color:Tomato;'><i>nicotine</i></b> (0.4 mg/kg, s.c.) produced a rapid and prolonged increase in extracellular levels of noradrenaline in the hippocampus of conscious animals, reaching a maximum in the first 10 min sample. In anaesthetised animals the maximum occurred 20 min after administration, but the subsequent response profile was similar. In both anaesthetised and freely moving animals <b style='color:Tomato;'><i>nicotine</i></b> increased extracellular levels of dihydroxyphenylacetic acid and homovanillic acid in the hippocampus, but failed to alter levels of dopamine or 5-hydroxyindoleacetic acid. In anaesthetised animals intrahippocampal administration of <b style='color:Tomato;'><i>nicotine</i></b> (250 microM over 10 min via the dialysis probe) significantly increased extracellular levels of noradrenaline; the response was shortlasting, being evident only in the 10 min sample during exposure to the drug. Local administration of <b style='color:Tomato;'><i>nicotine</i></b> failed to alter extracellular levels of any other amine or metabolite measured. <b style='color:Tomato;'><i>mecamylamine</i></b> (25 microM), a nicotinic channel blocker, administered intrahippocampally 10 min prior to an intrahippocampal administration of <b style='color:Tomato;'><i>nicotine</i></b> completely blocked the increase in noradrenaline. However, intrahippocampal administration of <b style='color:Tomato;'><i>mecamylamine</i></b> (25 microM) for 10 min, or for the duration of recording, failed to antagonise the effect of a systemic administration of <b style='color:Tomato;'><i>nicotine</i></b> (0.4 mg/kg, s.c.) on extracellular levels of noradrenaline, dihydroxyphenylacetic acid or homovanillic acid. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>contrast</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>mecamylamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>microM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>close</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>locus</i></b> <b style='color:DodgerBlue;'><i>coeruleus</i></b> <b style='color:DodgerBlue;'><i>abolished</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>noradrenaline</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>ipsilateral</i></b> <b style='color:DodgerBlue;'><i>hippocampus</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.4</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>s.c</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>trimethaphan</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>microM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Administration of <b style='color:Tomato;'><i>mecamylamine</i></b> also attenuated increases in dihydroxyphenylacetic acid and homovanillic acid, suggesting that the response of these metabolites may be associated with the functional metabolism of noradrenergic neurones. Locus coeruleus administration of kynurenic acid (1 mM), a non-specific excitatory amino acid antagonist, was without effect. Finally, application of <b style='color:Tomato;'><i>nicotine</i></b> (50 microM) close to the locus coeruleus significantly increased extracellular levels of noradrenaline in the ipsilateral hippocampus.(ABSTRACT TRUNCATED AT 400 WORDS)","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"contrast","start":3,"end":11,"id":1,"ws":true},{"text":"administration","start":12,"end":26,"id":2,"ws":true},{"text":"of","start":27,"end":29,"id":3,"ws":true},{"text":"mecamylamine","start":30,"end":42,"id":4,"ws":true},{"text":"(","start":43,"end":44,"id":5,"ws":true},{"text":"50","start":45,"end":47,"id":6,"ws":true},{"text":"microM","start":48,"end":54,"id":7,"ws":true},{"text":")","start":55,"end":56,"id":8,"ws":true},{"text":"close","start":57,"end":62,"id":9,"ws":true},{"text":"to","start":63,"end":65,"id":10,"ws":true},{"text":"the","start":66,"end":69,"id":11,"ws":true},{"text":"locus","start":70,"end":75,"id":12,"ws":true},{"text":"coeruleus","start":76,"end":85,"id":13,"ws":true},{"text":"abolished","start":86,"end":95,"id":14,"ws":true},{"text":"the","start":96,"end":99,"id":15,"ws":true},{"text":"increase","start":100,"end":108,"id":16,"ws":true},{"text":"in","start":109,"end":111,"id":17,"ws":true},{"text":"noradrenaline","start":112,"end":125,"id":18,"ws":true},{"text":"levels","start":126,"end":132,"id":19,"ws":true},{"text":"in","start":133,"end":135,"id":20,"ws":true},{"text":"the","start":136,"end":139,"id":21,"ws":true},{"text":"ipsilateral","start":140,"end":151,"id":22,"ws":true},{"text":"hippocampus","start":152,"end":163,"id":23,"ws":true},{"text":"following","start":164,"end":173,"id":24,"ws":true},{"text":"a","start":174,"end":175,"id":25,"ws":true},{"text":"systemic","start":176,"end":184,"id":26,"ws":true},{"text":"administration","start":185,"end":199,"id":27,"ws":true},{"text":"of","start":200,"end":202,"id":28,"ws":true},{"text":"nicotine","start":203,"end":211,"id":29,"ws":true},{"text":"(","start":212,"end":213,"id":30,"ws":true},{"text":"0.4","start":214,"end":217,"id":31,"ws":true},{"text":"mg/kg","start":218,"end":223,"id":32,"ws":true},{"text":",","start":224,"end":225,"id":33,"ws":true},{"text":"s.c","start":226,"end":229,"id":34,"ws":true},{"text":".","start":230,"end":231,"id":35,"ws":true},{"text":")","start":232,"end":233,"id":36,"ws":true},{"text":",","start":234,"end":235,"id":37,"ws":true},{"text":"while","start":236,"end":241,"id":38,"ws":true},{"text":"trimethaphan","start":242,"end":254,"id":39,"ws":true},{"text":"(","start":255,"end":256,"id":40,"ws":true},{"text":"50","start":257,"end":259,"id":41,"ws":true},{"text":"microM","start":260,"end":266,"id":42,"ws":true},{"text":")","start":267,"end":268,"id":43,"ws":true},{"text":",","start":269,"end":270,"id":44,"ws":true},{"text":"a","start":271,"end":272,"id":45,"ws":true},{"text":"nicotine","start":273,"end":281,"id":46,"ws":true},{"text":"receptor","start":282,"end":290,"id":47,"ws":true},{"text":"antagonist","start":291,"end":301,"id":48,"ws":true},{"text":",","start":302,"end":303,"id":49,"ws":true},{"text":"significantly","start":304,"end":317,"id":50,"ws":true},{"text":"reduced","start":318,"end":325,"id":51,"ws":true},{"text":"the","start":326,"end":329,"id":52,"ws":true},{"text":"response","start":330,"end":338,"id":53,"ws":true},{"text":".","start":339,"end":340,"id":54,"ws":false}],"spans":[{"start":30,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},{"start":203,"end":211,"token_start":29,"token_end":29,"label":"DRUG"},{"start":273,"end":281,"token_start":46,"token_end":46,"label":"DRUG"}],"_input_hash":-911700971,"_task_hash":-53237618,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":4,"child":29,"head_span":{"start":30,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":203,"end":211,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10","NEG1T1"],"answer":"accept"}
{"text":"We profiled the intra-individual changes in the levels of 59 target proteins using an antibody suspension bead array in serial plasma samples from 44 MS patients during treatment with natalizumab followed by fingolimod .","paragraph":"<h3><u>Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.</u></h3>Multiple sclerosis (MS) treatment options have improved significantly over the past decades, but the consequences of MS can still be devastating and the needs for monitoring treatment surveillance are considerable. In the current study we used affinity proteomics technology to identify potential biomarkers which could ultimately be used to as facilitate treatment decisions. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>profiled</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>intra-individual</i></b> <b style='color:DodgerBlue;'><i>changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>59</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>proteins</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>suspension</i></b> <b style='color:DodgerBlue;'><i>bead</i></b> <b style='color:DodgerBlue;'><i>array</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>serial</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>samples</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>44</i></b> <b style='color:DodgerBlue;'><i>MS</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>natalizumab</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>fingolimod</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Nine proteins showed decreasing plasma levels during <b style='color:Tomato;'><i>natalizumab</i></b> treatment, with PEBP1 and RTN3 displaying the most significant changes. Protein levels remained stable during <b style='color:Tomato;'><i>fingolimod</i></b> treatment for both proteins. The decreasing PEBP1 levels during <b style='color:Tomato;'><i>natalizumab</i></b> treatment could be validated using ELISA and replicated in an independent cohort. These results support the use of this technology as a high throughput method of identifying potentially useful biomarkers of MS treatment.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"profiled","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"intra-individual","start":16,"end":32,"id":3,"ws":true},{"text":"changes","start":33,"end":40,"id":4,"ws":true},{"text":"in","start":41,"end":43,"id":5,"ws":true},{"text":"the","start":44,"end":47,"id":6,"ws":true},{"text":"levels","start":48,"end":54,"id":7,"ws":true},{"text":"of","start":55,"end":57,"id":8,"ws":true},{"text":"59","start":58,"end":60,"id":9,"ws":true},{"text":"target","start":61,"end":67,"id":10,"ws":true},{"text":"proteins","start":68,"end":76,"id":11,"ws":true},{"text":"using","start":77,"end":82,"id":12,"ws":true},{"text":"an","start":83,"end":85,"id":13,"ws":true},{"text":"antibody","start":86,"end":94,"id":14,"ws":true},{"text":"suspension","start":95,"end":105,"id":15,"ws":true},{"text":"bead","start":106,"end":110,"id":16,"ws":true},{"text":"array","start":111,"end":116,"id":17,"ws":true},{"text":"in","start":117,"end":119,"id":18,"ws":true},{"text":"serial","start":120,"end":126,"id":19,"ws":true},{"text":"plasma","start":127,"end":133,"id":20,"ws":true},{"text":"samples","start":134,"end":141,"id":21,"ws":true},{"text":"from","start":142,"end":146,"id":22,"ws":true},{"text":"44","start":147,"end":149,"id":23,"ws":true},{"text":"MS","start":150,"end":152,"id":24,"ws":true},{"text":"patients","start":153,"end":161,"id":25,"ws":true},{"text":"during","start":162,"end":168,"id":26,"ws":true},{"text":"treatment","start":169,"end":178,"id":27,"ws":true},{"text":"with","start":179,"end":183,"id":28,"ws":true},{"text":"natalizumab","start":184,"end":195,"id":29,"ws":true},{"text":"followed","start":196,"end":204,"id":30,"ws":true},{"text":"by","start":205,"end":207,"id":31,"ws":true},{"text":"fingolimod","start":208,"end":218,"id":32,"ws":true},{"text":".","start":219,"end":220,"id":33,"ws":false}],"spans":[{"start":184,"end":195,"token_start":29,"token_end":29,"label":"DRUG"},{"start":208,"end":218,"token_start":32,"token_end":32,"label":"DRUG"}],"_input_hash":-1064026020,"_task_hash":-1313078217,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":29,"child":32,"head_span":{"start":184,"end":195,"token_start":29,"token_end":29,"label":"DRUG"},"child_span":{"start":208,"end":218,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Biochemical modulation with high-dose tamoxifen may sensitize HCC cells to doxorubicin-induced apoptosis and improve the clinical response to doxorubicin in patients with advanced HCC .","paragraph":"<h3><u>Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.</u></h3>Hepatocellular carcinoma (HCC) is one of the most common cancers and is the leading cause of cancer death in Taiwan. Curative surgery is feasible for only about 30% of patients. Transarterial embolization or chemoembolization (TAE/TACE) has been demonstrated to provide a survival benefit compared with supportive care for HCC patients with adequate liver reserves, tumors confined to the liver, and no evidence of portal vein thrombosis. Percutaneous ethanol injection (PEI) may provide long-term disease control if the extent of liver tumors is limited (3 or less in number and less than 3 cm in diameter). The relative efficacy of TAE/TACE, PEI, and other locoregional treatment modalities, such as radiofrequency ablation or cryosurgery, remains unclear. Radiotherapy has been used mostly as a salvage therapy in combination with other locoregional modalities. Despite the incorporation of 3-dimensional conformal technology, radiation-induced liver injury remains an important problem, especially for patients with hepatitis B-related cirrhosis. Systemic therapy is difficult for HCC because of the underlying cirrhosis and accompanying hypersplenism and peripheral cytopenia. HCC is typically resistant to most cytotoxic agents. <b style='color:DodgerBlue;'><i>Biochemical</i></b> <b style='color:DodgerBlue;'><i>modulation</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>sensitize</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>doxorubicin-induced</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>thalidomide</i></b>, which inhibits angiogenesis induced by vascular endothelial growth factor and <b style='color:Tomato;'><i>basic fibroblast growth factor</i></b>, can produce a response in some HCC patients. Future research on drug therapy for HCC will focus on identification of tumor-specific targets.","tokens":[{"text":"Biochemical","start":0,"end":11,"id":0,"ws":true},{"text":"modulation","start":12,"end":22,"id":1,"ws":true},{"text":"with","start":23,"end":27,"id":2,"ws":true},{"text":"high-dose","start":28,"end":37,"id":3,"ws":true},{"text":"tamoxifen","start":38,"end":47,"id":4,"ws":true},{"text":"may","start":48,"end":51,"id":5,"ws":true},{"text":"sensitize","start":52,"end":61,"id":6,"ws":true},{"text":"HCC","start":62,"end":65,"id":7,"ws":true},{"text":"cells","start":66,"end":71,"id":8,"ws":true},{"text":"to","start":72,"end":74,"id":9,"ws":true},{"text":"doxorubicin-induced","start":75,"end":94,"id":10,"ws":true},{"text":"apoptosis","start":95,"end":104,"id":11,"ws":true},{"text":"and","start":105,"end":108,"id":12,"ws":true},{"text":"improve","start":109,"end":116,"id":13,"ws":true},{"text":"the","start":117,"end":120,"id":14,"ws":true},{"text":"clinical","start":121,"end":129,"id":15,"ws":true},{"text":"response","start":130,"end":138,"id":16,"ws":true},{"text":"to","start":139,"end":141,"id":17,"ws":true},{"text":"doxorubicin","start":142,"end":153,"id":18,"ws":true},{"text":"in","start":154,"end":156,"id":19,"ws":true},{"text":"patients","start":157,"end":165,"id":20,"ws":true},{"text":"with","start":166,"end":170,"id":21,"ws":true},{"text":"advanced","start":171,"end":179,"id":22,"ws":true},{"text":"HCC","start":180,"end":183,"id":23,"ws":true},{"text":".","start":184,"end":185,"id":24,"ws":false}],"spans":[{"start":38,"end":47,"token_start":4,"token_end":4,"label":"DRUG"},{"start":142,"end":153,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":-629360410,"_task_hash":279352929,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":4,"child":18,"head_span":{"start":38,"end":47,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":142,"end":153,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"In this study , a novel combinational targeted drug delivery system was developed by encapsulating antiangiogenesis drug bevacizumab into liposomes and encapsulating chemotherapy drug doxorubicin ( DOX ) into immunoliposomes where the human epidermal growth factor receptor 2 ( HER2 ) antibody was used as a targeting ligand .","paragraph":"<h3><u>Targeted multidrug delivery system to overcome chemoresistance in breast cancer.</u></h3>Chemotherapy has been widely used in breast cancer patients to reduce tumor size. However, most anticancer agents cannot differentiate between cancerous and normal cells, resulting in severe systemic toxicity. In addition, acquired drug resistance during the chemotherapy treatment further decreases treatment efficacy. With the proper treatment strategy, nanodrug carriers, such as liposomes/immunoliposomes, may be able to reduce undesired side effects of chemotherapy, to overcome the acquired multidrug resistance, and to further improve the treatment efficacy. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>novel</i></b> <b style='color:DodgerBlue;'><i>combinational</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>delivery</i></b> <b style='color:DodgerBlue;'><i>system</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>encapsulating</i></b> <b style='color:DodgerBlue;'><i>antiangiogenesis</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>liposomes</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>encapsulating</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DOX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>immunoliposomes</i></b> <b style='color:DodgerBlue;'><i>where</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HER2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>targeting</i></b> <b style='color:DodgerBlue;'><i>ligand</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This novel combinational system was tested in vitro using a HER2 positive and multidrug resistant breast cancer cell line (BT-474/MDR), and in vivo using a xenograft mouse tumor model. In vitro cell culture experiments show that immunoliposome delivery led to a high cell nucleus accumulation of DOX, whereas free DOX was observed mostly near the cell membrane and in cytoplasm due to the action of P-gp. Combining liposomal <b style='color:Tomato;'><i>bevacizumab</i></b> with immunoliposomal DOX achieved the best tumor growth inhibition and the lowest toxicity. Tumor size decreased steadily within a 60-day observation period indicating a potential synergistic effect between DOX and <b style='color:Tomato;'><i>bevacizumab</i></b> through the targeted delivery. Our findings clearly indicate that tumor growth was significantly delayed in the combinational liposomal drug delivery group. This novel combinational therapy has great potential for the treatment of patients with HER2/MDR double positive breast cancer.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"study","start":8,"end":13,"id":2,"ws":true},{"text":",","start":14,"end":15,"id":3,"ws":true},{"text":"a","start":16,"end":17,"id":4,"ws":true},{"text":"novel","start":18,"end":23,"id":5,"ws":true},{"text":"combinational","start":24,"end":37,"id":6,"ws":true},{"text":"targeted","start":38,"end":46,"id":7,"ws":true},{"text":"drug","start":47,"end":51,"id":8,"ws":true},{"text":"delivery","start":52,"end":60,"id":9,"ws":true},{"text":"system","start":61,"end":67,"id":10,"ws":true},{"text":"was","start":68,"end":71,"id":11,"ws":true},{"text":"developed","start":72,"end":81,"id":12,"ws":true},{"text":"by","start":82,"end":84,"id":13,"ws":true},{"text":"encapsulating","start":85,"end":98,"id":14,"ws":true},{"text":"antiangiogenesis","start":99,"end":115,"id":15,"ws":true},{"text":"drug","start":116,"end":120,"id":16,"ws":true},{"text":"bevacizumab","start":121,"end":132,"id":17,"ws":true},{"text":"into","start":133,"end":137,"id":18,"ws":true},{"text":"liposomes","start":138,"end":147,"id":19,"ws":true},{"text":"and","start":148,"end":151,"id":20,"ws":true},{"text":"encapsulating","start":152,"end":165,"id":21,"ws":true},{"text":"chemotherapy","start":166,"end":178,"id":22,"ws":true},{"text":"drug","start":179,"end":183,"id":23,"ws":true},{"text":"doxorubicin","start":184,"end":195,"id":24,"ws":true},{"text":"(","start":196,"end":197,"id":25,"ws":true},{"text":"DOX","start":198,"end":201,"id":26,"ws":true},{"text":")","start":202,"end":203,"id":27,"ws":true},{"text":"into","start":204,"end":208,"id":28,"ws":true},{"text":"immunoliposomes","start":209,"end":224,"id":29,"ws":true},{"text":"where","start":225,"end":230,"id":30,"ws":true},{"text":"the","start":231,"end":234,"id":31,"ws":true},{"text":"human","start":235,"end":240,"id":32,"ws":true},{"text":"epidermal","start":241,"end":250,"id":33,"ws":true},{"text":"growth","start":251,"end":257,"id":34,"ws":true},{"text":"factor","start":258,"end":264,"id":35,"ws":true},{"text":"receptor","start":265,"end":273,"id":36,"ws":true},{"text":"2","start":274,"end":275,"id":37,"ws":true},{"text":"(","start":276,"end":277,"id":38,"ws":true},{"text":"HER2","start":278,"end":282,"id":39,"ws":true},{"text":")","start":283,"end":284,"id":40,"ws":true},{"text":"antibody","start":285,"end":293,"id":41,"ws":true},{"text":"was","start":294,"end":297,"id":42,"ws":true},{"text":"used","start":298,"end":302,"id":43,"ws":true},{"text":"as","start":303,"end":305,"id":44,"ws":true},{"text":"a","start":306,"end":307,"id":45,"ws":true},{"text":"targeting","start":308,"end":317,"id":46,"ws":true},{"text":"ligand","start":318,"end":324,"id":47,"ws":true},{"text":".","start":325,"end":326,"id":48,"ws":false}],"spans":[{"start":121,"end":132,"token_start":17,"token_end":17,"label":"DRUG"},{"start":184,"end":195,"token_start":24,"token_end":24,"label":"DRUG"}],"_input_hash":-1798842881,"_task_hash":-1651673306,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":17,"child":24,"head_span":{"start":121,"end":132,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":184,"end":195,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"The combination of vincristine , methotrexate , and bleomycin in this dosage schedule has a response rate lower than that reported with single-agent treatment of advanced head and neck cancers .","paragraph":"<h3><u>Combination chemotherapy with vincristine, bleomycin, and methotrexate for advanced head and neck cancers.</u></h3>Thirty-three patients with a histologically confirmed diagnosis of advanced squamous cell carcinoma of the head and neck were treated with a combination of <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, and <b style='color:Tomato;'><i>bleomycin</i></b>. The regimen was as follows: Day 1, <b style='color:Tomato;'><i>vincristine</i></b> (2 mg iv) and <b style='color:Tomato;'><i>methotrexate</i></b> (200 mg/m2 iv over 24 hours); Day 2, <b style='color:Tomato;'><i>bleomycin</i></b> (15 mg/day by iv infusion for 48 hours). Folinic acid rescue began 36 hours after the start of <b style='color:Tomato;'><i>methotrexate</i></b>. The regimen was repeated at intervals of 3 weeks. Toxicity was minimal but the overall response rate was only 24% (three complete responses and five partial responses) and the median duration of remission was only 16 weeks overall. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>dosage</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>single-agent</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"vincristine","start":19,"end":30,"id":3,"ws":true},{"text":",","start":31,"end":32,"id":4,"ws":true},{"text":"methotrexate","start":33,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"and","start":48,"end":51,"id":7,"ws":true},{"text":"bleomycin","start":52,"end":61,"id":8,"ws":true},{"text":"in","start":62,"end":64,"id":9,"ws":true},{"text":"this","start":65,"end":69,"id":10,"ws":true},{"text":"dosage","start":70,"end":76,"id":11,"ws":true},{"text":"schedule","start":77,"end":85,"id":12,"ws":true},{"text":"has","start":86,"end":89,"id":13,"ws":true},{"text":"a","start":90,"end":91,"id":14,"ws":true},{"text":"response","start":92,"end":100,"id":15,"ws":true},{"text":"rate","start":101,"end":105,"id":16,"ws":true},{"text":"lower","start":106,"end":111,"id":17,"ws":true},{"text":"than","start":112,"end":116,"id":18,"ws":true},{"text":"that","start":117,"end":121,"id":19,"ws":true},{"text":"reported","start":122,"end":130,"id":20,"ws":true},{"text":"with","start":131,"end":135,"id":21,"ws":true},{"text":"single-agent","start":136,"end":148,"id":22,"ws":true},{"text":"treatment","start":149,"end":158,"id":23,"ws":true},{"text":"of","start":159,"end":161,"id":24,"ws":true},{"text":"advanced","start":162,"end":170,"id":25,"ws":true},{"text":"head","start":171,"end":175,"id":26,"ws":true},{"text":"and","start":176,"end":179,"id":27,"ws":true},{"text":"neck","start":180,"end":184,"id":28,"ws":true},{"text":"cancers","start":185,"end":192,"id":29,"ws":true},{"text":".","start":193,"end":194,"id":30,"ws":false}],"spans":[{"start":19,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},{"start":33,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":61,"token_start":8,"token_end":8,"label":"DRUG"}],"_input_hash":1599131446,"_task_hash":435446057,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":19,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":33,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":8,"child":5,"head_span":{"start":52,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":33,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10","NEG1T1"],"answer":"accept"}
{"text":"One unit of total dose intensity corresponds to , for example , 20 mg m2 week of cisplatin , or 25 mg m2 week of doxorubicin , or 350 mg m2 week of cyclophosphamide .","paragraph":"<h3><u>Dose intensity analysis in advanced ovarian cancer patients.</u></h3>To determine if chemotherapy dose intensity influences treatment outcome in advanced ovarian cancer, all randomised studies of first line chemotherapy, published between 1975 and 1989, were analysed for relationships between planned dose intensity and (a) objective response and (b) median survival. Total dose intensity of each study regimen was calculated and a weighted regression model providing for systemic differences in response or survival among studies was utilised. Hence, treatment arms of different studies were never directly compared. In addition, relative dose intensities of individual drugs within combinations was similarly evaluated. The improvement in objective response rate when adding one unit of total dose intensity ranged between 12% and 16% depending on baseline response rate. The improvement in median survival when adding one unit of total dose intensity ranged between 2 and 4 months. <b style='color:DodgerBlue;'><i>One</i></b> <b style='color:DodgerBlue;'><i>unit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>intensity</i></b> <b style='color:DodgerBlue;'><i>corresponds</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>example</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>m2</i></b> <b style='color:DodgerBlue;'><i>week</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>m2</i></b> <b style='color:DodgerBlue;'><i>week</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>350</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>m2</i></b> <b style='color:DodgerBlue;'><i>week</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The analysis of individual drugs suggested that <b style='color:Tomato;'><i>doxorubicin</i></b> and the platinum compounds were about equally effective, with <b style='color:Tomato;'><i>cyclophosphamide</i></b> being less effective. The methodological benefits and limitations of the approach used and the implication of the results are discussed.","tokens":[{"text":"One","start":0,"end":3,"id":0,"ws":true},{"text":"unit","start":4,"end":8,"id":1,"ws":true},{"text":"of","start":9,"end":11,"id":2,"ws":true},{"text":"total","start":12,"end":17,"id":3,"ws":true},{"text":"dose","start":18,"end":22,"id":4,"ws":true},{"text":"intensity","start":23,"end":32,"id":5,"ws":true},{"text":"corresponds","start":33,"end":44,"id":6,"ws":true},{"text":"to","start":45,"end":47,"id":7,"ws":true},{"text":",","start":48,"end":49,"id":8,"ws":true},{"text":"for","start":50,"end":53,"id":9,"ws":true},{"text":"example","start":54,"end":61,"id":10,"ws":true},{"text":",","start":62,"end":63,"id":11,"ws":true},{"text":"20","start":64,"end":66,"id":12,"ws":true},{"text":"mg","start":67,"end":69,"id":13,"ws":true},{"text":"m2","start":70,"end":72,"id":14,"ws":true},{"text":"week","start":73,"end":77,"id":15,"ws":true},{"text":"of","start":78,"end":80,"id":16,"ws":true},{"text":"cisplatin","start":81,"end":90,"id":17,"ws":true},{"text":",","start":91,"end":92,"id":18,"ws":true},{"text":"or","start":93,"end":95,"id":19,"ws":true},{"text":"25","start":96,"end":98,"id":20,"ws":true},{"text":"mg","start":99,"end":101,"id":21,"ws":true},{"text":"m2","start":102,"end":104,"id":22,"ws":true},{"text":"week","start":105,"end":109,"id":23,"ws":true},{"text":"of","start":110,"end":112,"id":24,"ws":true},{"text":"doxorubicin","start":113,"end":124,"id":25,"ws":true},{"text":",","start":125,"end":126,"id":26,"ws":true},{"text":"or","start":127,"end":129,"id":27,"ws":true},{"text":"350","start":130,"end":133,"id":28,"ws":true},{"text":"mg","start":134,"end":136,"id":29,"ws":true},{"text":"m2","start":137,"end":139,"id":30,"ws":true},{"text":"week","start":140,"end":144,"id":31,"ws":true},{"text":"of","start":145,"end":147,"id":32,"ws":true},{"text":"cyclophosphamide","start":148,"end":164,"id":33,"ws":true},{"text":".","start":165,"end":166,"id":34,"ws":false}],"spans":[{"start":113,"end":124,"token_start":25,"token_end":25,"label":"DRUG"},{"start":148,"end":164,"token_start":33,"token_end":33,"label":"DRUG"}],"_input_hash":-1523219472,"_task_hash":-505987640,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The sensitivity of MXT(+ ) and MXT(- ) against a pattern of therapeutically established anti-breast cancer drugs ( cDDP , cisplatin ; JM-8 , carboplatin ; DX , adriamycin ; 5-FU , 5-fluorouracil ; MTX , methotrexate ; VLB vinblastine ) was studied by use of a computerized , kinetic chemosensitivity assay based on quantification of biomass by staining cells with crystal violet .","paragraph":"<h3><u>Establishment and Characterization of New Murine Breast Cancer Cell Lines.</u></h3>The establishment of two new breast cancer cell lines, MXT(+) and MXT(-), derived from the murine breast cancer models MXT-M-3, 2 MC (hormone-sensitive) and MXT-M-3, 2 (ovex) MC (hormone-insensitive), is described. Characterization of the cell lines was performed by investigation of morphology, steroid hormone receptor state, growth kinetics, and drug response as well as by cytogenetic analysis. MXT(+) contains estrogen receptors (ER; 6.9 fmol/mg protein) as well as progesterone receptors (PgR; 9.2 fmol/mg protein) and therefore is inhibited by <b style='color:Tomato;'><i>tamoxifen</i></b> (Tam). MXT(-) proved to be ER(-) but PgR(+) (23.4 fmol/mg protein) and, as expected, resistant against Tam. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>sensitivity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>MXT(+</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MXT(-</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pattern</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>therapeutically</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>anti-breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>cDDP</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>JM-8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>DX</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>MTX</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>VLB</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>computerized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>kinetic</i></b> <b style='color:DodgerBlue;'><i>chemosensitivity</i></b> <b style='color:DodgerBlue;'><i>assay</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>quantification</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>biomass</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>staining</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>crystal</i></b> <b style='color:DodgerBlue;'><i>violet</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For each compound the inhibition profile reflecting cytostatic, transient cytotoxic, or cytocidal drug effects as well as development of resistance was evaluated. The following order of activity was found: MTX >, VLB >/= DX > cDDP >/= 5-FU > JM-8. The test data of 5-FU, VLB, cDDP, and Tam on MXT(+) as well as on MXT(-) were compared with those from studies on ER(+) and ER(-) human breast cancer cell lines (MCF-7, ZR-75-1, T-47-D, and MDA-MB-231, respectively). They revealed comparable inhibition profiles and sensitivities of human and murine breast cancer cell lines, an indication that the results achieved in combined in vitro-/in vivo tests by use of the murine test models MXT(+), MXT(-), MXT-M-3, 2 MC, and MXT-M-3, 2(ovex) MC are relevant for therapy in humans.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"sensitivity","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"MXT(+","start":19,"end":24,"id":3,"ws":true},{"text":")","start":25,"end":26,"id":4,"ws":true},{"text":"and","start":27,"end":30,"id":5,"ws":true},{"text":"MXT(-","start":31,"end":36,"id":6,"ws":true},{"text":")","start":37,"end":38,"id":7,"ws":true},{"text":"against","start":39,"end":46,"id":8,"ws":true},{"text":"a","start":47,"end":48,"id":9,"ws":true},{"text":"pattern","start":49,"end":56,"id":10,"ws":true},{"text":"of","start":57,"end":59,"id":11,"ws":true},{"text":"therapeutically","start":60,"end":75,"id":12,"ws":true},{"text":"established","start":76,"end":87,"id":13,"ws":true},{"text":"anti-breast","start":88,"end":99,"id":14,"ws":true},{"text":"cancer","start":100,"end":106,"id":15,"ws":true},{"text":"drugs","start":107,"end":112,"id":16,"ws":true},{"text":"(","start":113,"end":114,"id":17,"ws":true},{"text":"cDDP","start":115,"end":119,"id":18,"ws":true},{"text":",","start":120,"end":121,"id":19,"ws":true},{"text":"cisplatin","start":122,"end":131,"id":20,"ws":true},{"text":";","start":132,"end":133,"id":21,"ws":true},{"text":"JM-8","start":134,"end":138,"id":22,"ws":true},{"text":",","start":139,"end":140,"id":23,"ws":true},{"text":"carboplatin","start":141,"end":152,"id":24,"ws":true},{"text":";","start":153,"end":154,"id":25,"ws":true},{"text":"DX","start":155,"end":157,"id":26,"ws":true},{"text":",","start":158,"end":159,"id":27,"ws":true},{"text":"adriamycin","start":160,"end":170,"id":28,"ws":true},{"text":";","start":171,"end":172,"id":29,"ws":true},{"text":"5-FU","start":173,"end":177,"id":30,"ws":true},{"text":",","start":178,"end":179,"id":31,"ws":true},{"text":"5-fluorouracil","start":180,"end":194,"id":32,"ws":true},{"text":";","start":195,"end":196,"id":33,"ws":true},{"text":"MTX","start":197,"end":200,"id":34,"ws":true},{"text":",","start":201,"end":202,"id":35,"ws":true},{"text":"methotrexate","start":203,"end":215,"id":36,"ws":true},{"text":";","start":216,"end":217,"id":37,"ws":true},{"text":"VLB","start":218,"end":221,"id":38,"ws":true},{"text":"vinblastine","start":222,"end":233,"id":39,"ws":true},{"text":")","start":234,"end":235,"id":40,"ws":true},{"text":"was","start":236,"end":239,"id":41,"ws":true},{"text":"studied","start":240,"end":247,"id":42,"ws":true},{"text":"by","start":248,"end":250,"id":43,"ws":true},{"text":"use","start":251,"end":254,"id":44,"ws":true},{"text":"of","start":255,"end":257,"id":45,"ws":true},{"text":"a","start":258,"end":259,"id":46,"ws":true},{"text":"computerized","start":260,"end":272,"id":47,"ws":true},{"text":",","start":273,"end":274,"id":48,"ws":true},{"text":"kinetic","start":275,"end":282,"id":49,"ws":true},{"text":"chemosensitivity","start":283,"end":299,"id":50,"ws":true},{"text":"assay","start":300,"end":305,"id":51,"ws":true},{"text":"based","start":306,"end":311,"id":52,"ws":true},{"text":"on","start":312,"end":314,"id":53,"ws":true},{"text":"quantification","start":315,"end":329,"id":54,"ws":true},{"text":"of","start":330,"end":332,"id":55,"ws":true},{"text":"biomass","start":333,"end":340,"id":56,"ws":true},{"text":"by","start":341,"end":343,"id":57,"ws":true},{"text":"staining","start":344,"end":352,"id":58,"ws":true},{"text":"cells","start":353,"end":358,"id":59,"ws":true},{"text":"with","start":359,"end":363,"id":60,"ws":true},{"text":"crystal","start":364,"end":371,"id":61,"ws":true},{"text":"violet","start":372,"end":378,"id":62,"ws":true},{"text":".","start":379,"end":380,"id":63,"ws":false}],"spans":[{"start":141,"end":152,"token_start":24,"token_end":24,"label":"DRUG"},{"start":203,"end":215,"token_start":36,"token_end":36,"label":"DRUG"},{"start":222,"end":233,"token_start":39,"token_end":39,"label":"DRUG"}],"_input_hash":235879158,"_task_hash":-425918920,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Sixteen pretreated patients ( mean age 44 , range 26 - 59 ) with relapsed ( 8) or resistant ( 8) NHL were treated with 1 - 4 cycles of Dexa-BEAM ( dexamethasone , BCNU , etoposide , cytarabine , melphalan ) in order to attain maximal response .","paragraph":"<h3><u>Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.</u></h3>The aim of the present study was to evaluate the feasibility and response of the Dexa-BEAM regimen as a salvage therapy followed by high-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBCST) in responding patients with high-grade relapsed or resistant aggressive non-Hodgkin's lymphoma (NHL). <b style='color:DodgerBlue;'><i>Sixteen</i></b> <b style='color:DodgerBlue;'><i>pretreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>44</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>26</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>59</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>relapsed</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>8)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>8)</i></b> <b style='color:DodgerBlue;'><i>NHL</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Dexa-BEAM</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>BCNU</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>melphalan</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>order</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>attain</i></b> <b style='color:DodgerBlue;'><i>maximal</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patients achieving complete response (CR) or partial response (PR) received HDCT with PBSCT. The conditioning regimen used was BEAM. Three patients achieved CR and one patient PR, resulting in an overall response rate of 25%. Three of four responding patients underwent high-dose chemotherapy and were successfully transplanted with autologous blood stem cells. Progressive disease developed in one patient after transplantation. Myelosuppression (WHO grade III- grade IV), the major side effect, was observed in all courses of Dexa-BEAM. Myelosuppression-related infection WHO grade IV occurred in four patients. The protocol was not well tolerated in this heavily pretreated group of patients with four severe myelosuppression-related infections WHO grade IV and one treatment-related death. The overall response rate in this study is not comparable to other salvage regimens published and led to the discontinuation of the trial. In conclusion Dexa-BEAM was only effective in a minority of patients with refractory or relapsed aggressive NHL and was not useful as a cytoreductive regimen prior to HDCT.","tokens":[{"text":"Sixteen","start":0,"end":7,"id":0,"ws":true},{"text":"pretreated","start":8,"end":18,"id":1,"ws":true},{"text":"patients","start":19,"end":27,"id":2,"ws":true},{"text":"(","start":28,"end":29,"id":3,"ws":true},{"text":"mean","start":30,"end":34,"id":4,"ws":true},{"text":"age","start":35,"end":38,"id":5,"ws":true},{"text":"44","start":39,"end":41,"id":6,"ws":true},{"text":",","start":42,"end":43,"id":7,"ws":true},{"text":"range","start":44,"end":49,"id":8,"ws":true},{"text":"26","start":50,"end":52,"id":9,"ws":true},{"text":"-","start":53,"end":54,"id":10,"ws":true},{"text":"59","start":55,"end":57,"id":11,"ws":true},{"text":")","start":58,"end":59,"id":12,"ws":true},{"text":"with","start":60,"end":64,"id":13,"ws":true},{"text":"relapsed","start":65,"end":73,"id":14,"ws":true},{"text":"(","start":74,"end":75,"id":15,"ws":true},{"text":"8)","start":76,"end":78,"id":16,"ws":true},{"text":"or","start":79,"end":81,"id":17,"ws":true},{"text":"resistant","start":82,"end":91,"id":18,"ws":true},{"text":"(","start":92,"end":93,"id":19,"ws":true},{"text":"8)","start":94,"end":96,"id":20,"ws":true},{"text":"NHL","start":97,"end":100,"id":21,"ws":true},{"text":"were","start":101,"end":105,"id":22,"ws":true},{"text":"treated","start":106,"end":113,"id":23,"ws":true},{"text":"with","start":114,"end":118,"id":24,"ws":true},{"text":"1","start":119,"end":120,"id":25,"ws":true},{"text":"-","start":121,"end":122,"id":26,"ws":true},{"text":"4","start":123,"end":124,"id":27,"ws":true},{"text":"cycles","start":125,"end":131,"id":28,"ws":true},{"text":"of","start":132,"end":134,"id":29,"ws":true},{"text":"Dexa-BEAM","start":135,"end":144,"id":30,"ws":true},{"text":"(","start":145,"end":146,"id":31,"ws":true},{"text":"dexamethasone","start":147,"end":160,"id":32,"ws":true},{"text":",","start":161,"end":162,"id":33,"ws":true},{"text":"BCNU","start":163,"end":167,"id":34,"ws":true},{"text":",","start":168,"end":169,"id":35,"ws":true},{"text":"etoposide","start":170,"end":179,"id":36,"ws":true},{"text":",","start":180,"end":181,"id":37,"ws":true},{"text":"cytarabine","start":182,"end":192,"id":38,"ws":true},{"text":",","start":193,"end":194,"id":39,"ws":true},{"text":"melphalan","start":195,"end":204,"id":40,"ws":true},{"text":")","start":205,"end":206,"id":41,"ws":true},{"text":"in","start":207,"end":209,"id":42,"ws":true},{"text":"order","start":210,"end":215,"id":43,"ws":true},{"text":"to","start":216,"end":218,"id":44,"ws":true},{"text":"attain","start":219,"end":225,"id":45,"ws":true},{"text":"maximal","start":226,"end":233,"id":46,"ws":true},{"text":"response","start":234,"end":242,"id":47,"ws":true},{"text":".","start":243,"end":244,"id":48,"ws":false}],"spans":[{"start":147,"end":160,"token_start":32,"token_end":32,"label":"DRUG"},{"start":163,"end":167,"token_start":34,"token_end":34,"label":"DRUG"},{"start":170,"end":179,"token_start":36,"token_end":36,"label":"DRUG"},{"start":182,"end":192,"token_start":38,"token_end":38,"label":"DRUG"},{"start":195,"end":204,"token_start":40,"token_end":40,"label":"DRUG"}],"_input_hash":-657623954,"_task_hash":-112937844,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":32,"child":34,"head_span":{"start":147,"end":160,"token_start":32,"token_end":32,"label":"DRUG"},"child_span":{"start":163,"end":167,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":34,"child":36,"head_span":{"start":163,"end":167,"token_start":34,"token_end":34,"label":"DRUG"},"child_span":{"start":170,"end":179,"token_start":36,"token_end":36,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":36,"child":38,"head_span":{"start":170,"end":179,"token_start":36,"token_end":36,"label":"DRUG"},"child_span":{"start":182,"end":192,"token_start":38,"token_end":38,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":38,"child":40,"head_span":{"start":182,"end":192,"token_start":38,"token_end":38,"label":"DRUG"},"child_span":{"start":195,"end":204,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"The sedative and selected cardiopulmonary effects of acepromazine alone or in combination with methadone , morphine , or tramadol were compared in sheep .","paragraph":"<h3><u>The Effect of Acepromazine Alone or in Combination with Methadone, Morphine, or Tramadol on Sedation and Selected Cardiopulmonary Variables in Sheep.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>sedative</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>selected</i></b> <b style='color:DodgerBlue;'><i>cardiopulmonary</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>acepromazine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>methadone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>sheep</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Six ewes were randomly assigned to treatments: A (0.05\u2009mg/kg ace<b style='color:Tomato;'><i>promazine</i></b>), AM (A plus 0.5\u2009mg/kg <b style='color:Tomato;'><i>methadone</i></b>), AMO (A plus 0.5\u2009mg/kg morphine), and AT (A plus 5\u2009mg/kg <b style='color:Tomato;'><i>tramadol</i></b>). Parameters were assessed before sedative drug administration (baseline) and every 15 minutes thereafter, for two hours. Treatments A and AM were associated with increases in sedation score for 60 minutes and treatments AMO and AT for 30 minutes; however, there were no significant differences between treatments. There was a decrease in mean arterial pressure compared to baseline values in treatment A at 15, 45, 60, and 90 minutes, in treatment AM at 15 minutes, and in treatment AT from 45 to 120 minutes. Arterial blood carbon dioxide pressure increased at all time points in all treatments. Arterial oxygen pressure decreased in treatment AMO at 15, 30, and 120 minutes and in treatment AT at 15-45, 105, and 120 minutes, compared to baseline. Ace<b style='color:Tomato;'><i>promazine</i></b> alone causes a level of sedation similar to that observed when it is coadministered with opioids <b style='color:Tomato;'><i>methadone</i></b>, morphine, and <b style='color:Tomato;'><i>tramadol</i></b>. These combinations did not cause clinical cardiopulmonary changes.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"sedative","start":4,"end":12,"id":1,"ws":true},{"text":"and","start":13,"end":16,"id":2,"ws":true},{"text":"selected","start":17,"end":25,"id":3,"ws":true},{"text":"cardiopulmonary","start":26,"end":41,"id":4,"ws":true},{"text":"effects","start":42,"end":49,"id":5,"ws":true},{"text":"of","start":50,"end":52,"id":6,"ws":true},{"text":"acepromazine","start":53,"end":65,"id":7,"ws":true},{"text":"alone","start":66,"end":71,"id":8,"ws":true},{"text":"or","start":72,"end":74,"id":9,"ws":true},{"text":"in","start":75,"end":77,"id":10,"ws":true},{"text":"combination","start":78,"end":89,"id":11,"ws":true},{"text":"with","start":90,"end":94,"id":12,"ws":true},{"text":"methadone","start":95,"end":104,"id":13,"ws":true},{"text":",","start":105,"end":106,"id":14,"ws":true},{"text":"morphine","start":107,"end":115,"id":15,"ws":true},{"text":",","start":116,"end":117,"id":16,"ws":true},{"text":"or","start":118,"end":120,"id":17,"ws":true},{"text":"tramadol","start":121,"end":129,"id":18,"ws":true},{"text":"were","start":130,"end":134,"id":19,"ws":true},{"text":"compared","start":135,"end":143,"id":20,"ws":true},{"text":"in","start":144,"end":146,"id":21,"ws":true},{"text":"sheep","start":147,"end":152,"id":22,"ws":true},{"text":".","start":153,"end":154,"id":23,"ws":false}],"spans":[{"start":53,"end":65,"token_start":7,"token_end":7,"label":"DRUG"},{"start":95,"end":104,"token_start":13,"token_end":13,"label":"DRUG"},{"start":107,"end":115,"token_start":15,"token_end":15,"label":"DRUG"},{"start":121,"end":129,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":537227705,"_task_hash":-1012258608,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":7,"child":13,"head_span":{"start":53,"end":65,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":95,"end":104,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":7,"child":13,"head_span":{"start":53,"end":65,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":95,"end":104,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":15,"child":13,"head_span":{"start":107,"end":115,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":95,"end":104,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":7,"child":18,"head_span":{"start":53,"end":65,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":121,"end":129,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB1T0","COMB2T0","COMB3T0"],"answer":"accept"}
{"text":"Thirty-four patients with newly diagnosed advanced epithelial ovarian cancer , FIGO stage III/IV , were treated for six to nine cycles with paclitaxel ( 175 mg/m(2 ) ) and carboplatin ( area under the curve [ AUC ] 5 ) every 3 weeks .","paragraph":"<h3><u>Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study.</u></h3>We have previously shown that interferon-gamma 1b (IFN-gamma) in combination with <b style='color:Tomato;'><i>cyclophosphamide</i></b> and cisplatin significantly prolongs progression-free survival in ovarian cancer. In this phase I/II study, we examined if administration of IFN-gamma is also safe in combination with the current standard treatment, <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:DodgerBlue;'><i>Thirty-four</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>newly</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>FIGO</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>III/IV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> IFN-gamma was administered in an escalating dose from 6 days/cycle with 0.025 mg sc up to 9 days/cycle with 0.1 mg sc. As expected, administration of IFN-gamma was associated with flu-like symptoms. Grade 3/4 neutropenia was observed in 74% (25 out of 34) of patients. Other side effects, in particular peripheral neuropathies, were within the previously observed ranges for the <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b> combination. Overall response rate (complete or partial response) in patients who received either six or nine doses (0.1 mg) of IFN-gamma/cycle (n = 28) was 71%. IFN-gamma is safe in combination with <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> for first-line treatment of patients with advanced ovarian cancer. This combination should be further evaluated as an immunotherapeutic treatment option for ovarian cancer.","tokens":[{"text":"Thirty-four","start":0,"end":11,"id":0,"ws":true},{"text":"patients","start":12,"end":20,"id":1,"ws":true},{"text":"with","start":21,"end":25,"id":2,"ws":true},{"text":"newly","start":26,"end":31,"id":3,"ws":true},{"text":"diagnosed","start":32,"end":41,"id":4,"ws":true},{"text":"advanced","start":42,"end":50,"id":5,"ws":true},{"text":"epithelial","start":51,"end":61,"id":6,"ws":true},{"text":"ovarian","start":62,"end":69,"id":7,"ws":true},{"text":"cancer","start":70,"end":76,"id":8,"ws":true},{"text":",","start":77,"end":78,"id":9,"ws":true},{"text":"FIGO","start":79,"end":83,"id":10,"ws":true},{"text":"stage","start":84,"end":89,"id":11,"ws":true},{"text":"III/IV","start":90,"end":96,"id":12,"ws":true},{"text":",","start":97,"end":98,"id":13,"ws":true},{"text":"were","start":99,"end":103,"id":14,"ws":true},{"text":"treated","start":104,"end":111,"id":15,"ws":true},{"text":"for","start":112,"end":115,"id":16,"ws":true},{"text":"six","start":116,"end":119,"id":17,"ws":true},{"text":"to","start":120,"end":122,"id":18,"ws":true},{"text":"nine","start":123,"end":127,"id":19,"ws":true},{"text":"cycles","start":128,"end":134,"id":20,"ws":true},{"text":"with","start":135,"end":139,"id":21,"ws":true},{"text":"paclitaxel","start":140,"end":150,"id":22,"ws":true},{"text":"(","start":151,"end":152,"id":23,"ws":true},{"text":"175","start":153,"end":156,"id":24,"ws":true},{"text":"mg/m(2","start":157,"end":163,"id":25,"ws":true},{"text":")","start":164,"end":165,"id":26,"ws":true},{"text":")","start":166,"end":167,"id":27,"ws":true},{"text":"and","start":168,"end":171,"id":28,"ws":true},{"text":"carboplatin","start":172,"end":183,"id":29,"ws":true},{"text":"(","start":184,"end":185,"id":30,"ws":true},{"text":"area","start":186,"end":190,"id":31,"ws":true},{"text":"under","start":191,"end":196,"id":32,"ws":true},{"text":"the","start":197,"end":200,"id":33,"ws":true},{"text":"curve","start":201,"end":206,"id":34,"ws":true},{"text":"[","start":207,"end":208,"id":35,"ws":true},{"text":"AUC","start":209,"end":212,"id":36,"ws":true},{"text":"]","start":213,"end":214,"id":37,"ws":true},{"text":"5","start":215,"end":216,"id":38,"ws":true},{"text":")","start":217,"end":218,"id":39,"ws":true},{"text":"every","start":219,"end":224,"id":40,"ws":true},{"text":"3","start":225,"end":226,"id":41,"ws":true},{"text":"weeks","start":227,"end":232,"id":42,"ws":true},{"text":".","start":233,"end":234,"id":43,"ws":false}],"spans":[{"start":140,"end":150,"token_start":22,"token_end":22,"label":"DRUG"},{"start":172,"end":183,"token_start":29,"token_end":29,"label":"DRUG"}],"_input_hash":-1375103160,"_task_hash":565022345,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":22,"child":29,"head_span":{"start":140,"end":150,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":172,"end":183,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"Cancer and Leukemia Group B designed a phase II trial of lenalidomide + bortezomib for relapsed/refractory mantle cell lymphoma ( MCL ) .","paragraph":"<h3><u>Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).</u></h3> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Leukemia</i></b> <b style='color:DodgerBlue;'><i>Group</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lenalidomide</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>mantle</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MCL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Induction therapy was <b style='color:Tomato;'><i>lenalidomide</i></b> (days 1-14) plus <b style='color:Tomato;'><i>bortezomib</i></b> (days 1/4/8/11), every 21 days for eight cycles. Complete/partial responders (CR, PR) received maintenance <b style='color:Tomato;'><i>lenalidomide</i></b> (days 1-14) and <b style='color:Tomato;'><i>bortezomib</i></b> (days 1/8), every 21 days. Primary endpoint was overall response rate; secondary endpoints were CR rate, progression-free (PFS), event-free (EFS) and overall survival (OS). Fifty-three eligible patients, median age 67 years, were accrued. Median number of cycles received was 4 (range, 1-82). Median followup was 46 (range, 12-67) months. Best response was CR 15%, PR 25%. 5/8 CR, and 4/13 PR patients received maintenance. Six CR and one PR patient remain in remission (median, 3.2 years). Thirty-three (62%) patients have died. One-year PFS, EFS and OS are 40%, 25% and 68%, respectively. This combination will not be pursued further. ","tokens":[{"text":"Cancer","start":0,"end":6,"id":0,"ws":true},{"text":"and","start":7,"end":10,"id":1,"ws":true},{"text":"Leukemia","start":11,"end":19,"id":2,"ws":true},{"text":"Group","start":20,"end":25,"id":3,"ws":true},{"text":"B","start":26,"end":27,"id":4,"ws":true},{"text":"designed","start":28,"end":36,"id":5,"ws":true},{"text":"a","start":37,"end":38,"id":6,"ws":true},{"text":"phase","start":39,"end":44,"id":7,"ws":true},{"text":"II","start":45,"end":47,"id":8,"ws":true},{"text":"trial","start":48,"end":53,"id":9,"ws":true},{"text":"of","start":54,"end":56,"id":10,"ws":true},{"text":"lenalidomide","start":57,"end":69,"id":11,"ws":true},{"text":"+","start":70,"end":71,"id":12,"ws":true},{"text":"bortezomib","start":72,"end":82,"id":13,"ws":true},{"text":"for","start":83,"end":86,"id":14,"ws":true},{"text":"relapsed/refractory","start":87,"end":106,"id":15,"ws":true},{"text":"mantle","start":107,"end":113,"id":16,"ws":true},{"text":"cell","start":114,"end":118,"id":17,"ws":true},{"text":"lymphoma","start":119,"end":127,"id":18,"ws":true},{"text":"(","start":128,"end":129,"id":19,"ws":true},{"text":"MCL","start":130,"end":133,"id":20,"ws":true},{"text":")","start":134,"end":135,"id":21,"ws":true},{"text":".","start":136,"end":137,"id":22,"ws":false}],"spans":[{"start":57,"end":69,"token_start":11,"token_end":11,"label":"DRUG"},{"start":72,"end":82,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":-1910827248,"_task_hash":3187628,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":57,"end":69,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":72,"end":82,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The present authors investigated whether AMP induced a greater imbalance in the ventilation/perfusion ratio than methacholine ( MCh ) , at an equivalent degree of bronchoconstriction , with and without salbutamol pre-medication .","paragraph":"<h3><u>Adenosine 5'-monophosphate in asthma: gas exchange and sputum cellular responses.</u></h3>Adenosine 5'-monophosphate (AMP) bronchoprovocation reproduces the lung function abnormalities that occur spontaneously during acute asthma and detects peripheral airway inflammation better than direct bronchoconstrictive agents. Pulmonary gas exchange disturbances may reflect changes in small airways related to airway inflammation rather than bronchoconstriction alone. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>authors</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>AMP</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>imbalance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>ventilation/perfusion</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>methacholine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MCh</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>equivalent</i></b> <b style='color:DodgerBlue;'><i>degree</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bronchoconstriction</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:MediumOrchid;'><i>salbutamol</i></b> <b style='color:DodgerBlue;'><i>pre-medication</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In total, 36 asthmatics were studied in three randomised, double-blind, crossover studies: 1) before and after AMP or MCh; 2) before and 30 min after <b style='color:Tomato;'><i>salbutamol</i></b> or placebo, followed by AMP; or 3) MCh challenge. Sputum was collected before and 4 h post-challenge. Compared with MCh, AMP provoked similar pulmonary gas exchange abnormalities at an equivalent degree of intense bronchoconstriction (forced expiratory volume in one second decrease of 28-44%). While <b style='color:Tomato;'><i>salbutamol</i></b> blocked AMP- or MCh-induced bronchoconstriction, arterial oxygen tension (P(a,O(2))) and alveolar-arterial oxygen tension difference (P(A-a,O(2))) disturbances induced by AMP and MCh were only partially blocked (P(a,O(2)) by 46 and 42%, respectively; P(A-a,O(2)) by 58 and 57%, respectively). Compared with MCh, AMP increased the percentage of neutrophils (mean+/-se increased from 28+/-4% to 38+/-4%), but this increase did not occur after <b style='color:Tomato;'><i>salbutamol</i></b> pre-treatment. Both adenosine 5'-monophosphate and <b style='color:Tomato;'><i>methacholine</i></b> induced similar peripheral airway dysfunction. The fully inhibited adenosine 5'-monophosphate-induced neutrophilia with residual hypoxaemia observed after <b style='color:Tomato;'><i>salbutamol</i></b> treatment is probably related to beta(2)-agonists acting on both bronchial and pulmonary circulation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"authors","start":12,"end":19,"id":2,"ws":true},{"text":"investigated","start":20,"end":32,"id":3,"ws":true},{"text":"whether","start":33,"end":40,"id":4,"ws":true},{"text":"AMP","start":41,"end":44,"id":5,"ws":true},{"text":"induced","start":45,"end":52,"id":6,"ws":true},{"text":"a","start":53,"end":54,"id":7,"ws":true},{"text":"greater","start":55,"end":62,"id":8,"ws":true},{"text":"imbalance","start":63,"end":72,"id":9,"ws":true},{"text":"in","start":73,"end":75,"id":10,"ws":true},{"text":"the","start":76,"end":79,"id":11,"ws":true},{"text":"ventilation/perfusion","start":80,"end":101,"id":12,"ws":true},{"text":"ratio","start":102,"end":107,"id":13,"ws":true},{"text":"than","start":108,"end":112,"id":14,"ws":true},{"text":"methacholine","start":113,"end":125,"id":15,"ws":true},{"text":"(","start":126,"end":127,"id":16,"ws":true},{"text":"MCh","start":128,"end":131,"id":17,"ws":true},{"text":")","start":132,"end":133,"id":18,"ws":true},{"text":",","start":134,"end":135,"id":19,"ws":true},{"text":"at","start":136,"end":138,"id":20,"ws":true},{"text":"an","start":139,"end":141,"id":21,"ws":true},{"text":"equivalent","start":142,"end":152,"id":22,"ws":true},{"text":"degree","start":153,"end":159,"id":23,"ws":true},{"text":"of","start":160,"end":162,"id":24,"ws":true},{"text":"bronchoconstriction","start":163,"end":182,"id":25,"ws":true},{"text":",","start":183,"end":184,"id":26,"ws":true},{"text":"with","start":185,"end":189,"id":27,"ws":true},{"text":"and","start":190,"end":193,"id":28,"ws":true},{"text":"without","start":194,"end":201,"id":29,"ws":true},{"text":"salbutamol","start":202,"end":212,"id":30,"ws":true},{"text":"pre-medication","start":213,"end":227,"id":31,"ws":true},{"text":".","start":228,"end":229,"id":32,"ws":false}],"spans":[{"start":113,"end":125,"token_start":15,"token_end":15,"label":"DRUG"},{"start":202,"end":212,"token_start":30,"token_end":30,"label":"DRUG"}],"_input_hash":479251856,"_task_hash":83557576,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"answer":"ignore"}
{"text":"Phentolamine , phenoxybenzamine , clonidine , isoproterenol , and propranolol given ICV or systemically showed no effect on either SHS or SG behaviors .","paragraph":"<h3><u>The involvement of serotonergic neurons in the central nervous system as the possible mechanism for slow head-shaking behavior induced by methamphetamine in rats.</u></h3>Following the IV administration of d-<b style='color:Tomato;'><i>methamphetamine</i></b> (MA), rats showed slow head shaking (SHS) and stereotyped gnawing (SG) behaviors in a dose-dependent manner. <b style='color:Tomato;'><i>methysergide</i></b>, cyrpoheptadine, and p-chlorophenylalanine given intracerebroventricularly (ICV) or systemically significantly blocked SHS behavior induced by 10 mg/kg MA. Combined administration of L-5-hydroxytryptophan and peripheral decarboxylase inhibitor (Ro 4-4602) enhanced SHS behavior. Tyrosine hydroxylase inhibitor (H44/68) blocked SG behaviors, but dopamine-beta-hydroxylase inhibitors (FLA 63 and U-14, 624) and combined administration of L-3,4-dihydroxyphenylalanine and Ro-4-4602 enhanced it. These drugs did not affect SHS behavior. <b style='color:MediumOrchid;'><i>Phentolamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>phenoxybenzamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>isoproterenol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>ICV</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>systemically</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>SHS</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>SG</i></b> <b style='color:DodgerBlue;'><i>behaviors</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These results suggest that SHS behavior is produced by the activation of seronergic neurons in the central nervous system and are consistent with the view that SG behaviors are mediated through the release of dopamine. Some neuroleptics inhibited SHS as well as SG behaviors, but the older of inhibitory activity of neuroleptics onSHS behavior was quite different from their effects on SG behaviors induced by MA or apomorphine.","tokens":[{"text":"Phentolamine","start":0,"end":12,"id":0,"ws":true},{"text":",","start":13,"end":14,"id":1,"ws":true},{"text":"phenoxybenzamine","start":15,"end":31,"id":2,"ws":true},{"text":",","start":32,"end":33,"id":3,"ws":true},{"text":"clonidine","start":34,"end":43,"id":4,"ws":true},{"text":",","start":44,"end":45,"id":5,"ws":true},{"text":"isoproterenol","start":46,"end":59,"id":6,"ws":true},{"text":",","start":60,"end":61,"id":7,"ws":true},{"text":"and","start":62,"end":65,"id":8,"ws":true},{"text":"propranolol","start":66,"end":77,"id":9,"ws":true},{"text":"given","start":78,"end":83,"id":10,"ws":true},{"text":"ICV","start":84,"end":87,"id":11,"ws":true},{"text":"or","start":88,"end":90,"id":12,"ws":true},{"text":"systemically","start":91,"end":103,"id":13,"ws":true},{"text":"showed","start":104,"end":110,"id":14,"ws":true},{"text":"no","start":111,"end":113,"id":15,"ws":true},{"text":"effect","start":114,"end":120,"id":16,"ws":true},{"text":"on","start":121,"end":123,"id":17,"ws":true},{"text":"either","start":124,"end":130,"id":18,"ws":true},{"text":"SHS","start":131,"end":134,"id":19,"ws":true},{"text":"or","start":135,"end":137,"id":20,"ws":true},{"text":"SG","start":138,"end":140,"id":21,"ws":true},{"text":"behaviors","start":141,"end":150,"id":22,"ws":true},{"text":".","start":151,"end":152,"id":23,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},{"start":34,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"}],"_input_hash":435973489,"_task_hash":1541833158,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":15,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":2,"child":4,"head_span":{"start":15,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":34,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":6,"child":4,"head_span":{"start":46,"end":59,"token_start":6,"token_end":6,"label":null},"child_span":{"start":34,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":6,"head_span":{"start":66,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":46,"end":59,"token_start":6,"token_end":6,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"We also investigated the effect of combined docetaxel and octreotide on growth factors secreted from prostate cancer cells using a human growth factor antibody array .","paragraph":"<h3><u>Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.</u></h3>OBJECTIVE To evaluate the effects of combined treatment with <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>octreotide</i></b>, a <b style='color:Tomato;'><i>somatostatin</i></b> analogue, on human hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145, and on some growth factors related to tumour growth and angiogenesis in prostate cancer. MATERIALS AND METHODS A cell proliferation assay was used to assess the cytotoxicity of the drugs. To verify apoptosis, both DNA fragmentation (by enzyme-linked immunosorbent assay) and caspase 3/7 activity were measured. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factors</i></b> <b style='color:DodgerBlue;'><i>secreted</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>array</i></b> <b style='color:DodgerBlue;'><i>.</i></b> RESULTS The combination of <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>octreotide</i></b> resulted in significant synergistic cytotoxic activity and apoptosis, which was dose- and time-dependent. The combined treatment also resulted in significantly less secretion of stem cell factor and platelet-derived growth factor-AB in PC-3 cells, and transforming growth factor-beta and <b style='color:Tomato;'><i>basic fibroblast growth factor</i></b> in DU-145 cells, than in untreated controls. CONCLUSION <b style='color:Tomato;'><i>octreotide</i></b>, a <b style='color:Tomato;'><i>somatostatin</i></b> analogue, combined with <b style='color:Tomato;'><i>docetaxel</i></b> might provide a rationale treatment option for hormone-refractory prostate cancer cells, not only by direct inhibition of cell proliferation but also by inhibiting the secretion of growth factors.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"also","start":3,"end":7,"id":1,"ws":true},{"text":"investigated","start":8,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"effect","start":25,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"combined","start":35,"end":43,"id":6,"ws":true},{"text":"docetaxel","start":44,"end":53,"id":7,"ws":true},{"text":"and","start":54,"end":57,"id":8,"ws":true},{"text":"octreotide","start":58,"end":68,"id":9,"ws":true},{"text":"on","start":69,"end":71,"id":10,"ws":true},{"text":"growth","start":72,"end":78,"id":11,"ws":true},{"text":"factors","start":79,"end":86,"id":12,"ws":true},{"text":"secreted","start":87,"end":95,"id":13,"ws":true},{"text":"from","start":96,"end":100,"id":14,"ws":true},{"text":"prostate","start":101,"end":109,"id":15,"ws":true},{"text":"cancer","start":110,"end":116,"id":16,"ws":true},{"text":"cells","start":117,"end":122,"id":17,"ws":true},{"text":"using","start":123,"end":128,"id":18,"ws":true},{"text":"a","start":129,"end":130,"id":19,"ws":true},{"text":"human","start":131,"end":136,"id":20,"ws":true},{"text":"growth","start":137,"end":143,"id":21,"ws":true},{"text":"factor","start":144,"end":150,"id":22,"ws":true},{"text":"antibody","start":151,"end":159,"id":23,"ws":true},{"text":"array","start":160,"end":165,"id":24,"ws":true},{"text":".","start":166,"end":167,"id":25,"ws":false}],"spans":[{"start":44,"end":53,"token_start":7,"token_end":7,"label":"DRUG"},{"start":58,"end":68,"token_start":9,"token_end":9,"label":"DRUG"}],"_input_hash":-1230807703,"_task_hash":-2125876560,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":44,"end":53,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":58,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"After debulking surgery , a combination of carboplatin and paclitaxel is considered to be the best treatment option in terms of survival and quality of life .","paragraph":"<h3><u>Future options for first-line therapy of advanced ovarian cancer.</u></h3>The current standard of treatment for patients with advanced ovarian cancer has been established in light of the results from various clinical trials. <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>debulking</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>best</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>terms</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>quality</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>life</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, since most patients on this chemotherapy modality will experience relapse, several studies have explored, and continue to do so, various modifications and alternatives to standard therapy in order to attain improved efficacy. Various modifications of dose, schedule, or route of standard regimens have shown no benefit, apart from intraperitoneal therapy, which has produced mixed results and would benefit from a definitive trial. Studies of maintenance/consolidation therapy have been mainly negative, although a small number of trials have produced enough positive data to prompt two new studies powered to detect survival benefits. Various phase II trials have investigated \"targeted therapies,\" but until now no positive results have been recorded. Translational studies are needed to identify patients who will benefit from such specific treatment strategies. The current most evaluated modification of standard therapy is the addition of a third non-cross-resistant drug to <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b>. Data for the addition of anthracyclines have either been negative (<b style='color:Tomato;'><i>epirubicin</i></b>) or not yet analyzed (pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b>), while evaluable data are shortly expected for the addition of <b style='color:Tomato;'><i>topotecan</i></b>. Data on the addition of <b style='color:Tomato;'><i>gemcitabine</i></b> are eagerly awaited from two phase III trials.","tokens":[{"text":"After","start":0,"end":5,"id":0,"ws":true},{"text":"debulking","start":6,"end":15,"id":1,"ws":true},{"text":"surgery","start":16,"end":23,"id":2,"ws":true},{"text":",","start":24,"end":25,"id":3,"ws":true},{"text":"a","start":26,"end":27,"id":4,"ws":true},{"text":"combination","start":28,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"carboplatin","start":43,"end":54,"id":7,"ws":true},{"text":"and","start":55,"end":58,"id":8,"ws":true},{"text":"paclitaxel","start":59,"end":69,"id":9,"ws":true},{"text":"is","start":70,"end":72,"id":10,"ws":true},{"text":"considered","start":73,"end":83,"id":11,"ws":true},{"text":"to","start":84,"end":86,"id":12,"ws":true},{"text":"be","start":87,"end":89,"id":13,"ws":true},{"text":"the","start":90,"end":93,"id":14,"ws":true},{"text":"best","start":94,"end":98,"id":15,"ws":true},{"text":"treatment","start":99,"end":108,"id":16,"ws":true},{"text":"option","start":109,"end":115,"id":17,"ws":true},{"text":"in","start":116,"end":118,"id":18,"ws":true},{"text":"terms","start":119,"end":124,"id":19,"ws":true},{"text":"of","start":125,"end":127,"id":20,"ws":true},{"text":"survival","start":128,"end":136,"id":21,"ws":true},{"text":"and","start":137,"end":140,"id":22,"ws":true},{"text":"quality","start":141,"end":148,"id":23,"ws":true},{"text":"of","start":149,"end":151,"id":24,"ws":true},{"text":"life","start":152,"end":156,"id":25,"ws":true},{"text":".","start":157,"end":158,"id":26,"ws":false}],"spans":[{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},{"start":59,"end":69,"token_start":9,"token_end":9,"label":"DRUG"}],"_input_hash":-2087220835,"_task_hash":-2030697542,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":59,"end":69,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Seventy-nine postmenopausal patients received aminoglutethimide ( AG ; 750 mg daily ) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy .","paragraph":"<h3><u>Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity.</u></h3> <b style='color:DodgerBlue;'><i>Seventy-nine</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>aminoglutethimide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AG</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>750</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>hydrocortisone</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>hormonal</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Fourteen of 64 patients, tolerating the drug and assessable for response, achieved a complete or partial response. Disease stabilisation occurred in a further 2 patients giving a response rate of 25% in these patients. Median duration of response was 10 months. Response rates to AG were not significantly different whether or not there had been a response to previous hormonal therapy but a trend to higher response rates in ER rich tumours was observed. Those with a longer interval from first relapse to the start of AG appeared more likely to respond. Side-effects were noted in 35 patients overall (44%) and in 70% of those over the age of 65 years. Treatment was discontinued because of toxicity in 10 patients and there was one death due to agranulocytosis. AG is active in postmenopausal breast cancer following failure of first-line hormonal therapy, toxicity limiting its use earlier in the disease.","tokens":[{"text":"Seventy-nine","start":0,"end":12,"id":0,"ws":true},{"text":"postmenopausal","start":13,"end":27,"id":1,"ws":true},{"text":"patients","start":28,"end":36,"id":2,"ws":true},{"text":"received","start":37,"end":45,"id":3,"ws":true},{"text":"aminoglutethimide","start":46,"end":63,"id":4,"ws":true},{"text":"(","start":64,"end":65,"id":5,"ws":true},{"text":"AG","start":66,"end":68,"id":6,"ws":true},{"text":";","start":69,"end":70,"id":7,"ws":true},{"text":"750","start":71,"end":74,"id":8,"ws":true},{"text":"mg","start":75,"end":77,"id":9,"ws":true},{"text":"daily","start":78,"end":83,"id":10,"ws":true},{"text":")","start":84,"end":85,"id":11,"ws":true},{"text":"and","start":86,"end":89,"id":12,"ws":true},{"text":"hydrocortisone","start":90,"end":104,"id":13,"ws":true},{"text":"therapy","start":105,"end":112,"id":14,"ws":true},{"text":"for","start":113,"end":116,"id":15,"ws":true},{"text":"metastatic","start":117,"end":127,"id":16,"ws":true},{"text":"or","start":128,"end":130,"id":17,"ws":true},{"text":"locally","start":131,"end":138,"id":18,"ws":true},{"text":"recurrent","start":139,"end":148,"id":19,"ws":true},{"text":"breast","start":149,"end":155,"id":20,"ws":true},{"text":"cancer","start":156,"end":162,"id":21,"ws":true},{"text":"following","start":163,"end":172,"id":22,"ws":true},{"text":"the","start":173,"end":176,"id":23,"ws":true},{"text":"failure","start":177,"end":184,"id":24,"ws":true},{"text":"of","start":185,"end":187,"id":25,"ws":true},{"text":"other","start":188,"end":193,"id":26,"ws":true},{"text":"hormonal","start":194,"end":202,"id":27,"ws":true},{"text":"therapy","start":203,"end":210,"id":28,"ws":true},{"text":".","start":211,"end":212,"id":29,"ws":false}],"spans":[{"start":46,"end":63,"token_start":4,"token_end":4,"label":"DRUG"},{"start":90,"end":104,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":1920362136,"_task_hash":1195775076,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":4,"child":13,"head_span":{"start":46,"end":63,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":90,"end":104,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Considerations of both molecular biology and data from in vitro studies suggest a potential for the combination of docetaxel ( Taxotere ; Rh\u00f4ne-Poulenc Rorer , Antony , France ) with estramustine in the treatment of patients with hormone-refractory prostate cancer .","paragraph":"<h3><u>Docetaxel (Taxotere) in hormone-refractory prostate cancer.</u></h3> <b style='color:DodgerBlue;'><i>Considerations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>biology</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxotere</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Rh\u00f4ne-Poulenc</i></b> <b style='color:DodgerBlue;'><i>Rorer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Antony</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>France</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hormone-refractory</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Based on data from two phase I studies, the <b style='color:Tomato;'><i>docetaxel</i></b> dose recommended for phase II study in combination with <b style='color:Tomato;'><i>estramustine</i></b> in minimally and extensively pretreated patients is 70 mg/m2 and 60 mg/m2, respectively. The dose-limiting toxicity was neutropenia. In one phase I study, 63% of the 34 patients treated showed at least a 50% decline in prostate-specific antigen. An objective response was seen in 28% of patients with measurable disease, and overall median survival (22.8 months) is highly encouraging. In the second study, 82% of 17 patients showed a greater than 50% decline in prostate-specific antigen and, at the 70 mg/m2 dose level, two of six patients showed prostate-specific antigen normalization. Phase II studies have demonstrated more than 50% declines in 59% to 88% of patients treated at 70 mg/m2. Although reduction of the dose of <b style='color:Tomato;'><i>estramustine</i></b> appears to result in a somewhat lower response rate, the contribution made by <b style='color:Tomato;'><i>estramustine</i></b> to the efficacy of the <b style='color:Tomato;'><i>estramustine</i></b>/<b style='color:Tomato;'><i>docetaxel</i></b> combination must be established by randomized trials. <b style='color:Tomato;'><i>dexamethasone</i></b>, however, does not appear to significantly contribute to the response rate of <b style='color:Tomato;'><i>estramustine</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>. Phase III studies comparing <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>estramustine</i></b> with <b style='color:Tomato;'><i>mitoxantrone</i></b> plus corticosteroids are currently being planned. If the promise of <b style='color:Tomato;'><i>docetaxel</i></b> hormone-refractory prostate cancer is realized, it may be appropriate to design clinical trials that evaluate <b style='color:Tomato;'><i>docetaxel</i></b>-based regimens as adjuvant therapy in patients who are at a high risk for relapse after definitive local therapy.","tokens":[{"text":"Considerations","start":0,"end":14,"id":0,"ws":true},{"text":"of","start":15,"end":17,"id":1,"ws":true},{"text":"both","start":18,"end":22,"id":2,"ws":true},{"text":"molecular","start":23,"end":32,"id":3,"ws":true},{"text":"biology","start":33,"end":40,"id":4,"ws":true},{"text":"and","start":41,"end":44,"id":5,"ws":true},{"text":"data","start":45,"end":49,"id":6,"ws":true},{"text":"from","start":50,"end":54,"id":7,"ws":true},{"text":"in","start":55,"end":57,"id":8,"ws":true},{"text":"vitro","start":58,"end":63,"id":9,"ws":true},{"text":"studies","start":64,"end":71,"id":10,"ws":true},{"text":"suggest","start":72,"end":79,"id":11,"ws":true},{"text":"a","start":80,"end":81,"id":12,"ws":true},{"text":"potential","start":82,"end":91,"id":13,"ws":true},{"text":"for","start":92,"end":95,"id":14,"ws":true},{"text":"the","start":96,"end":99,"id":15,"ws":true},{"text":"combination","start":100,"end":111,"id":16,"ws":true},{"text":"of","start":112,"end":114,"id":17,"ws":true},{"text":"docetaxel","start":115,"end":124,"id":18,"ws":true},{"text":"(","start":125,"end":126,"id":19,"ws":true},{"text":"Taxotere","start":127,"end":135,"id":20,"ws":true},{"text":";","start":136,"end":137,"id":21,"ws":true},{"text":"Rh\u00f4ne-Poulenc","start":138,"end":151,"id":22,"ws":true},{"text":"Rorer","start":152,"end":157,"id":23,"ws":true},{"text":",","start":158,"end":159,"id":24,"ws":true},{"text":"Antony","start":160,"end":166,"id":25,"ws":true},{"text":",","start":167,"end":168,"id":26,"ws":true},{"text":"France","start":169,"end":175,"id":27,"ws":true},{"text":")","start":176,"end":177,"id":28,"ws":true},{"text":"with","start":178,"end":182,"id":29,"ws":true},{"text":"estramustine","start":183,"end":195,"id":30,"ws":true},{"text":"in","start":196,"end":198,"id":31,"ws":true},{"text":"the","start":199,"end":202,"id":32,"ws":true},{"text":"treatment","start":203,"end":212,"id":33,"ws":true},{"text":"of","start":213,"end":215,"id":34,"ws":true},{"text":"patients","start":216,"end":224,"id":35,"ws":true},{"text":"with","start":225,"end":229,"id":36,"ws":true},{"text":"hormone-refractory","start":230,"end":248,"id":37,"ws":true},{"text":"prostate","start":249,"end":257,"id":38,"ws":true},{"text":"cancer","start":258,"end":264,"id":39,"ws":true},{"text":".","start":265,"end":266,"id":40,"ws":false}],"spans":[{"start":115,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},{"start":183,"end":195,"token_start":30,"token_end":30,"label":"DRUG"}],"_input_hash":-244306730,"_task_hash":1482466855,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":18,"child":30,"head_span":{"start":115,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":183,"end":195,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Catecholamine determinations showed that the administration of doxorubicin under hyperthermic conditions increased the liberation of both epinephrine and norepinephrine .","paragraph":"<h3><u>Hyperthermia potentiates doxorubicin-related cardiotoxic effects.</u></h3>The intercurrent administration of <b style='color:Tomato;'><i>doxorubicin</i></b> hydrochloride to a patient undergoing whole-body hyperthermia for the treatment of metastatic cancer repeatedly produced ventricular irritability and cardiac dysfunction. Individually, <b style='color:Tomato;'><i>doxorubicin</i></b> and hyperthermia were tolerated by the patient without incident. <b style='color:DodgerBlue;'><i>Catecholamine</i></b> <b style='color:DodgerBlue;'><i>determinations</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>hyperthermic</i></b> <b style='color:DodgerBlue;'><i>conditions</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>liberation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>norepinephrine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The acute synergistic cardiotoxic effects occurred with <b style='color:Tomato;'><i>doxorubicin</i></b> dosages that were severalfold less than those associated with only mild and transient ECG disturbances under normothermic conditions.","tokens":[{"text":"Catecholamine","start":0,"end":13,"id":0,"ws":true},{"text":"determinations","start":14,"end":28,"id":1,"ws":true},{"text":"showed","start":29,"end":35,"id":2,"ws":true},{"text":"that","start":36,"end":40,"id":3,"ws":true},{"text":"the","start":41,"end":44,"id":4,"ws":true},{"text":"administration","start":45,"end":59,"id":5,"ws":true},{"text":"of","start":60,"end":62,"id":6,"ws":true},{"text":"doxorubicin","start":63,"end":74,"id":7,"ws":true},{"text":"under","start":75,"end":80,"id":8,"ws":true},{"text":"hyperthermic","start":81,"end":93,"id":9,"ws":true},{"text":"conditions","start":94,"end":104,"id":10,"ws":true},{"text":"increased","start":105,"end":114,"id":11,"ws":true},{"text":"the","start":115,"end":118,"id":12,"ws":true},{"text":"liberation","start":119,"end":129,"id":13,"ws":true},{"text":"of","start":130,"end":132,"id":14,"ws":true},{"text":"both","start":133,"end":137,"id":15,"ws":true},{"text":"epinephrine","start":138,"end":149,"id":16,"ws":true},{"text":"and","start":150,"end":153,"id":17,"ws":true},{"text":"norepinephrine","start":154,"end":168,"id":18,"ws":true},{"text":".","start":169,"end":170,"id":19,"ws":false}],"spans":[{"start":63,"end":74,"token_start":7,"token_end":7,"label":"DRUG"},{"start":138,"end":149,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-1816149437,"_task_hash":-719071743,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We have evaluated the combination of ifosfamide , carboplatin and etoposide ( ICE regimen ) along with mesna in 26 previously untreated patients with non small cell lung cancer ( NSCLC ) .","paragraph":"<h3><u>Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ICE</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>along</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mesna</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>26</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>non</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Thirteen stage III B and 13 stage IV patients received intermediate doses of <b style='color:Tomato;'><i>ifosfamide</i></b> (1000 mg/m2), <b style='color:Tomato;'><i>carboplatin</i></b> (120 mg/m2) and <b style='color:Tomato;'><i>etoposide</i></b> (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"have","start":3,"end":7,"id":1,"ws":true},{"text":"evaluated","start":8,"end":17,"id":2,"ws":true},{"text":"the","start":18,"end":21,"id":3,"ws":true},{"text":"combination","start":22,"end":33,"id":4,"ws":true},{"text":"of","start":34,"end":36,"id":5,"ws":true},{"text":"ifosfamide","start":37,"end":47,"id":6,"ws":true},{"text":",","start":48,"end":49,"id":7,"ws":true},{"text":"carboplatin","start":50,"end":61,"id":8,"ws":true},{"text":"and","start":62,"end":65,"id":9,"ws":true},{"text":"etoposide","start":66,"end":75,"id":10,"ws":true},{"text":"(","start":76,"end":77,"id":11,"ws":true},{"text":"ICE","start":78,"end":81,"id":12,"ws":true},{"text":"regimen","start":82,"end":89,"id":13,"ws":true},{"text":")","start":90,"end":91,"id":14,"ws":true},{"text":"along","start":92,"end":97,"id":15,"ws":true},{"text":"with","start":98,"end":102,"id":16,"ws":true},{"text":"mesna","start":103,"end":108,"id":17,"ws":true},{"text":"in","start":109,"end":111,"id":18,"ws":true},{"text":"26","start":112,"end":114,"id":19,"ws":true},{"text":"previously","start":115,"end":125,"id":20,"ws":true},{"text":"untreated","start":126,"end":135,"id":21,"ws":true},{"text":"patients","start":136,"end":144,"id":22,"ws":true},{"text":"with","start":145,"end":149,"id":23,"ws":true},{"text":"non","start":150,"end":153,"id":24,"ws":true},{"text":"small","start":154,"end":159,"id":25,"ws":true},{"text":"cell","start":160,"end":164,"id":26,"ws":true},{"text":"lung","start":165,"end":169,"id":27,"ws":true},{"text":"cancer","start":170,"end":176,"id":28,"ws":true},{"text":"(","start":177,"end":178,"id":29,"ws":true},{"text":"NSCLC","start":179,"end":184,"id":30,"ws":true},{"text":")","start":185,"end":186,"id":31,"ws":true},{"text":".","start":187,"end":188,"id":32,"ws":false}],"spans":[{"start":37,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},{"start":50,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},{"start":66,"end":75,"token_start":10,"token_end":10,"label":"DRUG"},{"start":103,"end":108,"token_start":17,"token_end":17,"label":"DRUG"}],"_input_hash":1008507485,"_task_hash":1106495308,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":37,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":50,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":17,"head_span":{"start":66,"end":75,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":103,"end":108,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Progestin therapy has become an established endocrine modality for the treatment of metastatic breast cancer , with medroxyprogesterone acetate and megestrol acetate being the most widely used agents .","paragraph":"<h3><u>High-dose progestin therapy for metastatic breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>Progestin</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>endocrine</i></b> <b style='color:DodgerBlue;'><i>modality</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>medroxyprogesterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>megestrol</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both drugs display similar effectiveness as initial and secondary therapy for patients with advanced disease, with combined complete and partial response rates of approximately 30% to 40%. Uncontrolled trials have suggested that high doses of <b style='color:Tomato;'><i>medroxyprogesterone</i></b> may be more effective than lower doses, but randomized trials have yielded conflicting results. Clinical trials of <b style='color:Tomato;'><i>megestrol</i></b> acetate have demonstrated it to be an affective, well-tolerated oral progestin, and a recent randomized trial has suggested that higher <b style='color:Tomato;'><i>megestrol</i></b> acetate doses may be associated with not only improved response but also improved time to disease progression and survival. Further trials of high-dose <b style='color:Tomato;'><i>megestrol</i></b> acetate for both initial and secondary therapy are under way, and their results will provide valuable information concerning the role of such treatment.","tokens":[{"text":"Progestin","start":0,"end":9,"id":0,"ws":true},{"text":"therapy","start":10,"end":17,"id":1,"ws":true},{"text":"has","start":18,"end":21,"id":2,"ws":true},{"text":"become","start":22,"end":28,"id":3,"ws":true},{"text":"an","start":29,"end":31,"id":4,"ws":true},{"text":"established","start":32,"end":43,"id":5,"ws":true},{"text":"endocrine","start":44,"end":53,"id":6,"ws":true},{"text":"modality","start":54,"end":62,"id":7,"ws":true},{"text":"for","start":63,"end":66,"id":8,"ws":true},{"text":"the","start":67,"end":70,"id":9,"ws":true},{"text":"treatment","start":71,"end":80,"id":10,"ws":true},{"text":"of","start":81,"end":83,"id":11,"ws":true},{"text":"metastatic","start":84,"end":94,"id":12,"ws":true},{"text":"breast","start":95,"end":101,"id":13,"ws":true},{"text":"cancer","start":102,"end":108,"id":14,"ws":true},{"text":",","start":109,"end":110,"id":15,"ws":true},{"text":"with","start":111,"end":115,"id":16,"ws":true},{"text":"medroxyprogesterone","start":116,"end":135,"id":17,"ws":true},{"text":"acetate","start":136,"end":143,"id":18,"ws":true},{"text":"and","start":144,"end":147,"id":19,"ws":true},{"text":"megestrol","start":148,"end":157,"id":20,"ws":true},{"text":"acetate","start":158,"end":165,"id":21,"ws":true},{"text":"being","start":166,"end":171,"id":22,"ws":true},{"text":"the","start":172,"end":175,"id":23,"ws":true},{"text":"most","start":176,"end":180,"id":24,"ws":true},{"text":"widely","start":181,"end":187,"id":25,"ws":true},{"text":"used","start":188,"end":192,"id":26,"ws":true},{"text":"agents","start":193,"end":199,"id":27,"ws":true},{"text":".","start":200,"end":201,"id":28,"ws":false}],"spans":[{"start":116,"end":135,"token_start":17,"token_end":17,"label":"DRUG"},{"start":148,"end":157,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":1819263175,"_task_hash":1060340276,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This phase I was study conducted to establish the maximum tolerated dose , dose-limiting toxicity , and recommended dose of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer .","paragraph":"<h3><u>Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>establish</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>dose-limiting</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-six patients were treated with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (600 mg m(-2), intravenous bolus) followed by <b style='color:Tomato;'><i>docetaxel</i></b> (60, 75 or 85 mg m(-2), 1-h intravenous infusion) every 3 weeks. The maximum tolerated dose was <b style='color:Tomato;'><i>docetaxel</i></b> 85 mg m(-2) with <b style='color:Tomato;'><i>cyclophosphamide</i></b> 600 mg m(-2), the dose-limiting toxicity being febrile neutropenia. Grade 4 neutropenia was experienced by all patients, but was generally brief. Otherwise, the combination was well tolerated with few acute and no chronic non-haematological toxicities of grade 3/4. Activity was observed at all dose levels and disease sites, and the overall response rate was 42% (95% confidence interval 22-61%). The pharmacokinetics of <b style='color:Tomato;'><i>docetaxel</i></b> were not modified by <b style='color:Tomato;'><i>cyclophosphamide</i></b> coadministration. These findings establish a recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> 75 mg m(-2) in combination with <b style='color:Tomato;'><i>cyclophosphamide</i></b> 600 mg m(-2) every three weeks for phase II evaluation.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"phase","start":5,"end":10,"id":1,"ws":true},{"text":"I","start":11,"end":12,"id":2,"ws":true},{"text":"was","start":13,"end":16,"id":3,"ws":true},{"text":"study","start":17,"end":22,"id":4,"ws":true},{"text":"conducted","start":23,"end":32,"id":5,"ws":true},{"text":"to","start":33,"end":35,"id":6,"ws":true},{"text":"establish","start":36,"end":45,"id":7,"ws":true},{"text":"the","start":46,"end":49,"id":8,"ws":true},{"text":"maximum","start":50,"end":57,"id":9,"ws":true},{"text":"tolerated","start":58,"end":67,"id":10,"ws":true},{"text":"dose","start":68,"end":72,"id":11,"ws":true},{"text":",","start":73,"end":74,"id":12,"ws":true},{"text":"dose-limiting","start":75,"end":88,"id":13,"ws":true},{"text":"toxicity","start":89,"end":97,"id":14,"ws":true},{"text":",","start":98,"end":99,"id":15,"ws":true},{"text":"and","start":100,"end":103,"id":16,"ws":true},{"text":"recommended","start":104,"end":115,"id":17,"ws":true},{"text":"dose","start":116,"end":120,"id":18,"ws":true},{"text":"of","start":121,"end":123,"id":19,"ws":true},{"text":"docetaxel","start":124,"end":133,"id":20,"ws":true},{"text":"in","start":134,"end":136,"id":21,"ws":true},{"text":"combination","start":137,"end":148,"id":22,"ws":true},{"text":"with","start":149,"end":153,"id":23,"ws":true},{"text":"cyclophosphamide","start":154,"end":170,"id":24,"ws":true},{"text":"as","start":171,"end":173,"id":25,"ws":true},{"text":"first-line","start":174,"end":184,"id":26,"ws":true},{"text":"chemotherapy","start":185,"end":197,"id":27,"ws":true},{"text":"for","start":198,"end":201,"id":28,"ws":true},{"text":"metastatic","start":202,"end":212,"id":29,"ws":true},{"text":"breast","start":213,"end":219,"id":30,"ws":true},{"text":"cancer","start":220,"end":226,"id":31,"ws":true},{"text":".","start":227,"end":228,"id":32,"ws":false}],"spans":[{"start":124,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},{"start":154,"end":170,"token_start":24,"token_end":24,"label":"DRUG"}],"_input_hash":540704940,"_task_hash":-1782928497,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":20,"child":24,"head_span":{"start":124,"end":133,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":154,"end":170,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"An improved method has been developed for the determination of the major neutral steroids ( cholesterol and 5 beta-cholestan-3 beta-ol ) and unconjugated bile acids ( deoxycholic acid and lithocholic acid ) in human faeces , using capillary gas chromatography with flame ionization detection .","paragraph":"<h3><u>Improved method for the determination of the major neutral steroids and unconjugated bile acids in human faeces using capillary gas chromatography.</u></h3> <b style='color:DodgerBlue;'><i>An</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>developed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>major</i></b> <b style='color:DodgerBlue;'><i>neutral</i></b> <b style='color:DodgerBlue;'><i>steroids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>beta-cholestan-3</i></b> <b style='color:DodgerBlue;'><i>beta-ol</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>unconjugated</i></b> <b style='color:DodgerBlue;'><i>bile</i></b> <b style='color:DodgerBlue;'><i>acids</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>deoxycholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lithocholic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>faeces</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>capillary</i></b> <b style='color:DodgerBlue;'><i>gas</i></b> <b style='color:DodgerBlue;'><i>chromatography</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>flame</i></b> <b style='color:DodgerBlue;'><i>ionization</i></b> <b style='color:DodgerBlue;'><i>detection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The freeze-dried faecal sample was subjected to a two-stage Soxhlet extraction followed by an aqueous alkali-organic solvent partition step to separate neutral steroids from bile acids. The neutral steroids were analysed as their trimethylsilyl ether derivatives on an OV-1 capillary column. The bile acids were further purified on a Sep-Pak C18 cartridge and then fractionated on a Sep-Pak SIL cartridge. Unconjugated bile acids were analysed as their methyl ester-trimethylsilyl ether derivatives also on an OV-1 capillary column. Quantitation of neutral steroids and unconjugated bile acids was achieved by reference to appropriate internal standards, added to the faecal extract immediately after the Soxhlet extraction stage. The method is being used in a study of the effect of diet on the metabolic activity of human gut flora.","tokens":[{"text":"An","start":0,"end":2,"id":0,"ws":true},{"text":"improved","start":3,"end":11,"id":1,"ws":true},{"text":"method","start":12,"end":18,"id":2,"ws":true},{"text":"has","start":19,"end":22,"id":3,"ws":true},{"text":"been","start":23,"end":27,"id":4,"ws":true},{"text":"developed","start":28,"end":37,"id":5,"ws":true},{"text":"for","start":38,"end":41,"id":6,"ws":true},{"text":"the","start":42,"end":45,"id":7,"ws":true},{"text":"determination","start":46,"end":59,"id":8,"ws":true},{"text":"of","start":60,"end":62,"id":9,"ws":true},{"text":"the","start":63,"end":66,"id":10,"ws":true},{"text":"major","start":67,"end":72,"id":11,"ws":true},{"text":"neutral","start":73,"end":80,"id":12,"ws":true},{"text":"steroids","start":81,"end":89,"id":13,"ws":true},{"text":"(","start":90,"end":91,"id":14,"ws":true},{"text":"cholesterol","start":92,"end":103,"id":15,"ws":true},{"text":"and","start":104,"end":107,"id":16,"ws":true},{"text":"5","start":108,"end":109,"id":17,"ws":true},{"text":"beta-cholestan-3","start":110,"end":126,"id":18,"ws":true},{"text":"beta-ol","start":127,"end":134,"id":19,"ws":true},{"text":")","start":135,"end":136,"id":20,"ws":true},{"text":"and","start":137,"end":140,"id":21,"ws":true},{"text":"unconjugated","start":141,"end":153,"id":22,"ws":true},{"text":"bile","start":154,"end":158,"id":23,"ws":true},{"text":"acids","start":159,"end":164,"id":24,"ws":true},{"text":"(","start":165,"end":166,"id":25,"ws":true},{"text":"deoxycholic","start":167,"end":178,"id":26,"ws":true},{"text":"acid","start":179,"end":183,"id":27,"ws":true},{"text":"and","start":184,"end":187,"id":28,"ws":true},{"text":"lithocholic","start":188,"end":199,"id":29,"ws":true},{"text":"acid","start":200,"end":204,"id":30,"ws":true},{"text":")","start":205,"end":206,"id":31,"ws":true},{"text":"in","start":207,"end":209,"id":32,"ws":true},{"text":"human","start":210,"end":215,"id":33,"ws":true},{"text":"faeces","start":216,"end":222,"id":34,"ws":true},{"text":",","start":223,"end":224,"id":35,"ws":true},{"text":"using","start":225,"end":230,"id":36,"ws":true},{"text":"capillary","start":231,"end":240,"id":37,"ws":true},{"text":"gas","start":241,"end":244,"id":38,"ws":true},{"text":"chromatography","start":245,"end":259,"id":39,"ws":true},{"text":"with","start":260,"end":264,"id":40,"ws":true},{"text":"flame","start":265,"end":270,"id":41,"ws":true},{"text":"ionization","start":271,"end":281,"id":42,"ws":true},{"text":"detection","start":282,"end":291,"id":43,"ws":true},{"text":".","start":292,"end":293,"id":44,"ws":false}],"spans":[{"start":167,"end":178,"token_start":26,"token_end":26,"label":"DRUG"},{"start":188,"end":199,"token_start":29,"token_end":29,"label":"DRUG"}],"_input_hash":2106492790,"_task_hash":-1060891084,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"4EGI-1 showed enhanced cytotoxicity in combination with pemetrexed or gemcitabine .","paragraph":"<h3><u>4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.</u></h3>Deregulation of cap-dependent translation has been implicated in the malignant transformation of numerous human tissues. 4EGI-1, a novel small-molecule inhibitor of cap-dependent translation, disrupts formation of the eukaryotic initiation factor 4F (eIF4F) complex. The effects of 4EGI-1-mediated inhibition of translation initiation in malignant pleural mesothelioma (MPM) were examined. 4EGI-1 preferentially inhibited cell viability and induced apoptosis in MPM cells compared to normal mesothelial (LP9) cells. This effect was associated with hypophosphorylation of 4E-binding protein 1 (4E-BP1) and decreased protein levels of the cancer-related genes, c-myc and osteopontin. <b style='color:DodgerBlue;'><i>4EGI-1</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>cytotoxicity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Translatome-wide polysome microarray analysis revealed a large cohort of genes that were translationally regulated upon treatment with 4EGI-1. The 4EGI-1-regulated translatome was negatively correlated to a previously published translatome regulated by eIF4E overexpression in human mammary epithelial cells, which is in agreement with the notion that 4EGI-1 inhibits the eIF4F complex. These data indicate that inhibition of the eIF4F complex by 4EGI-1 or similar translation inhibitors could be a strategy for treating mesothelioma. Genome wide translational profiling identified a large cohort of promising target genes that should be further evaluated for their potential significance in the treatment of MPM.","tokens":[{"text":"4EGI-1","start":0,"end":6,"id":0,"ws":true},{"text":"showed","start":7,"end":13,"id":1,"ws":true},{"text":"enhanced","start":14,"end":22,"id":2,"ws":true},{"text":"cytotoxicity","start":23,"end":35,"id":3,"ws":true},{"text":"in","start":36,"end":38,"id":4,"ws":true},{"text":"combination","start":39,"end":50,"id":5,"ws":true},{"text":"with","start":51,"end":55,"id":6,"ws":true},{"text":"pemetrexed","start":56,"end":66,"id":7,"ws":true},{"text":"or","start":67,"end":69,"id":8,"ws":true},{"text":"gemcitabine","start":70,"end":81,"id":9,"ws":true},{"text":".","start":82,"end":83,"id":10,"ws":false}],"spans":[{"start":0,"end":6,"token_start":0,"token_end":0,"label":"DRUG"},{"start":56,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},{"start":70,"end":81,"token_start":9,"token_end":9,"label":"DRUG"}],"_input_hash":-1889524847,"_task_hash":-101335447,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":0,"child":7,"head_span":{"start":0,"end":6,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":56,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":0,"child":9,"head_span":{"start":0,"end":6,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG10","NEG1T0","NEG20","NEG2T0"],"answer":"accept"}
{"text":"In the NCI-60 cell line dataset , overexpression of the kinesin KIFC3 is significantly correlated with resistance to both docetaxel ( P < 0.001 ) and paclitaxel ( P < 0.001 ) , but not to platinum-based chemotherapy , including carboplatin ( P = 0.49 ) and cisplatin ( P = 0.10 ) .","paragraph":"<h3><u>Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.</u></h3>Breast cancer is a genetically heterogenous disease with subtypes differing in prognosis and chemosensitivity. The basal-like breast cancer (BLBC) molecular subtype is associated with poorer outcomes, but is more responsive to taxane-based chemotherapy. Kinesins are intracellular transport proteins that interact with microtubules, which are also the mechanistic target for taxanes. We investigated the relationship between taxane resistance in BLBC and kinesins using both expression and functional studies. Kinesin (KIF) expression was evaluated in three settings in relation to taxane resistance: (i) the NCI-60 cancer cell lines, (ii) pre-treatment samples from four BLBC patient cohorts receiving neoadjuvant chemotherapy regimens with and without taxanes, and (iii) post-treatment samples from residual breast cancer following neoadjuvant taxane-containing chemotherapy. We used a novel functional approach to gene modification, validation-based insertional mutagenesis, to select kinesin-overexpressing clones of BLBC cells for evaluation of related mechanisms of taxane resistance. In the NCI-60 cell line dataset, overexpression of the kinesin KIFC3 is significantly correlated with resistance to both <b style='color:Tomato;'><i>docetaxel</i></b> (P\u00a0<\u00a00.001) and <b style='color:Tomato;'><i>paclitaxel</i></b> (P\u00a0<\u00a00.001), but not to platinum-based chemotherapy, including <b style='color:Tomato;'><i>carboplatin</i></b> (P\u00a0=\u00a00.49) and cisplatin (P\u00a0=\u00a00.10). Overexpression of KIFC3 and KIF5A in pre-chemotherapy samples similarly predicted resistance to <b style='color:Tomato;'><i>paclitaxel</i></b> in the MDACC cohorts (P\u00a0=\u00a00.01); no KIF predicted resistance to <b style='color:Tomato;'><i>fluorouracil</i></b>-<b style='color:Tomato;'><i>epirubicin</i></b>-<b style='color:Tomato;'><i>cyclophosphamide</i></b> or cisplatin in BLBC patient cohorts treated without taxanes. KIF12 is the most overexpressed KIF gene in post-chemotherapy taxane-resistant residual breast cancers (2.8-fold-change). Functional studies established that overexpression of KIFC3, KIF5A, and KIF12 were specific in mediating resistance to <b style='color:Tomato;'><i>docetaxel</i></b> and not <b style='color:Tomato;'><i>vincristine</i></b> or <b style='color:Tomato;'><i>doxorubicin</i></b>. Mutation of the ATP-binding domain of a kinesin abolished its ability to mediate <b style='color:Tomato;'><i>docetaxel</i></b> resistance. Overall, kinesin overexpression correlates with specific taxane resistance in BLBC cell lines and tissues. Our results suggest a novel approach for drug development to overcome taxane resistance in breast cancer through concurrent or sequential use of kinesin inhibitors <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NCI-60</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>dataset</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>kinesin</i></b> <b style='color:DodgerBlue;'><i>KIFC3</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>correlated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>platinum-based</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.49</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.10</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b>ns are intracellular transport proteins that interact with microtubules, which are also the mechanistic target for taxanes. We investigated the relationship between taxane resistance in BLBC and kinesins using both expression and functional studies. Kinesin (KIF) expression was evaluated in three settings in relation to taxane resistance: (i) the NCI-60 cancer cell lines, (ii) pre-treatment samples from four BLBC patient cohorts receiving neoadjuvant chemotherapy regimens with and without taxanes, and (iii) post-treatment samples from residual breast cancer following neoadjuvant taxane-containing chemotherapy. We used a novel functional approach to gene modification, validation-based insertional mutagenesis, to select kinesin-overexpressing clones of BLBC cells for evaluation of related mechanisms of taxane resistance. In the NCI-60 cell line dataset, overexpression of the kinesin KIFC3 is significantly correlated with resistance to both <b style='color:Tomato;'><i>docetaxel</i></b> (P\u00a0<\u00a00.001) and <b style='color:Tomato;'><i>paclitaxel</i></b> (P\u00a0<\u00a00.001), but not to platinum-based chemotherapy, including <b style='color:Tomato;'><i>carboplatin</i></b> (P\u00a0=\u00a00.49) and cisplatin (P\u00a0=\u00a00.10). Overexpression of KIFC3 and KIF5A in pre-chemotherapy samples similarly predicted resistance to <b style='color:Tomato;'><i>paclitaxel</i></b> in the MDACC cohorts (P\u00a0=\u00a00.01); no KIF predicted resistance to <b style='color:Tomato;'><i>fluorouracil</i></b>-<b style='color:Tomato;'><i>epirubicin</i></b>-<b style='color:Tomato;'><i>cyclophosphamide</i></b> or cisplatin in BLBC patient cohorts treated without taxanes. KIF12 is the most overexpressed KIF gene in post-chemotherapy taxane-resistant residual breast cancers (2.8-fold-change). Functional studies established that overexpression of KIFC3, KIF5A, and KIF12 were specific in mediating resistance to <b style='color:Tomato;'><i>docetaxel</i></b> and not <b style='color:Tomato;'><i>vincristine</i></b> or <b style='color:Tomato;'><i>doxorubicin</i></b>. Mutation of the ATP-binding domain of a kinesin abolished its ability to mediate <b style='color:Tomato;'><i>docetaxel</i></b> resistance. Overall, kinesin overexpression correlates with specific taxane resistance in BLBC cell lines and tissues. Our results suggest a novel approach for drug development to overcome taxane resistance in breast cancer through concurrent or sequential use of kinesin inhibitors.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"NCI-60","start":7,"end":13,"id":2,"ws":true},{"text":"cell","start":14,"end":18,"id":3,"ws":true},{"text":"line","start":19,"end":23,"id":4,"ws":true},{"text":"dataset","start":24,"end":31,"id":5,"ws":true},{"text":",","start":32,"end":33,"id":6,"ws":true},{"text":"overexpression","start":34,"end":48,"id":7,"ws":true},{"text":"of","start":49,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"kinesin","start":56,"end":63,"id":10,"ws":true},{"text":"KIFC3","start":64,"end":69,"id":11,"ws":true},{"text":"is","start":70,"end":72,"id":12,"ws":true},{"text":"significantly","start":73,"end":86,"id":13,"ws":true},{"text":"correlated","start":87,"end":97,"id":14,"ws":true},{"text":"with","start":98,"end":102,"id":15,"ws":true},{"text":"resistance","start":103,"end":113,"id":16,"ws":true},{"text":"to","start":114,"end":116,"id":17,"ws":true},{"text":"both","start":117,"end":121,"id":18,"ws":true},{"text":"docetaxel","start":122,"end":131,"id":19,"ws":true},{"text":"(","start":132,"end":133,"id":20,"ws":true},{"text":"P","start":134,"end":135,"id":21,"ws":true},{"text":"<","start":136,"end":137,"id":22,"ws":true},{"text":"0.001","start":138,"end":143,"id":23,"ws":true},{"text":")","start":144,"end":145,"id":24,"ws":true},{"text":"and","start":146,"end":149,"id":25,"ws":true},{"text":"paclitaxel","start":150,"end":160,"id":26,"ws":true},{"text":"(","start":161,"end":162,"id":27,"ws":true},{"text":"P","start":163,"end":164,"id":28,"ws":true},{"text":"<","start":165,"end":166,"id":29,"ws":true},{"text":"0.001","start":167,"end":172,"id":30,"ws":true},{"text":")","start":173,"end":174,"id":31,"ws":true},{"text":",","start":175,"end":176,"id":32,"ws":true},{"text":"but","start":177,"end":180,"id":33,"ws":true},{"text":"not","start":181,"end":184,"id":34,"ws":true},{"text":"to","start":185,"end":187,"id":35,"ws":true},{"text":"platinum-based","start":188,"end":202,"id":36,"ws":true},{"text":"chemotherapy","start":203,"end":215,"id":37,"ws":true},{"text":",","start":216,"end":217,"id":38,"ws":true},{"text":"including","start":218,"end":227,"id":39,"ws":true},{"text":"carboplatin","start":228,"end":239,"id":40,"ws":true},{"text":"(","start":240,"end":241,"id":41,"ws":true},{"text":"P","start":242,"end":243,"id":42,"ws":true},{"text":"=","start":244,"end":245,"id":43,"ws":true},{"text":"0.49","start":246,"end":250,"id":44,"ws":true},{"text":")","start":251,"end":252,"id":45,"ws":true},{"text":"and","start":253,"end":256,"id":46,"ws":true},{"text":"cisplatin","start":257,"end":266,"id":47,"ws":true},{"text":"(","start":267,"end":268,"id":48,"ws":true},{"text":"P","start":269,"end":270,"id":49,"ws":true},{"text":"=","start":271,"end":272,"id":50,"ws":true},{"text":"0.10","start":273,"end":277,"id":51,"ws":true},{"text":")","start":278,"end":279,"id":52,"ws":true},{"text":".","start":280,"end":281,"id":53,"ws":false}],"spans":[{"start":122,"end":131,"token_start":19,"token_end":19,"label":"DRUG"},{"start":150,"end":160,"token_start":26,"token_end":26,"label":"DRUG"},{"start":228,"end":239,"token_start":40,"token_end":40,"label":"DRUG"}],"_input_hash":566668688,"_task_hash":937242338,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Due to the broad and early use of percutaneous coronary intervention ( PCI ) as well as due to innovations in the antithrombotic and anticoagulation regime with the use of more effective P2Y12-receptor antagonists as well as the use of Fondaparinux and Bivalirudin , a continuous improvement of the prognosis and reduction of ischemic events could be achieved in ACS patients over the last few years .","paragraph":"<h3><u>[Acute coronary syndrome].</u></h3>The acute coronary syndrome (ACS) still remains a common disease in the preclinical as well as in the intrahospital emergency setting. Different clinical types of an ACS, such as unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI) have to be differentiated diagnostically, prognostically and in terms of the best therapeutic strategy. <b style='color:DodgerBlue;'><i>Due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broad</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>early</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>percutaneous</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>intervention</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>innovations</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antithrombotic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anticoagulation</i></b> <b style='color:DodgerBlue;'><i>regime</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>P2Y12-receptor</i></b> <b style='color:DodgerBlue;'><i>antagonists</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Fondaparinux</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Bivalirudin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>reduction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ischemic</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>achieved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ACS</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>last</i></b> <b style='color:DodgerBlue;'><i>few</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, the increased bleeding rate, particularly when using those new substances, remains a relevant problem. Future studies are warranted to clarify if certain combinations of substances may be better suited to achieve the optimal balance between reduction of cardiovascular events on the one hand and bleeding risk on the other hand.","tokens":[{"text":"Due","start":0,"end":3,"id":0,"ws":true},{"text":"to","start":4,"end":6,"id":1,"ws":true},{"text":"the","start":7,"end":10,"id":2,"ws":true},{"text":"broad","start":11,"end":16,"id":3,"ws":true},{"text":"and","start":17,"end":20,"id":4,"ws":true},{"text":"early","start":21,"end":26,"id":5,"ws":true},{"text":"use","start":27,"end":30,"id":6,"ws":true},{"text":"of","start":31,"end":33,"id":7,"ws":true},{"text":"percutaneous","start":34,"end":46,"id":8,"ws":true},{"text":"coronary","start":47,"end":55,"id":9,"ws":true},{"text":"intervention","start":56,"end":68,"id":10,"ws":true},{"text":"(","start":69,"end":70,"id":11,"ws":true},{"text":"PCI","start":71,"end":74,"id":12,"ws":true},{"text":")","start":75,"end":76,"id":13,"ws":true},{"text":"as","start":77,"end":79,"id":14,"ws":true},{"text":"well","start":80,"end":84,"id":15,"ws":true},{"text":"as","start":85,"end":87,"id":16,"ws":true},{"text":"due","start":88,"end":91,"id":17,"ws":true},{"text":"to","start":92,"end":94,"id":18,"ws":true},{"text":"innovations","start":95,"end":106,"id":19,"ws":true},{"text":"in","start":107,"end":109,"id":20,"ws":true},{"text":"the","start":110,"end":113,"id":21,"ws":true},{"text":"antithrombotic","start":114,"end":128,"id":22,"ws":true},{"text":"and","start":129,"end":132,"id":23,"ws":true},{"text":"anticoagulation","start":133,"end":148,"id":24,"ws":true},{"text":"regime","start":149,"end":155,"id":25,"ws":true},{"text":"with","start":156,"end":160,"id":26,"ws":true},{"text":"the","start":161,"end":164,"id":27,"ws":true},{"text":"use","start":165,"end":168,"id":28,"ws":true},{"text":"of","start":169,"end":171,"id":29,"ws":true},{"text":"more","start":172,"end":176,"id":30,"ws":true},{"text":"effective","start":177,"end":186,"id":31,"ws":true},{"text":"P2Y12-receptor","start":187,"end":201,"id":32,"ws":true},{"text":"antagonists","start":202,"end":213,"id":33,"ws":true},{"text":"as","start":214,"end":216,"id":34,"ws":true},{"text":"well","start":217,"end":221,"id":35,"ws":true},{"text":"as","start":222,"end":224,"id":36,"ws":true},{"text":"the","start":225,"end":228,"id":37,"ws":true},{"text":"use","start":229,"end":232,"id":38,"ws":true},{"text":"of","start":233,"end":235,"id":39,"ws":true},{"text":"Fondaparinux","start":236,"end":248,"id":40,"ws":true},{"text":"and","start":249,"end":252,"id":41,"ws":true},{"text":"Bivalirudin","start":253,"end":264,"id":42,"ws":true},{"text":",","start":265,"end":266,"id":43,"ws":true},{"text":"a","start":267,"end":268,"id":44,"ws":true},{"text":"continuous","start":269,"end":279,"id":45,"ws":true},{"text":"improvement","start":280,"end":291,"id":46,"ws":true},{"text":"of","start":292,"end":294,"id":47,"ws":true},{"text":"the","start":295,"end":298,"id":48,"ws":true},{"text":"prognosis","start":299,"end":308,"id":49,"ws":true},{"text":"and","start":309,"end":312,"id":50,"ws":true},{"text":"reduction","start":313,"end":322,"id":51,"ws":true},{"text":"of","start":323,"end":325,"id":52,"ws":true},{"text":"ischemic","start":326,"end":334,"id":53,"ws":true},{"text":"events","start":335,"end":341,"id":54,"ws":true},{"text":"could","start":342,"end":347,"id":55,"ws":true},{"text":"be","start":348,"end":350,"id":56,"ws":true},{"text":"achieved","start":351,"end":359,"id":57,"ws":true},{"text":"in","start":360,"end":362,"id":58,"ws":true},{"text":"ACS","start":363,"end":366,"id":59,"ws":true},{"text":"patients","start":367,"end":375,"id":60,"ws":true},{"text":"over","start":376,"end":380,"id":61,"ws":true},{"text":"the","start":381,"end":384,"id":62,"ws":true},{"text":"last","start":385,"end":389,"id":63,"ws":true},{"text":"few","start":390,"end":393,"id":64,"ws":true},{"text":"years","start":394,"end":399,"id":65,"ws":true},{"text":".","start":400,"end":401,"id":66,"ws":false}],"spans":[{"start":236,"end":248,"token_start":40,"token_end":40,"label":"DRUG"},{"start":253,"end":264,"token_start":42,"token_end":42,"label":"DRUG"}],"_input_hash":404066514,"_task_hash":-1688296172,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":40,"child":42,"head_span":{"start":236,"end":248,"token_start":40,"token_end":40,"label":"DRUG"},"child_span":{"start":253,"end":264,"token_start":42,"token_end":42,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"The results of the antibiotic treatment analyses revealed that ofloxacin and kanamycin were effective against biofilm cells , whereas ampicillin did not kill the cells , resulting in regrowth of the biofilm after the ampicillin treatment was discontinued .","paragraph":"<h3><u>Increased antibiotic resistance of Escherichia coli in mature biofilms.</u></h3>Biofilms are considered to be highly resistant to antimicrobial agents. Several mechanisms have been proposed to explain this high resistance of biofilms, including restricted penetration of antimicrobial agents into biofilms, slow growth owing to nutrient limitation, expression of genes involved in the general stress response, and emergence of a biofilm-specific phenotype. However, since combinations of these factors are involved in most biofilm studies, it is still difficult to fully understand the mechanisms of biofilm resistance to antibiotics. In this study, the antibiotic susceptibility of Escherichia coli cells in biofilms was investigated with exclusion of the effects of the restricted penetration of antimicrobial agents into biofilms and the slow growth owing to nutrient limitation. Three different antibiotics, <b style='color:Tomato;'><i>ampicillin</i></b> (100 microg/ml), <b style='color:Tomato;'><i>kanamycin</i></b> (25 microg/ml), and ofloxacin (10 microg/ml), were applied directly to cells in the deeper layers of mature biofilms that developed in flow cells after removal of the surface layers of the biofilms. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>analyses</i></b> <b style='color:DodgerBlue;'><i>revealed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>ofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>kanamycin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>biofilm</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>kill</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>resulting</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>regrowth</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>biofilm</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>.</i></b> LIVE/DEAD staining revealed that a small fraction of resistant cells emerged in the deeper layers of the mature biofilms and that these cells were still alive even after 24 h of <b style='color:Tomato;'><i>ampicillin</i></b> treatment. Furthermore, to determine which genes in the biofilm cells are induced, allowing increased resistance to <b style='color:Tomato;'><i>ampicillin</i></b>, global gene expression was analyzed at different stages of biofilm formation, the attachment, colony formation, and maturation stages. The results showed that significant changes in gene expression occurred during biofilm formation, which were partly induced by rpoS expression. Based on the experimental data, it is likely that the observed resistance of biofilms can be attributed to formation of <b style='color:Tomato;'><i>ampicillin</i></b>-resistant subpopulations in the deeper layers of mature biofilms but not in young colony biofilms and that the production and resistance of the subpopulations were aided by biofilm-specific phenotypes, like slow growth and induction of rpoS-mediated stress responses.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"the","start":15,"end":18,"id":3,"ws":true},{"text":"antibiotic","start":19,"end":29,"id":4,"ws":true},{"text":"treatment","start":30,"end":39,"id":5,"ws":true},{"text":"analyses","start":40,"end":48,"id":6,"ws":true},{"text":"revealed","start":49,"end":57,"id":7,"ws":true},{"text":"that","start":58,"end":62,"id":8,"ws":true},{"text":"ofloxacin","start":63,"end":72,"id":9,"ws":true},{"text":"and","start":73,"end":76,"id":10,"ws":true},{"text":"kanamycin","start":77,"end":86,"id":11,"ws":true},{"text":"were","start":87,"end":91,"id":12,"ws":true},{"text":"effective","start":92,"end":101,"id":13,"ws":true},{"text":"against","start":102,"end":109,"id":14,"ws":true},{"text":"biofilm","start":110,"end":117,"id":15,"ws":true},{"text":"cells","start":118,"end":123,"id":16,"ws":true},{"text":",","start":124,"end":125,"id":17,"ws":true},{"text":"whereas","start":126,"end":133,"id":18,"ws":true},{"text":"ampicillin","start":134,"end":144,"id":19,"ws":true},{"text":"did","start":145,"end":148,"id":20,"ws":true},{"text":"not","start":149,"end":152,"id":21,"ws":true},{"text":"kill","start":153,"end":157,"id":22,"ws":true},{"text":"the","start":158,"end":161,"id":23,"ws":true},{"text":"cells","start":162,"end":167,"id":24,"ws":true},{"text":",","start":168,"end":169,"id":25,"ws":true},{"text":"resulting","start":170,"end":179,"id":26,"ws":true},{"text":"in","start":180,"end":182,"id":27,"ws":true},{"text":"regrowth","start":183,"end":191,"id":28,"ws":true},{"text":"of","start":192,"end":194,"id":29,"ws":true},{"text":"the","start":195,"end":198,"id":30,"ws":true},{"text":"biofilm","start":199,"end":206,"id":31,"ws":true},{"text":"after","start":207,"end":212,"id":32,"ws":true},{"text":"the","start":213,"end":216,"id":33,"ws":true},{"text":"ampicillin","start":217,"end":227,"id":34,"ws":true},{"text":"treatment","start":228,"end":237,"id":35,"ws":true},{"text":"was","start":238,"end":241,"id":36,"ws":true},{"text":"discontinued","start":242,"end":254,"id":37,"ws":true},{"text":".","start":255,"end":256,"id":38,"ws":false}],"spans":[{"start":63,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},{"start":77,"end":86,"token_start":11,"token_end":11,"label":"DRUG"},{"start":134,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},{"start":217,"end":227,"token_start":34,"token_end":34,"label":"DRUG"}],"_input_hash":-1931687123,"_task_hash":-884963348,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Enzalutamide , a novel androgen receptor ( AR ) antagonist , prolongs overall survival of patients with castration-resistant prostate cancer ( CRPC ) ; however , patients eventually progress with enzalutamide resistance .","paragraph":"<h3><u>Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.</u></h3> <b style='color:MediumOrchid;'><i>Enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>novel</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>prolongs</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CRPC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>however</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>eventually</i></b> <b style='color:DodgerBlue;'><i>progress</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We studied the efficacy of <b style='color:Tomato;'><i>sorafenib</i></b> combined with <b style='color:Tomato;'><i>enzalutamide</i></b> in a CRPC model and explored a potential strategy to improve <b style='color:Tomato;'><i>enzalutamide</i></b> efficacy in\u00a0vitro and in LNCaP xenografts. The results indicated that <b style='color:Tomato;'><i>enzalutamide</i></b> combined with <b style='color:Tomato;'><i>sorafenib</i></b> potently decreased cell proliferation and induced apoptosis in the prostate cancer cell lineLNCaP. In castrate-resistant LNCaP xenografts, the combination of <b style='color:Tomato;'><i>enzalutamide</i></b> with <b style='color:Tomato;'><i>sorafenib</i></b> significantly suppressed tumor growth compared with eachsingle agent. Western blots and immunohistochemical staining assay showed that the expression of AR was down-regulated, and the extracellular signal-regulated kinase (ERK) signaling pathway was inhibited after combination treatment, suggesting a synergistic inhibitory effect on the AR and ERK pathways. These results demonstrated that <b style='color:Tomato;'><i>sorafenib</i></b> therapy improved the efficacy of <b style='color:Tomato;'><i>enzalutamide</i></b> in the CRPC model, indicating a promising therapeutic strategy for clinical CRPC patients.","tokens":[{"text":"Enzalutamide","start":0,"end":12,"id":0,"ws":true},{"text":",","start":13,"end":14,"id":1,"ws":true},{"text":"a","start":15,"end":16,"id":2,"ws":true},{"text":"novel","start":17,"end":22,"id":3,"ws":true},{"text":"androgen","start":23,"end":31,"id":4,"ws":true},{"text":"receptor","start":32,"end":40,"id":5,"ws":true},{"text":"(","start":41,"end":42,"id":6,"ws":true},{"text":"AR","start":43,"end":45,"id":7,"ws":true},{"text":")","start":46,"end":47,"id":8,"ws":true},{"text":"antagonist","start":48,"end":58,"id":9,"ws":true},{"text":",","start":59,"end":60,"id":10,"ws":true},{"text":"prolongs","start":61,"end":69,"id":11,"ws":true},{"text":"overall","start":70,"end":77,"id":12,"ws":true},{"text":"survival","start":78,"end":86,"id":13,"ws":true},{"text":"of","start":87,"end":89,"id":14,"ws":true},{"text":"patients","start":90,"end":98,"id":15,"ws":true},{"text":"with","start":99,"end":103,"id":16,"ws":true},{"text":"castration-resistant","start":104,"end":124,"id":17,"ws":true},{"text":"prostate","start":125,"end":133,"id":18,"ws":true},{"text":"cancer","start":134,"end":140,"id":19,"ws":true},{"text":"(","start":141,"end":142,"id":20,"ws":true},{"text":"CRPC","start":143,"end":147,"id":21,"ws":true},{"text":")","start":148,"end":149,"id":22,"ws":true},{"text":";","start":150,"end":151,"id":23,"ws":true},{"text":"however","start":152,"end":159,"id":24,"ws":true},{"text":",","start":160,"end":161,"id":25,"ws":true},{"text":"patients","start":162,"end":170,"id":26,"ws":true},{"text":"eventually","start":171,"end":181,"id":27,"ws":true},{"text":"progress","start":182,"end":190,"id":28,"ws":true},{"text":"with","start":191,"end":195,"id":29,"ws":true},{"text":"enzalutamide","start":196,"end":208,"id":30,"ws":true},{"text":"resistance","start":209,"end":219,"id":31,"ws":true},{"text":".","start":220,"end":221,"id":32,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":196,"end":208,"token_start":30,"token_end":30,"label":"DRUG"}],"_input_hash":9522732,"_task_hash":829610189,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"MTT assay was employed to examine the proliferation of five HCC cell lines treated with various concentrations of crizotinib or ceritinib .","paragraph":"<h3><u>Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.</u></h3>Our study was to examine the roles of <b style='color:Tomato;'><i>crizotinib</i></b> and <b style='color:Tomato;'><i>ceritinib</i></b> in hepatocellular carcinoma (HCC) cells and explore the possible mechanisms. <b style='color:DodgerBlue;'><i>MTT</i></b> <b style='color:DodgerBlue;'><i>assay</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>employed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>examine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>proliferation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lines</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>various</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>crizotinib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ceritinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> HepG2 and HCCLM3 cells were incubated with 2\u2009nmol/l <b style='color:Tomato;'><i>ceritinib</i></b> for 1 week, followed by crystal violet staining and cell counting. Protein amounts of t-ALK, p-ALK, t-AKT, p-AKT, t-ERK, p-ERK, Mcl-1, survivin, and XIAP in HepG2 cells under different culture conditions were evaluated by western blot. HepG2 and HCCLM3 cells were treated with vehicle or <b style='color:Tomato;'><i>ceritinib</i></b> and measured by flow cytometry apoptosis analysis with Annexin-V/propidium iodide staining. MTT assay showed that both <b style='color:Tomato;'><i>crizotinib</i></b> and <b style='color:Tomato;'><i>ceritinib</i></b> suppressed the proliferation of various human HCC cells. Crystal violet staining analysis also indicated that <b style='color:Tomato;'><i>ceritinib</i></b> effectively inhibited human HCC cell proliferation. Western blot analysis indicated that both <b style='color:Tomato;'><i>crizotinib</i></b> and <b style='color:Tomato;'><i>ceritinib</i></b> inhibited ALK, AKT, and ERK phosphorylations. In addition, <b style='color:Tomato;'><i>ceritinib</i></b> reduced antiapoptotic gene expressions in HepG2 cells. Flow cytometry analysis indicated that <b style='color:Tomato;'><i>ceritinib</i></b> induced HepG2 and HCCLM3 cells apoptosis. ALK inhibitor exhibited antitumor effects by inhibiting ALK activation, repressing AKT and ERK pathways, and suppressing antiapoptotic gene expressions, which subsequently promoted apoptosis and suppressed HCC cell proliferations.","tokens":[{"text":"MTT","start":0,"end":3,"id":0,"ws":true},{"text":"assay","start":4,"end":9,"id":1,"ws":true},{"text":"was","start":10,"end":13,"id":2,"ws":true},{"text":"employed","start":14,"end":22,"id":3,"ws":true},{"text":"to","start":23,"end":25,"id":4,"ws":true},{"text":"examine","start":26,"end":33,"id":5,"ws":true},{"text":"the","start":34,"end":37,"id":6,"ws":true},{"text":"proliferation","start":38,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"five","start":55,"end":59,"id":9,"ws":true},{"text":"HCC","start":60,"end":63,"id":10,"ws":true},{"text":"cell","start":64,"end":68,"id":11,"ws":true},{"text":"lines","start":69,"end":74,"id":12,"ws":true},{"text":"treated","start":75,"end":82,"id":13,"ws":true},{"text":"with","start":83,"end":87,"id":14,"ws":true},{"text":"various","start":88,"end":95,"id":15,"ws":true},{"text":"concentrations","start":96,"end":110,"id":16,"ws":true},{"text":"of","start":111,"end":113,"id":17,"ws":true},{"text":"crizotinib","start":114,"end":124,"id":18,"ws":true},{"text":"or","start":125,"end":127,"id":19,"ws":true},{"text":"ceritinib","start":128,"end":137,"id":20,"ws":true},{"text":".","start":138,"end":139,"id":21,"ws":false}],"spans":[{"start":114,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},{"start":128,"end":137,"token_start":20,"token_end":20,"label":"DRUG"}],"_input_hash":-1035158449,"_task_hash":-1656735105,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Fifty-two consecutive patients with advanced NSCLC were treated with carboplatin AUC 6 according to Calvert 's formula on day 1 , combined with vinorelbine , 25 mg/m(2 ) on days 1 and 8 .","paragraph":"<h3><u>Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.</u></h3>Chemotherapy regimens for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) provide typically palliation or limited symptom-free survival. We investigated the efficacy, in terms of response rate and time to progression, of a combination chemotherapy containing <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> as a first-line treatment for inoperable NSCLC. <b style='color:DodgerBlue;'><i>Fifty-two</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>Calvert</i></b> <b style='color:DodgerBlue;'><i>'s</i></b> <b style='color:DodgerBlue;'><i>formula</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therapy was given every 3 weeks. The median age was 66 years (range, 40-80); ECOG performance status was 0 in 20, 1 in 25 and 2 in 7 patients. According to an intent-to-treat analysis, response rate (partial and complete responses) in 52 assessable patients was 18/52 (34.6%; 95% confidence interval, 22-47%). In addition, 16 patients (30.8%) had stable disease and 18/52 (34.6%; 95% CI, 22-47%) progressed while on treatment. Median time to progression and overall survival were 7, 5 and 12.3 months, respectively. Grade 3/4 granulocytopenia was observed in 18/8 patients (34.6/15.4%). Grade 3/4 nadirs generally lasted no more than 7 days, and no neutropenic fever was reported. The treatment was generally very well tolerated: grade 1 or 2 nausea and vomiting was observed in 12 and 4 patients, respectively, and grade 2 neuropathy in 5% of cases. Statistical analysis did not highlight any significant differences in clinical benefit (partial and complete responses and stable disease), time to progression, or grade 3-4 hematologic and non-hematological toxicity according to age (<or=65 vs. >65 years). <b style='color:Tomato;'><i>carboplatin</i></b> AUC 6 and <b style='color:Tomato;'><i>vinorelbine</i></b> was found to be an efficacious regimen as a first-line treatment for inoperable lung cancer patients and was also subjectively very well tolerated in aged patients. The regimen warrants further investigation in the emerging subgroup of aged patients in order to draw firm conclusions.","tokens":[{"text":"Fifty-two","start":0,"end":9,"id":0,"ws":true},{"text":"consecutive","start":10,"end":21,"id":1,"ws":true},{"text":"patients","start":22,"end":30,"id":2,"ws":true},{"text":"with","start":31,"end":35,"id":3,"ws":true},{"text":"advanced","start":36,"end":44,"id":4,"ws":true},{"text":"NSCLC","start":45,"end":50,"id":5,"ws":true},{"text":"were","start":51,"end":55,"id":6,"ws":true},{"text":"treated","start":56,"end":63,"id":7,"ws":true},{"text":"with","start":64,"end":68,"id":8,"ws":true},{"text":"carboplatin","start":69,"end":80,"id":9,"ws":true},{"text":"AUC","start":81,"end":84,"id":10,"ws":true},{"text":"6","start":85,"end":86,"id":11,"ws":true},{"text":"according","start":87,"end":96,"id":12,"ws":true},{"text":"to","start":97,"end":99,"id":13,"ws":true},{"text":"Calvert","start":100,"end":107,"id":14,"ws":true},{"text":"'s","start":108,"end":110,"id":15,"ws":true},{"text":"formula","start":111,"end":118,"id":16,"ws":true},{"text":"on","start":119,"end":121,"id":17,"ws":true},{"text":"day","start":122,"end":125,"id":18,"ws":true},{"text":"1","start":126,"end":127,"id":19,"ws":true},{"text":",","start":128,"end":129,"id":20,"ws":true},{"text":"combined","start":130,"end":138,"id":21,"ws":true},{"text":"with","start":139,"end":143,"id":22,"ws":true},{"text":"vinorelbine","start":144,"end":155,"id":23,"ws":true},{"text":",","start":156,"end":157,"id":24,"ws":true},{"text":"25","start":158,"end":160,"id":25,"ws":true},{"text":"mg/m(2","start":161,"end":167,"id":26,"ws":true},{"text":")","start":168,"end":169,"id":27,"ws":true},{"text":"on","start":170,"end":172,"id":28,"ws":true},{"text":"days","start":173,"end":177,"id":29,"ws":true},{"text":"1","start":178,"end":179,"id":30,"ws":true},{"text":"and","start":180,"end":183,"id":31,"ws":true},{"text":"8","start":184,"end":185,"id":32,"ws":true},{"text":".","start":186,"end":187,"id":33,"ws":false}],"spans":[{"start":69,"end":80,"token_start":9,"token_end":9,"label":"DRUG"},{"start":144,"end":155,"token_start":23,"token_end":23,"label":"DRUG"}],"_input_hash":1382371405,"_task_hash":-307318680,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":23,"child":9,"head_span":{"start":144,"end":155,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":69,"end":80,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"The well-tolerated , oral combination chemotherapy with six cycles of Leukeran plus methotrexate plus fluorouracil ( LMF ) plus repeated BCG skin scarifications was used .","paragraph":"<h3><u>Adjuvant chemoimmunotherapy with LMF plus BCG in node-negative and node-positive breast cancer - intermediate report at 4 years.</u></h3>A randomized surgical adjuvant trial in 242 evaluable patients with T1-3a, N0-1, and M0 breast cancer was initiated 4 years ago. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>well-tolerated</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Leukeran</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LMF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>BCG</i></b> <b style='color:DodgerBlue;'><i>skin</i></b> <b style='color:DodgerBlue;'><i>scarifications</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After 4 years, the following results were seen: (1) significant increase of relapse-free (RFS) and also overall survival (S) in both pre- and postmenopausal node-negative patients versus surgical controls (RFS 91.1 vs. 701%, P = 0.003; S 96 vs. 88%, P = 0.03); (2) no significant increase of RFS or S in pre- and postmenopausal node-positive patients versus surgical controls (RFS 50.1 versus 44%, P = 0.49; S 70 versus 68 %, P = 0.9, respectively); (3) Patients receiving greater than 90% of the planned LMF dose showed significantly better survival after 4 years; and (4) Nonrandomized comparison with concurrent Swiss adjuvant studies with LMF alone indicate no beneficial or harmful effect of BCG skin scarifications in addition to the six-cycle LMF.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"well-tolerated","start":4,"end":18,"id":1,"ws":true},{"text":",","start":19,"end":20,"id":2,"ws":true},{"text":"oral","start":21,"end":25,"id":3,"ws":true},{"text":"combination","start":26,"end":37,"id":4,"ws":true},{"text":"chemotherapy","start":38,"end":50,"id":5,"ws":true},{"text":"with","start":51,"end":55,"id":6,"ws":true},{"text":"six","start":56,"end":59,"id":7,"ws":true},{"text":"cycles","start":60,"end":66,"id":8,"ws":true},{"text":"of","start":67,"end":69,"id":9,"ws":true},{"text":"Leukeran","start":70,"end":78,"id":10,"ws":true},{"text":"plus","start":79,"end":83,"id":11,"ws":true},{"text":"methotrexate","start":84,"end":96,"id":12,"ws":true},{"text":"plus","start":97,"end":101,"id":13,"ws":true},{"text":"fluorouracil","start":102,"end":114,"id":14,"ws":true},{"text":"(","start":115,"end":116,"id":15,"ws":true},{"text":"LMF","start":117,"end":120,"id":16,"ws":true},{"text":")","start":121,"end":122,"id":17,"ws":true},{"text":"plus","start":123,"end":127,"id":18,"ws":true},{"text":"repeated","start":128,"end":136,"id":19,"ws":true},{"text":"BCG","start":137,"end":140,"id":20,"ws":true},{"text":"skin","start":141,"end":145,"id":21,"ws":true},{"text":"scarifications","start":146,"end":160,"id":22,"ws":true},{"text":"was","start":161,"end":164,"id":23,"ws":true},{"text":"used","start":165,"end":169,"id":24,"ws":true},{"text":".","start":170,"end":171,"id":25,"ws":false}],"spans":[{"start":84,"end":96,"token_start":12,"token_end":12,"label":"DRUG"},{"start":102,"end":114,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":-568125822,"_task_hash":-1308779229,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":84,"end":96,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":102,"end":114,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Thirty-five adult recurrent GBM patients , divided randomly in two groups of 19 and 16 cases , had been treated with two regimens of chemotherapy : a ) ' eight-drugs-in-one-day ' ; b ) procarbazine + CCNU + vincristine ( PCV ) respectively .","paragraph":"<h3><u>Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients.</u></h3> <b style='color:DodgerBlue;'><i>Thirty-five</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>GBM</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>divided</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>16</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>eight-drugs-in-one-day</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>b</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>procarbazine</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>CCNU</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Chemotherapy was planned at the tumour relapse and delivered as long as tolerated without irreversible sequelae or until the CT scan showed tumor progression. Multiple agents are used simultaneously in the therapeutic approach using 'eight-in-one' to kill as many heterogeneous cells of malignant glial tumor as possible and minimize the emergence of cellular resistance to chemotherapy. Rate response to chemotherapy and the median adjunctive survival time (6.5 and 6 months, respectively) are not significantly different in the two arms of this study. Our experience with such an aggressive multi-drugs combination 'eight-in-one-day' was disappointing if compared with less toxic, better tolerated and easy delivered (PCV) regimen.","tokens":[{"text":"Thirty-five","start":0,"end":11,"id":0,"ws":true},{"text":"adult","start":12,"end":17,"id":1,"ws":true},{"text":"recurrent","start":18,"end":27,"id":2,"ws":true},{"text":"GBM","start":28,"end":31,"id":3,"ws":true},{"text":"patients","start":32,"end":40,"id":4,"ws":true},{"text":",","start":41,"end":42,"id":5,"ws":true},{"text":"divided","start":43,"end":50,"id":6,"ws":true},{"text":"randomly","start":51,"end":59,"id":7,"ws":true},{"text":"in","start":60,"end":62,"id":8,"ws":true},{"text":"two","start":63,"end":66,"id":9,"ws":true},{"text":"groups","start":67,"end":73,"id":10,"ws":true},{"text":"of","start":74,"end":76,"id":11,"ws":true},{"text":"19","start":77,"end":79,"id":12,"ws":true},{"text":"and","start":80,"end":83,"id":13,"ws":true},{"text":"16","start":84,"end":86,"id":14,"ws":true},{"text":"cases","start":87,"end":92,"id":15,"ws":true},{"text":",","start":93,"end":94,"id":16,"ws":true},{"text":"had","start":95,"end":98,"id":17,"ws":true},{"text":"been","start":99,"end":103,"id":18,"ws":true},{"text":"treated","start":104,"end":111,"id":19,"ws":true},{"text":"with","start":112,"end":116,"id":20,"ws":true},{"text":"two","start":117,"end":120,"id":21,"ws":true},{"text":"regimens","start":121,"end":129,"id":22,"ws":true},{"text":"of","start":130,"end":132,"id":23,"ws":true},{"text":"chemotherapy","start":133,"end":145,"id":24,"ws":true},{"text":":","start":146,"end":147,"id":25,"ws":true},{"text":"a","start":148,"end":149,"id":26,"ws":true},{"text":")","start":150,"end":151,"id":27,"ws":true},{"text":"'","start":152,"end":153,"id":28,"ws":true},{"text":"eight-drugs-in-one-day","start":154,"end":176,"id":29,"ws":true},{"text":"'","start":177,"end":178,"id":30,"ws":true},{"text":";","start":179,"end":180,"id":31,"ws":true},{"text":"b","start":181,"end":182,"id":32,"ws":true},{"text":")","start":183,"end":184,"id":33,"ws":true},{"text":"procarbazine","start":185,"end":197,"id":34,"ws":true},{"text":"+","start":198,"end":199,"id":35,"ws":true},{"text":"CCNU","start":200,"end":204,"id":36,"ws":true},{"text":"+","start":205,"end":206,"id":37,"ws":true},{"text":"vincristine","start":207,"end":218,"id":38,"ws":true},{"text":"(","start":219,"end":220,"id":39,"ws":true},{"text":"PCV","start":221,"end":224,"id":40,"ws":true},{"text":")","start":225,"end":226,"id":41,"ws":true},{"text":"respectively","start":227,"end":239,"id":42,"ws":true},{"text":".","start":240,"end":241,"id":43,"ws":false}],"spans":[{"start":185,"end":197,"token_start":34,"token_end":34,"label":"DRUG"},{"start":207,"end":218,"token_start":38,"token_end":38,"label":"DRUG"}],"_input_hash":1059034665,"_task_hash":-1901402949,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":34,"child":36,"head_span":{"start":185,"end":197,"token_start":34,"token_end":34,"label":"DRUG"},"child_span":{"start":200,"end":204,"token_start":36,"token_end":36,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":38,"child":36,"head_span":{"start":207,"end":218,"token_start":38,"token_end":38,"label":"DRUG"},"child_span":{"start":200,"end":204,"token_start":36,"token_end":36,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"The opposite directional EPM responses to agonists ( adrenaline , isoprenaline ) and antagonist ( propranolol ) of beta-adrenoreceptors was shown .","paragraph":"<h3><u>[Effect of ultra-low dose of ionizing radiation on the surface potential of erythrocytes].</u></h3>Effect of ionizing radiation in ultralow dose (5 microGy) on responses of erythrocyte electrophoretic motility (EPM) as a result of adrenoreceptor ligands binding (0.01-100 microM) has been investigated. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>opposite</i></b> <b style='color:DodgerBlue;'><i>directional</i></b> <b style='color:DodgerBlue;'><i>EPM</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>agonists</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>adrenaline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>isoprenaline</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>beta-adrenoreceptors</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>.</i></b> At that, EPM response to the radiation coincides both with the direction and value of acting the beta-adrenoreceptor agonists depressing EPM. The EPM response to a combined action of beta-adrenoreceptors antagonist, <b style='color:Tomato;'><i>propranolol</i></b> (10 microM), and ionizing radiation is additive. The above listed is capable to evidence about the essential role of adrenoreceptors at formation of erythrocyte membrane surface charge under action of ionizing radiation in ultralow doses.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"opposite","start":4,"end":12,"id":1,"ws":true},{"text":"directional","start":13,"end":24,"id":2,"ws":true},{"text":"EPM","start":25,"end":28,"id":3,"ws":true},{"text":"responses","start":29,"end":38,"id":4,"ws":true},{"text":"to","start":39,"end":41,"id":5,"ws":true},{"text":"agonists","start":42,"end":50,"id":6,"ws":true},{"text":"(","start":51,"end":52,"id":7,"ws":true},{"text":"adrenaline","start":53,"end":63,"id":8,"ws":true},{"text":",","start":64,"end":65,"id":9,"ws":true},{"text":"isoprenaline","start":66,"end":78,"id":10,"ws":true},{"text":")","start":79,"end":80,"id":11,"ws":true},{"text":"and","start":81,"end":84,"id":12,"ws":true},{"text":"antagonist","start":85,"end":95,"id":13,"ws":true},{"text":"(","start":96,"end":97,"id":14,"ws":true},{"text":"propranolol","start":98,"end":109,"id":15,"ws":true},{"text":")","start":110,"end":111,"id":16,"ws":true},{"text":"of","start":112,"end":114,"id":17,"ws":true},{"text":"beta-adrenoreceptors","start":115,"end":135,"id":18,"ws":true},{"text":"was","start":136,"end":139,"id":19,"ws":true},{"text":"shown","start":140,"end":145,"id":20,"ws":true},{"text":".","start":146,"end":147,"id":21,"ws":false}],"spans":[{"start":66,"end":78,"token_start":10,"token_end":10,"label":"DRUG"},{"start":98,"end":109,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":72349615,"_task_hash":-1409854081,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":53,"end":63,"token_start":8,"token_end":8,"label":null},"child_span":{"start":66,"end":78,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":18,"head_span":{"start":98,"end":109,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":115,"end":135,"token_start":18,"token_end":18,"label":null},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"In humans with glucagonoma-associated NME , skin lesions usually respond to octreotide , a somatostatin analogue that inhibits glucagon release .","paragraph":"<h3><u>Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.</u></h3>Necrolytic migratory erythema (NME; also known as superficial necrolytic dermatitis) is a syndrome most often associated with certain chronic liver diseases or pancreatic glucagonomas. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>humans</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>glucagonoma-associated</i></b> <b style='color:DodgerBlue;'><i>NME</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>skin</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>usually</i></b> <b style='color:DodgerBlue;'><i>respond</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>analogue</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibits</i></b> <b style='color:DodgerBlue;'><i>glucagon</i></b> <b style='color:DodgerBlue;'><i>release</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this report an 11-year-old golden retriever dog with pancreatic glucagonoma and metastasis to the regional lymph nodes, spleen and liver was diagnosed with NME. The dog exhibited erosions, ulcers and crusts on the paws, pressure points, muzzle, periocular area and prepuce. The dog was also anorexic and had difficulty walking. Because metastasis precluded surgery, treatment was initiated with subcutaneous <b style='color:Tomato;'><i>octreotide</i></b> (2 \u03bcg/kg twice daily). Skin lesions and systemic clinical signs improved markedly within 5 days. The dosage was increased to nearly 3 \u03bcg/kg twice daily and signs almost completely resolved within 10 days. Anorexia was the major adverse effect observed. During the following month, both dosage (1-3.7 \u03bcg/kg) and frequency (two to four times daily) of the <b style='color:Tomato;'><i>octreotide</i></b> injections were adjusted to permit control of clinical signs while maintaining adequate appetite. Temporary cessation of <b style='color:Tomato;'><i>octreotide</i></b> administration resulted in the rapid recurrence of skin lesions. Resuming injections led to improvement of clinical signs within 48 h. The dog was later euthanized because of progressive metastatic disease. In conclusion, subcutaneous <b style='color:Tomato;'><i>octreotide</i></b> injections were beneficial in this dog with glucagonoma-associated NME. This <b style='color:Tomato;'><i>somatostatin</i></b> analogue could be a valuable option to treat canine patients with non-resectable or relapsing pancreatic glucagonoma-associated NME.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"humans","start":3,"end":9,"id":1,"ws":true},{"text":"with","start":10,"end":14,"id":2,"ws":true},{"text":"glucagonoma-associated","start":15,"end":37,"id":3,"ws":true},{"text":"NME","start":38,"end":41,"id":4,"ws":true},{"text":",","start":42,"end":43,"id":5,"ws":true},{"text":"skin","start":44,"end":48,"id":6,"ws":true},{"text":"lesions","start":49,"end":56,"id":7,"ws":true},{"text":"usually","start":57,"end":64,"id":8,"ws":true},{"text":"respond","start":65,"end":72,"id":9,"ws":true},{"text":"to","start":73,"end":75,"id":10,"ws":true},{"text":"octreotide","start":76,"end":86,"id":11,"ws":true},{"text":",","start":87,"end":88,"id":12,"ws":true},{"text":"a","start":89,"end":90,"id":13,"ws":true},{"text":"somatostatin","start":91,"end":103,"id":14,"ws":true},{"text":"analogue","start":104,"end":112,"id":15,"ws":true},{"text":"that","start":113,"end":117,"id":16,"ws":true},{"text":"inhibits","start":118,"end":126,"id":17,"ws":true},{"text":"glucagon","start":127,"end":135,"id":18,"ws":true},{"text":"release","start":136,"end":143,"id":19,"ws":true},{"text":".","start":144,"end":145,"id":20,"ws":false}],"spans":[{"start":76,"end":86,"token_start":11,"token_end":11,"label":"DRUG"},{"start":91,"end":103,"token_start":14,"token_end":14,"label":"DRUG"}],"_input_hash":250626995,"_task_hash":-1258400696,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A total of 32 H. pylori clones isolated from a biopsy sample coming from a patient with gastric cancer previously treated for H. pylori infection , were analyzed for : the genetic variability by amplified fragment polymorphism analysis ; the vacA , cagA virulence status by PCR ; the antimicrobial susceptibility by minimum inhibitory concentrations with the agar dilution method towards amoxicillin , clarithromycin , levofloxacin and tinidazole .","paragraph":"<h3><u>A model of Helicobacter pylori persistence in a case of gastric cancer.</u></h3>The aim of this work was to analyze several clones of Helicobacter pylori isolated from a patient with gastric cancer, to evaluate i) genetic variability ii) virulence factors profile and iii) antimicrobial susceptibility against the drugs commonly used in the H. pylori therapy. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>32</i></b> <b style='color:DodgerBlue;'><i>H.</i></b> <b style='color:DodgerBlue;'><i>pylori</i></b> <b style='color:DodgerBlue;'><i>clones</i></b> <b style='color:DodgerBlue;'><i>isolated</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>biopsy</i></b> <b style='color:DodgerBlue;'><i>sample</i></b> <b style='color:DodgerBlue;'><i>coming</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>H.</i></b> <b style='color:DodgerBlue;'><i>pylori</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>analyzed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>genetic</i></b> <b style='color:DodgerBlue;'><i>variability</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>amplified</i></b> <b style='color:DodgerBlue;'><i>fragment</i></b> <b style='color:DodgerBlue;'><i>polymorphism</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>vacA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cagA</i></b> <b style='color:DodgerBlue;'><i>virulence</i></b> <b style='color:DodgerBlue;'><i>status</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>PCR</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antimicrobial</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>minimum</i></b> <b style='color:DodgerBlue;'><i>inhibitory</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>agar</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>method</i></b> <b style='color:DodgerBlue;'><i>towards</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tinidazole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The patient showed a mixed infection with the presence of at least 3 different strains. The clones isolated possessed the vacA, cagA virulence factors with a different allelic combination (vacA s1/i1/m1; s1/i1i2/m1; s2/i2/m2; s2/i1i2/m2) together with repeated cagA EPIYA motif pattern P1P2P3P3P3. Moreover, a pattern of multi-drug resistance was disclosed in the different clones. The presence of multiple H. pylori strains colonizing the same patient, with the main virulence factors displaying a different allelic combination and a different multi-drug resistance among isolates, point out the role of genetic variability generating, in time, more virulent and adapted strains.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"total","start":2,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"32","start":11,"end":13,"id":3,"ws":true},{"text":"H.","start":14,"end":16,"id":4,"ws":true},{"text":"pylori","start":17,"end":23,"id":5,"ws":true},{"text":"clones","start":24,"end":30,"id":6,"ws":true},{"text":"isolated","start":31,"end":39,"id":7,"ws":true},{"text":"from","start":40,"end":44,"id":8,"ws":true},{"text":"a","start":45,"end":46,"id":9,"ws":true},{"text":"biopsy","start":47,"end":53,"id":10,"ws":true},{"text":"sample","start":54,"end":60,"id":11,"ws":true},{"text":"coming","start":61,"end":67,"id":12,"ws":true},{"text":"from","start":68,"end":72,"id":13,"ws":true},{"text":"a","start":73,"end":74,"id":14,"ws":true},{"text":"patient","start":75,"end":82,"id":15,"ws":true},{"text":"with","start":83,"end":87,"id":16,"ws":true},{"text":"gastric","start":88,"end":95,"id":17,"ws":true},{"text":"cancer","start":96,"end":102,"id":18,"ws":true},{"text":"previously","start":103,"end":113,"id":19,"ws":true},{"text":"treated","start":114,"end":121,"id":20,"ws":true},{"text":"for","start":122,"end":125,"id":21,"ws":true},{"text":"H.","start":126,"end":128,"id":22,"ws":true},{"text":"pylori","start":129,"end":135,"id":23,"ws":true},{"text":"infection","start":136,"end":145,"id":24,"ws":true},{"text":",","start":146,"end":147,"id":25,"ws":true},{"text":"were","start":148,"end":152,"id":26,"ws":true},{"text":"analyzed","start":153,"end":161,"id":27,"ws":true},{"text":"for","start":162,"end":165,"id":28,"ws":true},{"text":":","start":166,"end":167,"id":29,"ws":true},{"text":"the","start":168,"end":171,"id":30,"ws":true},{"text":"genetic","start":172,"end":179,"id":31,"ws":true},{"text":"variability","start":180,"end":191,"id":32,"ws":true},{"text":"by","start":192,"end":194,"id":33,"ws":true},{"text":"amplified","start":195,"end":204,"id":34,"ws":true},{"text":"fragment","start":205,"end":213,"id":35,"ws":true},{"text":"polymorphism","start":214,"end":226,"id":36,"ws":true},{"text":"analysis","start":227,"end":235,"id":37,"ws":true},{"text":";","start":236,"end":237,"id":38,"ws":true},{"text":"the","start":238,"end":241,"id":39,"ws":true},{"text":"vacA","start":242,"end":246,"id":40,"ws":true},{"text":",","start":247,"end":248,"id":41,"ws":true},{"text":"cagA","start":249,"end":253,"id":42,"ws":true},{"text":"virulence","start":254,"end":263,"id":43,"ws":true},{"text":"status","start":264,"end":270,"id":44,"ws":true},{"text":"by","start":271,"end":273,"id":45,"ws":true},{"text":"PCR","start":274,"end":277,"id":46,"ws":true},{"text":";","start":278,"end":279,"id":47,"ws":true},{"text":"the","start":280,"end":283,"id":48,"ws":true},{"text":"antimicrobial","start":284,"end":297,"id":49,"ws":true},{"text":"susceptibility","start":298,"end":312,"id":50,"ws":true},{"text":"by","start":313,"end":315,"id":51,"ws":true},{"text":"minimum","start":316,"end":323,"id":52,"ws":true},{"text":"inhibitory","start":324,"end":334,"id":53,"ws":true},{"text":"concentrations","start":335,"end":349,"id":54,"ws":true},{"text":"with","start":350,"end":354,"id":55,"ws":true},{"text":"the","start":355,"end":358,"id":56,"ws":true},{"text":"agar","start":359,"end":363,"id":57,"ws":true},{"text":"dilution","start":364,"end":372,"id":58,"ws":true},{"text":"method","start":373,"end":379,"id":59,"ws":true},{"text":"towards","start":380,"end":387,"id":60,"ws":true},{"text":"amoxicillin","start":388,"end":399,"id":61,"ws":true},{"text":",","start":400,"end":401,"id":62,"ws":true},{"text":"clarithromycin","start":402,"end":416,"id":63,"ws":true},{"text":",","start":417,"end":418,"id":64,"ws":true},{"text":"levofloxacin","start":419,"end":431,"id":65,"ws":true},{"text":"and","start":432,"end":435,"id":66,"ws":true},{"text":"tinidazole","start":436,"end":446,"id":67,"ws":true},{"text":".","start":447,"end":448,"id":68,"ws":false}],"spans":[{"start":388,"end":399,"token_start":61,"token_end":61,"label":"DRUG"},{"start":402,"end":416,"token_start":63,"token_end":63,"label":"DRUG"},{"start":419,"end":431,"token_start":65,"token_end":65,"label":"DRUG"},{"start":436,"end":446,"token_start":67,"token_end":67,"label":"DRUG"}],"_input_hash":-1202125667,"_task_hash":372294735,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Gemcitabine IC50 value for both of these cell line is 0.03 microg/ml ; however , 30 - 48 % of the pancreatic cancer cells are resistant to gemcitabine even at concentrations > 100 microg/ml .","paragraph":"<h3><u>Potentiation of gemcitabine by Turmeric Force in pancreatic cancer cell lines.</u></h3><b style='color:Tomato;'><i>gemcitabine</i></b> is a first line cancer drug widely used for the treatment of pancreatic cancer. However, its therapeutic efficiency is significantly limited by resistance of pancreatic cancer cells to this and other chemotherapeutic drugs. We have investigated the cytotoxic effect of Turmeric Force (TF), a supercritical and hydroethanolic extract of turmeric, alone and in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> in two pancreatic carcinoma cell lines (BxPC3 and Panc-1). TF is highly cytotoxic to BxPC3 and Panc-1 cell lines with IC50 values of 1.0 and 1.22 microg/ml, respectively with superior cytotoxicity than <b style='color:Tomato;'><i>curcumin</i></b>. <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>IC50</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>0.03</i></b> <b style='color:DodgerBlue;'><i>microg/ml</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>however</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>48</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>microg/ml</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In comparison, TF induced cell death in 96% of the cells at 50 microg/ml. The combination of <b style='color:Tomato;'><i>gemcitabine</i></b> and TF was synergistic with IC90 levels achieved in both pancreatic cancer cell lines at lower concentrations. CalcuSyn analysis of cytotoxicity data showed that the <b style='color:Tomato;'><i>gemcitabine</i></b> + Turmeric Force combination has strong synergism with combination index (CI) values of 0.050 and 0.183 in BxPC3 and Panc-1 lines, respectively at IC50 level. This synergistic effect is due to the increased inhibitory effect of the combination on nuclear factor-kappaB activity and signal transducer and activator of transcription factor 3 expression as compared to the single agent.","tokens":[{"text":"Gemcitabine","start":0,"end":11,"id":0,"ws":true},{"text":"IC50","start":12,"end":16,"id":1,"ws":true},{"text":"value","start":17,"end":22,"id":2,"ws":true},{"text":"for","start":23,"end":26,"id":3,"ws":true},{"text":"both","start":27,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"these","start":35,"end":40,"id":6,"ws":true},{"text":"cell","start":41,"end":45,"id":7,"ws":true},{"text":"line","start":46,"end":50,"id":8,"ws":true},{"text":"is","start":51,"end":53,"id":9,"ws":true},{"text":"0.03","start":54,"end":58,"id":10,"ws":true},{"text":"microg/ml","start":59,"end":68,"id":11,"ws":true},{"text":";","start":69,"end":70,"id":12,"ws":true},{"text":"however","start":71,"end":78,"id":13,"ws":true},{"text":",","start":79,"end":80,"id":14,"ws":true},{"text":"30","start":81,"end":83,"id":15,"ws":true},{"text":"-","start":84,"end":85,"id":16,"ws":true},{"text":"48","start":86,"end":88,"id":17,"ws":true},{"text":"%","start":89,"end":90,"id":18,"ws":true},{"text":"of","start":91,"end":93,"id":19,"ws":true},{"text":"the","start":94,"end":97,"id":20,"ws":true},{"text":"pancreatic","start":98,"end":108,"id":21,"ws":true},{"text":"cancer","start":109,"end":115,"id":22,"ws":true},{"text":"cells","start":116,"end":121,"id":23,"ws":true},{"text":"are","start":122,"end":125,"id":24,"ws":true},{"text":"resistant","start":126,"end":135,"id":25,"ws":true},{"text":"to","start":136,"end":138,"id":26,"ws":true},{"text":"gemcitabine","start":139,"end":150,"id":27,"ws":true},{"text":"even","start":151,"end":155,"id":28,"ws":true},{"text":"at","start":156,"end":158,"id":29,"ws":true},{"text":"concentrations","start":159,"end":173,"id":30,"ws":true},{"text":">","start":174,"end":175,"id":31,"ws":true},{"text":"100","start":176,"end":179,"id":32,"ws":true},{"text":"microg/ml","start":180,"end":189,"id":33,"ws":true},{"text":".","start":190,"end":191,"id":34,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":139,"end":150,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":-839784509,"_task_hash":-326911417,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"After day 6 , the combined cyclosporine and dexamethasone treatment group became extremely catabolic and experienced a sharp decline in liver DNA .","paragraph":"<h3><u>Liver regeneration during immunosuppression.</u></h3>As a preface to studies on the feasibility of liver segment transplantation, we studied the course of liver regeneration in immunosuppressed rats. Partial hepatectomies were performed in young adult male rats who were then treated with daily <b style='color:Tomato;'><i>cyclosporin</i></b>e, <b style='color:Tomato;'><i>dexamethasone</i></b>, the combination of both agents, or vehicle. Body weight, liver weight, and liver DNA content were measured in subgroups of rats studied at various times after partial hepatectomy. All treated animals experienced weight loss, a phenomenon most marked in animals treated with both <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>cyclosporin</i></b>e. The DNA content of regenerating liver increased initially after partial hepatectomy in all animals. Restoring their original hepatic DNA in a fashion indistinguishable from controls, animals treated with <b style='color:Tomato;'><i>cyclosporin</i></b>e increased liver DNA four fold within the first six days after partial hepatectomy. Animals treated with <b style='color:Tomato;'><i>dexamethasone</i></b> and both <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>cyclosporin</i></b>e increased their complement of liver DNA 2.5 fold, to 80% of that originally present. <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>became</i></b> <b style='color:DodgerBlue;'><i>extremely</i></b> <b style='color:DodgerBlue;'><i>catabolic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>experienced</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sharp</i></b> <b style='color:DodgerBlue;'><i>decline</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>liver</i></b> <b style='color:DodgerBlue;'><i>DNA</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that despite the deleterious effects of <b style='color:Tomato;'><i>cyclosporin</i></b>e and <b style='color:Tomato;'><i>dexamethasone</i></b>, especially in combination, on weight gain following partial hepatectomy, these agents do not prevent DNA synthesis and the accretion of new liver mass. We are encouraged by these studies to proceed with experimental studies on the normal growth and repair of liver segments transplanted into an immunosuppressed host.","tokens":[{"text":"After","start":0,"end":5,"id":0,"ws":true},{"text":"day","start":6,"end":9,"id":1,"ws":true},{"text":"6","start":10,"end":11,"id":2,"ws":true},{"text":",","start":12,"end":13,"id":3,"ws":true},{"text":"the","start":14,"end":17,"id":4,"ws":true},{"text":"combined","start":18,"end":26,"id":5,"ws":true},{"text":"cyclosporine","start":27,"end":39,"id":6,"ws":true},{"text":"and","start":40,"end":43,"id":7,"ws":true},{"text":"dexamethasone","start":44,"end":57,"id":8,"ws":true},{"text":"treatment","start":58,"end":67,"id":9,"ws":true},{"text":"group","start":68,"end":73,"id":10,"ws":true},{"text":"became","start":74,"end":80,"id":11,"ws":true},{"text":"extremely","start":81,"end":90,"id":12,"ws":true},{"text":"catabolic","start":91,"end":100,"id":13,"ws":true},{"text":"and","start":101,"end":104,"id":14,"ws":true},{"text":"experienced","start":105,"end":116,"id":15,"ws":true},{"text":"a","start":117,"end":118,"id":16,"ws":true},{"text":"sharp","start":119,"end":124,"id":17,"ws":true},{"text":"decline","start":125,"end":132,"id":18,"ws":true},{"text":"in","start":133,"end":135,"id":19,"ws":true},{"text":"liver","start":136,"end":141,"id":20,"ws":true},{"text":"DNA","start":142,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":27,"end":39,"token_start":6,"token_end":6,"label":"DRUG"},{"start":44,"end":57,"token_start":8,"token_end":8,"label":"DRUG"}],"_input_hash":1418695473,"_task_hash":-1499812915,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":27,"end":39,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":44,"end":57,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Resting acetylcholine output is increased when the bathing medium is changed in the following ways:(a ) sodium replacement by sucrose , trometamol or lithium;(b ) addition of ouabain or p-hydroxymercuribenzoate ( PHMB ) , or withdrawal of potassium;(c ) the combination of PHMB and partial sodium replacement;(d ) addition of potassium ; this increase in output becomes greater in the absence of sodium.3 .","paragraph":"<h3><u>The mechanism of acetylcholine release from parasympathetic nerves.</u></h3>1. The output of acetylcholine from the plexus of the guinea-pig ileum longitudinal strip has been used to study the mechanism of acetylcholine release. From the effects of hexamethonium and tetrodotoxin, it was inferred that 60% of the normal resting output is due to propagated activity in the plexus, and 40% to spontaneous release. Tetrodotoxin virtually abolishes the increase in output in response to electrical stimulation.2. <b style='color:DodgerBlue;'><i>Resting</i></b> <b style='color:DodgerBlue;'><i>acetylcholine</i></b> <b style='color:DodgerBlue;'><i>output</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bathing</i></b> <b style='color:DodgerBlue;'><i>medium</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>changed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>ways:(a</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>replacement</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>sucrose</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>trometamol</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>lithium;(b</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ouabain</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>p-hydroxymercuribenzoate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PHMB</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>withdrawal</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>potassium;(c</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PHMB</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>partial</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>replacement;(d</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>potassium</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>output</i></b> <b style='color:DodgerBlue;'><i>becomes</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>sodium.3</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The resting output is virtually abolished by calcium withdrawal, and is restored by barium substitution for calcium. It is also reduced by raising the magnesium concentration.4. The enhanced resting output in response to sodium withdrawal also occurs in the absence of calcium.5. Cooling to 5 degrees C greatly reduces both the resting output and the output in response to raised potassium concentration or to electrical stimulation.6. The increase in resting output due to potassium excess is slight up to 25 mM [K(+)](o), but increases thereafter with about the fourth power of the potassium concentration; it is resistant to tetrodotoxin.7. Synthesis of acetylcholine by the longitudinal strip is increased when output is enhanced by electrical stimulation, by potassium excess or by addition of barium, so that the acetylcholine content of the strip is maintained approximately normal. Synthesis is reduced, in relation to output, by potassium lack or by treatment with <b style='color:Tomato;'><i>ouabain</i></b>, and is virtually abolished by sodium withdrawal.8. The theory is discussed that acetylcholine release depends on inhibition of the activity of a (Na(+) + K(+) + Mg(2+))-activated ATPase at the axonal membrane.","tokens":[{"text":"Resting","start":0,"end":7,"id":0,"ws":true},{"text":"acetylcholine","start":8,"end":21,"id":1,"ws":true},{"text":"output","start":22,"end":28,"id":2,"ws":true},{"text":"is","start":29,"end":31,"id":3,"ws":true},{"text":"increased","start":32,"end":41,"id":4,"ws":true},{"text":"when","start":42,"end":46,"id":5,"ws":true},{"text":"the","start":47,"end":50,"id":6,"ws":true},{"text":"bathing","start":51,"end":58,"id":7,"ws":true},{"text":"medium","start":59,"end":65,"id":8,"ws":true},{"text":"is","start":66,"end":68,"id":9,"ws":true},{"text":"changed","start":69,"end":76,"id":10,"ws":true},{"text":"in","start":77,"end":79,"id":11,"ws":true},{"text":"the","start":80,"end":83,"id":12,"ws":true},{"text":"following","start":84,"end":93,"id":13,"ws":true},{"text":"ways:(a","start":94,"end":101,"id":14,"ws":true},{"text":")","start":102,"end":103,"id":15,"ws":true},{"text":"sodium","start":104,"end":110,"id":16,"ws":true},{"text":"replacement","start":111,"end":122,"id":17,"ws":true},{"text":"by","start":123,"end":125,"id":18,"ws":true},{"text":"sucrose","start":126,"end":133,"id":19,"ws":true},{"text":",","start":134,"end":135,"id":20,"ws":true},{"text":"trometamol","start":136,"end":146,"id":21,"ws":true},{"text":"or","start":147,"end":149,"id":22,"ws":true},{"text":"lithium;(b","start":150,"end":160,"id":23,"ws":true},{"text":")","start":161,"end":162,"id":24,"ws":true},{"text":"addition","start":163,"end":171,"id":25,"ws":true},{"text":"of","start":172,"end":174,"id":26,"ws":true},{"text":"ouabain","start":175,"end":182,"id":27,"ws":true},{"text":"or","start":183,"end":185,"id":28,"ws":true},{"text":"p-hydroxymercuribenzoate","start":186,"end":210,"id":29,"ws":true},{"text":"(","start":211,"end":212,"id":30,"ws":true},{"text":"PHMB","start":213,"end":217,"id":31,"ws":true},{"text":")","start":218,"end":219,"id":32,"ws":true},{"text":",","start":220,"end":221,"id":33,"ws":true},{"text":"or","start":222,"end":224,"id":34,"ws":true},{"text":"withdrawal","start":225,"end":235,"id":35,"ws":true},{"text":"of","start":236,"end":238,"id":36,"ws":true},{"text":"potassium;(c","start":239,"end":251,"id":37,"ws":true},{"text":")","start":252,"end":253,"id":38,"ws":true},{"text":"the","start":254,"end":257,"id":39,"ws":true},{"text":"combination","start":258,"end":269,"id":40,"ws":true},{"text":"of","start":270,"end":272,"id":41,"ws":true},{"text":"PHMB","start":273,"end":277,"id":42,"ws":true},{"text":"and","start":278,"end":281,"id":43,"ws":true},{"text":"partial","start":282,"end":289,"id":44,"ws":true},{"text":"sodium","start":290,"end":296,"id":45,"ws":true},{"text":"replacement;(d","start":297,"end":311,"id":46,"ws":true},{"text":")","start":312,"end":313,"id":47,"ws":true},{"text":"addition","start":314,"end":322,"id":48,"ws":true},{"text":"of","start":323,"end":325,"id":49,"ws":true},{"text":"potassium","start":326,"end":335,"id":50,"ws":true},{"text":";","start":336,"end":337,"id":51,"ws":true},{"text":"this","start":338,"end":342,"id":52,"ws":true},{"text":"increase","start":343,"end":351,"id":53,"ws":true},{"text":"in","start":352,"end":354,"id":54,"ws":true},{"text":"output","start":355,"end":361,"id":55,"ws":true},{"text":"becomes","start":362,"end":369,"id":56,"ws":true},{"text":"greater","start":370,"end":377,"id":57,"ws":true},{"text":"in","start":378,"end":380,"id":58,"ws":true},{"text":"the","start":381,"end":384,"id":59,"ws":true},{"text":"absence","start":385,"end":392,"id":60,"ws":true},{"text":"of","start":393,"end":395,"id":61,"ws":true},{"text":"sodium.3","start":396,"end":404,"id":62,"ws":true},{"text":".","start":405,"end":406,"id":63,"ws":false}],"spans":[{"start":136,"end":146,"token_start":21,"token_end":21,"label":"DRUG"},{"start":175,"end":182,"token_start":27,"token_end":27,"label":"DRUG"}],"_input_hash":-1700702606,"_task_hash":1583915252,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Carbachol stimulation of SH-SY5Y cells dose-dependently stimulated the activation of the transcription factors NFkappaB and AP-1 as revealed by electrophoretic mobility shift assay ( EMSA ) , while pre-exposure of SH-SY5Y cells for 24 h with 1 ng/ml IL-1beta completely suppressed the carbachol response .","paragraph":"<h3><u>Interaction of interleukin-1beta with muscarinic acetylcholine receptor-mediated signaling cascade in cholinergically differentiated SH-SY5Y cells.</u></h3>Increased expression of interleukin (IL)-1beta has been found in Alzheimer brain, raising the question whether plaque-associated up-regulation of IL-1beta may contribute to neurodegeneration. IL-1beta is capable to induce a number of events that also occur in Alzheimer's disease such as stimulation of the amyloidogenic pathway of amyloid precursor protein processing. However, less is known on participation of IL-1beta in specific cholinergic cell loss. To reveal whether IL-1beta affects muscarinic acetylcholine receptor (mAChR)-mediated intracellular signaling, cholinergically differentiated SH-SY5Y cells were exposed to IL-1beta for various periods of time followed by stimulation of mAChR with <b style='color:Tomato;'><i>carbachol</i></b> for 1 h, and key molecules of cholinergic signaling cascades were determined including phosphoinositide hydrolysis, DNA-binding capacity of NFkappaB and AP-1, and activity of acetylcholinesterase (AChE). <b style='color:MediumOrchid;'><i>Carbachol</i></b> <b style='color:DodgerBlue;'><i>stimulation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>SH-SY5Y</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>dose-dependently</i></b> <b style='color:DodgerBlue;'><i>stimulated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>activation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>transcription</i></b> <b style='color:DodgerBlue;'><i>factors</i></b> <b style='color:DodgerBlue;'><i>NFkappaB</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>AP-1</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>revealed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>electrophoretic</i></b> <b style='color:DodgerBlue;'><i>mobility</i></b> <b style='color:DodgerBlue;'><i>shift</i></b> <b style='color:DodgerBlue;'><i>assay</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EMSA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>pre-exposure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>SH-SY5Y</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>ng/ml</i></b> <b style='color:DodgerBlue;'><i>IL-1beta</i></b> <b style='color:DodgerBlue;'><i>completely</i></b> <b style='color:DodgerBlue;'><i>suppressed</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>carbachol</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>.</i></b> mAChR-mediated enhancements of AChE activity by <b style='color:Tomato;'><i>carbachol</i></b> were impaired following pre-exposure of SH-SY5Y cells with IL-1beta, already detectable at a concentration of 1 ng/ml and 1 h of exposure time. The data indicate that IL-1beta may interfere with the cholinergic signal transduction cascade by inhibiting transcription factor activation, thus providing another mechanism by which IL-1beta may induce cholinergic dysfunction in Alzheimer's disease.","tokens":[{"text":"Carbachol","start":0,"end":9,"id":0,"ws":true},{"text":"stimulation","start":10,"end":21,"id":1,"ws":true},{"text":"of","start":22,"end":24,"id":2,"ws":true},{"text":"SH-SY5Y","start":25,"end":32,"id":3,"ws":true},{"text":"cells","start":33,"end":38,"id":4,"ws":true},{"text":"dose-dependently","start":39,"end":55,"id":5,"ws":true},{"text":"stimulated","start":56,"end":66,"id":6,"ws":true},{"text":"the","start":67,"end":70,"id":7,"ws":true},{"text":"activation","start":71,"end":81,"id":8,"ws":true},{"text":"of","start":82,"end":84,"id":9,"ws":true},{"text":"the","start":85,"end":88,"id":10,"ws":true},{"text":"transcription","start":89,"end":102,"id":11,"ws":true},{"text":"factors","start":103,"end":110,"id":12,"ws":true},{"text":"NFkappaB","start":111,"end":119,"id":13,"ws":true},{"text":"and","start":120,"end":123,"id":14,"ws":true},{"text":"AP-1","start":124,"end":128,"id":15,"ws":true},{"text":"as","start":129,"end":131,"id":16,"ws":true},{"text":"revealed","start":132,"end":140,"id":17,"ws":true},{"text":"by","start":141,"end":143,"id":18,"ws":true},{"text":"electrophoretic","start":144,"end":159,"id":19,"ws":true},{"text":"mobility","start":160,"end":168,"id":20,"ws":true},{"text":"shift","start":169,"end":174,"id":21,"ws":true},{"text":"assay","start":175,"end":180,"id":22,"ws":true},{"text":"(","start":181,"end":182,"id":23,"ws":true},{"text":"EMSA","start":183,"end":187,"id":24,"ws":true},{"text":")","start":188,"end":189,"id":25,"ws":true},{"text":",","start":190,"end":191,"id":26,"ws":true},{"text":"while","start":192,"end":197,"id":27,"ws":true},{"text":"pre-exposure","start":198,"end":210,"id":28,"ws":true},{"text":"of","start":211,"end":213,"id":29,"ws":true},{"text":"SH-SY5Y","start":214,"end":221,"id":30,"ws":true},{"text":"cells","start":222,"end":227,"id":31,"ws":true},{"text":"for","start":228,"end":231,"id":32,"ws":true},{"text":"24","start":232,"end":234,"id":33,"ws":true},{"text":"h","start":235,"end":236,"id":34,"ws":true},{"text":"with","start":237,"end":241,"id":35,"ws":true},{"text":"1","start":242,"end":243,"id":36,"ws":true},{"text":"ng/ml","start":244,"end":249,"id":37,"ws":true},{"text":"IL-1beta","start":250,"end":258,"id":38,"ws":true},{"text":"completely","start":259,"end":269,"id":39,"ws":true},{"text":"suppressed","start":270,"end":280,"id":40,"ws":true},{"text":"the","start":281,"end":284,"id":41,"ws":true},{"text":"carbachol","start":285,"end":294,"id":42,"ws":true},{"text":"response","start":295,"end":303,"id":43,"ws":true},{"text":".","start":304,"end":305,"id":44,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":285,"end":294,"token_start":42,"token_end":42,"label":"DRUG"}],"_input_hash":-98030732,"_task_hash":1585876306,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Future drug development will focus on the clinical usefulness of three-drug regimens ( including gemcitabine , paclitaxel or docetaxel , and a platinum salt ) , and nonplatinum-based combinations , as well as showing the impact of adjuvant postcystectomy chemotherapy on survival .","paragraph":"<h3><u>The present and future of combination chemotherapy in bladder cancer.</u></h3>The combination of <b style='color:Tomato;'><i>methotrexate</i></b>, <b style='color:Tomato;'><i>vinblastine</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, and cisplatin (MVAC) has dominated the landscape of chemotherapy for advanced bladder cancer for over 15 years. Randomized studies have shown its superiority over cisplatin alone or in combination with <b style='color:Tomato;'><i>cyclophosphamide</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b>. However, it exhibits a significant toxicity profile and achieves only a slight impact on overall survival. <b style='color:Tomato;'><i>gemcitabine</i></b> is among the new cytotoxic drugs in development for treatment of advanced urothelial cancer. The combination of <b style='color:Tomato;'><i>gemcitabine</i></b> and cisplatin represents a new standard alternative of treatment in the disease based on similar efficacy to and lower toxicity than the classic MVAC regimen. <b style='color:DodgerBlue;'><i>Future</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>will</i></b> <b style='color:DodgerBlue;'><i>focus</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>usefulness</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>three-drug</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>salt</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>nonplatinum-based</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>showing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>postcystectomy</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Future","start":0,"end":6,"id":0,"ws":true},{"text":"drug","start":7,"end":11,"id":1,"ws":true},{"text":"development","start":12,"end":23,"id":2,"ws":true},{"text":"will","start":24,"end":28,"id":3,"ws":true},{"text":"focus","start":29,"end":34,"id":4,"ws":true},{"text":"on","start":35,"end":37,"id":5,"ws":true},{"text":"the","start":38,"end":41,"id":6,"ws":true},{"text":"clinical","start":42,"end":50,"id":7,"ws":true},{"text":"usefulness","start":51,"end":61,"id":8,"ws":true},{"text":"of","start":62,"end":64,"id":9,"ws":true},{"text":"three-drug","start":65,"end":75,"id":10,"ws":true},{"text":"regimens","start":76,"end":84,"id":11,"ws":true},{"text":"(","start":85,"end":86,"id":12,"ws":true},{"text":"including","start":87,"end":96,"id":13,"ws":true},{"text":"gemcitabine","start":97,"end":108,"id":14,"ws":true},{"text":",","start":109,"end":110,"id":15,"ws":true},{"text":"paclitaxel","start":111,"end":121,"id":16,"ws":true},{"text":"or","start":122,"end":124,"id":17,"ws":true},{"text":"docetaxel","start":125,"end":134,"id":18,"ws":true},{"text":",","start":135,"end":136,"id":19,"ws":true},{"text":"and","start":137,"end":140,"id":20,"ws":true},{"text":"a","start":141,"end":142,"id":21,"ws":true},{"text":"platinum","start":143,"end":151,"id":22,"ws":true},{"text":"salt","start":152,"end":156,"id":23,"ws":true},{"text":")","start":157,"end":158,"id":24,"ws":true},{"text":",","start":159,"end":160,"id":25,"ws":true},{"text":"and","start":161,"end":164,"id":26,"ws":true},{"text":"nonplatinum-based","start":165,"end":182,"id":27,"ws":true},{"text":"combinations","start":183,"end":195,"id":28,"ws":true},{"text":",","start":196,"end":197,"id":29,"ws":true},{"text":"as","start":198,"end":200,"id":30,"ws":true},{"text":"well","start":201,"end":205,"id":31,"ws":true},{"text":"as","start":206,"end":208,"id":32,"ws":true},{"text":"showing","start":209,"end":216,"id":33,"ws":true},{"text":"the","start":217,"end":220,"id":34,"ws":true},{"text":"impact","start":221,"end":227,"id":35,"ws":true},{"text":"of","start":228,"end":230,"id":36,"ws":true},{"text":"adjuvant","start":231,"end":239,"id":37,"ws":true},{"text":"postcystectomy","start":240,"end":254,"id":38,"ws":true},{"text":"chemotherapy","start":255,"end":267,"id":39,"ws":true},{"text":"on","start":268,"end":270,"id":40,"ws":true},{"text":"survival","start":271,"end":279,"id":41,"ws":true},{"text":".","start":280,"end":281,"id":42,"ws":false}],"spans":[{"start":97,"end":108,"token_start":14,"token_end":14,"label":"DRUG"},{"start":111,"end":121,"token_start":16,"token_end":16,"label":"DRUG"},{"start":125,"end":134,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":-1111497360,"_task_hash":2145726638,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Erlotinib was deemed more effective than gefitinib in preventing intracranial lesions and prolonging survival ; however , prospective studies are needed to confirm these results .","paragraph":"<h3><u>Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.</u></h3>Brain metastases (BM) is one of the most crucial distant metastases in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. There is no consensus about which EGFR tyrosine kinase inhibitor (TKI) is most effective against BM in such patients. Here, we compared prognoses of patients with EGFR-TKI na\u00efve EGFR-positive BM treated with <b style='color:Tomato;'><i>erlotinib</i></b> or <b style='color:Tomato;'><i>gefitinib</i></b> after BM diagnosis. Of 269 patients with NSCLC treated with EGFR-TKIs at a single institution, we reviewed medical records of 205 patients with documented EGFR mutations. Eleven patients were administered <b style='color:Tomato;'><i>erlotinib</i></b>, and 52 patients were administered <b style='color:Tomato;'><i>gefitinib</i></b> as the first-line EGFR-TKI treatment after diagnosis. We used propensity score matching to balance patient backgrounds between groups, and the log-rank test to compare survival curves. Patients with BM at the induction of chemotherapy had a poorer prognosis than those without BM [median overall survival (OS) 18.5 vs. 28.0\u00a0months]. Meanwhile, there was no significant difference in OS between those with or without BM at the initiation of EGFR-TKI treatment (20.3 vs. 23.8\u00a0months). Median OS of patients treated with <b style='color:Tomato;'><i>erlotinib</i></b> was not significantly longer than that of patients treated with <b style='color:Tomato;'><i>gefitinib</i></b> (25.0 vs. 18.1\u00a0months). The presence of BM at the initiation of EGFR-TKI treatment had no apparent effect on survival. <b style='color:MediumOrchid;'><i>Erlotinib</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>deemed</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preventing</i></b> <b style='color:DodgerBlue;'><i>intracranial</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>prolonging</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>however</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>confirm</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Erlotinib","start":0,"end":9,"id":0,"ws":true},{"text":"was","start":10,"end":13,"id":1,"ws":true},{"text":"deemed","start":14,"end":20,"id":2,"ws":true},{"text":"more","start":21,"end":25,"id":3,"ws":true},{"text":"effective","start":26,"end":35,"id":4,"ws":true},{"text":"than","start":36,"end":40,"id":5,"ws":true},{"text":"gefitinib","start":41,"end":50,"id":6,"ws":true},{"text":"in","start":51,"end":53,"id":7,"ws":true},{"text":"preventing","start":54,"end":64,"id":8,"ws":true},{"text":"intracranial","start":65,"end":77,"id":9,"ws":true},{"text":"lesions","start":78,"end":85,"id":10,"ws":true},{"text":"and","start":86,"end":89,"id":11,"ws":true},{"text":"prolonging","start":90,"end":100,"id":12,"ws":true},{"text":"survival","start":101,"end":109,"id":13,"ws":true},{"text":";","start":110,"end":111,"id":14,"ws":true},{"text":"however","start":112,"end":119,"id":15,"ws":true},{"text":",","start":120,"end":121,"id":16,"ws":true},{"text":"prospective","start":122,"end":133,"id":17,"ws":true},{"text":"studies","start":134,"end":141,"id":18,"ws":true},{"text":"are","start":142,"end":145,"id":19,"ws":true},{"text":"needed","start":146,"end":152,"id":20,"ws":true},{"text":"to","start":153,"end":155,"id":21,"ws":true},{"text":"confirm","start":156,"end":163,"id":22,"ws":true},{"text":"these","start":164,"end":169,"id":23,"ws":true},{"text":"results","start":170,"end":177,"id":24,"ws":true},{"text":".","start":178,"end":179,"id":25,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":41,"end":50,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":984442827,"_task_hash":1174759069,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combinations of troxacitabine with ara-C , topotecan and idarubicin are active in patients with refractory acute myeloid leukemia ( AML ) .","paragraph":"<h3><u>Troxacitabine-based therapy of refractory leukemia.</u></h3>Unique among currently approved or in-development nucleoside analogs, troxacitabine (Troxatyl) is an L-nucleoside with significant cytotoxic activity. Its stereochemistry and cellular transport characteristics render it insensitive to some tumor cell mechanisms of resistance to D-nucleosides, such as <b style='color:Tomato;'><i>cytarabine</i></b> and <b style='color:Tomato;'><i>fludarabine</i></b>. Troxacitabine's dose-limiting toxicities were mucositis and hand-foot syndrome in patients with refractory leukemia. Three complete and one partial remissions were observed in 30 patients with refractory acute myeloid leukemia on a Phase I study. Significant activity in blastic phase of chronic myeloid leukemia was seen on a Phase II study. <b style='color:DodgerBlue;'><i>Combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>troxacitabine</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>ara-C</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>idarubicin</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Phase II studies in patients with refractory lymphoproliferative diseases are ongoing. Troxacitabine merits further study in patients with hematological malignancies.","tokens":[{"text":"Combinations","start":0,"end":12,"id":0,"ws":true},{"text":"of","start":13,"end":15,"id":1,"ws":true},{"text":"troxacitabine","start":16,"end":29,"id":2,"ws":true},{"text":"with","start":30,"end":34,"id":3,"ws":true},{"text":"ara-C","start":35,"end":40,"id":4,"ws":true},{"text":",","start":41,"end":42,"id":5,"ws":true},{"text":"topotecan","start":43,"end":52,"id":6,"ws":true},{"text":"and","start":53,"end":56,"id":7,"ws":true},{"text":"idarubicin","start":57,"end":67,"id":8,"ws":true},{"text":"are","start":68,"end":71,"id":9,"ws":true},{"text":"active","start":72,"end":78,"id":10,"ws":true},{"text":"in","start":79,"end":81,"id":11,"ws":true},{"text":"patients","start":82,"end":90,"id":12,"ws":true},{"text":"with","start":91,"end":95,"id":13,"ws":true},{"text":"refractory","start":96,"end":106,"id":14,"ws":true},{"text":"acute","start":107,"end":112,"id":15,"ws":true},{"text":"myeloid","start":113,"end":120,"id":16,"ws":true},{"text":"leukemia","start":121,"end":129,"id":17,"ws":true},{"text":"(","start":130,"end":131,"id":18,"ws":true},{"text":"AML","start":132,"end":135,"id":19,"ws":true},{"text":")","start":136,"end":137,"id":20,"ws":true},{"text":".","start":138,"end":139,"id":21,"ws":false}],"spans":[{"start":43,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},{"start":57,"end":67,"token_start":8,"token_end":8,"label":"DRUG"}],"_input_hash":-1694426383,"_task_hash":399252354,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":16,"end":29,"token_start":2,"token_end":2,"label":null},"child_span":{"start":35,"end":40,"token_start":4,"token_end":4,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":8,"head_span":{"start":43,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":57,"end":67,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":4,"child":6,"head_span":{"start":35,"end":40,"token_start":4,"token_end":4,"label":null},"child_span":{"start":43,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Epinephrine , phenylephrine , levonordefrin , felypressin , and norepinephrine have all been utilized in conjunction with the local anesthetics by the various medical professions .","paragraph":"<h3><u>Vasoconstrictive agents commonly used in combination with local anesthetics: a literature review.</u></h3>A review of the current medical literature concerning the use of various vasoconstrictive agents with local anesthetics is presented. These agents are employed in podiatry primarily for the purpose of prolonging the duration of anesthesia and surgical hemostasis. <b style='color:MediumOrchid;'><i>Epinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>levonordefrin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>felypressin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>norepinephrine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>utilized</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>conjunction</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>local</i></b> <b style='color:DodgerBlue;'><i>anesthetics</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>various</i></b> <b style='color:DodgerBlue;'><i>medical</i></b> <b style='color:DodgerBlue;'><i>professions</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although controversy surrounds the use of these agents, this article should assist the podiatric physician in making an informed decision.","tokens":[{"text":"Epinephrine","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"phenylephrine","start":14,"end":27,"id":2,"ws":true},{"text":",","start":28,"end":29,"id":3,"ws":true},{"text":"levonordefrin","start":30,"end":43,"id":4,"ws":true},{"text":",","start":44,"end":45,"id":5,"ws":true},{"text":"felypressin","start":46,"end":57,"id":6,"ws":true},{"text":",","start":58,"end":59,"id":7,"ws":true},{"text":"and","start":60,"end":63,"id":8,"ws":true},{"text":"norepinephrine","start":64,"end":78,"id":9,"ws":true},{"text":"have","start":79,"end":83,"id":10,"ws":true},{"text":"all","start":84,"end":87,"id":11,"ws":true},{"text":"been","start":88,"end":92,"id":12,"ws":true},{"text":"utilized","start":93,"end":101,"id":13,"ws":true},{"text":"in","start":102,"end":104,"id":14,"ws":true},{"text":"conjunction","start":105,"end":116,"id":15,"ws":true},{"text":"with","start":117,"end":121,"id":16,"ws":true},{"text":"the","start":122,"end":125,"id":17,"ws":true},{"text":"local","start":126,"end":131,"id":18,"ws":true},{"text":"anesthetics","start":132,"end":143,"id":19,"ws":true},{"text":"by","start":144,"end":146,"id":20,"ws":true},{"text":"the","start":147,"end":150,"id":21,"ws":true},{"text":"various","start":151,"end":158,"id":22,"ws":true},{"text":"medical","start":159,"end":166,"id":23,"ws":true},{"text":"professions","start":167,"end":178,"id":24,"ws":true},{"text":".","start":179,"end":180,"id":25,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":14,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":46,"end":57,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":609514079,"_task_hash":-1481207485,"_session_id":"drug_drug_pilot_split-dana_a","_view_id":"blocks","relations":[],"radio":["POS1T0"],"answer":"accept"}
{"text":"In this present study , we determined the mechanistic basis for ixazomib combination with the HDAC inhibitor , belinostat , in HL and TCL cells lines ( ixazomib-sensitive/resistant clones ) and primary tumour cells .","paragraph":"<h3><u>Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.</u></h3><b style='color:Tomato;'><i>ixazomib</i></b> activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mechanistic</i></b> <b style='color:DodgerBlue;'><i>basis</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>ixazomib</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>HDAC</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>belinostat</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>HL</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>TCL</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>lines</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ixazomib-sensitive/resistant</i></b> <b style='color:DodgerBlue;'><i>clones</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>tumour</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In <b style='color:Tomato;'><i>ixazomib</i></b>-treated TCL and HL cells, transient inhibition followed by full recovery of proteasomal activity observed was accompanied by induction of proteasomal gene expression with NFE2L2 (also termed NRF2) as a prominent upstream regulator. Downregulation of both NFE2L2 and proteasomal gene expression (validated by quantitative real time polymerase chain reaction) occurred with <b style='color:Tomato;'><i>belinostat</i></b> treatment in Jurkat and L428 cells. In addition, CRISPR/Cas9 mediated knockdown of NFE2L2 in Jurkat cells resulted in a significant decrease in cell viability with <b style='color:Tomato;'><i>ixazomib</i></b> compared with untreated control cells. Using transcriptomic and proteasomal activity evaluation of <b style='color:Tomato;'><i>ixazomib</i></b>, <b style='color:Tomato;'><i>belinostat</i></b>, or <b style='color:Tomato;'><i>ixazomib</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>belinostat</i></b> treated cells, we observed that NFE2L2, proteasome gene expression and functional recovery were abrogated by <b style='color:Tomato;'><i>ixazomib</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>belinostat</i></b> combination, resulting in synergistic drug activity in <b style='color:Tomato;'><i>ixazomib</i></b>-sensitive and -resistant cell lines and primary cells. Altogether, these results suggest that the synergistic activity of <b style='color:Tomato;'><i>ixazomib</i></b>\u00a0+\u00a0<b style='color:Tomato;'><i>belinostat</i></b> is mediated via inhibition NFE2L2-dependent proteasomal recovery and extended proteasomal inhibition culminating in increased cell death.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"present","start":8,"end":15,"id":2,"ws":true},{"text":"study","start":16,"end":21,"id":3,"ws":true},{"text":",","start":22,"end":23,"id":4,"ws":true},{"text":"we","start":24,"end":26,"id":5,"ws":true},{"text":"determined","start":27,"end":37,"id":6,"ws":true},{"text":"the","start":38,"end":41,"id":7,"ws":true},{"text":"mechanistic","start":42,"end":53,"id":8,"ws":true},{"text":"basis","start":54,"end":59,"id":9,"ws":true},{"text":"for","start":60,"end":63,"id":10,"ws":true},{"text":"ixazomib","start":64,"end":72,"id":11,"ws":true},{"text":"combination","start":73,"end":84,"id":12,"ws":true},{"text":"with","start":85,"end":89,"id":13,"ws":true},{"text":"the","start":90,"end":93,"id":14,"ws":true},{"text":"HDAC","start":94,"end":98,"id":15,"ws":true},{"text":"inhibitor","start":99,"end":108,"id":16,"ws":true},{"text":",","start":109,"end":110,"id":17,"ws":true},{"text":"belinostat","start":111,"end":121,"id":18,"ws":true},{"text":",","start":122,"end":123,"id":19,"ws":true},{"text":"in","start":124,"end":126,"id":20,"ws":true},{"text":"HL","start":127,"end":129,"id":21,"ws":true},{"text":"and","start":130,"end":133,"id":22,"ws":true},{"text":"TCL","start":134,"end":137,"id":23,"ws":true},{"text":"cells","start":138,"end":143,"id":24,"ws":true},{"text":"lines","start":144,"end":149,"id":25,"ws":true},{"text":"(","start":150,"end":151,"id":26,"ws":true},{"text":"ixazomib-sensitive/resistant","start":152,"end":180,"id":27,"ws":true},{"text":"clones","start":181,"end":187,"id":28,"ws":true},{"text":")","start":188,"end":189,"id":29,"ws":true},{"text":"and","start":190,"end":193,"id":30,"ws":true},{"text":"primary","start":194,"end":201,"id":31,"ws":true},{"text":"tumour","start":202,"end":208,"id":32,"ws":true},{"text":"cells","start":209,"end":214,"id":33,"ws":true},{"text":".","start":215,"end":216,"id":34,"ws":false}],"spans":[{"start":64,"end":72,"token_start":11,"token_end":11,"label":"DRUG"},{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"}],"_input_hash":-260701175,"_task_hash":1471394050,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":11,"child":18,"head_span":{"start":64,"end":72,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T0"],"answer":"accept"}
{"text":"Unsuspected hyperglycemia caused prolonged postanesthetic coma in a nondiabetic patient treated with IV diazoxide and furosemide .","paragraph":"<h3><u>Hyperglycemic hyperosmolar nonketotic coma following diazoxide, anesthesia and operation.</u></h3> <b style='color:DodgerBlue;'><i>Unsuspected</i></b> <b style='color:DodgerBlue;'><i>hyperglycemia</i></b> <b style='color:DodgerBlue;'><i>caused</i></b> <b style='color:DodgerBlue;'><i>prolonged</i></b> <b style='color:DodgerBlue;'><i>postanesthetic</i></b> <b style='color:DodgerBlue;'><i>coma</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>nondiabetic</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:MediumOrchid;'><i>diazoxide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>furosemide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combined effect of these drugs with general anesthesia and surgical stress was postulated as the cause of the hyperglycemia. Blood glucose should be measured during and after general anesthesia in patients who are potential candidates for hyperglycemic hyperosmolar nonketotic coma.","tokens":[{"text":"Unsuspected","start":0,"end":11,"id":0,"ws":true},{"text":"hyperglycemia","start":12,"end":25,"id":1,"ws":true},{"text":"caused","start":26,"end":32,"id":2,"ws":true},{"text":"prolonged","start":33,"end":42,"id":3,"ws":true},{"text":"postanesthetic","start":43,"end":57,"id":4,"ws":true},{"text":"coma","start":58,"end":62,"id":5,"ws":true},{"text":"in","start":63,"end":65,"id":6,"ws":true},{"text":"a","start":66,"end":67,"id":7,"ws":true},{"text":"nondiabetic","start":68,"end":79,"id":8,"ws":true},{"text":"patient","start":80,"end":87,"id":9,"ws":true},{"text":"treated","start":88,"end":95,"id":10,"ws":true},{"text":"with","start":96,"end":100,"id":11,"ws":true},{"text":"IV","start":101,"end":103,"id":12,"ws":true},{"text":"diazoxide","start":104,"end":113,"id":13,"ws":true},{"text":"and","start":114,"end":117,"id":14,"ws":true},{"text":"furosemide","start":118,"end":128,"id":15,"ws":true},{"text":".","start":129,"end":130,"id":16,"ws":false}],"spans":[{"start":104,"end":113,"token_start":13,"token_end":13,"label":"DRUG"},{"start":118,"end":128,"token_start":15,"token_end":15,"label":"DRUG"}],"_input_hash":1411933490,"_task_hash":-1448189909,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The data suggest that simultaneous use of verapamil or nifedipine may protect against digitalis-induced mechanical toxicity .","paragraph":"<h3><u>Digitalis-induced mechanical toxicity: protection by slow Ca++ channel blockers.</u></h3>In the in vitro perfusion of the isolated heart, toxic doses of cardiac glycosides produce an inotropic response which is followed by a decline in contractile force and an increase in the resting tension. Several reports in the literature indicate that the subsequent decline in contractile force may be related to cardiac cellular Ca++ overload. The purpose of the present study was to determine if the slow Ca++ channel blockers such as <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>nifedipine</i></b>, which block Ca++ influx through voltage-dependent gated channels, can reduce or prevent the digitalis-induced decline in contractile force (mechanical toxicity). Langendorff preparations of isolated perfused guinea pig heart were used for the present study. The data obtained demonstrate that 1 to 2 microM <b style='color:Tomato;'><i>ouabain</i></b> in the perfusion medium produced mechanical toxicity in the hearts after an initial inotropic response. <b style='color:Tomato;'><i>verapamil</i></b> or <b style='color:Tomato;'><i>nifedipine</i></b>, when combined with <b style='color:Tomato;'><i>ouabain</i></b> in the perfusion medium, increased the magnitude of the inotropic response and delayed or abolished the mechanical toxicity in a dose-dependent manner. No changes in the sarcolemmal Na+,K+-adenosine triphosphatase or <b style='color:Tomato;'><i>ouabain</i></b> binding were observed in the presence of <b style='color:Tomato;'><i>verapamil</i></b> or <b style='color:Tomato;'><i>nifedipine</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>nifedipine</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>protect</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>digitalis-induced</i></b> <b style='color:DodgerBlue;'><i>mechanical</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"data","start":4,"end":8,"id":1,"ws":true},{"text":"suggest","start":9,"end":16,"id":2,"ws":true},{"text":"that","start":17,"end":21,"id":3,"ws":true},{"text":"simultaneous","start":22,"end":34,"id":4,"ws":true},{"text":"use","start":35,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"verapamil","start":42,"end":51,"id":7,"ws":true},{"text":"or","start":52,"end":54,"id":8,"ws":true},{"text":"nifedipine","start":55,"end":65,"id":9,"ws":true},{"text":"may","start":66,"end":69,"id":10,"ws":true},{"text":"protect","start":70,"end":77,"id":11,"ws":true},{"text":"against","start":78,"end":85,"id":12,"ws":true},{"text":"digitalis-induced","start":86,"end":103,"id":13,"ws":true},{"text":"mechanical","start":104,"end":114,"id":14,"ws":true},{"text":"toxicity","start":115,"end":123,"id":15,"ws":true},{"text":".","start":124,"end":125,"id":16,"ws":false}],"spans":[{"start":42,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},{"start":55,"end":65,"token_start":9,"token_end":9,"label":"DRUG"}],"_input_hash":-1085908887,"_task_hash":-1022354710,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":42,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":55,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"These data do not replicate results of a prior study obtained with atenolol and suggest that only a subset of hypertensive individuals show reduced Type A behavior with propranolol .","paragraph":"<h3><u>Comparative effects of two beta-blockers on cardiovascular reactivity and type A behavior in hypertensives.</u></h3>This study compared the effects of beta-blockers differing in degree of central nervous system penetration on Type A behavior and cardiovascular reactivity to mental stress. Forty-six male hypertensives were assigned randomly to receive either highly lipophilic and nonselective <b style='color:Tomato;'><i>propranolol</i></b>, hydrophilic and cardioselective <b style='color:Tomato;'><i>atenolol</i></b>, the diuretic hydro<b style='color:Tomato;'><i>chlorothiazide</i></b>, or placebo. Subjects were administered parallel forms of the Structured Interview (SI) and performed mental arithmetic and a cognitive task prior to and after 6 weeks of therapy. Results indicated that diuretic and placebo subjects (subsequently combined into a single control group) did not differ and that both beta-blockers reduced heart rate but not blood pressure reactivity to mental stress (p less than 0.02), an effect that was strongest during the mental arithmetic test. Analysis of SI components indicated a reduction only in explosive speech for beta-blockers versus controls (p less than 0.05). For global SI classifications, seven out of 12 subjects (58%) receiving <b style='color:Tomato;'><i>propranolol</i></b>, three of 12 (25%) receiving <b style='color:Tomato;'><i>atenolol</i></b>, and four of 22 control subjects (18%) became less Type A (p less than 0.05). <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>do</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>replicate</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>obtained</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>atenolol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>subset</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hypertensive</i></b> <b style='color:DodgerBlue;'><i>individuals</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>Type</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>behavior</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Central nervous system mechanisms may be important in producing these effects.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"data","start":6,"end":10,"id":1,"ws":true},{"text":"do","start":11,"end":13,"id":2,"ws":true},{"text":"not","start":14,"end":17,"id":3,"ws":true},{"text":"replicate","start":18,"end":27,"id":4,"ws":true},{"text":"results","start":28,"end":35,"id":5,"ws":true},{"text":"of","start":36,"end":38,"id":6,"ws":true},{"text":"a","start":39,"end":40,"id":7,"ws":true},{"text":"prior","start":41,"end":46,"id":8,"ws":true},{"text":"study","start":47,"end":52,"id":9,"ws":true},{"text":"obtained","start":53,"end":61,"id":10,"ws":true},{"text":"with","start":62,"end":66,"id":11,"ws":true},{"text":"atenolol","start":67,"end":75,"id":12,"ws":true},{"text":"and","start":76,"end":79,"id":13,"ws":true},{"text":"suggest","start":80,"end":87,"id":14,"ws":true},{"text":"that","start":88,"end":92,"id":15,"ws":true},{"text":"only","start":93,"end":97,"id":16,"ws":true},{"text":"a","start":98,"end":99,"id":17,"ws":true},{"text":"subset","start":100,"end":106,"id":18,"ws":true},{"text":"of","start":107,"end":109,"id":19,"ws":true},{"text":"hypertensive","start":110,"end":122,"id":20,"ws":true},{"text":"individuals","start":123,"end":134,"id":21,"ws":true},{"text":"show","start":135,"end":139,"id":22,"ws":true},{"text":"reduced","start":140,"end":147,"id":23,"ws":true},{"text":"Type","start":148,"end":152,"id":24,"ws":true},{"text":"A","start":153,"end":154,"id":25,"ws":true},{"text":"behavior","start":155,"end":163,"id":26,"ws":true},{"text":"with","start":164,"end":168,"id":27,"ws":true},{"text":"propranolol","start":169,"end":180,"id":28,"ws":true},{"text":".","start":181,"end":182,"id":29,"ws":false}],"spans":[{"start":67,"end":75,"token_start":12,"token_end":12,"label":"DRUG"},{"start":169,"end":180,"token_start":28,"token_end":28,"label":"DRUG"}],"_input_hash":674665286,"_task_hash":1233105951,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Since 2011 , the approval of four different classes of novel drugs ( the anti-CTLA-4 agent , ipilimumab ; BRAF inhibitors [ BRAFi ] ; MEK inhibitors [ MEKi ] ; and the anti-PD-1 drug , pembrolizumab ) has revolutionized the care of advanced melanoma , with the disease becoming a model for the development of new treatments for other types of cancer .","paragraph":"<h3><u>Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma.</u></h3> <b style='color:DodgerBlue;'><i>Since</i></b> <b style='color:DodgerBlue;'><i>2011</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>approval</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>classes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>novel</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-CTLA-4</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>BRAF</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>BRAFi</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>MEK</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>MEKi</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-PD-1</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>revolutionized</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>care</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>becoming</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>types</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Further advances in the treatment of melanoma represented some of the key highlights of the European Society of Medical Oncology (ESMO) 2014 congress. The first phase III trial of an anti-PD-1 agent to report the CA209-037 study included 405 patients with metastatic melanoma previously treated with <b style='color:Tomato;'><i>ipilimumab</i></b> who were randomized 2:1 to receive <b style='color:Tomato;'><i>nivolumab</i></b> 3 mg/kg every 2 weeks or investigator's choice chemotherapy. <b style='color:Tomato;'><i>nivolumab</i></b> was associated with a higher response rate than chemotherapy and was well tolerated, with adverse events mostly low grade and manageable using recommended treatment algorithms. New data on other immunotherapies, namely <b style='color:Tomato;'><i>ipilimumab</i></b> and <b style='color:Tomato;'><i>pembrolizumab</i></b>, were also reported. In addition, outside of immunotherapy, combination approaches involving targeted agents were also a major focus of ESMO this year, with two major phase III studies of combined BRAF inhibition and MEK inhibition being reported. Overall, new clinical trial findings reported at ESMO further endorse the view that melanoma, given the continued development of novel, effective compounds, can accurately be described as the most \"dynamic\" field of oncology at present.","tokens":[{"text":"Since","start":0,"end":5,"id":0,"ws":true},{"text":"2011","start":6,"end":10,"id":1,"ws":true},{"text":",","start":11,"end":12,"id":2,"ws":true},{"text":"the","start":13,"end":16,"id":3,"ws":true},{"text":"approval","start":17,"end":25,"id":4,"ws":true},{"text":"of","start":26,"end":28,"id":5,"ws":true},{"text":"four","start":29,"end":33,"id":6,"ws":true},{"text":"different","start":34,"end":43,"id":7,"ws":true},{"text":"classes","start":44,"end":51,"id":8,"ws":true},{"text":"of","start":52,"end":54,"id":9,"ws":true},{"text":"novel","start":55,"end":60,"id":10,"ws":true},{"text":"drugs","start":61,"end":66,"id":11,"ws":true},{"text":"(","start":67,"end":68,"id":12,"ws":true},{"text":"the","start":69,"end":72,"id":13,"ws":true},{"text":"anti-CTLA-4","start":73,"end":84,"id":14,"ws":true},{"text":"agent","start":85,"end":90,"id":15,"ws":true},{"text":",","start":91,"end":92,"id":16,"ws":true},{"text":"ipilimumab","start":93,"end":103,"id":17,"ws":true},{"text":";","start":104,"end":105,"id":18,"ws":true},{"text":"BRAF","start":106,"end":110,"id":19,"ws":true},{"text":"inhibitors","start":111,"end":121,"id":20,"ws":true},{"text":"[","start":122,"end":123,"id":21,"ws":true},{"text":"BRAFi","start":124,"end":129,"id":22,"ws":true},{"text":"]","start":130,"end":131,"id":23,"ws":true},{"text":";","start":132,"end":133,"id":24,"ws":true},{"text":"MEK","start":134,"end":137,"id":25,"ws":true},{"text":"inhibitors","start":138,"end":148,"id":26,"ws":true},{"text":"[","start":149,"end":150,"id":27,"ws":true},{"text":"MEKi","start":151,"end":155,"id":28,"ws":true},{"text":"]","start":156,"end":157,"id":29,"ws":true},{"text":";","start":158,"end":159,"id":30,"ws":true},{"text":"and","start":160,"end":163,"id":31,"ws":true},{"text":"the","start":164,"end":167,"id":32,"ws":true},{"text":"anti-PD-1","start":168,"end":177,"id":33,"ws":true},{"text":"drug","start":178,"end":182,"id":34,"ws":true},{"text":",","start":183,"end":184,"id":35,"ws":true},{"text":"pembrolizumab","start":185,"end":198,"id":36,"ws":true},{"text":")","start":199,"end":200,"id":37,"ws":true},{"text":"has","start":201,"end":204,"id":38,"ws":true},{"text":"revolutionized","start":205,"end":219,"id":39,"ws":true},{"text":"the","start":220,"end":223,"id":40,"ws":true},{"text":"care","start":224,"end":228,"id":41,"ws":true},{"text":"of","start":229,"end":231,"id":42,"ws":true},{"text":"advanced","start":232,"end":240,"id":43,"ws":true},{"text":"melanoma","start":241,"end":249,"id":44,"ws":true},{"text":",","start":250,"end":251,"id":45,"ws":true},{"text":"with","start":252,"end":256,"id":46,"ws":true},{"text":"the","start":257,"end":260,"id":47,"ws":true},{"text":"disease","start":261,"end":268,"id":48,"ws":true},{"text":"becoming","start":269,"end":277,"id":49,"ws":true},{"text":"a","start":278,"end":279,"id":50,"ws":true},{"text":"model","start":280,"end":285,"id":51,"ws":true},{"text":"for","start":286,"end":289,"id":52,"ws":true},{"text":"the","start":290,"end":293,"id":53,"ws":true},{"text":"development","start":294,"end":305,"id":54,"ws":true},{"text":"of","start":306,"end":308,"id":55,"ws":true},{"text":"new","start":309,"end":312,"id":56,"ws":true},{"text":"treatments","start":313,"end":323,"id":57,"ws":true},{"text":"for","start":324,"end":327,"id":58,"ws":true},{"text":"other","start":328,"end":333,"id":59,"ws":true},{"text":"types","start":334,"end":339,"id":60,"ws":true},{"text":"of","start":340,"end":342,"id":61,"ws":true},{"text":"cancer","start":343,"end":349,"id":62,"ws":true},{"text":".","start":350,"end":351,"id":63,"ws":false}],"spans":[{"start":93,"end":103,"token_start":17,"token_end":17,"label":"DRUG"},{"start":185,"end":198,"token_start":36,"token_end":36,"label":"DRUG"}],"_input_hash":-2139318960,"_task_hash":-1517708554,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combination immune checkpoint blockade with concurrent administration of the anti-ctla4 antibody ipilimumab and the anti-PD-1 antibody nivolumab has demonstrated impressive responses in patients with advanced melanoma and other diseases .","paragraph":"<h3><u>Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.</u></h3> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>immune</i></b> <b style='color:DodgerBlue;'><i>checkpoint</i></b> <b style='color:DodgerBlue;'><i>blockade</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>concurrent</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-ctla4</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>anti-PD-1</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>impressive</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>diseases</i></b> <b style='color:DodgerBlue;'><i>.</i></b> That combination has also been associated with increased toxicity, including rare immune-related adverse events. Here we describe a case of fatal steroid-refractory myocarditis and panmyositis associated with the use of this combination in a patient with metastatic melanoma. Correlative studies indicated increased levels of serum interleukin 6 in this patient at the onset of toxicity, suggesting a possible role for anti-interleukin 6 receptor antibodies in the treatment of subsequent cases of this rare, but fatal, toxicity.","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"immune","start":12,"end":18,"id":1,"ws":true},{"text":"checkpoint","start":19,"end":29,"id":2,"ws":true},{"text":"blockade","start":30,"end":38,"id":3,"ws":true},{"text":"with","start":39,"end":43,"id":4,"ws":true},{"text":"concurrent","start":44,"end":54,"id":5,"ws":true},{"text":"administration","start":55,"end":69,"id":6,"ws":true},{"text":"of","start":70,"end":72,"id":7,"ws":true},{"text":"the","start":73,"end":76,"id":8,"ws":true},{"text":"anti-ctla4","start":77,"end":87,"id":9,"ws":true},{"text":"antibody","start":88,"end":96,"id":10,"ws":true},{"text":"ipilimumab","start":97,"end":107,"id":11,"ws":true},{"text":"and","start":108,"end":111,"id":12,"ws":true},{"text":"the","start":112,"end":115,"id":13,"ws":true},{"text":"anti-PD-1","start":116,"end":125,"id":14,"ws":true},{"text":"antibody","start":126,"end":134,"id":15,"ws":true},{"text":"nivolumab","start":135,"end":144,"id":16,"ws":true},{"text":"has","start":145,"end":148,"id":17,"ws":true},{"text":"demonstrated","start":149,"end":161,"id":18,"ws":true},{"text":"impressive","start":162,"end":172,"id":19,"ws":true},{"text":"responses","start":173,"end":182,"id":20,"ws":true},{"text":"in","start":183,"end":185,"id":21,"ws":true},{"text":"patients","start":186,"end":194,"id":22,"ws":true},{"text":"with","start":195,"end":199,"id":23,"ws":true},{"text":"advanced","start":200,"end":208,"id":24,"ws":true},{"text":"melanoma","start":209,"end":217,"id":25,"ws":true},{"text":"and","start":218,"end":221,"id":26,"ws":true},{"text":"other","start":222,"end":227,"id":27,"ws":true},{"text":"diseases","start":228,"end":236,"id":28,"ws":true},{"text":".","start":237,"end":238,"id":29,"ws":false}],"spans":[{"start":97,"end":107,"token_start":11,"token_end":11,"label":"DRUG"},{"start":135,"end":144,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":-237187387,"_task_hash":977427508,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[{"head":11,"child":16,"head_span":{"start":97,"end":107,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":135,"end":144,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
{"text":"Proton pump inhibitors , including omeprazole , rabeprazole , lansoprazole , and pantoprazole , achieved simultaneous enantioselective determination in the human plasma by chiral LC-MS/MS .","paragraph":"<h3><u>Simultaneous enantioselective determination of omeprazole, rabeprazole, lansoprazole and pantoprazole enantiomers in human plasma by chiral liquid chromatography/tandem mass spectrometry.</u></h3> <b style='color:DodgerBlue;'><i>Proton</i></b> <b style='color:DodgerBlue;'><i>pump</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>rabeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lansoprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pantoprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>achieved</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>enantioselective</i></b> <b style='color:DodgerBlue;'><i>determination</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>chiral</i></b> <b style='color:DodgerBlue;'><i>LC-MS/MS</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The four corresponding stable isotope-labeled proton pump inhibitors were adopted as the internal standards. Each enantiomer and the internal standards were extracted with acetonitrile which containing 0.1% ammonia, then separated with a Chiralpak IC column (5 \u03bcm, 4.6 mm \u00d7 150 mm) within 10 minutes. The mobile phase was composed of acetonitrile-ammonium acetate (10 mM) containing 0.2% acetic acid (50:50, v/v). To quantify all enantiomers, API 4000 tandem mass spectrometer was required, and multiple reaction monitoring transitions were performed on m/z 360.1\u2192242.1, 384.1\u2192200.1, 370.1\u2192252.1, and 346.1\u2192198.1, respectively. No significant matrix effect was observed for all analytes. The calibration curve for all enantiomers were linear from 1.25 to 2500 ng/mL. The precisions for intra- and inter-run were < 14.2%, and the accuracy fell in the interval of -5.3 to 8.1%. Stability of samples was confirmed under the storage and processing conditions. The developed method was also suitable for separation and determination of ilaprazole enantiomers. The validated method combining the equilibrium dialysis method was applied to the protein binding ratio studies of four pairs proton pump inhibitor enantiomers in human plasma. This article is protected by copyright. All rights reserved.","tokens":[{"text":"Proton","start":0,"end":6,"id":0,"ws":true},{"text":"pump","start":7,"end":11,"id":1,"ws":true},{"text":"inhibitors","start":12,"end":22,"id":2,"ws":true},{"text":",","start":23,"end":24,"id":3,"ws":true},{"text":"including","start":25,"end":34,"id":4,"ws":true},{"text":"omeprazole","start":35,"end":45,"id":5,"ws":true},{"text":",","start":46,"end":47,"id":6,"ws":true},{"text":"rabeprazole","start":48,"end":59,"id":7,"ws":true},{"text":",","start":60,"end":61,"id":8,"ws":true},{"text":"lansoprazole","start":62,"end":74,"id":9,"ws":true},{"text":",","start":75,"end":76,"id":10,"ws":true},{"text":"and","start":77,"end":80,"id":11,"ws":true},{"text":"pantoprazole","start":81,"end":93,"id":12,"ws":true},{"text":",","start":94,"end":95,"id":13,"ws":true},{"text":"achieved","start":96,"end":104,"id":14,"ws":true},{"text":"simultaneous","start":105,"end":117,"id":15,"ws":true},{"text":"enantioselective","start":118,"end":134,"id":16,"ws":true},{"text":"determination","start":135,"end":148,"id":17,"ws":true},{"text":"in","start":149,"end":151,"id":18,"ws":true},{"text":"the","start":152,"end":155,"id":19,"ws":true},{"text":"human","start":156,"end":161,"id":20,"ws":true},{"text":"plasma","start":162,"end":168,"id":21,"ws":true},{"text":"by","start":169,"end":171,"id":22,"ws":true},{"text":"chiral","start":172,"end":178,"id":23,"ws":true},{"text":"LC-MS/MS","start":179,"end":187,"id":24,"ws":true},{"text":".","start":188,"end":189,"id":25,"ws":false}],"spans":[{"start":35,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":48,"end":59,"token_start":7,"token_end":7,"label":"DRUG"},{"start":62,"end":74,"token_start":9,"token_end":9,"label":"DRUG"},{"start":81,"end":93,"token_start":12,"token_end":12,"label":"DRUG"}],"_input_hash":1799305620,"_task_hash":-486919357,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These results indicate that amodiaquine may be a potent alternative to chloroquine in Madagascar .","paragraph":"<h3><u>In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.</u></h3><b style='color:Tomato;'><i>chloroquine</i></b> has been used in Madagascar since 1945 and remains the first-line treatment for uncomplicated cases of malaria. Low-grades of resistance type R1 and R2 have been reported. Thus, in vitro tests were performed in order to monitor the drug sensitivity of Plasmodium falciparum from different study sites, with the aim of identifying alternatives to <b style='color:Tomato;'><i>chloroquine</i></b>. <b style='color:Tomato;'><i>chloroquine</i></b> IC50 values ranged from 0.2 nM to 283.4 nM (n = 190, mean IC50 = 52.6 nM; 95% CI = 46.1-59.1 nM). Fifteen isolates (7.9%) were <b style='color:Tomato;'><i>chloroquine</i></b>-resistant. One <b style='color:Tomato;'><i>mefloquine</i></b>-resistant isolate was detected (1/139). The test isolates were sensitive to <b style='color:Tomato;'><i>amodiaquine</i></b> (n = 118), <b style='color:Tomato;'><i>quinine</i></b> (n = 212), <b style='color:Tomato;'><i>pyrimethamine</i></b> (n = 86) and cycloguanil (n = 79). The median IC50 for <b style='color:Tomato;'><i>amodiaquine</i></b> was 12.3 nM (mean IC50 = 15.3 nM, 95% CI = 13.3-17.3 nM). <b style='color:Tomato;'><i>amodiaquine</i></b> was 3.4 times as active as <b style='color:Tomato;'><i>chloroquine</i></b> in vitro and 7 times as active as <b style='color:Tomato;'><i>quinine</i></b> against P. falciparum. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>indicate</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>amodiaquine</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>alternative</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Madagascar</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There was positive correlation between tested quinoline-containing drugs activities, which suggests in vitro cross-susceptibility.","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"results","start":6,"end":13,"id":1,"ws":true},{"text":"indicate","start":14,"end":22,"id":2,"ws":true},{"text":"that","start":23,"end":27,"id":3,"ws":true},{"text":"amodiaquine","start":28,"end":39,"id":4,"ws":true},{"text":"may","start":40,"end":43,"id":5,"ws":true},{"text":"be","start":44,"end":46,"id":6,"ws":true},{"text":"a","start":47,"end":48,"id":7,"ws":true},{"text":"potent","start":49,"end":55,"id":8,"ws":true},{"text":"alternative","start":56,"end":67,"id":9,"ws":true},{"text":"to","start":68,"end":70,"id":10,"ws":true},{"text":"chloroquine","start":71,"end":82,"id":11,"ws":true},{"text":"in","start":83,"end":85,"id":12,"ws":true},{"text":"Madagascar","start":86,"end":96,"id":13,"ws":true},{"text":".","start":97,"end":98,"id":14,"ws":false}],"spans":[{"start":28,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},{"start":71,"end":82,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":1024772344,"_task_hash":-966661874,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Numerous clinical trials are ongoing or completed , including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer .","paragraph":"<h3><u>Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.</u></h3>Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. <b style='color:Tomato;'><i>trastuzumab</i></b>, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response. Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors. <b style='color:DodgerBlue;'><i>Numerous</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>ongoing</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>completed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mammalian</i></b> <b style='color:DodgerBlue;'><i>target</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-resistant</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This review considers the molecular mechanisms associated with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer. ","tokens":[{"text":"Numerous","start":0,"end":8,"id":0,"ws":true},{"text":"clinical","start":9,"end":17,"id":1,"ws":true},{"text":"trials","start":18,"end":24,"id":2,"ws":true},{"text":"are","start":25,"end":28,"id":3,"ws":true},{"text":"ongoing","start":29,"end":36,"id":4,"ws":true},{"text":"or","start":37,"end":39,"id":5,"ws":true},{"text":"completed","start":40,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"including","start":52,"end":61,"id":8,"ws":true},{"text":"phase","start":62,"end":67,"id":9,"ws":true},{"text":"3","start":68,"end":69,"id":10,"ws":true},{"text":"data","start":70,"end":74,"id":11,"ws":true},{"text":"for","start":75,"end":78,"id":12,"ws":true},{"text":"the","start":79,"end":82,"id":13,"ws":true},{"text":"mammalian","start":83,"end":92,"id":14,"ws":true},{"text":"target","start":93,"end":99,"id":15,"ws":true},{"text":"of","start":100,"end":102,"id":16,"ws":true},{"text":"rapamycin","start":103,"end":112,"id":17,"ws":true},{"text":"inhibitor","start":113,"end":122,"id":18,"ws":true},{"text":"everolimus","start":123,"end":133,"id":19,"ws":true},{"text":"in","start":134,"end":136,"id":20,"ws":true},{"text":"patients","start":137,"end":145,"id":21,"ws":true},{"text":"with","start":146,"end":150,"id":22,"ws":true},{"text":"HER2-resistant","start":151,"end":165,"id":23,"ws":true},{"text":"breast","start":166,"end":172,"id":24,"ws":true},{"text":"cancer","start":173,"end":179,"id":25,"ws":true},{"text":".","start":180,"end":181,"id":26,"ws":false}],"spans":[{"start":103,"end":112,"token_start":17,"token_end":17,"label":"DRUG"},{"start":123,"end":133,"token_start":19,"token_end":19,"label":"DRUG"}],"_input_hash":1164537413,"_task_hash":-120440066,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In addition , many challenging issues remain to be solved including patients education , side effect monitoring during sunitinib treatment , the influence of difference between the Eastern patients and the Western counterparts on sunitinib treatment schedule , and the choice of regimen after imatinib and sunitinib failure , etc .","paragraph":"<h3><u>[Challenges of gastrointestinal stromal tumor in the era of targeted therapy].</u></h3>Targeted drugs has improved the overall survival of patients with gastrointestinal stromal tumor (GIST). However, there are some difficulties and controversies. <b style='color:Tomato;'><i>imatinib</i></b> adjuvant therapy improves recurrence-free survival, but the treatment duration has not been determined. Furthermore, whether adjuvant therapy is beneficial to the GIST with c-kit exon 9 mutation and wild type is unclear. There are currently no prospective randomized controlled trials on the role of combination of surgery with tyrosine kinase inhibitor in patients with metastatic GIST. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>many</i></b> <b style='color:DodgerBlue;'><i>challenging</i></b> <b style='color:DodgerBlue;'><i>issues</i></b> <b style='color:DodgerBlue;'><i>remain</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>solved</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>education</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>side</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>monitoring</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>influence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>difference</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Eastern</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Western</i></b> <b style='color:DodgerBlue;'><i>counterparts</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>schedule</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>choice</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>etc</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Difficulties exist in the discovery of new targets in the downstream of kit gene and the concurrent use of multiple targeted drugs. This article analyzes these problems in order to achieve a consensus and discuss future directions.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"addition","start":3,"end":11,"id":1,"ws":true},{"text":",","start":12,"end":13,"id":2,"ws":true},{"text":"many","start":14,"end":18,"id":3,"ws":true},{"text":"challenging","start":19,"end":30,"id":4,"ws":true},{"text":"issues","start":31,"end":37,"id":5,"ws":true},{"text":"remain","start":38,"end":44,"id":6,"ws":true},{"text":"to","start":45,"end":47,"id":7,"ws":true},{"text":"be","start":48,"end":50,"id":8,"ws":true},{"text":"solved","start":51,"end":57,"id":9,"ws":true},{"text":"including","start":58,"end":67,"id":10,"ws":true},{"text":"patients","start":68,"end":76,"id":11,"ws":true},{"text":"education","start":77,"end":86,"id":12,"ws":true},{"text":",","start":87,"end":88,"id":13,"ws":true},{"text":"side","start":89,"end":93,"id":14,"ws":true},{"text":"effect","start":94,"end":100,"id":15,"ws":true},{"text":"monitoring","start":101,"end":111,"id":16,"ws":true},{"text":"during","start":112,"end":118,"id":17,"ws":true},{"text":"sunitinib","start":119,"end":128,"id":18,"ws":true},{"text":"treatment","start":129,"end":138,"id":19,"ws":true},{"text":",","start":139,"end":140,"id":20,"ws":true},{"text":"the","start":141,"end":144,"id":21,"ws":true},{"text":"influence","start":145,"end":154,"id":22,"ws":true},{"text":"of","start":155,"end":157,"id":23,"ws":true},{"text":"difference","start":158,"end":168,"id":24,"ws":true},{"text":"between","start":169,"end":176,"id":25,"ws":true},{"text":"the","start":177,"end":180,"id":26,"ws":true},{"text":"Eastern","start":181,"end":188,"id":27,"ws":true},{"text":"patients","start":189,"end":197,"id":28,"ws":true},{"text":"and","start":198,"end":201,"id":29,"ws":true},{"text":"the","start":202,"end":205,"id":30,"ws":true},{"text":"Western","start":206,"end":213,"id":31,"ws":true},{"text":"counterparts","start":214,"end":226,"id":32,"ws":true},{"text":"on","start":227,"end":229,"id":33,"ws":true},{"text":"sunitinib","start":230,"end":239,"id":34,"ws":true},{"text":"treatment","start":240,"end":249,"id":35,"ws":true},{"text":"schedule","start":250,"end":258,"id":36,"ws":true},{"text":",","start":259,"end":260,"id":37,"ws":true},{"text":"and","start":261,"end":264,"id":38,"ws":true},{"text":"the","start":265,"end":268,"id":39,"ws":true},{"text":"choice","start":269,"end":275,"id":40,"ws":true},{"text":"of","start":276,"end":278,"id":41,"ws":true},{"text":"regimen","start":279,"end":286,"id":42,"ws":true},{"text":"after","start":287,"end":292,"id":43,"ws":true},{"text":"imatinib","start":293,"end":301,"id":44,"ws":true},{"text":"and","start":302,"end":305,"id":45,"ws":true},{"text":"sunitinib","start":306,"end":315,"id":46,"ws":true},{"text":"failure","start":316,"end":323,"id":47,"ws":true},{"text":",","start":324,"end":325,"id":48,"ws":true},{"text":"etc","start":326,"end":329,"id":49,"ws":true},{"text":".","start":330,"end":331,"id":50,"ws":false}],"spans":[{"start":119,"end":128,"token_start":18,"token_end":18,"label":"DRUG"},{"start":230,"end":239,"token_start":34,"token_end":34,"label":"DRUG"},{"start":293,"end":301,"token_start":44,"token_end":44,"label":"DRUG"},{"start":306,"end":315,"token_start":46,"token_end":46,"label":"DRUG"}],"_input_hash":-2083749131,"_task_hash":-966983240,"_session_id":"drug_drug_pilot_split-dana_n","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Seventeen patients were enrolled in an open-label , phase I , dose-escalation study and were treated with intravenous paclitaxel 135 - 175 mg/m(2 ) over 1 hour on day 1 , followed by intravenous topotecan 1.25 - 1.5 mg/m(2 ) over 30 minutes on days 1 - 3 of a 21-day course .","paragraph":"<h3><u>Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.</u></h3>Extensive-stage small cell lung cancer (SCLC) is an aggressive disease with a median survival of approximately 8 months. Although current combination chemotherapy regimens provide high initial tumor response rates, they have not translated into large gains in survival. <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> have nonoverlapping mechanisms of action and are active agents in SCLC. Additionally, these two agents demonstrate in vitro synergy in animal and human tumor models. We investigated the maximum tolerated dose of 3-day <b style='color:Tomato;'><i>topotecan</i></b> in combination with <b style='color:Tomato;'><i>paclitaxel</i></b> in previously untreated patients with extensive SCLC. <b style='color:DodgerBlue;'><i>Seventeen</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>enrolled</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>open-label</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>dose-escalation</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>hour</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>1.25</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>1.5</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>minutes</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>21-day</i></b> <b style='color:DodgerBlue;'><i>course</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Sixty-nine courses of therapy were administered with no delays due to hematologic toxicity. Prophylactic hematologic support was required for 24% of patients. The <b style='color:Tomato;'><i>topotecan</i></b>/<b style='color:Tomato;'><i>paclitaxel</i></b> combination was well tolerated, with 24%, 12%, and 6% of patients experiencing grade 3/4 neutropenia, anemia, or thrombocytopenia, respectively. Dose-limiting neutropenia was seen in three of five patients treated with <b style='color:Tomato;'><i>topotecan</i></b> 1.5 mg/m(2) and <b style='color:Tomato;'><i>paclitaxel</i></b> 175 mg/m(2). Therefore, <b style='color:Tomato;'><i>topotecan</i></b> 1.5 mg/m(2) with <b style='color:Tomato;'><i>paclitaxel</i></b> 135 mg/m(2) was determined to be the maximum tolerated dose. Of the 17 evaluable patients, 53% achieved a partial response and 18% achieved stable disease. In summary, we have identified a regimen of <b style='color:Tomato;'><i>topotecan</i></b> 1.5 mg/m(2) and <b style='color:Tomato;'><i>paclitaxel</i></b> 135 mg/m(2) that was well tolerated and active in this patient group. Additional studies of <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> at these dose levels are needed to fully elucidate the efficacy of this combination in extensive SCLC.","tokens":[{"text":"Seventeen","start":0,"end":9,"id":0,"ws":true},{"text":"patients","start":10,"end":18,"id":1,"ws":true},{"text":"were","start":19,"end":23,"id":2,"ws":true},{"text":"enrolled","start":24,"end":32,"id":3,"ws":true},{"text":"in","start":33,"end":35,"id":4,"ws":true},{"text":"an","start":36,"end":38,"id":5,"ws":true},{"text":"open-label","start":39,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"phase","start":52,"end":57,"id":8,"ws":true},{"text":"I","start":58,"end":59,"id":9,"ws":true},{"text":",","start":60,"end":61,"id":10,"ws":true},{"text":"dose-escalation","start":62,"end":77,"id":11,"ws":true},{"text":"study","start":78,"end":83,"id":12,"ws":true},{"text":"and","start":84,"end":87,"id":13,"ws":true},{"text":"were","start":88,"end":92,"id":14,"ws":true},{"text":"treated","start":93,"end":100,"id":15,"ws":true},{"text":"with","start":101,"end":105,"id":16,"ws":true},{"text":"intravenous","start":106,"end":117,"id":17,"ws":true},{"text":"paclitaxel","start":118,"end":128,"id":18,"ws":true},{"text":"135","start":129,"end":132,"id":19,"ws":true},{"text":"-","start":133,"end":134,"id":20,"ws":true},{"text":"175","start":135,"end":138,"id":21,"ws":true},{"text":"mg/m(2","start":139,"end":145,"id":22,"ws":true},{"text":")","start":146,"end":147,"id":23,"ws":true},{"text":"over","start":148,"end":152,"id":24,"ws":true},{"text":"1","start":153,"end":154,"id":25,"ws":true},{"text":"hour","start":155,"end":159,"id":26,"ws":true},{"text":"on","start":160,"end":162,"id":27,"ws":true},{"text":"day","start":163,"end":166,"id":28,"ws":true},{"text":"1","start":167,"end":168,"id":29,"ws":true},{"text":",","start":169,"end":170,"id":30,"ws":true},{"text":"followed","start":171,"end":179,"id":31,"ws":true},{"text":"by","start":180,"end":182,"id":32,"ws":true},{"text":"intravenous","start":183,"end":194,"id":33,"ws":true},{"text":"topotecan","start":195,"end":204,"id":34,"ws":true},{"text":"1.25","start":205,"end":209,"id":35,"ws":true},{"text":"-","start":210,"end":211,"id":36,"ws":true},{"text":"1.5","start":212,"end":215,"id":37,"ws":true},{"text":"mg/m(2","start":216,"end":222,"id":38,"ws":true},{"text":")","start":223,"end":224,"id":39,"ws":true},{"text":"over","start":225,"end":229,"id":40,"ws":true},{"text":"30","start":230,"end":232,"id":41,"ws":true},{"text":"minutes","start":233,"end":240,"id":42,"ws":true},{"text":"on","start":241,"end":243,"id":43,"ws":true},{"text":"days","start":244,"end":248,"id":44,"ws":true},{"text":"1","start":249,"end":250,"id":45,"ws":true},{"text":"-","start":251,"end":252,"id":46,"ws":true},{"text":"3","start":253,"end":254,"id":47,"ws":true},{"text":"of","start":255,"end":257,"id":48,"ws":true},{"text":"a","start":258,"end":259,"id":49,"ws":true},{"text":"21-day","start":260,"end":266,"id":50,"ws":true},{"text":"course","start":267,"end":273,"id":51,"ws":true},{"text":".","start":274,"end":275,"id":52,"ws":false}],"spans":[{"start":118,"end":128,"token_start":18,"token_end":18,"label":"DRUG"},{"start":195,"end":204,"token_start":34,"token_end":34,"label":"DRUG"}],"_input_hash":381935772,"_task_hash":-169963030,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"We sought to compare rivaroxaban and warfarin 's impact on renal decline in patients with nonvalvular atrial fibrillation ( NVAF ) treated in routine practice .","paragraph":"<h3><u>Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis.</u></h3><b style='color:Tomato;'><i>warfarin</i></b> has been associated with renovascular calcification and worsening renal function, whereas <b style='color:Tomato;'><i>rivaroxaban</i></b> may provide a degree of renopreservation by decreasing vascular inflammation. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>sought</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:MediumOrchid;'><i>rivaroxaban</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>warfarin</i></b> <b style='color:DodgerBlue;'><i>'s</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>decline</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>nonvalvular</i></b> <b style='color:DodgerBlue;'><i>atrial</i></b> <b style='color:DodgerBlue;'><i>fibrillation</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NVAF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>routine</i></b> <b style='color:DodgerBlue;'><i>practice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using US MarketScan claims data from January 2012 to December 2017, we identified patients with NVAF newly initiated on <b style='color:Tomato;'><i>rivaroxaban</i></b> or <b style='color:Tomato;'><i>warfarin</i></b> with \u226512 months of continuous insurance coverage prior to initiation. Patients with stage 5 chronic kidney disease (CKD) or receiving hemodialysis at baseline were excluded. Outcomes included rates (events/100 person-years) of hospital or emergency department admission for acute kidney injury (AKI) or progression to stage 5 CKD or need for hemodialysis. Differences in baseline covariates between cohorts were adjusted using inverse probability-of-treatment weights based on propensity scores (absolute standardized differences <0.1 achieved for all covariates after adjustment). Patients were followed until an event, anticoagulant discontinuation/switch, insurance disenrollment, or end of data availability. Hazard ratios with 95% confidence intervals (CIs) were estimated using Cox regression. We assessed 36 318 <b style='color:Tomato;'><i>rivaroxaban</i></b> (19.8% received a dose <20 mg/d) and 36 281 <b style='color:Tomato;'><i>warfarin</i></b> users. Stages 3 and 4 CKD were present in 5% and 1% of patients at baseline, and proteinuria was present in 2%. <b style='color:Tomato;'><i>rivaroxaban</i></b> was associated with a 19% (95% CI = 13%-25%) reduction in the hazard of AKI (rates = 4.91 vs 8.45) and an 18% (95% CI = 9%-26%) reduction in progression to stage 5 CKD or hemodialysis (rates = 2.67 vs 4.12). <b style='color:Tomato;'><i>rivaroxaban</i></b> appears associated with lower hazards of undesirable renal end points versus <b style='color:Tomato;'><i>warfarin</i></b> in patients with NVAF.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"sought","start":3,"end":9,"id":1,"ws":true},{"text":"to","start":10,"end":12,"id":2,"ws":true},{"text":"compare","start":13,"end":20,"id":3,"ws":true},{"text":"rivaroxaban","start":21,"end":32,"id":4,"ws":true},{"text":"and","start":33,"end":36,"id":5,"ws":true},{"text":"warfarin","start":37,"end":45,"id":6,"ws":true},{"text":"'s","start":46,"end":48,"id":7,"ws":true},{"text":"impact","start":49,"end":55,"id":8,"ws":true},{"text":"on","start":56,"end":58,"id":9,"ws":true},{"text":"renal","start":59,"end":64,"id":10,"ws":true},{"text":"decline","start":65,"end":72,"id":11,"ws":true},{"text":"in","start":73,"end":75,"id":12,"ws":true},{"text":"patients","start":76,"end":84,"id":13,"ws":true},{"text":"with","start":85,"end":89,"id":14,"ws":true},{"text":"nonvalvular","start":90,"end":101,"id":15,"ws":true},{"text":"atrial","start":102,"end":108,"id":16,"ws":true},{"text":"fibrillation","start":109,"end":121,"id":17,"ws":true},{"text":"(","start":122,"end":123,"id":18,"ws":true},{"text":"NVAF","start":124,"end":128,"id":19,"ws":true},{"text":")","start":129,"end":130,"id":20,"ws":true},{"text":"treated","start":131,"end":138,"id":21,"ws":true},{"text":"in","start":139,"end":141,"id":22,"ws":true},{"text":"routine","start":142,"end":149,"id":23,"ws":true},{"text":"practice","start":150,"end":158,"id":24,"ws":true},{"text":".","start":159,"end":160,"id":25,"ws":false}],"spans":[{"start":21,"end":32,"token_start":4,"token_end":4,"label":"DRUG"},{"start":37,"end":45,"token_start":6,"token_end":6,"label":"DRUG"}],"_input_hash":1916413780,"_task_hash":-18757745,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Sulpiride is a nonsedative neuroleptic , pharmacologically related to metoclopramide , which has previously been shown to affect various gastric functions and to exert a beneficial effect in the treatment of duodenal ulcer .","paragraph":"<h3><u>Stimulation of pancreatic secretion by sulpiride.</u></h3> <b style='color:MediumOrchid;'><i>Sulpiride</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>nonsedative</i></b> <b style='color:DodgerBlue;'><i>neuroleptic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pharmacologically</i></b> <b style='color:DodgerBlue;'><i>related</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>metoclopramide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>affect</i></b> <b style='color:DodgerBlue;'><i>various</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>functions</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>exert</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>duodenal</i></b> <b style='color:DodgerBlue;'><i>ulcer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the present study the authors investigated the effects of <b style='color:Tomato;'><i>sulpiride</i></b> on pancreatic exocrine secretion. The intravenous injection of <b style='color:Tomato;'><i>sulpiride</i></b> (100 mg) during a constant infusion of secretin (0.5 CU/kg/hr) and cholecystokinin (0.5 IDU/kg/hr) significantly increased outputs of bicarbonate and enzymes in nine healthy subjects. The increase was maximal 20-30 min after <b style='color:Tomato;'><i>sulpiride</i></b> administration and lasted for the duration of the study (1 hr). Compared to pre<b style='color:Tomato;'><i>sulpiride</i></b> control levels, the mean maximum percent increase was 35% for bicarbonate, 39% for lipase, and 32% for chymotrypsin. It is concluded that <b style='color:Tomato;'><i>sulpiride</i></b> augments pancreatic secretion stimulated by submaximal doses of secretin and cholecystokinin. The mechanism of this effect is unknown.","tokens":[{"text":"Sulpiride","start":0,"end":9,"id":0,"ws":true},{"text":"is","start":10,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"nonsedative","start":15,"end":26,"id":3,"ws":true},{"text":"neuroleptic","start":27,"end":38,"id":4,"ws":true},{"text":",","start":39,"end":40,"id":5,"ws":true},{"text":"pharmacologically","start":41,"end":58,"id":6,"ws":true},{"text":"related","start":59,"end":66,"id":7,"ws":true},{"text":"to","start":67,"end":69,"id":8,"ws":true},{"text":"metoclopramide","start":70,"end":84,"id":9,"ws":true},{"text":",","start":85,"end":86,"id":10,"ws":true},{"text":"which","start":87,"end":92,"id":11,"ws":true},{"text":"has","start":93,"end":96,"id":12,"ws":true},{"text":"previously","start":97,"end":107,"id":13,"ws":true},{"text":"been","start":108,"end":112,"id":14,"ws":true},{"text":"shown","start":113,"end":118,"id":15,"ws":true},{"text":"to","start":119,"end":121,"id":16,"ws":true},{"text":"affect","start":122,"end":128,"id":17,"ws":true},{"text":"various","start":129,"end":136,"id":18,"ws":true},{"text":"gastric","start":137,"end":144,"id":19,"ws":true},{"text":"functions","start":145,"end":154,"id":20,"ws":true},{"text":"and","start":155,"end":158,"id":21,"ws":true},{"text":"to","start":159,"end":161,"id":22,"ws":true},{"text":"exert","start":162,"end":167,"id":23,"ws":true},{"text":"a","start":168,"end":169,"id":24,"ws":true},{"text":"beneficial","start":170,"end":180,"id":25,"ws":true},{"text":"effect","start":181,"end":187,"id":26,"ws":true},{"text":"in","start":188,"end":190,"id":27,"ws":true},{"text":"the","start":191,"end":194,"id":28,"ws":true},{"text":"treatment","start":195,"end":204,"id":29,"ws":true},{"text":"of","start":205,"end":207,"id":30,"ws":true},{"text":"duodenal","start":208,"end":216,"id":31,"ws":true},{"text":"ulcer","start":217,"end":222,"id":32,"ws":true},{"text":".","start":223,"end":224,"id":33,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":70,"end":84,"token_start":9,"token_end":9,"label":"DRUG"}],"_input_hash":1884006543,"_task_hash":620742003,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria , we re-assessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials : 44 received single-agent thalidomide , 41 single-agent lenalidomide , and 40 a combination of lenalidomide plus prednisone .","paragraph":"<h3><u>Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.</u></h3> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>International</i></b> <b style='color:DodgerBlue;'><i>Working</i></b> <b style='color:DodgerBlue;'><i>Group</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Myelofibrosis</i></b> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Research</i></b> <b style='color:DodgerBlue;'><i>consensus</i></b> <b style='color:DodgerBlue;'><i>criteria</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>re-assessed</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lenalidomide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>125</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>myelofibrosis</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>44</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>single-agent</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>41</i></b> <b style='color:DodgerBlue;'><i>single-agent</i></b> <b style='color:MediumOrchid;'><i>lenalidomide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lenalidomide</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The <b style='color:Tomato;'><i>thalidomide</i></b> group included significantly more untreated patients and patients with performance status of 2. The <b style='color:Tomato;'><i>lenalidomide</i></b>-based therapy produced higher efficacy (34%-38%) than <b style='color:Tomato;'><i>thalidomide</i></b> (16%; P = .06). Responses to <b style='color:Tomato;'><i>thalidomide</i></b> were seen within 3-15 weeks, whereas responses to the <b style='color:Tomato;'><i>lenalidomide</i></b>-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). <b style='color:Tomato;'><i>lenalidomide</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> therapy resulted in significantly longer response duration (median, 34 months) than single-agent <b style='color:Tomato;'><i>lenalidomide</i></b> or <b style='color:Tomato;'><i>thalidomide</i></b> (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the <b style='color:Tomato;'><i>lenalidomide</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of <b style='color:Tomato;'><i>lenalidomide</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> appears to be more effective and safer than single-agent <b style='color:Tomato;'><i>thalidomide</i></b> or <b style='color:Tomato;'><i>lenalidomide</i></b>.","tokens":[{"text":"With","start":0,"end":4,"id":0,"ws":true},{"text":"the","start":5,"end":8,"id":1,"ws":true},{"text":"use","start":9,"end":12,"id":2,"ws":true},{"text":"of","start":13,"end":15,"id":3,"ws":true},{"text":"the","start":16,"end":19,"id":4,"ws":true},{"text":"International","start":20,"end":33,"id":5,"ws":true},{"text":"Working","start":34,"end":41,"id":6,"ws":true},{"text":"Group","start":42,"end":47,"id":7,"ws":true},{"text":"for","start":48,"end":51,"id":8,"ws":true},{"text":"Myelofibrosis","start":52,"end":65,"id":9,"ws":true},{"text":"Treatment","start":66,"end":75,"id":10,"ws":true},{"text":"and","start":76,"end":79,"id":11,"ws":true},{"text":"Research","start":80,"end":88,"id":12,"ws":true},{"text":"consensus","start":89,"end":98,"id":13,"ws":true},{"text":"criteria","start":99,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"we","start":110,"end":112,"id":16,"ws":true},{"text":"re-assessed","start":113,"end":124,"id":17,"ws":true},{"text":"the","start":125,"end":128,"id":18,"ws":true},{"text":"efficacy","start":129,"end":137,"id":19,"ws":true},{"text":"of","start":138,"end":140,"id":20,"ws":true},{"text":"thalidomide","start":141,"end":152,"id":21,"ws":true},{"text":"and","start":153,"end":156,"id":22,"ws":true},{"text":"lenalidomide","start":157,"end":169,"id":23,"ws":true},{"text":"in","start":170,"end":172,"id":24,"ws":true},{"text":"125","start":173,"end":176,"id":25,"ws":true},{"text":"patients","start":177,"end":185,"id":26,"ws":true},{"text":"with","start":186,"end":190,"id":27,"ws":true},{"text":"myelofibrosis","start":191,"end":204,"id":28,"ws":true},{"text":"treated","start":205,"end":212,"id":29,"ws":true},{"text":"in","start":213,"end":215,"id":30,"ws":true},{"text":"3","start":216,"end":217,"id":31,"ws":true},{"text":"consecutive","start":218,"end":229,"id":32,"ws":true},{"text":"phase","start":230,"end":235,"id":33,"ws":true},{"text":"2","start":236,"end":237,"id":34,"ws":true},{"text":"trials","start":238,"end":244,"id":35,"ws":true},{"text":":","start":245,"end":246,"id":36,"ws":true},{"text":"44","start":247,"end":249,"id":37,"ws":true},{"text":"received","start":250,"end":258,"id":38,"ws":true},{"text":"single-agent","start":259,"end":271,"id":39,"ws":true},{"text":"thalidomide","start":272,"end":283,"id":40,"ws":true},{"text":",","start":284,"end":285,"id":41,"ws":true},{"text":"41","start":286,"end":288,"id":42,"ws":true},{"text":"single-agent","start":289,"end":301,"id":43,"ws":true},{"text":"lenalidomide","start":302,"end":314,"id":44,"ws":true},{"text":",","start":315,"end":316,"id":45,"ws":true},{"text":"and","start":317,"end":320,"id":46,"ws":true},{"text":"40","start":321,"end":323,"id":47,"ws":true},{"text":"a","start":324,"end":325,"id":48,"ws":true},{"text":"combination","start":326,"end":337,"id":49,"ws":true},{"text":"of","start":338,"end":340,"id":50,"ws":true},{"text":"lenalidomide","start":341,"end":353,"id":51,"ws":true},{"text":"plus","start":354,"end":358,"id":52,"ws":true},{"text":"prednisone","start":359,"end":369,"id":53,"ws":true},{"text":".","start":370,"end":371,"id":54,"ws":false}],"spans":[{"start":141,"end":152,"token_start":21,"token_end":21,"label":"DRUG"},{"start":157,"end":169,"token_start":23,"token_end":23,"label":"DRUG"},{"start":272,"end":283,"token_start":40,"token_end":40,"label":"DRUG"},{"start":302,"end":314,"token_start":44,"token_end":44,"label":"DRUG"},{"start":341,"end":353,"token_start":51,"token_end":51,"label":"DRUG"},{"start":359,"end":369,"token_start":53,"token_end":53,"label":"DRUG"}],"_input_hash":-98342227,"_task_hash":-1935295817,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":51,"child":53,"head_span":{"start":341,"end":353,"token_start":51,"token_end":51,"label":"DRUG"},"child_span":{"start":359,"end":369,"token_start":53,"token_end":53,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","POS1T1"],"answer":"accept"}
{"text":"AIHA and erythroid hypoplasia subsided after prednisolone and 3 courses of rituximab .","paragraph":"<h3><u>[Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].</u></h3>A 75-year-old woman was admitted for general fatigue. Diagnostic investigations showed no lymphadenopathy or hepatosplenomegaly. Laboratory examinations revealed severe anemia and an undetectable level of haptoglobin in the peripheral blood. A direct Coombs test was positive. Bone marrow examination showed abnormal, large, CD20-positive lymphocytes and erythroid hypoplasia. Accordingly, a diagnosis of primary diffuse large B-cell lymphoma (DLBCL) of the bone marrow with autoimmune hemolytic anemia (AIHA) and erythroid hypoplasia was made. The patient was treated with <b style='color:Tomato;'><i>prednisolone</i></b> and 3 courses of <b style='color:Tomato;'><i>rituximab</i></b>, followed by 6 courses of R-CHOP. <b style='color:DodgerBlue;'><i>AIHA</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>erythroid</i></b> <b style='color:DodgerBlue;'><i>hypoplasia</i></b> <b style='color:DodgerBlue;'><i>subsided</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment with 6 courses of R-CHOP resulted in complete remission. Isolated bone marrow disease as a presenting feature of DLBCL is very rare. Although malignant lymphomas are often associated with immunologic disorders, this is the first report of diffuse large B-cell lymphoma with isolated bone marrow disease and simultaneous autoimmune hemolytic anemia and erythroid hypoplasia. This case provides valuable information concerning the pathophysiology of an immunologic anomaly with malignant lymphoma.","tokens":[{"text":"AIHA","start":0,"end":4,"id":0,"ws":true},{"text":"and","start":5,"end":8,"id":1,"ws":true},{"text":"erythroid","start":9,"end":18,"id":2,"ws":true},{"text":"hypoplasia","start":19,"end":29,"id":3,"ws":true},{"text":"subsided","start":30,"end":38,"id":4,"ws":true},{"text":"after","start":39,"end":44,"id":5,"ws":true},{"text":"prednisolone","start":45,"end":57,"id":6,"ws":true},{"text":"and","start":58,"end":61,"id":7,"ws":true},{"text":"3","start":62,"end":63,"id":8,"ws":true},{"text":"courses","start":64,"end":71,"id":9,"ws":true},{"text":"of","start":72,"end":74,"id":10,"ws":true},{"text":"rituximab","start":75,"end":84,"id":11,"ws":true},{"text":".","start":85,"end":86,"id":12,"ws":false}],"spans":[{"start":45,"end":57,"token_start":6,"token_end":6,"label":"DRUG"},{"start":75,"end":84,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-925958972,"_task_hash":-9126492,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Although trans-sphenoidal surgery of a GH-secreting adenoma remains the first treatment at most centres , the role of somatostatin analogues , octreotide long-acting repeatable and lanreotide Autogel as primary therapy is still the subject of some debate .","paragraph":"<h3><u>Management of endocrine disease: GH excess: diagnosis and medical therapy.</u></h3>Acromegaly is predominantly caused by a pituitary adenoma, which secretes an excess of GH resulting in increased IGF1 levels. Most of the GH assays used currently measure only the levels of the 22 kDa form of GH. In theory, the diagnostic sensitivity may be lower compared with the previous assays, which have used polyclonal antibodies. Many GH-secreting adenomas are plurihormonal and may co-secrete prolactin, TSH and \u03b1-subunit. Hyperprolactinaemia is found in 30-40% of patients with acromegaly, and hyperprolactinaemia may occasionally be diagnosed before acromegaly is apparent. <b style='color:DodgerBlue;'><i>Although</i></b> <b style='color:DodgerBlue;'><i>trans-sphenoidal</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>GH-secreting</i></b> <b style='color:DodgerBlue;'><i>adenoma</i></b> <b style='color:DodgerBlue;'><i>remains</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>centres</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>role</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>analogues</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>long-acting</i></b> <b style='color:DodgerBlue;'><i>repeatable</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lanreotide</i></b> <b style='color:DodgerBlue;'><i>Autogel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>subject</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>some</i></b> <b style='color:DodgerBlue;'><i>debate</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although the normalisation of GH and IGF1 levels is the main objective in all patients with acromegaly, GH and IGF1 levels may be discordant, especially during <b style='color:Tomato;'><i>somatostatin</i></b> analogue therapy. This discordance usually takes the form of high GH levels and an IGF1 level towards the upper limit of the normal range. <b style='color:Tomato;'><i>pasireotide</i></b>, a new <b style='color:Tomato;'><i>somatostatin</i></b> analogue, may be more efficacious in some patients, but the drug has not yet been registered for acromegaly. Papers published on <b style='color:Tomato;'><i>pasireotide</i></b> have reported an increased risk of diabetes mellitus due to a reduction in insulin levels. Pegvisomant, the GH receptor antagonist, is indicated - alone or in combination with a <b style='color:Tomato;'><i>somatostatin</i></b> analogue - in most patients who fail to enter remission on a <b style='color:Tomato;'><i>somatostatin</i></b> analogue. Dopamine-D2-agonists may be effective as monotherapy in a few patients, but it may prove necessary to apply combination therapy involving a <b style='color:Tomato;'><i>somatostatin</i></b> analogue and/or pegvisomant.","tokens":[{"text":"Although","start":0,"end":8,"id":0,"ws":true},{"text":"trans-sphenoidal","start":9,"end":25,"id":1,"ws":true},{"text":"surgery","start":26,"end":33,"id":2,"ws":true},{"text":"of","start":34,"end":36,"id":3,"ws":true},{"text":"a","start":37,"end":38,"id":4,"ws":true},{"text":"GH-secreting","start":39,"end":51,"id":5,"ws":true},{"text":"adenoma","start":52,"end":59,"id":6,"ws":true},{"text":"remains","start":60,"end":67,"id":7,"ws":true},{"text":"the","start":68,"end":71,"id":8,"ws":true},{"text":"first","start":72,"end":77,"id":9,"ws":true},{"text":"treatment","start":78,"end":87,"id":10,"ws":true},{"text":"at","start":88,"end":90,"id":11,"ws":true},{"text":"most","start":91,"end":95,"id":12,"ws":true},{"text":"centres","start":96,"end":103,"id":13,"ws":true},{"text":",","start":104,"end":105,"id":14,"ws":true},{"text":"the","start":106,"end":109,"id":15,"ws":true},{"text":"role","start":110,"end":114,"id":16,"ws":true},{"text":"of","start":115,"end":117,"id":17,"ws":true},{"text":"somatostatin","start":118,"end":130,"id":18,"ws":true},{"text":"analogues","start":131,"end":140,"id":19,"ws":true},{"text":",","start":141,"end":142,"id":20,"ws":true},{"text":"octreotide","start":143,"end":153,"id":21,"ws":true},{"text":"long-acting","start":154,"end":165,"id":22,"ws":true},{"text":"repeatable","start":166,"end":176,"id":23,"ws":true},{"text":"and","start":177,"end":180,"id":24,"ws":true},{"text":"lanreotide","start":181,"end":191,"id":25,"ws":true},{"text":"Autogel","start":192,"end":199,"id":26,"ws":true},{"text":"as","start":200,"end":202,"id":27,"ws":true},{"text":"primary","start":203,"end":210,"id":28,"ws":true},{"text":"therapy","start":211,"end":218,"id":29,"ws":true},{"text":"is","start":219,"end":221,"id":30,"ws":true},{"text":"still","start":222,"end":227,"id":31,"ws":true},{"text":"the","start":228,"end":231,"id":32,"ws":true},{"text":"subject","start":232,"end":239,"id":33,"ws":true},{"text":"of","start":240,"end":242,"id":34,"ws":true},{"text":"some","start":243,"end":247,"id":35,"ws":true},{"text":"debate","start":248,"end":254,"id":36,"ws":true},{"text":".","start":255,"end":256,"id":37,"ws":false}],"spans":[{"start":118,"end":130,"token_start":18,"token_end":18,"label":"DRUG"},{"start":143,"end":153,"token_start":21,"token_end":21,"label":"DRUG"},{"start":181,"end":191,"token_start":25,"token_end":25,"label":"DRUG"}],"_input_hash":2141163777,"_task_hash":828236916,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":18,"child":21,"head_span":{"start":118,"end":130,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":143,"end":153,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":25,"child":21,"head_span":{"start":181,"end":191,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":143,"end":153,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"New combinations with novel agents such as capecitabine/oxaliplatin plus erlotinib or bevacizumab are currently under investigation .","paragraph":"<h3><u>Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.</u></h3>5-<b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU) plus <b style='color:Tomato;'><i>leucovorin</i></b> (LV) has been the mainstay of treatment for colorectal cancer (CRC), with infused schedules more widely adopted in Europe and bolus schedules preferred in North America. However, the effective, oral fluoropyrimidine <b style='color:Tomato;'><i>capecitabine</i></b> is increasingly replacing intravenous (IV) 5-FU/LV on both sides of the Atlantic. <b style='color:Tomato;'><i>capecitabine</i></b> generates 5-FU preferentially in tumor and is a well-established, first-line treatment for metastatic CRC. In this setting, <b style='color:Tomato;'><i>capecitabine</i></b> achieves a superior response rate, at least equivalent time to disease progression (TTP) and overall survival, and favorable safety compared with bolus 5-FU/LV. The benefits of <b style='color:Tomato;'><i>capecitabine</i></b> have been transfered into the adjuvant setting. Recent data from a large, international, randomized trial (Xeloda Adjuvant Chemotherapy Trial [X-ACT]) confirm that <b style='color:Tomato;'><i>capecitabine</i></b> (Xeloda, Roche Laboratories, Nutley, NJ) achieves favorable safety versus 5-FU/LV (Mayo Clinic regimen) and is at least as effective as IV 5-FU/LV in the adjuvant treatment of patients with resected stage III colon cancer. <b style='color:Tomato;'><i>capecitabine</i></b> is also an effective and well-tolerated combination partner for <b style='color:Tomato;'><i>oxaliplatin</i></b> (XELOX) and <b style='color:Tomato;'><i>irinotecan</i></b> (XELIRI), achieving high efficacy with a good safety profile. An extensive phase III clinical trial program is further establishing the potential of the simplified <b style='color:Tomato;'><i>capecitabine</i></b> combinations to improve outcomes and unify treatment practices in the metastatic and adjuvant settings. <b style='color:DodgerBlue;'><i>New</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>novel</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>capecitabine/oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>capecitabine</i></b> has also shown promising activity and good tolerability in combination with radiotherapy in rectal cancer.","tokens":[{"text":"New","start":0,"end":3,"id":0,"ws":true},{"text":"combinations","start":4,"end":16,"id":1,"ws":true},{"text":"with","start":17,"end":21,"id":2,"ws":true},{"text":"novel","start":22,"end":27,"id":3,"ws":true},{"text":"agents","start":28,"end":34,"id":4,"ws":true},{"text":"such","start":35,"end":39,"id":5,"ws":true},{"text":"as","start":40,"end":42,"id":6,"ws":true},{"text":"capecitabine/oxaliplatin","start":43,"end":67,"id":7,"ws":true},{"text":"plus","start":68,"end":72,"id":8,"ws":true},{"text":"erlotinib","start":73,"end":82,"id":9,"ws":true},{"text":"or","start":83,"end":85,"id":10,"ws":true},{"text":"bevacizumab","start":86,"end":97,"id":11,"ws":true},{"text":"are","start":98,"end":101,"id":12,"ws":true},{"text":"currently","start":102,"end":111,"id":13,"ws":true},{"text":"under","start":112,"end":117,"id":14,"ws":true},{"text":"investigation","start":118,"end":131,"id":15,"ws":true},{"text":".","start":132,"end":133,"id":16,"ws":false}],"spans":[{"start":73,"end":82,"token_start":9,"token_end":9,"label":"DRUG"},{"start":86,"end":97,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-679495533,"_task_hash":-111093207,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":43,"end":67,"token_start":7,"token_end":7,"label":null},"child_span":{"start":73,"end":82,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":7,"child":11,"head_span":{"start":43,"end":67,"token_start":7,"token_end":7,"label":null},"child_span":{"start":86,"end":97,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":["COMB1T0","COMB2T0"],"answer":"accept"}
{"text":"Dose intensity analysis of panobinostat and bortezomib by cycle in the panobinostat arm showed reductions of both agent doses during cycles 1 - 4 due to dose adjustments for AEs .","paragraph":"<h3><u>Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.</u></h3><b style='color:Tomato;'><i>panobinostat</i></b> in combination with <b style='color:Tomato;'><i>bortezomib</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> demonstrated a significant and clinically meaningful progression-free survival benefit compared with placebo, <b style='color:Tomato;'><i>bortezomib</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> in the phase 3 PANORAMA 1 (<b style='color:Tomato;'><i>panobinostat</i></b> Oral in Multiple Myeloma 1) trial. Despite this benefit, patients in the <b style='color:Tomato;'><i>panobinostat</i></b> arm experienced higher rates of adverse events (AEs) and higher rates of discontinuation due to AEs. This PANORAMA 1 subanalysis examined AEs between 2 treatment phases of the study (TP1 and TP2), in which administration frequency of <b style='color:Tomato;'><i>bortezomib</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> differed per protocol. The incidences of several key AEs were lower in both arms following the planned reduction of <b style='color:Tomato;'><i>bortezomib</i></b> dosing frequency in TP2. In the <b style='color:Tomato;'><i>panobinostat</i></b> arm, rates of thrombocytopenia (grade 3/4: TP1, 56\u00b77%; TP2, 6\u00b70%), diarrhoea (grade 3/4: TP1, 24\u00b71%; TP2, 7\u00b71%), and fatigue (grade 3/4: TP1, 16\u00b73%; TP2, 1\u00b78%) were lower in TP2 compared with TP1. <b style='color:DodgerBlue;'><i>Dose</i></b> <b style='color:DodgerBlue;'><i>intensity</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>panobinostat</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>panobinostat</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>reductions</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>adjustments</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>AEs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Exposure-adjusted analysis demonstrated a reduction in thrombocytopenia frequency in TP1 following dose adjustment. These results suggest that optimization of dosing with this regimen could improve tolerability, potentially leading to improved patient outcomes.","tokens":[{"text":"Dose","start":0,"end":4,"id":0,"ws":true},{"text":"intensity","start":5,"end":14,"id":1,"ws":true},{"text":"analysis","start":15,"end":23,"id":2,"ws":true},{"text":"of","start":24,"end":26,"id":3,"ws":true},{"text":"panobinostat","start":27,"end":39,"id":4,"ws":true},{"text":"and","start":40,"end":43,"id":5,"ws":true},{"text":"bortezomib","start":44,"end":54,"id":6,"ws":true},{"text":"by","start":55,"end":57,"id":7,"ws":true},{"text":"cycle","start":58,"end":63,"id":8,"ws":true},{"text":"in","start":64,"end":66,"id":9,"ws":true},{"text":"the","start":67,"end":70,"id":10,"ws":true},{"text":"panobinostat","start":71,"end":83,"id":11,"ws":true},{"text":"arm","start":84,"end":87,"id":12,"ws":true},{"text":"showed","start":88,"end":94,"id":13,"ws":true},{"text":"reductions","start":95,"end":105,"id":14,"ws":true},{"text":"of","start":106,"end":108,"id":15,"ws":true},{"text":"both","start":109,"end":113,"id":16,"ws":true},{"text":"agent","start":114,"end":119,"id":17,"ws":true},{"text":"doses","start":120,"end":125,"id":18,"ws":true},{"text":"during","start":126,"end":132,"id":19,"ws":true},{"text":"cycles","start":133,"end":139,"id":20,"ws":true},{"text":"1","start":140,"end":141,"id":21,"ws":true},{"text":"-","start":142,"end":143,"id":22,"ws":true},{"text":"4","start":144,"end":145,"id":23,"ws":true},{"text":"due","start":146,"end":149,"id":24,"ws":true},{"text":"to","start":150,"end":152,"id":25,"ws":true},{"text":"dose","start":153,"end":157,"id":26,"ws":true},{"text":"adjustments","start":158,"end":169,"id":27,"ws":true},{"text":"for","start":170,"end":173,"id":28,"ws":true},{"text":"AEs","start":174,"end":177,"id":29,"ws":true},{"text":".","start":178,"end":179,"id":30,"ws":false}],"spans":[{"start":27,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},{"start":71,"end":83,"token_start":11,"token_end":11,"label":"DRUG"}],"_input_hash":-352452241,"_task_hash":-525915643,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":27,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T1"],"answer":"accept"}
{"text":"Because the patient experienced nausea and vomiting , PMT/SDZ was replaced with TMP/SMX , atovaquone , and clindamycin .","paragraph":"<h3><u>Desensitization to trimethoprim-sulfamethoxazole in a toxoplasmic encephalitis patient who was intolerant to conventional treatments.</u></h3>Toxoplasma gondii is an obligate intracellular protozoan that causes toxoplasmic encephalitis (TE) in immunocompromised patients. We describe a case of a 29-year-old Japanese man presenting with headache and vomiting. He had previously been diagnosed with human immunodeficiency virus infection. Magnetic resonance imaging identified some nodules in his brain. We suspected TE and began treatment successively with parenteral <b style='color:Tomato;'><i>trimethoprim</i></b>-<b style='color:Tomato;'><i>sulfamethoxazole</i></b> (TMP/SMX) plus <b style='color:Tomato;'><i>clindamycin</i></b>. After that, we switched to <b style='color:Tomato;'><i>pyrimethamine</i></b> plus <b style='color:Tomato;'><i>sulfadiazine</i></b> (PMT/SDZ) because these drugs are the first-line treatment for TE. <b style='color:DodgerBlue;'><i>Because</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>experienced</i></b> <b style='color:DodgerBlue;'><i>nausea</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>vomiting</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>PMT/SDZ</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>replaced</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>TMP/SMX</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>atovaquone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, the patient could not tolerate them owing to their adverse reactions. Thus, we attempted oral desensitization to TMP/SMX to treat his TE. We began desensitization with 0.4/2 mg of TMP/SMX. The patient experienced morbilliform rash and elevated aminotransferase levels. Therefore, we administered a glycyrrhizin and an antihistamine and continued the last tolerable dose until these symptoms improved. After 37 days, we achieved desensitization to 160/800 mg of TMP/SMX, and the patient's symptoms improved. After using nested-polymerase chain reaction to identify T.\u00a0gondii DNA in his frozen cerebrospinal fluid, which was collected at admission, his diagnosis was confirmed as TE. This might be the first case to attempt desensitization to TMP/SMX to treat TE.","tokens":[{"text":"Because","start":0,"end":7,"id":0,"ws":true},{"text":"the","start":8,"end":11,"id":1,"ws":true},{"text":"patient","start":12,"end":19,"id":2,"ws":true},{"text":"experienced","start":20,"end":31,"id":3,"ws":true},{"text":"nausea","start":32,"end":38,"id":4,"ws":true},{"text":"and","start":39,"end":42,"id":5,"ws":true},{"text":"vomiting","start":43,"end":51,"id":6,"ws":true},{"text":",","start":52,"end":53,"id":7,"ws":true},{"text":"PMT/SDZ","start":54,"end":61,"id":8,"ws":true},{"text":"was","start":62,"end":65,"id":9,"ws":true},{"text":"replaced","start":66,"end":74,"id":10,"ws":true},{"text":"with","start":75,"end":79,"id":11,"ws":true},{"text":"TMP/SMX","start":80,"end":87,"id":12,"ws":true},{"text":",","start":88,"end":89,"id":13,"ws":true},{"text":"atovaquone","start":90,"end":100,"id":14,"ws":true},{"text":",","start":101,"end":102,"id":15,"ws":true},{"text":"and","start":103,"end":106,"id":16,"ws":true},{"text":"clindamycin","start":107,"end":118,"id":17,"ws":true},{"text":".","start":119,"end":120,"id":18,"ws":false}],"spans":[{"start":90,"end":100,"token_start":14,"token_end":14,"label":"DRUG"},{"start":107,"end":118,"token_start":17,"token_end":17,"label":"DRUG"}],"_input_hash":-1844534918,"_task_hash":-1062067499,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":80,"end":87,"token_start":12,"token_end":12,"label":null},"child_span":{"start":90,"end":100,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":17,"child":14,"head_span":{"start":107,"end":118,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":90,"end":100,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["COMB1T0"],"answer":"accept"}
{"text":"Streptomycin other aminoglycosides and ethambutol have poor CSF penetration and can not be agents of first choice for TBM treatment .","paragraph":"<h3><u>Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.</u></h3>Tuberculous meningitis (TBM) causes a devastating morbidity and mortality in adults and children. Even in patients presenting at an early stage of disease, deterioration may occur despite apparently adequate therapy. The literature relating to cerebrospinal fluid penetration of antituberculosis agents is reviewed. Amongst the essential antituberculosis agents <b style='color:Tomato;'><i>isoniazid</i></b> has the best CSF pharmacokinetics reaching peak concentrations (C(max)) only slightly less than in blood. <b style='color:Tomato;'><i>pyrazinamide</i></b> also has good CSF penetration and in children receiving dosages of 40\u00a0mg/kg the CSF C(max) exceeds the proposed minimal inhibitory concentration of 20\u00a0\u03bcg/ml. <b style='color:MediumOrchid;'><i>Streptomycin</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>aminoglycosides</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ethambutol</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>poor</i></b> <b style='color:DodgerBlue;'><i>CSF</i></b> <b style='color:DodgerBlue;'><i>penetration</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>choice</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>TBM</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Rifampicin at dosages used in adults seldom reaches CSF concentrations exceeding MIC, but does so more frequently in children when dosages of up to 20\u00a0mg/kg are used. The non-essential agents <b style='color:Tomato;'><i>ethionamide</i></b>, the fluoroquinolones, with the exception of <b style='color:Tomato;'><i>ciprofloxacin</i></b>, and cycloserine (terizadone) have relatively good CSF penetration and are recommended for TBM treatment. The dosages of the essential agents recommended for the treatment of TBM in children are INH 10\u00a0mg/kg (range 6-15\u00a0mg/kg bodyweight), rifampicin 15\u00a0mg/kg (range 10-20\u00a0mg/kg), <b style='color:Tomato;'><i>pyrazinamide</i></b> 35\u00a0mg/kg (range 30-40\u00a0mg/kg), <b style='color:Tomato;'><i>ethambutol</i></b> 20\u00a0mg/kg (range 15-25\u00a0mg/kg) and <b style='color:Tomato;'><i>streptomycin</i></b> 15\u00a0mg/kg (range 12-18\u00a0mg/kg). Amongst second-line agents ofloxacin, <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>moxifloxacin</i></b> should be used in dosages of 15-20\u00a0mg/kg, <b style='color:Tomato;'><i>ethionamide</i></b> 20\u00a0mg/kg in a single dose, if tolerated, and for cycloserine (terizadone) 15\u00a0mg/kg. Antituberculous chemotherapy should be started as soon as the diagnosis of TBM is considered.","tokens":[{"text":"Streptomycin","start":0,"end":12,"id":0,"ws":true},{"text":"other","start":13,"end":18,"id":1,"ws":true},{"text":"aminoglycosides","start":19,"end":34,"id":2,"ws":true},{"text":"and","start":35,"end":38,"id":3,"ws":true},{"text":"ethambutol","start":39,"end":49,"id":4,"ws":true},{"text":"have","start":50,"end":54,"id":5,"ws":true},{"text":"poor","start":55,"end":59,"id":6,"ws":true},{"text":"CSF","start":60,"end":63,"id":7,"ws":true},{"text":"penetration","start":64,"end":75,"id":8,"ws":true},{"text":"and","start":76,"end":79,"id":9,"ws":true},{"text":"can","start":80,"end":83,"id":10,"ws":true},{"text":"not","start":84,"end":87,"id":11,"ws":true},{"text":"be","start":88,"end":90,"id":12,"ws":true},{"text":"agents","start":91,"end":97,"id":13,"ws":true},{"text":"of","start":98,"end":100,"id":14,"ws":true},{"text":"first","start":101,"end":106,"id":15,"ws":true},{"text":"choice","start":107,"end":113,"id":16,"ws":true},{"text":"for","start":114,"end":117,"id":17,"ws":true},{"text":"TBM","start":118,"end":121,"id":18,"ws":true},{"text":"treatment","start":122,"end":131,"id":19,"ws":true},{"text":".","start":132,"end":133,"id":20,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":39,"end":49,"token_start":4,"token_end":4,"label":"DRUG"}],"_input_hash":1049731801,"_task_hash":-824356841,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Interaction between trastuzumab and chemotherapeutic agents ( fluorouracil , doxorubicin , cisplatin and paclitaxel ) was evaluated by the combination index ( CI ) .","paragraph":"<h3><u>Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced             apoptosis in gastric cancer cells with HER2 amplification.</u></h3>The purpose of this study was to explore the effect of <b style='color:Tomato;'><i>trastuzumab</i></b> in enhancing the activity of chemotherapeutic agents and the molecular basis of this effect. Two gastric cancer cell types with HER2 amplification, one sensitive (NCI\u2011N87) and one insensitive (MKN-7) to <b style='color:Tomato;'><i>trastuzumab</i></b>, were tested for the effects of <b style='color:Tomato;'><i>trastuzumab</i></b> on cell growth and cell signaling using MTS assay and western blotting, respectively. <b style='color:DodgerBlue;'><i>Interaction</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapeutic</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>index</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>fluorouracil</i></b>-induced apoptosis was evaluated using western blot for poly (ADP-ribose) polymerase (PARP). <b style='color:Tomato;'><i>trastuzumab</i></b> decreased phosphorylation of S6K, showed synergistic effect with <b style='color:Tomato;'><i>fluorouracil</i></b> or <b style='color:Tomato;'><i>doxorubicin</i></b>, and increased <b style='color:Tomato;'><i>fluorouracil</i></b>-induced apoptosis in NCI-N87 cells, but not in MKN-7 cells. While the mTOR inhibitor <b style='color:Tomato;'><i>everolimus</i></b> enhanced <b style='color:Tomato;'><i>fluorouracil</i></b>-induced apoptosis in both HER2-amplified cell lines, this was not the case in the gastric cancer cell lines without HER2 amplification. Consistently, while the EGFR/HER2 inhibitor Cl-387,785 inhibited cell growth of MKN-7, this growth inhibition did not accompany decrease in phosphorylation of S6K, and the compound did not enhance <b style='color:Tomato;'><i>fluorouracil</i></b>-induced apoptosis. In summary, inhibition of the mTOR/S6K signal may be a key molecular event in enhancing <b style='color:Tomato;'><i>fluorouracil</i></b>-induced apoptosis specifically in gastric cancer cells with HER2 amplification. mTOR inhibitors may therefore be attractive alternative drugs in gastric cancers with HER2 amplification regardless of their sensitivity to <b style='color:Tomato;'><i>trastuzumab</i></b>.","tokens":[{"text":"Interaction","start":0,"end":11,"id":0,"ws":true},{"text":"between","start":12,"end":19,"id":1,"ws":true},{"text":"trastuzumab","start":20,"end":31,"id":2,"ws":true},{"text":"and","start":32,"end":35,"id":3,"ws":true},{"text":"chemotherapeutic","start":36,"end":52,"id":4,"ws":true},{"text":"agents","start":53,"end":59,"id":5,"ws":true},{"text":"(","start":60,"end":61,"id":6,"ws":true},{"text":"fluorouracil","start":62,"end":74,"id":7,"ws":true},{"text":",","start":75,"end":76,"id":8,"ws":true},{"text":"doxorubicin","start":77,"end":88,"id":9,"ws":true},{"text":",","start":89,"end":90,"id":10,"ws":true},{"text":"cisplatin","start":91,"end":100,"id":11,"ws":true},{"text":"and","start":101,"end":104,"id":12,"ws":true},{"text":"paclitaxel","start":105,"end":115,"id":13,"ws":true},{"text":")","start":116,"end":117,"id":14,"ws":true},{"text":"was","start":118,"end":121,"id":15,"ws":true},{"text":"evaluated","start":122,"end":131,"id":16,"ws":true},{"text":"by","start":132,"end":134,"id":17,"ws":true},{"text":"the","start":135,"end":138,"id":18,"ws":true},{"text":"combination","start":139,"end":150,"id":19,"ws":true},{"text":"index","start":151,"end":156,"id":20,"ws":true},{"text":"(","start":157,"end":158,"id":21,"ws":true},{"text":"CI","start":159,"end":161,"id":22,"ws":true},{"text":")","start":162,"end":163,"id":23,"ws":true},{"text":".","start":164,"end":165,"id":24,"ws":false}],"spans":[{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},{"start":62,"end":74,"token_start":7,"token_end":7,"label":"DRUG"},{"start":77,"end":88,"token_start":9,"token_end":9,"label":"DRUG"},{"start":105,"end":115,"token_start":13,"token_end":13,"label":"DRUG"}],"_input_hash":-663145324,"_task_hash":-2043046591,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":2,"child":7,"head_span":{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":62,"end":74,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":2,"child":9,"head_span":{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":77,"end":88,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":2,"child":11,"head_span":{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":91,"end":100,"token_start":11,"token_end":11,"label":null},"color":"#c5bdf4","label":"COMB3"}],"radio":["COMB1T0","COMB2T0","COMB3T0"],"answer":"accept"}
{"text":"In the univariate analysis , nephritis , SLE activity , leucopenia , anti-dsDNA levels above 20 IU/mL , CH50 levels under 300 IU/mL , ever use of steroids , daily dose of prednisone higher than 10 mg and ever use of cyclophosphamide were significantly associated with infection .","paragraph":"<h3><u>Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients.</u></h3>We decided to analyse the incidence and characteristics of infection in systemic lupus erythematosus (SLE) and determine the related risks factors. One-hundred and ten SLE patients and 220 controls were prospectively followed up over three years and all the infectious episodes were recorded. A case-control design was established to identify risk factors of infection. Thirty-nine SLE patients suffered at least one infection (36%) versus 53 controls (22%), RR = 1.63 (P < 0.05). The incidence of urinary infections, pneumonia and bacteraemia without known focus was significantly greater in SLE. E. coli was the chief isolated microorganism (21.3%). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>univariate</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nephritis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>SLE</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>leucopenia</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>anti-dsDNA</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>above</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>IU/mL</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CH50</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>300</i></b> <b style='color:DodgerBlue;'><i>IU/mL</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ever</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>steroids</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>ever</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the multivariate analysis, total serum complement levels below 300 UU/mL and a daily dose of <b style='color:Tomato;'><i>prednisone</i></b> above 20 mg during at least one month plus ever use of <b style='color:Tomato;'><i>cyclophosphamide</i></b> were found to be significant (P < 0.0001). We conclude that patients with SLE have an increased overall risk for infection and they are especially prone to develop urinary infection, pneumonia and bacteraemia without focus. Hypocomplementaemia represents an independent predictive factor for infection. It seems mandatory to closely follow up SLE patients with low complement levels and instruct them to report any suspicious sign of infection, especially in those receiving more than 20 mg/day of <b style='color:Tomato;'><i>prednisone</i></b> who have also been administered <b style='color:Tomato;'><i>cyclophosphamide</i></b>.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"univariate","start":7,"end":17,"id":2,"ws":true},{"text":"analysis","start":18,"end":26,"id":3,"ws":true},{"text":",","start":27,"end":28,"id":4,"ws":true},{"text":"nephritis","start":29,"end":38,"id":5,"ws":true},{"text":",","start":39,"end":40,"id":6,"ws":true},{"text":"SLE","start":41,"end":44,"id":7,"ws":true},{"text":"activity","start":45,"end":53,"id":8,"ws":true},{"text":",","start":54,"end":55,"id":9,"ws":true},{"text":"leucopenia","start":56,"end":66,"id":10,"ws":true},{"text":",","start":67,"end":68,"id":11,"ws":true},{"text":"anti-dsDNA","start":69,"end":79,"id":12,"ws":true},{"text":"levels","start":80,"end":86,"id":13,"ws":true},{"text":"above","start":87,"end":92,"id":14,"ws":true},{"text":"20","start":93,"end":95,"id":15,"ws":true},{"text":"IU/mL","start":96,"end":101,"id":16,"ws":true},{"text":",","start":102,"end":103,"id":17,"ws":true},{"text":"CH50","start":104,"end":108,"id":18,"ws":true},{"text":"levels","start":109,"end":115,"id":19,"ws":true},{"text":"under","start":116,"end":121,"id":20,"ws":true},{"text":"300","start":122,"end":125,"id":21,"ws":true},{"text":"IU/mL","start":126,"end":131,"id":22,"ws":true},{"text":",","start":132,"end":133,"id":23,"ws":true},{"text":"ever","start":134,"end":138,"id":24,"ws":true},{"text":"use","start":139,"end":142,"id":25,"ws":true},{"text":"of","start":143,"end":145,"id":26,"ws":true},{"text":"steroids","start":146,"end":154,"id":27,"ws":true},{"text":",","start":155,"end":156,"id":28,"ws":true},{"text":"daily","start":157,"end":162,"id":29,"ws":true},{"text":"dose","start":163,"end":167,"id":30,"ws":true},{"text":"of","start":168,"end":170,"id":31,"ws":true},{"text":"prednisone","start":171,"end":181,"id":32,"ws":true},{"text":"higher","start":182,"end":188,"id":33,"ws":true},{"text":"than","start":189,"end":193,"id":34,"ws":true},{"text":"10","start":194,"end":196,"id":35,"ws":true},{"text":"mg","start":197,"end":199,"id":36,"ws":true},{"text":"and","start":200,"end":203,"id":37,"ws":true},{"text":"ever","start":204,"end":208,"id":38,"ws":true},{"text":"use","start":209,"end":212,"id":39,"ws":true},{"text":"of","start":213,"end":215,"id":40,"ws":true},{"text":"cyclophosphamide","start":216,"end":232,"id":41,"ws":true},{"text":"were","start":233,"end":237,"id":42,"ws":true},{"text":"significantly","start":238,"end":251,"id":43,"ws":true},{"text":"associated","start":252,"end":262,"id":44,"ws":true},{"text":"with","start":263,"end":267,"id":45,"ws":true},{"text":"infection","start":268,"end":277,"id":46,"ws":true},{"text":".","start":278,"end":279,"id":47,"ws":false}],"spans":[{"start":171,"end":181,"token_start":32,"token_end":32,"label":"DRUG"},{"start":216,"end":232,"token_start":41,"token_end":41,"label":"DRUG"}],"_input_hash":1619355540,"_task_hash":-283032394,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The results of this study demonstrated that combined treatment of simvastatin with chemotherapeutic agents such as irinotecan resulted in enhancement of growth inhibition and induction of prostate cancer cell apoptosis .","paragraph":"<h3><u>Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1.</u></h3>Prostate cancer is one of the most common malignant tumors around the world. Hyperlipidemia is considered as one of the most important risk factors for the development of prostate cancer. <b style='color:Tomato;'><i>simvastatin</i></b> is widely used for the treatment of hyperlipidemia and was previously shown to induce apoptosis in several cancer types including lung, colon, pancreas, breast, and prostate cancer. In this study we aimed to explore the potential role of <b style='color:Tomato;'><i>simvastatin</i></b> in enhancing <b style='color:Tomato;'><i>irinotecan</i></b>-induced apoptosis in prostate cancer cells. In addition, the underlying molecular mechanisms driving this potential effect of <b style='color:Tomato;'><i>simvastatin</i></b> were also explored. PC3 cells were treated with <b style='color:Tomato;'><i>simvastatin</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b> or combination. Cell viability was assessed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. Flow cytometry technique was used to analyze apoptosis and cell cycle progression. Western blot was used for detection of protein expression. Results showed that <b style='color:Tomato;'><i>simvastatin</i></b> has a significant anti-proliferative activity on PC3 cells. Combined treatment of <b style='color:Tomato;'><i>simvastatin</i></b> with <b style='color:Tomato;'><i>irinotecan</i></b> exhibited a significant inhibition of PC3 cell growth compared to each treatment alone. Flow cytometry analysis showed that PC3 cell treatment with <b style='color:Tomato;'><i>simvastatin</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> combination demonstrated a remarkable increase in the percentage of apoptotic cells and those accumulated at G0/G1 phase when compared to each treatment alone. Moreover, induction of apoptosis was caspase-independent. Western blot showed that apoptosis was accompanied by upregulation of GRP-78 level and downregulation of Mcl-1 levels in a time-dependent manner. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chemotherapeutic</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>enhancement</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"of","start":12,"end":14,"id":2,"ws":true},{"text":"this","start":15,"end":19,"id":3,"ws":true},{"text":"study","start":20,"end":25,"id":4,"ws":true},{"text":"demonstrated","start":26,"end":38,"id":5,"ws":true},{"text":"that","start":39,"end":43,"id":6,"ws":true},{"text":"combined","start":44,"end":52,"id":7,"ws":true},{"text":"treatment","start":53,"end":62,"id":8,"ws":true},{"text":"of","start":63,"end":65,"id":9,"ws":true},{"text":"simvastatin","start":66,"end":77,"id":10,"ws":true},{"text":"with","start":78,"end":82,"id":11,"ws":true},{"text":"chemotherapeutic","start":83,"end":99,"id":12,"ws":true},{"text":"agents","start":100,"end":106,"id":13,"ws":true},{"text":"such","start":107,"end":111,"id":14,"ws":true},{"text":"as","start":112,"end":114,"id":15,"ws":true},{"text":"irinotecan","start":115,"end":125,"id":16,"ws":true},{"text":"resulted","start":126,"end":134,"id":17,"ws":true},{"text":"in","start":135,"end":137,"id":18,"ws":true},{"text":"enhancement","start":138,"end":149,"id":19,"ws":true},{"text":"of","start":150,"end":152,"id":20,"ws":true},{"text":"growth","start":153,"end":159,"id":21,"ws":true},{"text":"inhibition","start":160,"end":170,"id":22,"ws":true},{"text":"and","start":171,"end":174,"id":23,"ws":true},{"text":"induction","start":175,"end":184,"id":24,"ws":true},{"text":"of","start":185,"end":187,"id":25,"ws":true},{"text":"prostate","start":188,"end":196,"id":26,"ws":true},{"text":"cancer","start":197,"end":203,"id":27,"ws":true},{"text":"cell","start":204,"end":208,"id":28,"ws":true},{"text":"apoptosis","start":209,"end":218,"id":29,"ws":true},{"text":".","start":219,"end":220,"id":30,"ws":false}],"spans":[{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"},{"start":115,"end":125,"token_start":16,"token_end":16,"label":"DRUG"}],"_input_hash":1936027661,"_task_hash":1901479781,"_session_id":"drug_drug_pilot_split-maytal","_view_id":"blocks","relations":[{"head":16,"child":10,"head_span":{"start":115,"end":125,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10","POS1T0"],"answer":"accept"}
